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ABSTRACT 
 
The observation that individuals living in malaria endemic regions who are 
repeatedly infected with P. falciparum can acquire immunity, first to severe, then to 
uncomplicated clinical episodes of malaria, and finally to high parasite densities, 
provides hope that a vaccine is achievable. Immunoglobulins have been identified as 
a key component of naturally acquired immunity and identifying the targets and 
mechanisms by which this protection is achieved is a clear research priority. To 
date, only a small proportion of the parasite proteome has been evaluated in the 
context of naturally acquired immunity. This thesis was aimed at contributing to this 
knowledge gap by identifying novel potential antigen targets of protective 
antibodies and validating these in samples from Tanzanian adults. 
 
First, to identify merozoite antigens that were immunogenic, I resolved proteins 
extracted from P. falciparum merozoites by two-dimensional gel electrophoresis 
and tested these for reactivity with immunoglobulins from malaria immune adults. 
Immunoreactive proteins were then identified by mass-spectrometry. In 
complementary studies, purified P. falciparum merozoites were treated with 
proteolytic enzymes to release proteins localised on the surface of merozoites, 
which were subsequently identified by mass-spectrometry. Using stringent criteria, 
where I combined the data obtained from 2D-immunoblots and surface-
trypsinization experiments with bioinformatics prediction (for the presence of a 
signal peptide and/or transmembrane domain), I narrowed down to 222 potential 
merozoite vaccine targets. These included known surface and/or immunogenic 
proteins such as the 6-cysteine proteins (Pf12, Pf38, Pf41), MSP-1, 3, 7, 9, 10, 
GLURP, AMA1, GAMA, MTRAP, LSA3 and RhopH3 as well as many unstudied 
proteins. From the set of unstudied proteins, I prioritised 27 antigens for 
immunoprofiling and identified 19 antigens that are targets of naturally acquired 
antibodies and potential novel vaccine candidates. 
 
Next, using a cohort of adults living in a village in Tanzania that experiences 
hyperendemic malaria transmission throughout the year, I examined antibody 
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responses to the novel potential vaccine candidates to test whether they were 
correlated with protective immunity. I began by identifying a panel of antigens that 
were immunogenic and elicited a stable antibody response in adults. Subsequently, I 
identified six antigens that were individually associated with protection from 
clinical episodes of malaria. Individuals who became ill during the follow-up period 
had significantly lower levels of these antibodies compared to those who did not. 
These antigens were the pantothenate transporter (PfPAT), a putative amino acid 
transporter (PF3D7_0629500), PF3D7_0830500, PF3D7_1025300, 
PF3D7_1345100 and PF3D7_1401600. In addition, the breadth of antibody 
responses to the tested antigens was associated with protection from clinical 
malaria. Finally, four of these six antigens strongly correlated with protective 
effector functions.  Antibody responses to PfPAT were strongly correlated to both 
the ability to fix soluble factor C1q (C1q-fixation) to merozoites as well as with 
their interaction with neutrophils to release reactive species (ADRB). In addition, 
antibody responses to the putative amino acid transporter, PF3D7_1345100 and 
PF3D7_1401600 were strongly associated with C1q-fixation ability. Recruitment of 
the soluble factor C1q onto the surface of merozoite results in lysis via the classical 
complement pathway. The release of reactive oxygen species by neutrophils is 
thought to be toxic to the intra-erythrocytic stages of the parasites and is associated 
with parasite clearance.  
 
This thesis shows that 19 antigens, some of which have been studied for the first 
time in this work, are targets of naturally acquired antibody responses. Six of these 
antigens appeared to be associated with protective immunity to malaria in adults and 
correlated strongly with immune effector mechanisms that are thought to be 
important for parasite clearance. These findings provide a set of antigens that 
warrant further evaluation for inclusion into the vaccine pre-clinical development 
pipeline. 
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CHAPTER 1  
Introduction 
1.0. Malaria: Burden of disease 
 
Malaria is a life-threatening disease characterised by an acute febrile illness, which 
was estimated by the World Health Organisation (WHO) to result in 212 million 
cases (uncertainty interval (UI): 148-304 million) and 429,000 deaths (UI: 235,000-
639,000) in 2015 [1]. Within the last one and a half decades however, there have 
been major gains in the control of the disease, which has resulted in an estimated 
drop by 21% and 29% in the malaria incidence rate and mortality, respectively, 
between 2000 and 2015 [1]. Despite these gains, 91 countries in sub-Saharan Africa, 
South-East Asia, Latin America and the Middle East continue to experience malaria 
transmission and individuals in these regions remain at risk [1]. The largest share of 
the global burden of malaria is experienced in Sub-Saharan Africa accounting for 
90% and 92% of the clinical cases and deaths respectively. Southeast Asia and the 
Middle East accounted for 7% and 2% of the clinical cases reported in 2015, 
respectively [1]. 
 
Five Plasmodium parasite species namely: P. falciparum, P. vivax, P. ovale, P. 
malariae and P. knowlesi cause malaria in humans. The majority of deaths (99%) 
due to malaria are caused by P. falciparum, although P. vivax is the dominant 
infective species outside Africa. Infection with P. knowlesi also results in severe 
disease and death, however transmission is limited to South-East Asia [2]. The 
symptoms following infection with P. malariae and P. ovale are often mild and 
rarely result in death. In individuals living in malaria endemic regions, the burden of 
disease occurs primarily in children aged 5 years and below. The WHO estimated 
that 70% or 303,000 (UI: 165,000-450,000) of the total deaths due to malaria in 
2015 occurred in this age group [1]. In addition, some populations in endemic 
regions are at particular risk, including pregnant women, HIV-infected individuals 
and non-immune individuals. 
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Several malaria control strategies are available that have contributed to the decline 
in the burden of disease and are discussed in detail in section 1.3 of this chapter. 
These strategies are primarily aimed at: i) vector control, ii) preventing disease in 
“at-risk” populations through prophylaxis, iii) rapid and accurate diagnosis and 
treatment of malaria and iv) continued malaria surveillance. So far, a highly 
effective vaccine against malaria has been elusive but pilot studies on the feasibility 
of the roll-out of the RTS’S vaccine are set to begin in 2018 offering some hope [1, 
3]. These control measures continue to be employed with the aim of achieving the 
three main goals that were set by the Global Technical Strategy for malaria between 
2016-2030 (GTS): i) To reduce the malaria incidence and mortality rates by 90% by 
the year 2030, ii) eliminate malaria from 35 countries by 2030 iii) prevent re-
establishment of malaria in countries that are malaria free [1]. To achieve these 
goals, there is no doubt that an effective vaccine is urgently needed. 
 
1.1. Plasmodium spp life cycle 
 
Malaria infection in humans is caused by intracellular obligate parasites of the 
Plasmodium spp. that are transmitted via the bite of an infected female mosquito of 
the Anopheles genus.  All the five human infective Plasmodium species have a 
similar life cycle that requires two hosts: the mosquito vector and the vertebrate host 
as shown in Figure 1.1 [4]. However, there are subtle differences in the length of the 
life cycle and in the parasite morphology at various developmental stages between 
the five species [5].  
 
As the female Anopheles mosquito takes a blood meal it injects around 10-100 
motile sporozoites into the dermis. These sporozoites first migrate to the capillaries, 
and then travel via the bloodstream to the liver. Sporozoites cross the liver 
sinusoidal cell barrier by the transversal of either endothelial cells or Küpffer cells 
(phagocytic cells resident in the liver) and migrate through several cells finally 
invading a hepatocyte where their subsequent development occurs. After hepatocyte 
invasion, the sporozoite is enclosed within a parasitophorous vacuole membrane 
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(PVM), which forms a physical barrier from the hepatocyte’s cytoplasm. Enclosed 
within the PVM, sporozoites undergo asexual development and replication, 
amplifying their numbers exponentially and developing into pre-erythrocytic 
schizonts that contain merozoites. One sporozoite developing within a hepatocyte 
can develop into 40,000 merozoites [6]. These merozoites are packaged within host 
membrane-surrounded vesicles called merosomes that bud off hepatocytes and are 
released into the blood circulation. This clinically silent phase is referred to as the 
pre-erythrocytic stage of the life cycle and lasts about 6-9 days for P. falciparum 
infection [4]. Pre-patent periods for P. vivax, P. ovale, P. malariae are 8-12, 10-14 
and 15-18 days respectively. It has been estimated that 40,000, 10,000, 15,000 and 
2,000 merozoites are produced per sporozoite during the pre-erythrocytic stage in P. 
falciparum, P. vivax, P. ovale and P. malariae infections respectively [7]. In P. 
vivax and P. ovale infections, some of the sporozoites do not immediately undergo 
asexual replication but enter a dormant phase and are called hypnozoites that can 
cause relapses weeks or months after an initial infection[8].  
 
After being released from merosomes into the blood circulation, merozoites attach 
to and invade red blood cells, initiating the erythrocytic stage of the life cycle. 
Merozoites develop within the erythrocytes through specific stages, termed the ring, 
trophozoite and schizont stages that are morphologically distinct by light 
microscopy. The young trophozoite is referred to as the ring form due to its 
morphology on Giemsa staining. As the trophozoite enlarges and changes in 
morphology, the parasite ingests the host cytoplasm and breaks down haemoglobin 
as a source of amino acids and energy. A by-product of this process, haemozoin, is 
visible as golden-brown to black crystalline granules in the mature stages. Nuclear 
division begins in the schizont stage followed by a budding process in mature 
schizonts where individual merozoites become visible resulting in erythrocytes 
containing segmented schizonts.  These schizonts rupture releasing newly formed 
merozoites into circulation that can invade other erythrocytes resulting in a cyclic 
blood-stage infection. This stage takes approximately 48 hours for P. falciparum, P. 
vivax and P. ovale infections, 24 hours for P. knowlesi and 72 hours for P. malariae 
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infections [5]. Triggered by poorly understood cues, a small proportion of newly 
invaded merozoites can differentiate into sexual gametocytes that after a series of 
developmental stages can be taken up by the Anopheles mosquito. The male and 
female gametocytes exit erythrocytes and undergo nuclear replication forming 
gametes within the mosquito mid-gut. The male gamete (microgamete) is 
morphologically distinct from the female gamete (macrogamete) as they contain 
flagella that render them motile. Within the midgut, the gametes fuse to form a 
zygote (diploid) that differentiates into a motile form referred to as an ookinete. The 
ookinete transverses the mosquito midgut wall forming oocysts within which 
haploid sporozoites develop. The oocysts rupture releasing newly formed 
sporozoites that travel through the haemocoele to invade the salivary glands of the 
mosquito from where they can then be transmitted to the human host [4]. 
 
Figure 1.1: The life cycle of the Plasmodium spp. The diagram shows the developmental stages of the parasite 
in the human and mosquito host. Figure adopted from Menard et al, 2013[9]. 
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1.2. Epidemiology of P. falciparum malaria: geographical distribution, clinical 
features and risk factors 
 
P. falciparum infections occur primarily within the tropics and are limited to sub-
Saharan Africa, South-East Asia, Latin America and the Middle East. In these 
regions however, the transmission intensity is not uniform and these differences 
influence the epidemiology of the disease [10].  Malaria transmission can vary 
greatly between regions and can occur throughout the year (perennial) or be highly 
seasonal with clear high and low transmission seasons occurring within a single 
calendar year. Various combinations or mixtures of these patterns have also been 
reported. The burden of malaria or its transmission intensity can be estimated using 
several indices such as the parasite prevalence in the 2-10 year olds (PfPP2-10) or the 
entomological inoculation rate (EIR), which is considered the gold standard [10]. 
The EIR estimates the number of infectious bites experienced per person per unit 
time. A second and easily obtainable metric is the PfPP2-10, which calculates the 
proportion of 2-10 year olds within a particular region that have detectable 
circulating parasites. Based on this metric, geographical regions can be classified as 
being hypoendemic, mesoendemic, hyperendemic or holoendemic if the PfPP2-10 
was less than 10%, 10-50%, 50-75% or greater than 75% respectively [10]. The 
epidemiology of clinical disease varies considerably between regions with varied 
transmission intensities. 
1.2.1. Clinical features of P. falciparum disease 
 
The clinical progression and outcome of malaria can be influenced by multiple 
factors, including genetic/inheritable traits, naturally acquired immunity, 
environmental factors and variation in parasite virulence [11].  In non-immune 
individuals, infection with P. falciparum is almost always symptomatic even at very 
low parasite densities. Patients often present with intermittent fever and non-specific 
symptoms such as headaches, malaise, abdominal pain, muscle aches and diarrhoea 
[12]. If prompt diagnosis and treatment is not received, the disease can progress to a 
more severe and life-threatening complex syndrome that affects multiple organs. 
The symptoms in these severe cases include impaired consciousness (including 
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unrousable coma), shock, respiratory distress, body convulsions, hypoxia (decreased 
oxygen supply to the tissues), hypovolemia (decreased blood volume circulating in 
the body), hypoglycaemia (low blood glucose levels) and tachypnoea (abnormally 
rapid breathing) [13]. The symptoms in severe cases of malaria in non-immune 
adults and children are similar with the exception that adults are more likely to 
present with jaundice and acute renal or hepatic failure in addition to the symptoms 
listed above [12]. In children, three main syndromes can be observed during the 
course of severe disease that include severe malarial anaemia, respiratory distress 
and cerebral malaria, which share some overlapping symptoms. These syndromes 
are associated with an increased risk of death with an estimated 1%, 15% or 18% of 
children dying if they develop severe anaemia, respiratory distress or cerebral 
malaria respectively [14]. The recommended treatment guidelines for severe malaria 
include either the immediate delivery of intravenous doses of artesunate or 
intramuscular treatment with artemether. After 24 hours, if the patient is able to 
tolerate oral medication, the full course of an Artemisinin-based combination 
therapy (ACT) should be provided [12]. 
1.2.2. Factors that influence the progression of disease 
 
The burden and severity of disease due to malaria is affected by multiple factors that 
can be classified as either being related to the geographical/social setting in which 
transmission occurs or in inherent properties of either the parasite or the host [14]. 
1.2.2.1. Geographical and social related factors 
 
The incidence profiles of severe disease and death due to malaria vary by age 
depending on the transmission intensity [15]. In areas of hypoendemic transmission, 
malaria infection and disease occur at low frequencies and both children and adults 
are at risk of severe complications and death. In contrast, in areas that are classified 
as being hyperendemic or holoendemic for malaria transmission, a distinct age-
pattern is observed with severe clinical disease and death occurring primarily in 
young children while this risk of severe disease and death declines in older children 
and rarely occurs in adults [16].  In addition, the inability to access prompt diagnosis 
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and treatment increases the burden and severity of disease. These can occur due to 
political instability as well as cultural and/or economic reasons in which adequate 
treatment and drugs are either unavailable, inaccessible or cannot be afforded [17].  
1.2.2.2. Host related factors 
 
All non-immune individuals such as travellers of any age are susceptible to the 
severe manifestations of malaria. In endemic regions however, naturally acquired 
immunity (NAI) results in a clear age-dependent susceptibility to disease, although 
the extent and effect of this immunity is influenced by the transmission intensity of 
a given region. Additional host-related factors can also influence the course of 
infection in malaria endemic regions. First, immuno-compromised individuals, such 
as those who have undergone splenectomy [18, 19] or have acquired HIV/AIDS are 
at an increased risk of severe malaria following infection compared to healthy adults 
[20, 21]. Secondly, despite acquiring effective immunity against both severe and 
mild cases of malaria, pregnant women may become infected with P. falciparum 
and experience anaemia despite a low peripheral parasite density, as the majority of 
parasites localise to the placenta (PAM). This is observed particularly during their 
first (primigravidae) and second pregnancies [22]. PAM is associated with increased 
risk of stillbirths, premature delivery, neonatal death and low infant birth weight 
[23]. Lastly, inheritable traits have been identified that are associated with reduced 
susceptibility to either clinical disease, high parasite densities or infections. These 
include genetic mutations that affect the structure, function or quantity of either 
haemoglobin, erythrocyte surface proteins or enzymes [24]. These inheritable traits 
are discussed in more detail in section 1.4. 
1.2.2.3.  Parasite related factors 
 
The severity of disease in children and pregnant women has been associated with 
several parasite related phenotypes. These include the emergence and prevalence of 
circulating drug-resistant parasites within a population, differences in parasite 
multiplication rates, and the ability of parasites to cytoadhere to tissues, organs and 
other cells. In addition, the ability of infected cells to adhere to: a) multiple 
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uninfected erythrocytes, a phenotype referred to as rosetting, b) clumping of 
infected erythrocytes to platelets and c) binding to dendritic cells have been 
associated with disease severity [13, 14, 25, 26]. 
 
Drug-resistant parasites: The spread of chloroquine resistance in the mid 1900s 
resulted in an increase in the mortality and severity of disease due to malaria in sub-
Saharan Africa. Mutations in the chloroquine resistance transporter (PfCRT), 
particularly in position 76 (K76T) alongside several other amino acid mutations 
resulted in resistant strains that spread rapidly throughout Africa and Southeast Asia 
[27]. This prompted a change in treatment guidelines and a renewed search for 
effective anti-malarial drugs. The WHO currently recommends the use of ACTs as 
the first line of treatment of uncomplicated malaria [12]. Unfortunately, resistance 
to artemisinin has also emerged in South-East Asia manifesting itself as delayed 
parasite clearance following ACT therapy [28]. Resistance is associated with 
mutations within a Kelch protein located on chromosome 13 (K13 propeller 
domains)[29]. At the moment, resistance to ACTs in Africa, measured by 
monitoring the rate of parasite clearance, has not been reported [30]. Nevertheless, 
there is urgent need to identify new drug targets before resistance spreads to sub-
Saharan Africa overturning the gains made in reducing disease and death in the last 
one and a half decades. 
 
Adhesion of infected erythrocytes to various tissues, organs or cells: A key feature 
of P. falciparum infection is the ability of the parasite to express its own proteins on 
the surface of infected erythrocytes [14]. These parasite-derived proteins facilitate 
the cytoadherance (binding of infected erythrocytes to endothelial cells) of late-
stage parasites to the brain, heart, liver, lungs, kidney, subcutaneous tissues, blood 
vessels and placenta with dire consequences [25]. Microvasculature obstruction by 
the mass of sequestered infected erythrocytes results in reduced blood flow and 
consequently oxygen, to tissues. In addition, systemic or local production of pro-
inflammatory cytokines due to sequestration contributes to the pathology observed 
in severe malaria [14, 25]. These organs vary in the type and quantity of host 
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receptors that can be bound by parasites. In addition, parasites vary in the receptor 
ligands that they express which influence the specificity and affinity of 
cytoadherance and consequently disease progression.  
 
The protein PfEMP1 is one of the widely studied parasite ligands that mediate this 
cytoadherence [31]. The diverse var gene family, consisting of 60 genes, encodes 
this highly variable protein that consists of an N-terminal segment (NTS), several 
duffy binding like (DBL) and cysteine rich inter-domain regions (CIDR) domains. 
A single infected erythrocyte will express a single var gene. In vitro studies 
demonstrated that in a clonal infection and in the absence of immunity, the majority 
of the infected erythrocytes (approximately 98%) would express a single var gene 
with the remaining infected cells switching to a different member of the gene family 
in the following cycle [32, 33]. However in natural human infections, the number of 
var genes expressed and the rate at which they switch in vivo is likely to depend on 
the level of pre-existing antibody responses as well as the host tissue to which the 
infected erythrocytes cytoadhere to [34]. The specific var gene expressed can 
influence disease outcomes. For example, the parasites responsible for PAM have 
unique cytoadherance properties characterised by low binding to CD36, a host 
receptor in the microvasculature (that is the target for many PfEMP1 proteins), and 
a high binding affinity to CSA, a host receptor in the placental intervillous space. 
These parasites express a unique PfEMP1 protein termed VAR2CSA [35] on the 
surface of infected erythrocytes. Similarly, differences in the ability of infected 
erythrocytes expressing different var genes, to bind to the host receptors ICAM-1 or 
CD36 are thought to be associated with cerebral malaria and other clinical 
phenotypes of severe malaria respectively [25, 36-38]. Specific PfEMP1 subtypes 
have been shown to be associated with severe childhood malaria [36, 39], and these 
were subsequently shown to bind to the previously unknown host receptor called 
endothelial protein C receptor (EPCR) [40]. 
 
Rosetting and platelet-mediated clumping by infected erythrocytes can be observed 
in vitro in parasite isolates obtained from infected individuals. These phenotypes are 
 30 
thought to be associated with parasite virulence and severe malaria [25]. Rosetting 
is thought to occur when PfEMP1 ligands on iRBCs bind to uninfected cells via 
CR1, heparin-sulfate like molecules and the blood group A and B antigens. This 
ability has been shown to be associated with severe malaria in Africa [41-46], and 
the PfEMP1 ligands encoded by group A var genes were shown to mediate this 
adhesion [25]. Platelet-mediated clumping on the other hand, is thought to be 
mediated by an unidentified parasite ligand that interacts with CD36, globular C1q 
receptors and P-selectin on platelets [25]. Platelet clumping has been reported in 
cerebral malaria patients [47] and the phenotype has been associated with severe 
malaria in Kenyan [48], Malawian [49] and Thai [50] children. 
 
Parasite multiplication rates (PMR): Differences in the rate at which parasites 
multiply have been thought to be associated with parasite virulence and the course 
of infection. In Thailand, in vitro PMR was significantly higher in isolates obtained 
from severe cases compared to uncomplicated malaria cases [51]. These differences 
however, have not been observed in isolates from Kenya and Mali [52]. Technical 
differences in the assays did not account for the discrepancy in these two studies as 
data from Thai isolates confirmed the initial findings made in Thailand [52]. The 
differences in transmission intensity and the levels of acquired immunity between 
South-East Asia and sub-Saharan Africa may partly explain the differences 
observed. South-East Asia is classified as a region of hypoendemic (low) 
transmission levels with low levels of acquired immunity within the population. In 
contrast, transmission levels in sSA vary ranging from hypoendemic to holoendemic 
malaria transmission with higher levels of pre-existing immunity present in 
individuals living in the regions of higher transmission intensity. Parasites adapted 
to grow in individuals lacking immunity reach high parasite densities quickly 
resulting in a high PMR. In contrast, parasites adapted to grow in semi-immune 
individuals may have evolved different mechanisms of virulence that are aimed at 
avoiding the host’s immune system to facilitate onward transmission and the fitness 
cost of this evolution may be observed as a reduced PMR. 
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Despite some understanding of the different factors that influence the course of 
infection leading to death, the exact mechanisms and sequence of events that lead to 
severe malaria are unknown. Nevertheless, there is an urgent need for effective 
control measures to prevent both infection and disease. The benefits of effective 
malaria control include the prevention of the severe manifestations of the disease 
and the long-term neurological sequelae [53], as well as having an impact on 
childhood morbidity and mortality due to other diseases such as bacterial infections 
whose prevalence has been directly linked to malaria [54]. 
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1.3. Control strategies for P. falciparum malaria 
 
Huge gains have been made since 2000 in the control of P. falciparum malaria, as 
shown by the reduction in deaths and clinical disease. These gains can be partly 
attributed to multiple control strategies in malaria-endemic regions [1, 10]. These 
include vector control measures, prophylaxis treatment in highly susceptible 
individuals and improvements in the rapid diagnosis and treatment of malaria. These 
are discussed briefly below. 
1.3.1. Vector control 
 
Vector control measures are aimed at reducing the interaction between the mosquito 
vector and the human host. These measures include the use of insecticide treated 
nets (ITN), indoor residual spraying (IRS) and the management of larval breeding 
grounds [1]. The WHO has recommended that all children 5 years and under as well 
as pregnant women should sleep under an ITN. The use of ITNs in children has 
been shown to result in a marked reduction in the incidence and mortality due to 
malaria in endemic regions and is estimated to account for 50% of the fall in 
parasite prevalence in 2-10 year old children in sub-Saharan Africa (sSA) [55]. 
However, these gains are at risk of reverting following reports of mosquito vectors 
developing resistance to the four classes of insecticides used for ITN and IRS.  
Single-nucleotide substitutions in the kdr gene in Anopheles gambiae are associated 
with resistance to pyrethroids, the insecticides exclusively used in ITNs. In addition, 
cross-resistance, where the acquisition of resistance to one drug results in resistance 
to other insecticides with similar modes of action has been reported causing concern 
for future vector control measures[10]. Despite these worrying trends, ITN use has 
still been reported to be effective even in regions reporting high levels of resistance 
to pyrethroids [56]. 
1.3.2. Chemoprevention 
 
Intermittent preventive treatment (IPT) in infants (IPTi), pregnant women (IPTp) 
and seasonal malaria chemoprevention (SMC) in children aged 3-59 months are 
control measures aimed at preventing clinical episodes of malaria in highly 
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susceptible populations. For the widely adopted IPTp strategy, two doses of 
Sulphadoxine-pyrimethamine (SP) were recommended for all pregnant women in 
their second trimester and were associated with a reduction in placental malaria, 
anaemia, neonatal mortality and low birth weight[57, 58]. IPTi using SP has been 
recommended for use in areas of high transmission intensity provided SP resistance 
has not compromised its efficacy.  Its use has been associated with over 30% 
protective efficacy against clinical episodes of malaria and hospital admissions 
associated with malaria parasitaemia [59]. In areas with highly seasonal malaria, 
SMC treatment with amodiaquine and SP has been associated with up to 80% 
reduction in clinical malaria and anaemia [60, 61]. Despite the clear potential gains 
and their recommendation by WHO, chemoprevention, particularly IPTi and SMC 
have not been fully adopted in endemic regions. While IPTp is in use in over 20 
countries in sSA, only 31% of eligible pregnant women received the full dose in 
2015 [1]. One concern over the widespread implementation of either of the above 
prophylaxis measures in endemic regions is the emergence and spread of drug-
resistant parasites that might make the control measure obsolete [62]. It is clear that 
the commitment by governments and policy makers to ensure the implementation of 
these policies in endemic region needs to be scaled up. 
1.3.3. Rapid diagnosis and treatment  
 
The prompt detection and treatment of malaria could facilitate the prevention of 
severe malaria and death in patients and reduce the time in which parasites can be 
transmitted to susceptible hosts. The WHO has recommended the confirmation of 
every suspected malaria case using either microscopy or a rapid diagnostic test 
(RDT). These RDTs offer the ability to provide rapid diagnosis within the 
community particularly where laboratories equipped with microscopes, electricity 
and skilled personnel are lacking. The most commonly used RDTs detect a single 
circulating parasite protein, HRP2. Despite their utility, there are now reports of 
circulating parasites that lack the HRP2/3 gene in Southeast Asia and East and 
Central Africa [63-67] that could potentially affect the sensitivity of these RDTs. 
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New tests that include the detection of non-HRP2 antigens are available to confirm 
false-negative RDT results and to ensure that no cases are overlooked [68]. 
 
ACTs are the current recommended first-line of treatment for uncomplicated 
malaria [12]. Resistance to artemisinin, one of the component drug in ACTs was 
first reported in South-East Asia where delayed parasite clearance was observed as 
discussed in section 1.2.2.3. Despite these findings, ACTs remained partially 
effective due to the function of the partner drug. However, high failure rates of 
clinical treatment in Cambodia have been reported against four different ACT 
regimens [69], representing a major challenge for control and elimination.  
1.3.4. Vaccines 
 
Vaccines have long been recognised to be one of the major contributors to public 
health due to their effect in reducing the morbidity and mortality caused by 
infectious diseases. Vaccinations function by priming the host immune response to 
make an adequate protective response on exposure to pathogens at a later date [70]. 
So far, a highly effective malaria vaccine has remained elusive. RTS, S/AS01 
(marketed under the trade name Mosquirix) is the only malaria vaccine that has 
been evaluated in phase III studies, resulting in an overall efficacy of only 29% and 
39% against severe malaria and clinical disease, respectively [71]. This efficacy 
however, waned over time to less than 0% over a 7-year follow-up period [72]. This 
suggested that over time, vaccinated individuals were at an increased risk of a 
clinical episode of malaria compared to non-vaccinated individuals probably due to 
the inefficient or inadequate acquisition of NAI in vaccinated individuals due to less 
exposure to the parasites. Although not highly efficacious, the RTS’S vaccine 
received a positive scientific opinion from the European Medicines Agency (EMA) 
[73, 74] and WHO has recommended pilot studies to commence in 3-5 countries in 
sSA to test the feasibility, safety and impact on mortality of the vaccine alongside 
control measures already in use. New effective drugs, vaccines and insecticides are 
urgently needed to achieve sustained P. falciparum malaria control and ultimately 
elimination.  
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1.4. Immunity to P. falciparum malaria 
 
Despite living in malaria-endemic regions, the susceptibility of individuals to both 
clinical disease and parasite infections vary. Epidemiological observations suggest 
that naturally acquired immunity to disease occurs with continuous exposure to 
malaria infections. Immunity to severe cases of non-cerebral malaria is thought to 
be acquired within the first two years of life [75]. Thereafter, children less than five 
years of age remain susceptible to clinical episodes of malaria, including cerebral 
malaria, but the incidence of these declines with age [76]. Older individuals seldom 
experience clinical episodes but remain susceptible to parasite infection. Despite 
these observations, differential susceptibility has further been observed even within 
highly susceptible age groups or populations that have been attributed to inherited 
traits such as Duffy-negativity, the sickle cell trait or G6PD-deficiency [24]. 
Genetically based and naturally acquired immunity to malaria are discussed in detail 
in section 1.4.1 and 1.4.2 respectively. 
 
1.4.1. Genetically based resistance to malaria 
 
Humans and Plasmodium have co-evolved for hundreds of years, with P. 
falciparum DNA being detected in Egyptian mummies that were dated to between 
500-2500BC (approximately 4000 years ago) [77]. This has resulted in the selection 
and/or fixation of inherited traits within the human population that confer protection 
against malaria. These genetic traits are highly prevalent in malaria endemic regions 
and include haemoglobinopathies, erythrocyte cell surface polymorphisms and 
immunogenic variants.  
1.4.1.1. Haemoglobinopathies 
 
Genetic mutations or variants that result in an altered production or structure of 
haemoglobin have been shown to confer resistance to malaria [24, 78, 79]. 
Haemoglobin consists of 2- and a 2- globin chains held as a tetramer and is found 
in the cytoplasm of erythrocytes. It is responsible for transport and distribution of 
oxygen within tissues. Haemoglobin disorders associated with protection from 
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malaria include: i) thalassemia (two types; -thalassemia or -thalassemia), ii) 
sickle-cell trait (HbAS), iii) haemoglobin C (HbC) and iv) haemoglobin E (HbE). 
Although not a genetic disorder, the persistence of foetal haemoglobin (HbF) in 
infants has been thought to contribute to the protection against P. falciparum 
infection and disease observed in the first 6 months of life. While the exact 
mechanisms of protection are unclear, it is though that the growth of parasites in 
HbF-containing erythrocytes compared to those with HbA is reduced, slowed or 
retarded [80-82].  
 
-Thalassemia is caused by a deletion of either one or both copies of the two -
globin genes on chromosome 16 resulting in a decreased synthesis of the 
corresponding protein. The loss of one gene resulting in either the heterozygous -
thalassemia (-/) or homozygotes (-/-) has been associated with protection 
from severe malaria compared to normal -globin phenotype (/) [83, 84]. 
Similarly -thalassemia is caused by mutations on the -globin gene on 
chromosome 11 resulting in decreased synthesis of the corresponding protein. These 
traits occur in Africa and Asia as shown in Figure 1.2, with a prevalence of up to 
48% and 17% for the -/ and -/- genotype respectively, reported in Kenyan 
children [83]. The mechanisms by which these traits confer protection is not fully 
understood with in vitro observations suggesting that P. falciparum infected - and 
-thalassemic erythrocytes bind higher levels of antibodies and were phagocytosed 
to a higher level when compared to normal erythrocytes [85-87]. In addition, -
thalassemia has been associated with complement receptor 1 (CR1) deficiency, a 
receptor on erythrocytes involved in merozoite invasion [88] and associated with 
forming rosettes, a feature associated with severe malaria [89]. 
 
The sickle cell trait is caused by mutations in the -globin gene that result in a 
change of the amino acid glutamic acid on position 6 to valine. The change results 
in structurally different haemoglobin molecules termed HbS, which polymerize and 
alter the shape of the erythrocyte forming a sickle shape. Homozygous forms of the 
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mutation, HbSS, results in sickle-cell disease and is fatal, while the heterozygous 
form (HbAS) is associated with protection from severe malaria [90]. The prevalence 
of the HbAS trait ranges from 10 to 40% across equatorial Africa and decreases to 
less than 2% in North Africa and South Africa where malaria transmission does not 
occur [91]. The proposed mechanisms by which sickle cell trait is protective include 
inhibition of parasite growth in HbAS erythrocytes, increased phagocytosis of sickle 
shaped parasite infected erythrocytes and reduced cytoadherance due to a reduction 
in the surface expression of the PfEMP-1 protein [24]. 
 
Additional variations in haemoglobin include HbC, caused by mutations on the -
globin gene that result in a change of the glutamic acid on position 6 to lysine, and 
HbE produced when the glutamic acid on position 26 is also replaced with a lysine 
residue. HbC is geographically restricted to West Africa while HbE is occurs in 
South-East Asia (Figure 1.2). The prevalence of HbC is approximately 16% in West 
Africa and has been associated with fewer episodes of malaria and lower parasite 
burden in Malian children [92] although the mechanism by which the protection is 
conferred remains unknown. The prevalence of the HbE trait ranges from 5-10% in 
South-East Asia however currently, there is no evidence of protection conferred 
against malaria [93]. 
1.4.1.2.  Polymorphisms affecting erythrocyte surface proteins 
 
Plasmodium spp undergo an essential phase of their life cycle within erythrocytes 
and genetic mutations that have altered the expression of erythrocyte membrane 
proteins have been associated with resistance to malaria infection. These mutations 
include Duffy negativity, Gerbich negativity, South-East Asian Ovalocytosis (SAO) 
and defects in CR1 expression. 
 
Duffy-negativity (Fy(a-b-)) is a phenotype that describes the lack of expression of 
the erythrocyte surface protein Duffy antigen receptor for chemokines (DARC) that 
results from a point mutation in the gene’s promoter region, which is 33 bases 
upstream from the initiation codon. The DARC was thought to be the obligatory 
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receptor for P. vivax Duffy binding protein (DBP) with its loss halting P. vivax 
invasion of erythrocytes. Duffy negativity has reached near fixation (frequency 
>98%) in West and Central Africa and also occurs in Papua New Guinea. This 
explains the lack of P. vivax transmission in West Africa. Individuals who are 
heterozygous have approximately 50% reduced expression of DARC on erythrocyte 
surfaces [94], which has been associated with reduced P. vivax infection of 
erythrocytes [95]. However, transmission of P. vivax to Duffy-negative individuals 
has been reported in Kenya, Ethiopia, Madagascar, the Brazilian Amazon, 
Cameroon and Angola suggesting that the parasite has evolved an alternative 
pathway for invasion [96, 97]. In line with this, a second invasion ligand has been 
recently identified in P. vivax called erythrocyte binding protein 2 (EBP2) that 
although shows a strong preference for Duffy-positive reticulocytes, minimal 
binding to Duffy-negative reticulocytes was observed [98]. It has yet to be 
established whether this weak interaction can facilitate invasion in Duffy-negative 
individuals.   
 
Figure 1.2: The geographical distribution of inheritable traits that influence malaria susceptibility. The 
map of the geographical distribution of hemoglobinopathies, erythrocyte polymorphisms and enzyme 
deficiencies that have been associated with protection from malaria. Figure is adapted from Lopez et al 
2010[24]. 
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Gerbich-negative blood group (Ge-), which occurs due to a deletion of exon 3 in the 
gene that encodes the glycophorin C (GYPCex3) surface protein, occurs at a high 
frequency of 46% in Papua New Guinea [99]. In vitro studies have shown that the 
mutation confers protection by preventing erythrocyte invasion by parasites using 
the EBA-140 invasion ligand [99]. However prospective studies have not yet 
demonstrated a protective effect of Gerbich negativity on malaria [100, 101]. A 
second geographically restricted polymorphism is ovalocytosis that is caused by the 
deletion of 27 base pairs in the gene encoding the erythrocyte membrane protein 
Band 3 on chromosome 17. Only the heterozygous form has been documented. It is 
prevalent in South-East Asia, causes no obvious clinical symptoms and is associated 
with protection from cerebral malaria [102]. Studies in vitro have suggested that the 
rigid ovalocytic erythrocytes are resistant to invasion by Plasmodium spp [103, 
104]. 
 
Lastly, the level of surface expression of the CR1 protein on erythrocytes has been 
proposed to play a role in resistance to clinical malaria. The 190-280 KDa surface 
protein is the receptor for the parasite ligand RH4 on merozoites [88] and is also 
thought to mediate rosetting, a phenomenon associated with severe malaria in which 
late-stage infected erythrocytes bind to multiple uninfected red blood cells in vitro 
[105, 106]. The number of CR1 molecules per erythrocyte varies from between 50-
1500, with marked reductions in rosetting observed in erythrocytes with less than 
100 CR1 molecules. Reduced numbers of CR1 on erythrocytes is common in 
malaria-endemic regions with over 80% of Papua New Guinean population having 
less than 200 CR1 molecules per erythrocyte [107, 108]. The level of CR1 
expression is influenced by both genetic factors and age, as was demonstrated 
recently in Kenyan children [89]. CR1 levels are genetically influenced by various 
mutations in the Knops blood group antigens, while the variations in the size of the 
antigen occur due to deletions or duplications in the long homology repeat units of 
the gene during crossover [109]. Low CR1 expression has been associated with 
protection from severe malaria in Papua New Guinea [107] and India [108]. 
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A recent large genome-wide study involving over 11,000 African children identified 
a new cluster of genes that were associated with 33% protection from severe malaria 
[110]. Interestingly, all mutations identified to be protective were either next to or 
were themselves genes that play a key role in erythrocytes, such as those encoding 
the glycophorin proteins on erythrocyte surface that are known host receptors for 
parasite ligands. 
1.4.1.3. Polymorphisms affecting enzyme activity  
 
Mutations that have altered the function of several enzymes within red blood cells 
have also been associated with protection from malaria [24]. The reduced enzyme 
activity of the glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase 
(PK) has been associated with resistance to malaria. The G6PD enzyme catalyses 
the conversion of NADP to its reduced form NADPH, which in turn protects 
erythrocytes from oxidative damage. Normal G6PD activity is reduced in infected 
erythrocytes compared to uninfected ones [111]. Many different mutations have 
been described in multiple populations that result in reduced activity resulting in 
G6PD deficiency. In vitro studies have suggested that infected G6PD-deficient 
erythrocytes are more susceptible to phagocytosis particularly at the ring stages, 
which may reflect the protective associations observed in endemic regions [112]. 
The PK enzyme catalyses an irreversible reaction in the glycolysis cycle required 
for ATP synthesis in cells including erythrocytes. PK-deficient human erythrocytes 
have demonstrated resistance to in vitro infection with P. falciparum parasites and 
similar to observations with G6PD-deficient infected erythrocytes, increased 
phagocytosis has been observed in ring-infected PK-deficient erythrocytes [113]. 
 
1.4.2. Innate immunity to malaria 
 
Insights into the role of innate immunity in malaria has been obtained from 
observations made in rodent malaria infections, in vivo evaluation of experimental 
P. falciparum infections in naïve individuals and in vitro evaluation of the effect of 
co-incubating parasitized erythrocytes with PBMCs from naïve donors. These innate 
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responses are thought to play a role in controlling the initial wave of parasitaemia 
prior to the development of adaptive immune responses [114]. In addition, immune 
cells that form part of the innate immune response act as bridge linking the innate 
response to adaptive responses. For instance, antigen-presenting cells such as 
dendritic cells are required to activate CD4+ T-cells that subsequently produce IFN 
as well as mediate antibody class switching to form the protective cytophillic 
antibodies observed in adaptive immune responses. The arms of the innate immune 
system that have been studied in the context of P. falciparum malaria include 
macrophages, NKT cells,  T-cells, dendritic cells and natural killer cells [114]. 
 
These innate immune cells have pattern recognition receptors (PRRs) that recognise 
pathogen-associated molecular patterns (PAMPs) on microbes resulting in 
activation of several downstream pathways that result in pathogen clearance [115]. 
P. falciparum PAMPs that have been identified include GPI anchors, haemozoin 
and immunostimulatory nucleic acid motifs. These molecules have been shown to 
interact with PRRs such as Toll-like receptors (TLRs) resulting in the induction of 
pro-inflammatory responses. For example, monocytes obtained from naïve 
individuals have been shown to be activated by haemozoin resulting in the 
production of TNF and IL-1 [116]. These pro-inflammatory responses such as 
IFN function by activating effector function in innate cells. For example, 
monocytes have been shown to phagocytose infected erythrocytes in the absence of 
malaria specific antibodies. Scavenger receptors on monocytes including CD36 are 
thought to mediate part of this antibody-independent phagocytosis [117].  
 
Unfortunately, the excessive induction of pro-inflammatory responses characterised 
by cytokines storms observed during acute malaria episodes partly contribute to the 
pathophysiological events observed in P. falciparum malaria. For examples, this 
cytokine storm is thought to suppress erythropoiesis contributing to the severe 
anaemia symptoms observed in P. falciparum infections [118]. 
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1.4.3. Naturally acquired immunity (NAI) to malaria 
 
Historical observations and epidemiological studies in malaria endemic regions 
suggest that immunity to malaria is acquired following continuous exposure to the 
parasite. This hypothesis was based on the observations of the differences in the 
susceptibility to clinical episodes in adult travellers from non-endemic regions (non-
exposed) and the adults resident in endemic regions [16]. Thereafter, 
epidemiological surveys in endemic regions demonstrated differences in the 
occurrence and frequency of disease as well as parasite densities between different 
age groups within the same geographical location and between different regions of 
endemicity [11]. In areas of high endemicity, a distinct age-dependent pattern in the 
frequency of clinical disease and in the density of parasites following infection was 
evident. Clinical disease rarely occurred in older children and adults and parasite 
densities similarly declined with age [119]. In contrast to this, the frequency of 
clinical episodes is uniformly distributed between age groups with older children 
and adults remaining susceptible to clinical episodes of malaria and high parasite 
densities in areas of low transmission intensity such as South-East Asia. NAI is 
generally thought to be: i) acquired at a rate that varies depending on the 
transmission intensity, ii) Plasmodium species specific, iii) achieved slowly and iv) 
requires continuous exposure (it is lost to some degree upon the cessation of 
exposure). 
 
Firstly, as described in section 1.2.2.1, transmission intensity which determines the 
degree of exposure experienced by each individual, has an important influence on 
the rate at which immunity is acquired [15]. In hypoendemic regions, both adults 
and children remain susceptible to clinical malaria in contrast to the observations 
made in hyper- and holoendemic regions. In holoendemic regions, young children 
and infants (less than 2 years) are susceptible to high parasite densities and severe 
clinical malaria. They appear to acquire immunity to severe malaria and its 
complications following very few infections [75]. Surprisingly, immunity to 
cerebral malaria seems to be acquired later than resistance to other severe disease 
syndromes, as slightly older children (2-4 years) remain susceptible to CM [15]. In 
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addition, in this young age group (under 5 years), high parasite densities do not 
always lead to clinical manifestations, and the specific mechanisms at play that 
allow tolerance to high parasite densities are not fully understood. Nevertheless, 
with exposure, older children become less susceptible to mild malaria and high 
parasite densities and adults rarely show any symptoms. Secondly, studies in the 
1920s using “malaria therapy” as treatment for neurosyphillis as well as 
epidemiological observations in endemic regions where both P. falciparum and P. 
vivax transmission occurred, established that the immunity acquired was species 
specific [120, 121]. NAI developed against one species was ineffective against the 
other.  
 
Thirdly, antigenic variation that was first demonstrated in 1965 in P. knowlesi [122], 
may partly explain the slow acquisition of NAI to malaria. In this study, a clonal 
infection resulted in waves of parasites that were antigenically distinct resulting in 
the generation of variant specific antibody responses [122]. This provided a possible 
explanation for the slow acquisition of immunity observed in humans. In addition, 
random mutations and recombination over the asexual and sexual stage of the life 
cycle generates diversity in parasites. As a result, it is thought that repeated 
infections with diverse parasites were required in order to accumulate a broad range 
of isolate and variant specific antibody responses that eventually provided 
protection under natural conditions. Lastly, this immunity appears to be lost to some 
degree when exposure ceases. For example, adults who have emigrated from 
endemic regions and settled in non-endemic countries seemed to become susceptible 
to clinical disease on travelling back to endemic regions. However, when compared 
to naïve adults, these adults still experienced less severe disease and symptoms 
suggesting that the acquired immunity is not lost completely [123-126]. Despite the 
lack of clear understanding of the acquisition of immunity, identifying the targets of 
NAI, the immunological mechanisms by which it is achieved and maintained and 
the potential immune evasion strategies employed by the parasite remains central to 
vaccine development. 
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1.5. Immune effector mechanisms in NAI 
 
The parasite has a complex life cycle in which some phases are extracellular while 
others are intracellular and localize to different regions of the host including the 
skin, liver and blood. As a result, different immune mechanisms are thought to be 
important and include both the innate and adaptive immune system. One of the key 
mediators of NAI are antibodies that can be targeted at either the pre-erythrocytic or 
erythrocytic stages of the life cycle. The importance of antibodies was first 
demonstrated in seminal studies in which the passive transfer of immunoglobulins 
from adults resident in endemic regions was successfully used to treat children 
hospitalised with malaria [127-129], including those who lived in a region that was 
geographically distinct from the source of the IgG [129, 130]. This treatment 
resulted in a rapid drop in the parasite densities and a resolution of fever [127]. 
Identifying the targets of these protective immunoglobulins has been a high priority 
for the research community. Targets identified to date include proteins on the motile 
sporozoites prior to hepatocyte invasion, merozoites prior to erythrocyte invasion, 
parasite-derived proteins expressed on the surface of iRBCs and circulating 
gametocytes.  
1.5.1. Pre-erythrocytic immunity 
 
Both antibodies and T-cell immunity are induced by the pre-erythrocytic stages of 
the parasite[131]. Antibodies can be involved in blocking a) sporozoite motility 
from the dermis to the liver[132], b) invasion of hepatocytes by blocking receptor-
ligand interactions[133] and c) interaction with monocytes and macrophages leading 
to the phagocytosis of sporozoites (Figure 1.3A) [134]. Once in the liver, infected 
hepatocytes can present parasite antigens on their MHC class I and II surface 
molecules.  These will then induce CD8+ and CD4+ T-cell responses respectively 
(Figure 1.3B) [135]. 
1.5.2. Erythrocytic immunity  
 
Antibodies are thought to be the main mediators of immunity during the asexual 
stages of the life cycle [136]. Erythrocytes lack MHC class I and II molecules and 
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are therefore unable to induce T-cell responses that would directly eliminate iRBCs. 
Antibodies targeted against the merozoite can function in multiple ways (Figure 
1.3C) that include: i) prevention of invasion and growth of the parasite in 
erythrocytes, ii) prevention of egress from schizonts [137], iii) interaction with 
soluble complement factors resulting in merozoite lysis [138] and iv) interaction 
with leucocytes such as monocytes/macrophages [139] and neutrophils [140, 141] 
leading to direct phagocytosis or release of toxic substances such as reactive oxygen 
species that result in parasite death (Figure 1.3C). Antibodies targeted at parasite-
derived proteins on infected erythrocytes function by preventing cytoadherance, 
interacting with macrophages leading to phagocytosis and agglutinating iRBC that 
can be cleared by the spleen (Figure 1.3D) [34, 142]. Although CD8+ T-cells are not 
involved during the erythrocytic stages, antigen-specific CD4+ T helper cells are 
required for optimal antibody production by influencing the maturation and 
multiplication of antigen specific B-cells and thus the isotype of IgG produced[143, 
144]. As a result, they can potentially influence the effectiveness of antibodies 
particularly those that interact with leucocytes via their cytophillic 
immunoglobulins. 
1.5.3. Immunity against sexual stages  
 
Gametocytes are also targets of natural-acquired immunoglobulins that are effective 
within the human and vector host. Gametocyte specific antibodies have been shown 
to interact with complement leading to gametocyte lysis within the human host 
(Figure 1.3E) [145]. In the mosquito vector, antibodies may function by a) 
prevention of gamete fusion and consequently zygote formation, b) induction of 
complement-lysis of gametes and ookinetes and c) prevention of ookinete motility, 
penetration of the midgut wall and formation of oocysts.  
 
The majority of the proposed effector mechanisms described above have been 
obtained from studies using rodent malaria infections. Prospective cohort studies in 
humans have been used to identify targets of antibodies and immune effector 
mechanisms that are associated with protection from clinical disease [136]. For 
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example, antigens on the surface of or secreted by merozoites elicit antibody 
responses that were found to be associated with protection from clinical disease and 
high parasite densities in Kenyan [146] and Papua New Guinean [147] children. 
Similarly, antibody mediated effector mechanisms such as the phagocytosis of 
sporozoites [134], infected red blood cells[148] and merozoites [139, 149], 
antibody-mediated respiratory burst (ADRB) [140], antibody-dependent cellular 
inhibition (ADCI) [150] and antibody-dependent recruitment of complement  (C1q-
fixing) [138, 145] have been described in naturally exposed individuals.  These 
effector mechanisms have each been shown to be associated with protective 
immunity. The specific parasite targets that elicit protective responses are the 
subjects of on going research. Additional insights into the targets and effector 
functions that are important can now be obtained from experimental human malaria 
challenge studies or naturally exposed populations [151, 152]. 
Figure 1.3: Adaptive immune effector mechanisms in P. falciparum malaria.  An illustration of the adaptive 
immune responses (antibodies and T-cells responses) targeted at the motile sporozoite (A), infected hepatocyte 
(B), free merozoites (C), infected red blood cells (D) and gametocytes (E).  
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1.6. Immune evasion mechanisms 
 
Despite the multiple immune-effector mechanisms elicited during natural infections, 
the parasite has developed elaborate evasion mechanisms that result in the 
development of clinical symptoms and the establishment of chronic infections. 
These mechanisms include the evasion of protective T-cell and antibody responses, 
avoidance of complement lysis, escape from clearance by the spleen and the 
occupation of host niches that may be protected from immune responses [153, 154].  
1.6.1. Redundancy in erythrocyte invasion pathways 
 
Invasion of erythrocytes by merozoites is a highly coordinated process that involves 
multiple proteins on the surface of the merozoite and secreted by merozoite 
organelles namely micronemes, rhoptries and dense granules. In rodent malaria, 
studies demonstrated that each merozoite derived from a single iRBC could express 
a different invasion ligand resulting in multiple erythrocyte invasion pathways 
(Figure 1.4A) [155]. In P. falciparum, two gene families important in this regard 
namely the reticulocyte-binding homologue  (RH) and the erythrocyte-binding 
homologue (EBL) families encode a total of 12 proteins as shown in Table 1.1. Two 
of these are pseudogenes, meaning that there are at least ten ligand/receptor 
combinations that can theoretically be used for invasion. Targeting these parasite 
invasion ligands has been shown to inhibit invasion in vitro in some strains, but 
genetic studies have shown that many of the ligands are redundant. This presumably 
facilitates the escape from pre-existing antibody responses in vivo [156]. To add to 
this complexity, some of these targets such as EBA-175 are polymorphic, eliciting 
strain specific responses. 
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Table 1.1: Table shows the P. falciparum invasion ligands and their host receptors  
Parasite ligand Host Receptor Notes 
Reticulocyte-binding homologue (Rh) family 
RH1 Unknown receptor Redundant 
RH2a Unknown receptor Redundant 
RH2b Unknown receptor Redundant 
RH3 - Pseudogene 
RH4 Complement receptor 1[88]  
RH5 Basigin [157] Essential pathway 
Erythrocyte-binding homologue (EBL) family 
EBA140 (BAEBL) Glycophorin C [158] Redundant 
EBA165 - Pseudogene 
EBA175 Glycophorin A [159] Redundant 
EBA181 (JESEBL) Unknown receptor Redundant 
MAEBL Unknown receptor Possibly involved in 
sporozoite invasion 
EBL1 Glycophorin B [160] Pseudogene in some 
strains 
 
1.6.2. Antigenic polymorphism  
 
Genetic polymorphisms at specific gene loci result in antigenically distinct variants 
of the protein in different parasite strains or clones. This type of diversity has had an 
influence on both naturally acquired and vaccine induced immunity. Strain-specific 
immunity was first observed in the “malaria therapy” studies in which immunity 
was not always effective against heterologous challenge using different strains. 
Random genetic mutations can be generated in the parasite genome over every 
asexual mitotic division. Further diversity can be generated during the sexual 
reproduction within the mosquito where the two haploid gametocytes will result in 
four haploid sporozoite progeny [161]. As a result, for some antigens, many 
different haplotypes have been observed (Figure 1.4C). In some cases, these 
different haplotypes are able to abolish recognition by antibody responses leading to 
the selection of these parasites within the population. Antibody responses to specific 
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antigens have been grouped according the strain specific responses they elicit 
(serogroups). For instance, the merozoite surface protein 2 (MSP2) is largely 
divided into 2 serogroups namely group A (3D7-like) and group B (K1-like) whose 
amino acids can differ by up to 36% between serogroups [162]. Allele-specific 
naturally acquired antibody responses have also been reported to merozoite antigens 
such as AMA1 [163, 164], MSP-1 [165, 166], -2 [167-169] and -3 [170] in many 
populations including Kenya, Gambia, Mali and Papua New Guinea. These strain-
specific responses are also induced following vaccination and are thought to have 
contributed to the low vaccine efficacy reported for the RTS’S [171], AMA1 [172] 
and MSP-2 [173] vaccines. In addition, some P. falciparum proteins contain blocks 
of highly repetitive protein sequences that can be present in several proteins. The 
number of the repeats present within an antigen confers a second source of 
polymorphism and is often highly immunogenic as illustrated with the 
circumsporozoite protein [174]. These highly immunogenic regions may act as a 
‘smoke screen’ by diverting antibody responses from targeting sections of a protein 
that would elicit protective responses. Proteins with highly repetitive sequences can 
also stimulate B cells independently of T-cell help resulting in limited B-cell 
memory against these antigens [175]. 
1.6.3. Antigenic variation 
 
Antigenic variation was first demonstrated in P. knowlesi chronic infections [122] 
where they showed that subsequent waves of infection by the same parasite were 
antigenically distinct at the late stages of the erythrocytic life cycle. In P. 
falciparum, antigenic variation refers to changes in the antigenic phenotype that 
occurs due to the regulated expression of members of a gene family in a clonal 
infection, during the natural course of an infection. Since then, the large and 
extremely diverse var gene family has been described that encodes the PfEMP1 
protein implicated in antigenic variation [34, 176]. Additional gene families 
implicated encode the RIFINS, STEVORS, SURFINS and PfMC-2TM proteins. 
These proteins on the surface of iRBCs are collectively termed as variant surface 
antigens (VSAs) and are targets of NAI eliciting variant-specific antibody 
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responses. The P. falciparum var gene family contains over 60 genes distributed 
across the 14 chromosomes whose expression is tightly regulated. Only one 
PfEMP1 type is expressed on a single iRBC and this can change in the following 
cycle creating a variant that is antigenically different and thus evade pre-existing 
antibody responses (Figure 1.4B). This type of antigenic escape coupled to antigenic 
polymorphisms within these 60 genes makes PfEMP1 a highly diverse protein that 
induces variant specific responses. In addition, PfEMP1 also contributes to parasite 
evasion through other mechanisms such as cytoadherance which is thought to 
facilitate avoidance of splenic clearance of iRBCs [34]. 
1.6.4. Occupation of host niches protected from immune responses 
 
Parasite development within various cells in the human host has in itself provided 
an immune evasion mechanism. For example, liver schizonts release merozoite into 
vesicles called merosomes whose membranes are derived from the host cell. These 
merosomes are released to the circulatory system and parasite specific proteins are 
shielded temporarily from antibody effector mechanisms. Development within 
erythrocytes is another example that affords the parasite protection from both T-cell 
immunity and complement-mediated lysis. Erythrocyte surface proteins such as 
CD59, CD55 (DAF), CD35 (CR1) and CD46 (MCP) are complement regulatory 
proteins that prevent the formation of the membrane attack complex and 
consequently lysis of red blood cell [177, 178]. 
1.6.5. Evasion of the complement system  
 
Recently, specific surface proteins Pf92 and PfGAP50 on merozoites and gametes, 
respectively, were shown to bind to a soluble complement regulatory factor called 
factor H [179, 180].  Recruitment of factor H prevents activation of the complement 
pathway protecting the parasite from lysis (Figure 1.4D). 
1.6.6. Epitope masking 
 
This is defined as the ability of non-parasite specific antibody responses to inhibit 
the binding of parasite specific antibodies to their epitopes. Recently, non-specific 
IgM have been shown to bind to PfEMP1 variants such as VAR2CSA and appears 
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to protect iRBCs from IgG mediated phagocytosis[181]. Similarly, IgM binding to 
merozoite surface protein DBLMSP1 and 2 is thought to mask IgG binding. The 
consequence of this inhibition has not been fully established[182]. 
 
 
Figure 1.4: Illustration of immune evasion mechanisms employed by P. falciparum blood stages. A) 
Redundancy in erythrocyte invasion pathway facilitated by merozoites expressing alternative invasion ligands 
(represented as merozoites with apical ends of different colours), B) Antigenic variation in which the expression 
of the PfEMP1 on the surface of infected erythrocytes switches within a clonal infection resulting in 
antigenically different late stages in the subsequent cycle (represented as infected erythrocytes with variant 
PfEMP1 in black and red), C) Antigenic polymorphisms at a single locus resulting in the possibility of parasites 
that are diverse at this particular loci (represented as merozoites expressing different alleles of the same surface 
protein (blue and red merozoites) and D) evasion of the complement system by binding soluble regulatory 
protein factor H (purple molecule) 
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1.7. P. falciparum vaccine candidates in clinical trials  
 
Effective vaccines are considered the most powerful tool within the public health 
sector for the prevention or the control of an infectious disease for the following 
reasons [70]: i) they function by eliciting a protective immune response which 
provides an individual with immunity against disease following subsequent natural 
exposure to the pathogen, ii) in addition to resulting in a decrease in morbidity and 
mortality, vaccines can circumvent the economic and social burden due to 
hospitalization that can have an influence on the economic growth and productivity 
of an afflicted population and iii) they reduce the reliance on pharmacological drugs 
and/or pesticides (in vector-borne infectious diseases), which run the risk of 
acquiring resistance that would make them obsolete. While resistance to efficacious 
vaccines has not been reported [183], if the coverage of a vaccine against 
pathogenic strains is limited, non-vaccine strains can become prominent as has been 
observed with  the PCV-7 vaccine [184] against S. pneumoniae.  
 
The demonstration of both acquired and vaccine induced immunity to P. falciparum 
malaria has provided a strong rationale for vaccine development for malaria. Over 
50 clinical trials have been conducted to evaluate vaccine candidates that have 
included whole parasite vaccines, sub-unit vaccines and combination of antigens in 
multi-subunit formulations. These have been derived from all three stages of the life 
cycle consisting of pre-erythrocytic, erythrocytic and transmission blocking 
candidates. There are strengths and weaknesses to targeting each stage. A 
completely effective pre-erythrocytic vaccine would halt parasite development at 
the liver stage, preventing disease altogether. However, a partially effective pre-
erythrocytic vaccine would not eliminate severe disease, although it could reduce 
both the frequency and extent of the blood stage infection following exposure, and 
potentially reduce the severity of disease. This may occur by limiting the number of 
sporozoites that develop into mature liver-stage schizont and consequently the 
inoculum that initiates the blood-stage of the infection. Alternatively, some parasite 
proteins are present during the liver and blood stages of P. falciparum infection and 
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a vaccine based on such a target might confer both liver and blood-stage protective 
immune responses. By contrast, vaccines targeting the blood-stages are aimed only 
at reducing the severity of disease and target proteins involved in merozoite 
invasion of erythrocytes or intra-erythrocytic parasite development. Lastly, 
transmission-blocking vaccines target sexual stages preventing parasite 
development within the mosquito and subsequently transmission to the human host, 
but will have no effect on protection from disease severity in immunised 
individuals. 
1.7.1. Whole sporozoite vaccines 
  
The first demonstration that experimental challenge with whole sporozoites 
conferred protection came from studies conducted in the early 1900s in which 
malaria was used to treat adult mental patients with neurosyphilis[121]. These early 
studies provided an opportunity to observe the clinical, parasitological and immune 
responses following a primary malarial infection and upon subsequent infection 
with either homologous or heterologous parasite strains[185]. A significant drop in 
the severity of symptoms, peak of parasitaemia and time to resolution of symptoms 
was observed in subsequent infections particularly with homologous strains and was 
more pronounced following repeated exposures[121]. Thereafter, in 1973, the first 
demonstration of sterile immunity following experimental challenge was observed 
using sporozoites from X-ray-irradiated mosquitoes[186, 187]. This immunity was 
subsequently shown to be dependent on the quantity of sporozoites used for 
immunization and conferred protection for a period of between 8-16 weeks[188]. 
Since then different sporozoite formulations have been or are currently under 
evaluation in clinical trials. These have included sporozoites that have been 
inactivated/attenuated through either radiation or genetically, or live non-attenuated 
sporozoites under prophylactic drug cover.  
1.7.1.1. Radiation attenuated sporozoites (RAS) 
 
Sporozoites attenuated through radiation treatment and delivered via mosquito bites 
were used in the first experimental human challenge that demonstrated sterile 
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protection [187]. Over 1000 irradiated infected mosquitoes were required per 
individual, to induce a response that was protective in subsequent challenge with 
parasites[189]. This route of vaccine delivery was recognised as the major obstacle 
with this approach. Since then, Sanaria Inc., a biotechnology company has made 
improvements in obtaining aseptic purified cryopreserved radiation-attenuated 
sporozoites (PfSPZ vaccine)[190]. This enabled the delivery of the vaccine directly 
overcoming the challenge of immunization via mosquito bites. This formulation has 
been tested widely in multiple clinical trials. Phase 1 trials showed limited 
protection when PfSPZ was delivered via the intra-dermal (ID) or the sub-cutaneous 
(SC) route while intravenous (IV) delivery offered sterile protection to all the 6 
healthy naïve adults challenged [191]. Since then the efficacy and duration of 
protection of PfSPZ has been tested in malaria-naïve adults showing protection 
against both homologous and heterologous challenge over a 12-month and 3-week 
period respectively [192]. Encouragingly, PfSPZ was safe and showed 49% efficacy 
against natural exposure in a randomised controlled trial involving healthy malaria-
exposed adults in Mali over a 6-month follow-up period[193]. 
1.7.1.2. Genetically attenuated sporozoites (GAS) 
 
A weakness of RAS is the precise dosing of radiation required for attenuation. As an 
alternative, genetic deletions of genes crucial for liver stage development have been 
used to generate GAS where the parasite life cycle arrests within the pre-
erythrocytic stages. Following the observation of complete sterile protection in 
mouse models, the first human trial involved sporozoites in which the 6-cys p52 and 
p36 genes had been deleted (GASs p52-/p36-)[194]. These knockout parasites had 
been evaluated in vitro and using humanised mouse models and showed arrested 
liver stage development, as these genes are required for PVM formation. 
Encouragingly, of the six healthy malaria-naïve adults immunised with GASs p52-
/p36- delivered via mosquito bite, five of the vaccinees remained free of 
parasitaemia for weeks after infection. In one individual, blood stage parasites were 
detected and clinical malaria experienced indicating substantial but incomplete 
attenuation [194]. Since then different knockout constructs have been tested for 
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complete attenuation in rodent and humanised mice models as well as in vitro 
hepatocyte infection. Complete attenuation has been recently reported for the GASs 
p52-/p36-/sap1- vaccine in which all the ten vaccinated adults remained parasite 
negative [195]. The effectiveness of the vaccine against challenge has yet to be 
reported. 
1.7.1.3. Sporozoite challenge under chemoprophylaxis cover (CPS) 
 
The chemoprophylaxis and sporozoite vaccination (CPS) strategy involves infection 
with live non-attenuated sporozoites under chloroquine cover that allows the 
completion of the pre-erythrocytic stage of the life-cycle releasing merozoites that 
initiate the blood stages. Chloroquine, which specifically targets the asexual stages, 
eliminates the blood-stage preventing clinical disease in vaccinated individuals. A 
phase 1 clinical trial involving 10 malaria-naïve adults vaccinated using the CPS 
(chloroquine) strategy via mosquito-bite showed complete sterile protection in all 10 
vaccinees [196] that was effective up to 28 months after vaccination in 4 of the 6 
vaccinated individuals[196]. These phase 1 results were replicated in additional 
studies involving malaria-naïve adults that involved escalating the dose of 
sporozoites used for vaccination[197] and in a CPS strategy in which chloroquine 
was replaced with mefloquine[198], a second licensed drug that targets asexual 
stages. As with RASs, the feasibility of vaccine delivery via mosquito bite was 
overcome using non-attenuated sporozoites from Sanaria. Inc. Complete sterile 
protection was recently observed in 9 malaria naïve individuals who were 
immunised with sporozoites via direct venous inoculation and challenged with 
sporozoites delivered by the same route[199].  
 
While the results from clinical trials with whole sporozoite vaccines are 
encouraging, a number of questions remain unanswered. These include: 1) 
establishing the duration of the protection conferred, 2) effectiveness of the 
vaccination strategy in naturally exposed populations including pregnant women, 
immuno-compromised individuals and infants whose immune systems differ 
considerably from healthy adults, 3) effectiveness against heterogeneous parasites in 
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the context of natural exposure and lastly the feasibility of producing sufficient 
number of vaccine doses for use in malaria-endemic regions. The ability to scale 
production of any of these approaches to the numbers needed to economically 
immunize hundreds of millions of individuals in Africa remains a significant 
question. 
 
1.7.2. Whole blood-stage vaccines  
 
Studies in the 1940s demonstrated complete protection in monkeys and ducks 
immunised with adjuvanted P. knowlesi and P. lophurae infected erythrocytes 
respectively [200]. In subsequent studies in the 1970s, P. falciparum infected 
erythrocytes in complete Freunds adjuvant conferred protection against subsequent 
P. falciparum challenge in Aotus monkeys [201]. Only one clinical trial in humans 
using blood stage parasites has been conducted. Four healthy adults were treated 
with ultra low doses of infected cryopreserved erythrocytes under drug cover 
(atovaquone, proguanil and chloroquine). In three vaccinees, parasite DNA was not 
detected by PCR over a two-week period following challenge while a delayed patent 
infection was detected in one vaccinee [202]. 
 
Since then, the use of radiation, chemically or genetically attenuated blood stages as 
well as low doses of infected erythrocytes with different adjuvants have been and 
continue to be tested in mouse models [203]. Data from trials in humans have not 
been made public yet [203]. The production of whole blood stage vaccine faces 
several challenges. The use of human red blood cells to propagate parasites carries 
the risk of containing infectious agents that can be transmitted and therefore require 
rigorous screening. Secondly, vaccination may result in the generation of antibodies 
against erythrocyte surface antigens that may target self- antigens (auto-antibodies). 
As with whole sporozoite vaccines, the production, storage, and delivery of 
sufficient quantity of vaccines for all those at risk remains a challenge [203]. 
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1.7.3. Sub-unit vaccines 
 
In the early 1980s, the advent of recombinant DNA technology enabled researchers 
to clone and express P. falciparum proteins[204] that could then be evaluated as 
sub-unit vaccine candidates. As shown in Table 1.2, this technology enabled the 
identification of the majority of vaccine antigens that have so far been evaluated. 
According to the WHO rainbow tables [205], 22 parasite antigens have been or are 
currently being evaluated in clinical trials either as single antigens or in combination 
forming multi-subunit vaccines, 18 of which were identified and described before 
the P. falciparum genome[206] was published in 2002. This represents less than 
0.5% of the proteins predicted to be encoded in the P. falciparum genome. The 
method of vaccine candidate discovery and the formulations under clinical trials are 
summarised in Table 1.2. 
1.7.3.1. Pre-erythrocytic sub-unit vaccine candidates 
 
Seven antigens (CSP, TRAP, LSA-1, LSA-3, STARP, EXP-1 and PfCelTOS) have 
been tested as pre-erythrocytic subunit vaccine candidates. These candidates are 
thought to function by eliciting antibody responses that target the motile sporozoite 
preventing hepatocyte invasion or elicit cellular responses that target infected 
hepatocytes. The most advanced candidate, CSP, is the parasite component of the 
RTS’S/AS01E vaccine that reduced the incidence of severe malaria and clinical 
disease by 29% and 39% respectively in phase III studies involving children aged 5-
17 months in malaria-endemic regions [71, 207]. Pilot studies to test the feasibility, 
safety and the impact on mortality of the vaccine are set to begin in 2018 in five 
sub-Saharan African countries [3].   
 
A second candidate, TRAP, has primarily been evaluated as part of a multi-
component vaccine termed ME-TRAP that consists of multiple B-cell and T-cell 
epitopes (both CD4+ and CD8+) fused to the TRAP protein. It is aimed at eliciting 
IFN responses to eliminate infected hepatocytes. Different formulations have been 
tested with initial regimens demonstrating no efficacy in field studies[208, 209]. An 
alternative formulation (ChAd63 ME-TRAP) has been tested demonstrating partial 
 58 
protection from parasite infection in Kenyan[210] and Senegalese adults[211]. 
Safety and immunogenicity trials with ChAd63 ME-TRAP have been conducted in 
children[212, 213], however their efficacy has yet to be reported. Similarly, 
PfCelTOS, a micronemal secreted protein is currently under evaluation in phase Ia 
trials. Protective efficacy was observed in P. berghei following both homologous 
and heterologous challenge with antibodies shown to inhibit sporozoite gliding and 
hepatocyte invasion[214]. The efficacy of this target in humans has yet to be 
reported. Lastly, multi-component pre-erythrocytic vaccines such as the FP9/MVA 
polyprotein that is composed of the TRAP, LSA-1, LSA-3, STARP, Pfs16 and 
EXP-1 showed no efficacy in phase I/IIa trials and was therefore discontinued from 
further evaluation[215]. A second multi-component DNA vaccine (polyepitope 
DNA EP1300) composed of multiple epitopes from CSP, TRAP; LSA-1 and EXP-1 
underwent phase 1a studies in malaria naïve adults in 2015, but the results have not 
yet been published.  
1.7.3.2. Erythrocytic sub-unit vaccine candidates 
 
Eleven blood-stage antigens are or have been evaluated in humans as vaccine 
candidates. These include MSP-1, -2 and -3, AMA1, GLURP, SERA5, RESA and 
EBA-175 all of which were identified in the pre-genome era. Only three targets 
namely RH5, TEX1 (also known as P27) and VAR2CSA, were identified after the 
genome was published, emphasising how many potential antigen targets remain to 
be studied. 
 
The most advanced blood stage vaccine is the GMZ2 that consists of the N-terminal 
of the GLURP protein fused to the C-terminal of MSP-3. Phase Ia and b studies in 
malaria naïve adults, semi-immune adults and children respectively, demonstrated 
safety and immunogenicity of the vaccine[216]. Recently however, a large 
multicentre phase 1b trial in children from Ghana, Burkina Faso and Uganda 
reported an overall vaccine efficacy of 14% against clinical episodes of malaria over 
a 6 month follow up period[217, 218]. The second blood-stage antigen MSP3 (181-
276), has similarly demonstrated good safety and immunogenicity in both naïve and 
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semi-immune adults and children[219]. Preliminary reports on a phase 1b trial in 
Burkina Faso indicated a reduced malaria incidence in vaccinated groups[220].  
 
Additional antigens that have been evaluated for efficacy in phase 2b studies and 
subsequently stopped, including EBA175 RII, FMP1/AS02A (MSP142), 
combination B (RESA, MSP1 and MSP2) and FMP2.1/AS02A (AMA1) vaccines. 
Low vaccine efficacies (less than 10%) against clinical malaria have been reported 
for FMP2.1/AS02A [172], FMP1/AS02A [221] and combination B [222]. In the 
trials evaluating the FMP2.1/AS02A and combination B formulations, evidence of 
allele specific efficacy was observed, which was thought to contribute to the low 
overall efficacy [223]. Since these trials, blood-stage vaccine formulations under 
evaluation have been aimed at overcoming the challenge of antigenic 
polymorphisms. Several approaches have been trialled, including: i) inclusion of 
multiple alleles of a single antigen such as the PfAMA1-DiCo, a diversity covering 
vaccine constructs that accounts for 97% of the amino acid variability observed in 
AMA1; ii) use of relatively conserved targets such as the SE36 (based on the N-
terminal region of SERA-5) that showed a reduced incidence of malaria in 
vaccinees compared to control individuals [224]. Another conserved blood-stage 
vaccine ChAd63 RH5+/- MVA RH5, targets the essential and relatively conserved 
merozoite invasion ligand RH5; 3) targeting multiple antigens from both the pre-
erythrocytic and blood-stages of the life cycle. These include GMZ2 vaccine and the 
NMRC-M3V-Ad-PfCA that consists of a combination of CSP and AMA1. Lastly, a 
vaccine targeted at preventing placental malaria, PRIMVAC is undergoing phase 
Ia/b evaluation in healthy adults in France and Burkina Faso. 
1.7.3.3. Transmission blocking sub-unit vaccine candidate (TBV) 
 
In the 1970s, it was demonstrated in avian, rodent and monkey Plasmodium that 
immunisation of the host with sexual stages (gametocytes) generated antibodies that 
inhibited infectivity and sexual development within the mosquito[225, 226]. 
Subsequent studies identified Pfs230 and Pfs25 as targets of monoclonal 
antibodies[227, 228] that reduced mosquito infectivity and these targets are 
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currently under evaluation in Phase 1a studies. The most advanced TBV is the Pfs25 
proteins that localises to the surface of zygotes and ookinetes. Phase 1a studies have 
demonstrated that the Pfs25-EPA/Alhydrogel is safe and immunogenic in malaria 
naïve humans and induced antibodies with transmission blocking activity[229] as 
measured using an in vitro standard membrane-feeding assays (SMFA). Current 
TBVs face several challenges in their development and testing. First, the production 
of vaccines that are immunogenic and generate antibodies with transmission 
blocking activity has been difficult. Second, while in vitro SMFA can measure the 
function of vaccine-induced antibodies, this method is not practical for evaluating 
vaccine efficacy in the field where the key indicator would be a drop in overall 
transmission intensity [230]. 
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Table 1.2: Table giving a summary of 21 parasite antigens that have or are under evaluation in clinical trials as sub-unit vaccines; adopted from the WHO Rainbow 
Tables[205]. 
Pre-genomic 
Pre-erythrocytic targets 
Antigen Discovery Vaccine constructs under clinical evaluation (past and present) 
Circumsporozoite protein (CSP) 1982: cDNA library screening using monoclonal 
antibodies obtained from mice immunized with P. 
knowlesi sporozoites and immunoprecipitation of 
protein extracts from P. knowlesi sporozoites[231] 
[232]. 
Phase I-III: RTS, S/AS01E 
Phase II: RTS, S/AS02A, 
Phase I: CSVAC, R21/AS01B, R21/Matrix-M1 
Phase I-II: NMRC-M3V-Ad-PfCA, DNA/MVA CSP 
Phase I: FP9 CSP + LSA-1 epitope/MVA CSP + LSA-1 epitope 
Phase I: HepB Core-Ag CSP-VLP 
Phase I-II: NMRC-MV-Ad-PfC, CSP long synthetic peptide 
Phase I-IIa: ChAd63/MVA (multivalent CS, ME-TRAP, AMA1) 
Phase I-IIa: RTS, S/AS01B + ChAd63 and MVA encoding ME-TRAP 
Phase I: polyepitope DNA EP1300, CSP. AMA1 virosomes 
TRAP (Thrombospondin related anonymous 
protein) also known as  
PfSSP2 (sporozoite surface protein 2) 
1988: Identified following the screening of the P. 
falciparum genome by Southern blot using a probe 
corresponding to the conserved region II of the 
circumsporozoite protein[233, 234]. 
Phase I-IIb: ChAd63/MVA ME-TRAP 
Phase I-II: FP9/MVA polyprotein 
Phase I: FP9 CSP + LSA-1 epitope/MVA CSP + LSA-1 epitope 
Phase I: DNA/MVA prime boost ME-TRAP 
Phase I: FP9 MVA prime boost ME-TRAP 
Phase I-IIa: ChAd63/MVA (multivalent CS, ME-TRAP, AMA1) 
Phase I-IIa: RTS, S/AS01B + ChAd63 and MVA encoding ME-TRAP 
Phase I: polyepitope DNA EP1300 
Liver stage antigen 1 (LSA1) 1987:  Screening of a genomic expression library using 
sera from individual exposed continuously to P. 
falciparum under chloroquine prophylaxis (sporozoite 
and liver-stage restricted sera)[235]. 
Phase I-IIb: ChAd63/MVA ME-TRAP 
Phase I-II: FMP011/AS01B 
Phase I-II: FMP011/AS02A 
Phase I-II: FP9/MVA polyprotein 
Phase I: polyepitope DNA EP1300 
Liver stage antigen 3 (LSA3) 1990: Screening of a genomic expression library using 
sera from individual exposed continuously to P. 
falciparum under chloroquine prophylaxis (sporozoite 
and liver-stage restricted sera)[236]. 
2007: screening cDNA library from erythrocytic stages 
using sera from malaria infected identifies LSA-3 as a 
liver and blood stage antigen[237]. 
Phase I-IIb: ChAd63/MVA ME-TRAP 
Phase I-II: FP9/MVA polyprotein 
Phase I-II: LSA-3 (inactive) 
Sporozoite Threonine and Asparagine-Rich 
Protein (STARP) 
1994: Screening of a P. falciparum expression library 
using sera from adults living in a malaria-endemic area 
Phase I-IIb: ChAd63/MVA ME-TRAP 
Phase I-II: FP9/MVA polyprotein 
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under long-term chloroquine prophylaxis (sporozoite 
and liver-stage restricted sera) [238] 
 
Pfs16 1991: Identified by screening a cDNA library 
generated from gametocyte RNA[239]. Rabbit 
polyclonal sera against the C-terminal region reacted 
with a 16KDa antigen from lysates obtained from 
gametocytes, gametes and sporozoites 
 
Phase I-II: FP9/MVA polyprotein 
 
Exported protein 1 (EXP-1) 1985: Screening of a cDNA expression library using 
sera from immune adults from Papua New 
Guinea[240]. 
Phase I-IIb: ChAd63/MVA ME-TRAP 
Phase I-II: FP9/MVA polyprotein 
Phase I: polyepitope DNA EP1300 
 
Erythrocytic targets 
Antigen Discovery Vaccine constructs under clinical evaluation (past and present) 
Merozoite surface protein 1 (MSP1) 1982: Immunoprecipitation of parasite lysate (schizont) 
using a monoclonal antibody that bound to the 
merozoite surface[241]. 
Phase I: FMP1/AS02, PfCP2.9  
Phase I-II: FMP1/AS02A 
Phase I: MSP1-C1/AlOH + CpG 
Phase I-II: Combination B (RESA, MSP1, MSP2) 
Phase I: JAIVAC (MSP1-19/EBA175), FMP010/AS01B 
Phase I-II: ChAd63/MVA MSP1 
Phase I: BSAM-2/Alhydrogel+CPG 7909, ChAd63 MSP1/MVA 
MSP1 
Merozoite surface protein 2 (MSP2) 1985: Immunoprecipitation of parasite lysate (schizont) 
using monoclonal antibodies that bound to the surface 
of merozoites[242]. 
Phase I-II: MSP2-C1/ISA720 
Phase I-II: Combination B (RESA, MSP1, MSP2) 
Merozoite surface protein 3 (MSP3) 1994: Screening of a cDNA library using antibodies 
that inhibited parasite growth in the ADCI assay and 
bound to the surface of merozoites[243]. 
Phase I-II: GMZ2 
Phase I-II: MSP3 (181-276) 
Apical Membrane Antigen 1 (AMA1) 1982: Screening P. knowlesi parasite lysate (schizont) 
using monoclonal antibodies with growth inhibitory 
activity[244]. 
Phase I: pfAMA1-DiCo 
Phase I-II: NMRC-M3V-Ad-PfCA 
Phase I-IIa: ChAd63/MVA (multivalent CS, ME-TRAP, AMA1) 
Phase I: PfCP2.9, AMA1-FVO (25-545), AMA1-C1/ISA720 
Phase I-II: FMP2.1/AS02A, AMA1-C1/Alhydrogel + CPG 7909 
Phase I: BSAM-2/Alhydrogel+CPG 7909,CSP. AMA1 virosomes 
Phase I-II: FMP2.1/AS01B, ChAd63 AMA1/MVA AMA1 
Phase I-II: ChAd63 AMA1/MVA AMA1 + alhydrogel/CPG7909 
Erythrocyte Binding antigen-175 (EBA175) 1985: Intact erythrocytes were used to affinity purify 
parasite ligands from P. falciparum culture 
Phase I-II: EBA175 RII 
Phase I: JAIVAC (MSP1-19/EBA175) 
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supernatant[245].  
Ring-infected surface antigen (RESA) 1983:  Screening of a cDNA expression library using 
immune sera that inhibited parasite growth in 
vitro[204, 246] 
Phase I-II: Combination B (RESA, MSP1, MSP2) 
 
Glutamate rich protein (GLURP) 1991: Screening of a P. falciparum expression library 
with human hyperimmune antibodies obtained 
following affinity purification using exoantigens 
(proteins released following schizont rupture). [247] 
Phase I-II: GMZ2 
Phase I: GLURP (85-213) 
 
Serine repeat antigen (SERA5) 1987: Affinity purification from parasite lysates 
(schizonts) using a monoclonal antibody that was 
generated from exoantigens purified from culture 
supernatant[248]. 
Phase I: SE36 
 
Transmission blocking targets 
Antigen Discovery Vaccine constructs under clinical evaluation (past and present) 
Pfs230 1983: Immunoprecipitation of parasite protein from 
female gametes using monoclonal antibodies that 
interfered with transmission of gametes to 
mosquitoes[227]. 
Phase I: Pfs 230D1M-EPA/Alhydrogel 
 
Pfs25 1985: Immunoprecipitation of parasite protein from 
macrogametes/zygotes using monoclonal antibodies 
that interfered with transmission of gametes to 
mosquitoes[228]. 
Phase I: Pfs 25 VLP 
Phase I: Pfs 25-EPA/Alhydrogel 
Phase I: ChAd63 Pfs25-IMMX313/MVA Pfs25-        IMX313 
 
 
Post-genomic 
 
Pre-erythrocytic 
Antigen Discovery Vaccine constructs under clinical evaluation (past and present) 
Cell-traversal protein for ookinetes and 
sporozoites (CelTOS) 
2006: Comparative analysis of expressed sequence tags 
(EST) databases of the salivary gland sporozoites and 
ookinetes to identify micronemal proteins[249]. 
Phase I: PfCelTOS FMP012 
Erythrocytic 
Antigen Discovery Vaccine constructs under clinical evaluation (past and present) 
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Trophozoite exported protein 1 (TEX1)(P27A: 
PFF0165c) 
2009: Bioinformatic screening for targets with -
helical coiled coil motifs, screening of synthetic 
peptides with immune sera and affinity-purified 
immunoglobulins inhibited parasite growth in the 
ADCI assay. 
Phase I: P27A 
VAR2CSA 2003: Compared the up-regulated gene in parasite 
isolates selected on adhesion to chondroitin sulphate A 
and isolates obtained from placental malaria (PAM) 
compared to isolates obtained from non-pregnant 
individuals[35]. 
Phase I: PRIMALVAC (PRIMVAC) 
RH5 2002: Functional genomics analysis of the P. 
falciparum database identified the PfRH family, which 
shared homology and feature with both the P. yoelii 
and P. vivax reticulocyte binding homolog families. 
Phase I: ChAd63 RH5 +/- MVA RH5 
 
Green: pre-erythrocytic candidates. Purple: erythrocytic candidates.  Blue: transmission blocking candidates
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1.8. Antigen discovery and pre-clinical evaluation for vaccine development 
 
Until the late 1990s, the conventional vaccination strategy had been based on the 
“isolate and purify the pathogen (or pathogen product) followed by an 
inactivation/attenuation/killing step then vaccinate susceptible hosts” approach. 
Edward Jenner had first applied a slightly different vaccination approach in 1796, 
where he used the wild-type cowpox (a less virulent poxvirus transmitted to humans 
form infected cattle) to vaccinate humans against the lethal smallpox virus [70, 
250]. This approach has successfully generated licensed vaccines against viruses 
such as measles, rubella, mumps, varicella (chickenpox) and infectious bacteria 
such as Mycoplasma tuberculosis and Clostridium tetani (tetanus toxoid vaccine) 
[70]. In the “-omics” era, several high-throughput approaches have been employed 
to identify potential vaccine candidates. These include reverse vaccinology, 
comparative genomics, proteomics, transcriptomic, bioinformatic and computational 
modelling approaches [251, 252]. In the context of P. falciparum vaccine discovery, 
the majority of vaccine candidates under clinical evaluation (17 (81%), were 
identified in the pre-genomic era (Table 1.2). These were identified primarily 
through the screening of genomic/cDNA expression libraries or testing the reactivity 
of parasite lysate material with monoclonal antibodies or sera of a defined 
specificity. In this era, antigen discovery was slow with only a single or few 
antigens reported in each publication. 
 
The publishing of the P. falciparum genome in 2002 [206] revealed that the parasite 
had over 5600 proteins, a daunting number to examine individually. To overcome 
this challenge, several systematic approaches have been employed for antigen 
discovery in P. falciparum, including reverse vaccinology, population genetic 
studies and proteomic approaches. Each of these approaches however, has been 
greatly aided by publicly available “omic” datasets. These data sets include the 
comparative genomics [253], proteomics [254, 255] and transcriptional profiling 
[256-258] of P. falciparum parasites that have provided valuable information for 
consideration when selecting new malaria vaccine targets. Datasets that are 
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currently publicly available on PlasmoDB include the proteomic analyses of 
sporozoites, trophozoites, merozoites and gametocytes obtained from the Pf3D7 and 
NF54 strains [254, 255] and the transcriptional profiling of the Pf3D7 and PfHB3 
strains throughout the intraerythrocytic developmental stages [259, 260], 
gametocytes and mosquito salivary gland sporozoites stages [260] to identify the 
stages in which candidates are expressed. In addition, large-scale genetic screens are 
now being carried out in the rodent Plasmodium model P. berghei, where 
essentiality data is now available for 50% of the genome, a high proportion of which 
have 1:1 orthologues in the P. falciparum genome [261]. 
 
1.8.1. Reverse vaccinology 
 
Reverse vaccinology was pioneered by Rappuoli and colleagues [262] and involves 
the high-throughput in silico screening of the entire genome of a pathogen to 
identify genes that encode proteins with characteristics that were associated with 
immunity. Once targets were selected they could then be evaluated for 
immunogenicity and functional protection using various biochemical and cellular 
assays. The protein characteristics prioritised included the presence of signal 
peptide, transmembrane domains or GPI-anchors that suggest a protein may be 
localised on the surface of a cell and therefore accessible to antibodies. In P. 
falciparum target discovery, several research groups have coupled reverse 
vaccinology and the available “omics” datasets to select and validate candidates 
from the genome. For example both Fan et al [263] and Anand et al [264], used the 
following criteria to select targets from the P. falciparum genome: i) elevated 
mRNA transcription at the schizont stage (40-48 hpi) and ii) presence of a signal 
peptide or iii) one or more transmembrane domains or GPI-anchor and iv) have 
homologues present in different organisms of known function. One study 
subsequently identified 7 proteins namely MSP3.5, MSRP2, ETRAMP11.2, 
ETRAMP14.1, RALP1, StAR-related lipid transfer protein and a conserved 
membrane protein (PF3D7_1459900) as immunogenic for the first time [263] while 
 67 
the second study characterised the rhoptry associated adhesin (PfRA) as a protein 
that translocates to the merozoite surface and interacts with erythrocytes [264].  
 
Similarly, the genes encoding approximately a quarter of the hypothetical P. 
falciparum proteins were obtained from the genome and recombinantly expressed 
and printed on protein arrays, which were used for screening for antibody responses 
in naturally exposed individuals [265-268]. They achieved this by combining a rapid 
in vitro transcription/translation system to antibody screening by protein arrays. In 
these studies, a large number of P. falciparum predicted open-reading frames 
(ORFs) were recombinantly expressed using either the wheat germ cell-free protein 
synthesis systems (WGCFS) [269, 270] or a rapid transcription/translation system 
[265]. These recombinant protein fragments were printed on a microarray chip for 
analysis using sera from vaccinated individuals or those living in a malaria endemic 
region, with varying degrees of exposure and susceptibility to P. falciparum malaria 
[263, 265, 271].  These approaches identified novel targets of antibodies elicited 
following natural and experimental infection as well as those in individuals with 
sterile immunity to malaria following sporozoite vaccination [271, 272]. In addition, 
novel blood-stage targets of protective immunity and markers of exposure at an 
individual and community level have been evaluated [265, 267]. These studies 
continue to provide potential vaccine candidates that need further evaluation, 
although depend heavily on the quality of the expressed recombinant proteins and 
how well they mimic epitopes present in endogenous antigens. 
 
1.8.2. Functional genomics 
 
Functional genomics refers to the comparisons of genes and genomes to identify 
proteins that share similarities suggesting shared or similar functions or interactions. 
In the context of P. falciparum, mining of the genome identified additional members 
of protein families [273-277], which shared homology and features with both the P. 
yoelii and P. vivax reticulocyte binding homolog families (functional genomics). 
One example is the RH family, which includes the reticulocyte binding proteins 
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(RBP) and the 235-kDa rhoptry protein initially described in P. vivax [278, 279] and 
P. yoelii [280, 281] respectively, and shown to be crucial in determining the red cell 
type invaded by merozoites. The P. falciparum members of this family are the RH 
genes, and the RH5 protein is a good example of a vaccine candidate identified 
through functional genomics [205]. Other members of the RH family continue to be 
evaluated in pre-clinical studies [282, 283]. Similarly, some members of the P. 
falciparum EBL family [284-288] were identified due to the similarities in the 
structure between these proteins and the Duffy-binding protein (DBP) of P. vivax. 
The characteristic features of these proteins include a cysteine-rich domain of 
approximately 35 kDa involved in host cell adhesion and first described in P. vivax 
[289] [289]and called the Duffy binding-like (DBL) domain. Members of the RH 
and EBL families continue to be evaluated as potential vaccine candidates, however 
the redundancy in the erythrocyte invasion pathways limits the utility of single 
targets with the exception of RH5 that is an essential invasion ligand[157]. 
 
1.8.3. Population genetic analysis 
 
Analysis of the genetic differences between P. falciparum isolates has identified 
genes that are highly polymorphic in which several alleles of the gene occur at 
intermediate frequencies. These frequencies are higher than would be expected from 
random mutation and are thought to occur as a consequence of selection from the 
host’s adaptive immune responses. Initial identification of targets under balancing 
selection were conducted using a panel of lab-adapted isolates and on a subset of 
genes [290]. These methods and findings were further validated using parasite 
isolates obtained from a Kenyan population [291]. The top hits identified from these 
studies namely MSPDBL1, MSPDBL2 and SURFIN 4.2 were evaluated in 
prospective cohort studies for immunogenicity and antibodies to MSPDBL2 were 
associated with protection from clinical episodes of malaria in Kenyan children 
[292]. These methods have been recently extended to a genome-wide scale using 
isolates from the Gambia identifying over 300 targets under balancing selection in 
the entire genome, raising the key challenge of down-selecting which targets to take 
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forward for pre-clinical evaluation. In addition, the vaccine efficacies of highly 
polymorphic antigens such as AMA1, MSP2 and CSP has been low, raising caveats 
about the use of similar polymorphic targets. If such targets are to be pursued, 
investment and continuous monitoring of the alleles in circulation in endemic 
regions would be required to guide in the development of a “diversity covering” 
vaccine. 
 
1.8.4. Screening genomic or cDNA expression libraries 
 
Genomic or cDNA libraries refer to a collection of cloned DNA or cDNA fragments 
that have been generated by enzymatic digestion and transformed into host cells 
(usually E.coli) after ligation into expression vectors. The polypeptide gene products 
of the genomic or cDNA E.coli clones generated can then be screened for binding to 
antibodies. For instance, the immunodominant pre-erythrocytic sporozoite surface 
protein, CSP, was identified by screening a cDNA library constructed from mRNA 
obtained from P. knowlesi infected salivary glands [232] as well as screening 
sporozoite lysate material [231]. In these studies, they used hybridoma technology 
to generate mAbs from spleen cells obtained from BALB/c mice, which had been 
intravenously injected four times with P. knowlesi sporozoites. They then 
characterised these mAbs by testing for reactivity to the surface of sporozoites and 
testing the ability of mAbs to block infection on intravenous transfer of co-
incubated sporozoites to rhesus monkeys. Thereafter, the protective monoclonal 
antibodies were used in immunoprecipitation experiments with sporozoite lysate 
material [231] as well as with the products of the cDNA expression library [232]. 
The specificity of this method was improved by analysing stage specific 
transcriptomes in which cDNA was generated from mRNA extracted from different 
stages of the life cycle. In addition, as shown in Table 1.2, the sera or monoclonal 
antibodies used were carefully selected. For example, the vaccine candidates LSA-
1, LSA-3 and STARP were identified by screening cDNA libraries using sera from 
individuals who had been continuously exposed to P. falciparum but were under 
chloroquine prophylaxis that was effective against the blood stages of development 
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[235, 236, 238]. As a result, antibodies from these individuals were specific for the 
pre-erythrocytic phase of the life cycle. Recently, the same method was used to 
screen a blood-stage cDNA expression library using sera from 2 year olds that were 
either resistant or susceptible to P. falciparum parasitaemia and disease [137]. The 
antigen identified is now known as PfSEA-1. Antibodies to PfSEA-1 blocked 
parasite replication by preventing merozoite egress and Tanzanian children who had 
these antibodies did not experience severe malaria [137]. 
 
1.8.5. Proteomic approaches 
 
Proteomics refers to the large-scale identification and/or quantification of the set of 
proteins produced in the biological context either by whole organisms, organs or 
organelles. This approach has been used widely in the pre and post-genome era of 
vaccine discovery in P. falciparum. The two primary methods that have been 
utilised include immunoprecipitation techniques and the identification of parasite 
surface proteins on the premise that these are accessible to circulating antibodies. 
 
Immunoprecipitation, also commonly referred to as “pull-down”, involves the 
precipitation of target antigens using monoclonal antibodies or immune sera. As 
shown in Table 1.2, it has been widely used in target identification. For example, 
monoclonal antibodies (mAbs) that had demonstrated in vitro parasite growth 
inhibitory activity [241, 242, 244] or interaction with monocytes leading to parasite 
death[243] were used in pull-down experiments to identify AMA1 [244], MSP-1 
[241], -2 [242] and -3 [243] in the pre-genomic era. Similarly in the post-genomic 
era, the interacting partners of MSP1 and RhopH3 were identified in pull-down 
experiments using merozoite lysates and the respective anti-sera raised against 
recombinant MSP1 and RhopH3 [293]. These identified additional surface proteins 
such as MSP-6, -7 and -9 as well as the rhoptry proteins RhopH1, RAP-1 and RAP-
3 as interaction partners of MSP-1. These are currently under pre-clinical evaluation 
as vaccine targets [147].  
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Membrane proteomics refers to the specific identification of proteins located within 
or associated with the surface of pathogens, which represent an ideal source of 
potential vaccine candidates as these proteins are exposed to the host immune 
system. A number of proteomic studies have been aimed at describing the merozoite 
sub proteomes, to identify merozoite anchored [294, 295], surface and secretory 
proteins [293, 296] as potential vaccine candidates. Detergent-resistant protein 
complexes as well as GPI-anchored membrane proteins obtained from P. falciparum 
schizonts were identified by mass-spectrometry. These identified new GPI-anchored 
and peripherally associated proteins such as Pf92, Pf12, Pf38, Pf113 and Pf41 and 
shown to be recognized by a pool of immune sera obtained from naturally exposed 
individuals [294]. Although none of these have reached clinical evaluation in 
humans, pre-clinical studies in humans [146, 147] and mice [297] continue to 
evaluate these targets [298]. Similarly, novel proteins on the surface of infected 
erythrocytes such as PIESP1 and PIESP2 [299] and recently on sporozoites from 
mosquito salivary glands [300, 301] have been identified using a capture and 
affinity purification technique. Data on their potential as vaccine targets have yet to 
be published. 
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1.9. Pre-clinical evaluation of potential vaccine candidates 
Despite the availability of the genome for over 14 years, less than 1% of the parasite 
proteome has been or is currently being evaluated in clinical trials as vaccine 
candidates. The timeline between antigen discovery and clinical trials in humans has 
ranged from as short as 3 years to as long as 20 years [161]. Many proteins have 
been proposed to be potential vaccine candidates however data on pre-clinical 
evaluation is lacking and few targets have made it to the vaccine development 
pipeline. With the increasing number of targets identified, prioritizing antigens for 
vaccine development has become a challenge and remains a bottleneck for vaccine 
development. 
 
Several pre-clinical evaluations should be considered to aid in prioritization. First, 
the responses generated following natural exposure to P. falciparum to these 
antigens should be evaluated in several cohorts to identify targets that are 
consistently associated with protection in varied transmission settings [302].  
Secondly, additional in vitro assays have been developed that correlate with 
immunity to malaria [136] and the reliance on a single assay to measure effector 
functions may not provide a comprehensive evaluation of antibody targets [136]. 
Antigens that are able to elicit antibodies with multiple immune effector 
mechanisms could be prioritized and in theory should generate highly efficacious 
vaccines. Thirdly, the development of humanised mouse models and P. 
falciparum/P. berghei chimeric parasite lines may offer a rapid way of testing 
vaccine candidates for immunogenicity and efficacy prior to vaccine studies in 
humans. Lastly, the setting up of facilities that allow controlled human malaria 
infections (CHMI) in malaria-endemic regions such as Kenya [151] and Tanzania 
[303] has been an expensive venture. However, they offer the ability to measure the 
efficacy of vaccines rapidly, within weeks or months by comparing the prevention 
or reduction in parasite multiplication rates in vaccinees and control subjects. 
Thereafter, the long-term vaccine efficacy against heterologous P. falciparum 
infection as occurs in the natural setting will need to be evaluated in classic Phase 
III studies.  
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1.10.  Aims and scope of the thesis 
 
Seminal studies conducted over 60 years ago demonstrated that naturally acquired 
immunoglobulins conferred protection against clinical disease and high parasite 
densities. However, to date, only a small proportion of the parasite proteome has 
been evaluated in this regard. The overall aim of this study was to identify novel 
merozoite targets of protective immunity.  Below, I outline the aims, rationale and a 
brief summary of the findings presented in the chapters of this thesis. 
 
In Chapter Two, the aim was to identify merozoite proteins that are recognised by 
immunoglobulins from malaria immune adults. I used a 2-dimensional gel 
electrophoresis technique to resolve proteins extracted from P. falciparum 
merozoites and tested them for reactivity with a pool of immunoglobulins from both 
immune and non-exposed adults. I identified a total of 339 proteins that appeared to 
be reactogenic. Seventeen percent of these proteins have been previously shown to 
be targets of naturally acquired antibodies thus validating my approach. I found that 
a large proportion of the identified targets had not been previously evaluated in the 
context of naturally acquired immunity. 
 
In Chapter Three, I set out to identify proteins that are localised on the surface of 
free merozoites. Although efforts have been made to identify merozoite membrane 
proteins, mining of PlasmoDB suggest the presence of many more unidentified 
proteins. I used complementary proteomic approaches that included cell surface 
trypsinization and biotinylation to identify surface proteins. I identified 374 putative 
merozoite surface proteins that included known GPI-anchored and peripherally 
associated proteins as well as membrane embedded multi-transmembrane proteins. 
Within this list include proteins that have been proposed to play roles in erythrocyte 
invasion and may be essential for P. falciparum survival. These may therefore 
represent attractive targets of naturally acquired immunity and consequently 
potential vaccine candidates. 
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Chapter Four focuses on the down-selection criteria I used to select a subset of 27 
antigens for immunoprofiling. I generated recombinant proteins for 22 of these 
proteins for the first time, and found that 19/22 (86%) were recognised by a pool of 
hyper-immune sera from malaria-exposed individuals but not sera from non-malaria 
exposed individuals. 
 
In Chapter Five, I measured antibody responses to eleven of the 22 recombinant 
antigens in a cohort of longitudinally monitored adults living in an area of 
hyperendemic P. falciparum transmission. I have i) confirmed that the recombinant 
proteins are recognised by sera from adults living in malaria endemic regions, ii) 
described the stability of antibody responses over a three-year period, iii) 
demonstrated that antibody responses to six antigens are significantly lower in 
adults who experienced a clinical episode compared to those who remained disease 
free and iv) established that the breadth of antibody responses to well-studied and 
newly identified immunogenic proteins are associated with protective immunity. 
 
In Chapter Six, I examined the role of antibody-mediated functional activity in 
protection against disease and parasite densities in a malaria exposed adults. I 
focussed on three functional assays: opsonic-phagocytosis of merozoites (OPA), 
antibody-dependent respiratory burst (ADRB) and antibody-dependent recruitment 
of complement factor C1q (C1q-fixation). Little is known about the contribution of 
these effector mechanisms to NAI in adults, as previous studies have been limited to 
the development and validation of these immunological assays. Using the same 
cohort of adults in Chapter five, I showed that: i) opsonic-phagocytosis and the 
ability to fix complement was associated with protective immunity and ii) a strong 
positive correlation between antibody responses to the newly identified 
immunogenic antigens and protective effector function namely ADRB and C1q-
fixation.  This provides some evidence of the possible mechanisms by which 
antibody responses to these novel potential vaccine candidates function.  
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Finally, in Chapter Seven, I provide a summary of the findings generated in this 
thesis and recommendations for future studies. 
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CHAPTER 2  
Plasmodium falciparum merozoite antigen discovery using 
immunoprecipitation and bi-dimensional gel electrophoresis 
 
2.0. Introduction 
 
Passive transfer studies conducted over 50 years ago established the role of naturally 
acquired antibodies in protection against P. falciparum malaria. In these studies, 
immunoglobulins from adults living in malaria-endemic regions were passively 
transferred to children admitted with a clinical diagnosis of malaria and high 
parasite densities. The result was a resolution of fever and a drop in parasite 
densities over a four day period to less than 1% of the initial densities [127]. These 
findings were replicated in subsequent studies where passive transfer using West-
African adult human IgG was used successfully to treat children from East and West 
Africa [128, 130], as well as Thai patients [129]. Since then, the targets of these 
“protective” antibodies and the mechanisms by which they mediate protection have 
been under investigation.  
 
Protective antibodies may be directed against a range of parasite proteins expressed 
during the multiple stages of the P. falciparum life cycle (see Chapter 1 section 1.1). 
These include pre-erythrocytic stage targets on the sporozoite or erythrocytic stage 
antigen targets present either on infected erythrocytes, merozoites or on 
gametocytes*. All clinical symptoms experienced during P. falciparum infection are 
a consequence of the erythrocytic stage of the life cycle, which are initiated by the 
invasion of merozoites into erythrocytes. P. falciparum merozoites are the only 
extracellular parasite forms at the asexual stage of the life cycle and are therefore 
directly exposed to the host’s blood stream and accessible to circulating antibodies 
[304, 305]. In addition, parasite derived antigens are exported onto the surface of 
                                                        
* Antibodies against gametocytes may serve as transmission blocking agents 
providing protection to endemic populations and not the individual per se. 
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infected erythrocytes in the late stages of the blood-stage of infection and are also 
major targets of naturally acquired antibodies [34, 142]. 
 
Identifying the targets of protective antibodies has remained a research priority 
since the discovery of their activity in passive transfer studies in humans. In the pre-
genomic era [206], antigen discovery was primarily achieved using two 
complementary methods. The first method involved the construction of genomic or 
complementary DNA libraries expressed in Escherichia coli that could be screened 
using sera from infected humans, mice or monkeys. For example, the screening of a 
blood-stage cDNA library using sera from Papua New Guinean adults led to the 
identification of the immunodominant blood-stage S-antigen [204, 306]. Similarly, 
three blood-stage antigens that were localised on the surface of merozoites were 
identified by screening a cDNA library constructed from late-stage P. falciparum 
mRNA using sera from Aotus monkeys immune to P. falciparum infection [307]. 
The second approach was enabled by the discovery of hybridoma technology in 
1975 [308], which permitted the in vitro production of monoclonal antibodies 
(mAbs) of defined specificities. These antibodies were then used to screen either 
cDNA libraries or parasite lysate material to identify target antigens. For example, a 
small number of known merozoite antigens that have in the past been considered 
leading vaccine candidates, such as AMA1 [244] and MSP-1 [241], -2 [242], -3 
[243]  (MSP- 1, 2, 3) relied on the screening and immunoprecipitation of parasite 
lysates with monoclonal antibodies of a defined specificity. Compared to the current 
techniques (described in Chapter 1 section 1.8), these methods led to the 
identification and characterisation of a relatively small number of antigens, over a 
long period of time. 
 
More recently, the completion of the reference P. falciparum 3D7 genome, has 
allowed the use of more systematic and/or hypothesis driven approaches that have 
led to the rapid identification of multiple immune targets as has been discussed in 
section 1.8.1. Four main techniques have been employed to identify immunogenic 
merozoite antigens: i) parasite population genetic analyses (section 1.8.3), ii) 
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proteomic identification of membrane proteins (section 1.8.5), iii) literature review 
and selection of antigens of known function that may be immunogenic and iv) the 
use of various protein expression systems to generate large panels of parasite 
proteins for immunoscreening as has been discussed in Chapter 1 section 1.8. 
Although these approaches have increased the number of antigens under study as 
potential vaccine candidates, I identified a large number of merozoite proteins on 
PlasmoDB (http://plasmodb.org) that are likely to be accessible to circulating 
antibodies (described in detail in section 2.5.1). Of these potential targets, only 
approximately 20% had been evaluated for immunogenicity at the time this thesis 
was written, indicating that many more are yet to be discovered, evaluated and 
prioritised. 
 
2.1. Rationale 
 
In this chapter, I sought to identify P. falciparum merozoite antigens that are 
immunogenic and therefore potential targets of protective antibodies. To do this, I 
used two complementary techniques: i) immunoprecipitation of P. falciparum 
merozoite lysates and ii) bi-dimensional gel electrophoresis coupled to western 
blots. For each technique, I used a pool of immunoglobulins from malaria-immune 
adults to identify potential protective antigens, while a pool of immunoglobulins 
from non-malaria exposed adults was used as a negative control.  
 
2.1.1. Immunoprecipitation 
 
Immunoprecipitation (IP) techniques have been successfully used to identify the 
targets of multiple monoclonal and human polyclonal antibodies against infectious 
agents such as Vibrio cholerae [309] and Epstein-Barr virus [310]. In the context of 
P. falciparum, IP techniques have mainly been used to “pull-down” targets in 
antigen discovery experiments and to identify protein-protein interacting partners. 
For example, monoclonal antibodies were used in pull-down experiments to identify 
targets such as AMA1, MSP1 and MSP3 in the pre-genomic era. Similarly, the 
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interacting partners of MSP1 and RhopH3 were identified in pull-down experiments 
using merozoite lysates and the respective anti-sera raised against recombinant 
MSP1 and RhopH3 [293]. While the above approaches have relied on either a 
monoclonal antibody or polyclonal sera against a single target, the extension of the 
technique to using polyclonal sera of broad specificity from malaria immune 
individuals could lead to the identification of multiple targets in a single experiment. 
For example, four novel P. yoelii blood-stage antigens were identified following 
pull-down experiments using pooled sera from mice that spontaneously cleared P. 
yoelii infection following challenge experiments [311]. The antigens that were 
identified in that study were subsequently shown to be partially protective in 
experimental immunization and challenge studies in mice [312]. I therefore sought 
to identify novel immunogenic P. falciparum merozoite targets by using a pool of 
purified immunoglobulins from malaria immune adults that is expected to have a 
wide range of specificities against merozoite expressed proteins. 
 
2.1.2. Two-dimensional gel electrophoresis (2DE) 
 
The two-dimensional gel electrophoresis (2DE) technique has been widely used for 
many infectious agents to provide a snapshot of a pathogen’s proteome at a specific 
time-point [313]. In this technique, complex mixtures of proteins are separated 
according to their isoelectric points (pI) in the first dimension of electrophoresis, 
followed by a subsequent separation according to their molecular weight by SDS gel 
electrophoresis in the second dimension. This can allow the resolution of 
approximately 2000 proteins to individual spots, which can be excised and 
identified by mass-spectrometry [314]. In malaria, it was first successfully used to 
identify P. falciparum merozoite and schizont specific proteins [315] and later used 
to identify extracellular secretory antigens at the erythrocytic stage of infection 
[316]. Coupling 2DE to serology has been employed in a few studies in the context 
of malaria. These have included i) identifying targets of protective antibodies 
against P. knowlesi schizont membrane proteins, using hyperimmune sera obtained 
from P. knowlesi infected rhesus monkeys (however, as the genome was not 
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available at that time, the identity of the immunoreactive targets remained unknown) 
[317], ii) identifying P. falciparum infected erythrocyte membrane proteins 
recognised by sera from briefly exposed individuals (travellers to malaria endemic 
region for a period of less than 6 months) [318] and iii) a serum factor, 2-
macroglobulin, that binds to the PfEMP1 variant HB3VAR06 [319]. One-
dimensional gel electrophoresis (1DE) has been used in two other studies to 
measure reactivity of parasite lysate with sera from individuals with varying degrees 
of exposure and immunity to P. falciparum malaria [320, 321]. Differences in the 
pattern of recognition of parasite lysate material were clearly visible. However, a 
known limitation of this method, that separates proteins according to their molecular 
weight only, is that many proteins would be almost identical in size and therefore 
resolves similarly on a 1DE gel. Therefore assigning immunogenicity to a particular 
protein becomes a challenge.  
 
I chose to use the 2DE technique coupled to western blotting to identify 
immunogenic merozoite antigens for the following reasons: i) 2DE technology is 
superior to 1D-SDS gel electrophoresis in the separation of complex protein 
mixtures into individual components, ii) a pool of purified immunoglobulins 
obtained from malaria immune adults expected to have a wide range of specificities, 
was available and would allow the identification of multiple immune targets and iii) 
the genome sequence of P. falciparum was publicly available and would aid in rapid 
target identification. 
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2.2. Overall Objectives 
 
To identify immunogenic P. falciparum merozoite antigens using complementary 
proteomic approaches. 
 
2.3. Specific Objectives 
 
• To identify immunogenic P. falciparum merozoite antigens using 
immunoprecipitation techniques. 
• To identify immunogenic P. falciparum merozoite antigens using two-
dimensional gel electrophoresis techniques coupled to fluorescent 
immunoblotting. 
 
2.4. Laboratory methods 
 
2.4.1. P. falciparum merozoite purification and characterisation 
 
The P. falciparum 3D7 strain (Pf3D7) and an isolate obtained from a child admitted 
to Kilifi County hospital in Kenya with cerebral malaria termed KIL9605, were 
maintained in in vitro culture through infection of human O+ erythrocytes grown in 
standard parasite culture media (RPMI 1640 media supplemented with 30mM 
HEPES, 0.05mg/ml hypoxanthine, 0.025mg/ml gentamicin, 2mg/ml D-glucose, 3% 
Albumax II and 7.5% sodium bicarbonate) at between 8-10% parasitemia and at 5% 
haematocrit. A high parasetemia was required to obtain sufficient quantity of 
merozoites for downstream analysis. Parasites were synchronised repeatedly with 5% 
D-sorbitol treatment to obtain a culture where the majority of infected erythrocytes 
were in the ring-stages. This method relies on a P. falciparum encoded permeability 
pathway that is located on erythrocyte surfaces in the trophozoite and schizont-stages 
but absent in the ring-stages. This new permeability pathway (transporters) allows 
entry of D-sorbitol in the late stages resulting in cell lysis [322].  Synchronous 
parasites were returned to culture and allowed to mature to the late-stages. A second 
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synchronization step that uses a magnetic column (Miltenyi Biotec) was performed 
to isolate late trophozoite and early schizont parasites stages. This magnetic 
separation exploits the presence of haemozoin in the food vacuole (a by-product of 
haemoglobin breakdown) of late stage parasites (trophozoites and schizonts) [323]. 
Haemozoin contains iron in the ferric state (Fe3+) that has strong magnetic properties, 
and this allows separation of late-stages from the ring stages and uninfected 
erythrocytes obtaining a purified trophozoite/schizont culture (96-99% purity) [324]. 
Purified mature parasite stages were returned to culture and monitored until a 
majority were segmented (approximately 44 hours post invasion). Segmented 
schizonts were incubated with 2.5uM of Compound 2 (4-[7-[(dimethylamino) 
methyl]-2-(4-fluorphenyl) imidazo [1,2-] pyridine-3-yl] pyrimidin-2-amine) for 6 
hours. This reagent prevents merozoite egress from schizonts by inhibiting protein 
kinase G (PfPKG) and blocking the release of the contents of the micronemes and 
exonemes [325]. This inhibition is reversible upon removal of the reagent. Treated 
schizonts were pelleted by centrifugation, resuspended and incubated in fresh media 
to allow egress to occur over 30 minutes to 1 hour. The culture was then filtered 
through a 1.2m Acrodisc filter to separate unruptured schizonts from released 
merozoites. Merozoites obtained were pelleted by centrifugation and used in 
downstream analyses.  
 
2.4.2. SDS-PAGE analysis and Western blot 
 
Parasite material was resolved on a 4-12 % NuPAGE Bis-Tris gel after a 10 minute 
incubation at 70°C with 50mM dithiothreitol (NuPAGE Sample reducing agent) and 
lithium dodecyl sulphate, pH 8.4 with glycerol (NuPAGE LDS sample buffer). Pre-
made gels were assembled on a X-cell Surelock mini-cell system and run using the 
MOPS SDS running buffer (50mM MOPS, 50mM Tris Base, 0.1% SDS, 1 mM 
EDTA, pH 7.7) for 90 minutes at 150 Volts.  Proteins that resolved well on an SDS 
gel were either stained with Coomassie brilliant blue stain overnight or transferred 
onto polyvinylidene fluoride (PVDF) membrane for Western blotting. PVDF 
membranes were soaked in 100% methanol for 30 seconds before a single rinse in 
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water followed by incubation in transfer buffer (20X NuPAGE Transfer buffer). Pre-
soaked sponge pads, blotting paper, resolved SDS gel, PVDF membranes, blotting 
paper and additional pre-soaked sponge pads were assembled in that order on the 
cathode core of the XCell II Blot module (Invitrogen) and sealed and assembled onto 
the X-cell Surelock mini-cell system.  The blot module was filled with transfer buffer 
and outer chamber filled ¾ way with distilled water and transfer done either at 30V 
for 1 hour at room temperature or overnight at 4°C at 10V. Following transfer, PVDF 
membranes were blocked in 5% non-fat milk/0.1% Tween20/PBS for 2 hours at 
room temperature before incubation with the respective primary antiserum at a 1:500 
dilution overnight at 4°C. To characterise the merozoite lysate we obtained from in 
vitro culture, we used sera obtained from rabbits that had been immunised with 
known recombinant merozoite antigens in previous studies conducted in J. Rayner’s 
laboratories. These antisera included anti-GAP45[326], anti-GAP50[326], anti-
MAHRP1, anti-MTIP [326], anti-MyoA [326], anti-MSP3 [327] and anti-EBA175 
(Malaria Research and Reference Reagent Resource centre, www.mr4.org). To 
identify immunogenic merozoite antigens, we used a pool of purified 
immunoglobulins from malaria immune adults (MIG)[328] and a pool of 
immunoglobulins from non-malaria exposed Swedish adults (NEG) as the primary 
antibody. After each incubation step, PVDF membranes were washed thrice with 
0.1% Tween20/PBS. Thereafter, anti-rabbit conjugated to horseradish peroxidase 
(HRP) at a 1:2000 dilution or anti-human IgG conjugated to HRP at various dilutions 
was incubated for 2 hours at room temperature. Detection of HRP reactivity on 
PVDF membranes was enabled using the Supersignal West Pico chemiluminescent 
subtrates (Thermoscientific) according to manufacturer’s instructions. The two 
substrates, peroxide and enhancer, were mixed at a 1:1 ratio and incubated with the 
PVDF membrane for 1 minute. Thereafter, excess subtrates were drained and the 
membrane developed by exposure onto a photographic film (Amersham Hyperfilm 
ECL) in the dark.  
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2.4.3. Purified IgG from malaria-immune and non-exposed individuals 
 
Sera from 17 Swedish adults, who had reported no exposure to malaria nor had 
travelled to malaria-endemic regions, were selected as our negative controls. These 
were assayed for reactivity to P. falciparum A4 strain schizont extract and apical 
membrane antigen (AMA1) as a confirmatory test.  To test for reactivity, 4HBX 
immulon plates were coated with 0.5ug/ml of recombinant AMA1 (kindly provided 
by Dr. Ed Remarque, Biomedical Primate Research Centre, Netherlands) or 
schizont extract at a 1:8000 dilution overnight at 4°C. Wells were washed four times 
with 0.05% tween20/PBS before incubation with block buffer (1% non-fat 
milk/0.05% tween20/PBS) for 5 hours at room temperature followed by incubation 
with test sera at a 1:1000 dilution overnight at 4°C. The following day, washed 
wells were incubated with rabbit-antihuman IgG conjugated to HRP for 3 hours at 
room temperature followed by HRP detection using the sigmaFAST (Sigma 
Aldrich) detection system. Optical density was measured at 492nm. To purify total 
immunoglobulin G from the Swedish sera, pooled sera were heat-inactivated at 
56°C for 30 minutes and IgG purified using Immunopure Plus Immobilized Protein 
G Gel (Pierce). Eluted IgG was buffer exchanged into phosphate buffered saline 
(PBS) thrice, purity confirmed by SDS-page under reducing conditions and stored at 
-20°C. A reference Malaria Immune Globulin (MIG) reagent (Central laboratory 
Blood Transfusion Service SRC, Switzerland) that contains 50mg/ml of 
immunoglobulins (98% IgG) purified from a pool of healthy 834 Malawian adult 
plasma samples was used as a positive control. This reagent was originally 
manufactured to test its potential use as an adjunct therapy to quinine in treatment of 
cerebral malaria[328]. 
 
2.4.4. Immuno-electron microscopy on merozoites using MIG and NEG 
 
To confirm that the merozoite preparation contained merozoites that were 
differentially reactive with the pool of positive and negative controls, it was 
prepared for transmission electron microscopy as follows. The P. falciparum 
merozoites were fixed in 4% paraformaldehyde dissolved in 0.1M phosphate buffer 
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at pH 7.4 for 1 hour at room temperature with gentle rotation.  They were then 
rinsed three times in buffer and infiltrated with 1% and then 10% gelatin before 
immersion in 2.3M sucrose in phosphate buffer overnight at 4°C for cryoprotection. 
The frozen samples were prepared by mounting onto aluminium pins and rapidly 
immersing in liquid nitrogen in preparation for ultrathin 80 nm sectioning on a 
Leica EM FC6 ultramicrotome. These ultra thin sections were labeled using purified 
immunoglobulins from non-exposed individuals (NEG) at a 1:500 dilution and MIG 
at a 1:10000 dilution followed by a goat anti-human IgG (H &L) conjugated to 
10nM gold (Abcam). Imaging was performed on an FEI 120kV Spirit Biotwin with 
a Teitz F4.15 CCD camera. 
 
2.4.5. Immunoprecipitation of proteins extracted from merozoites  
 
The immunoprecipitation protocol was tested using parasite culture supernatant 
obtained following schizont rupture, as this was more readily accessible in a soluble 
form compared to proteins extracted from purified merozoite lysates. Once the 
protocol was optimised, it was adapted for use with extracted merozoite proteins.   
 
To optimise the protocol, 300l of spent culture supernatant was incubated with 
200l of MIG at a 50g/ml concentration for 1 hour at room temperature with 
gentle rotation.  Fifty microliters of magnetic beads coupled to Protein G 
(Dynabeads Protein G, Invitrogen) were washed thrice with a citrate-phosphate 
buffer, pH 5.0 (wash buffer) using a magnet (DynaMag-2, Invitrogen). The antigen-
antibody mixture was added to the washed dynabeads and incubated for 2 hours at 
room temperature with rotation. Eppendorf tubes that contained Protein G coupled 
to magnetic beads were placed alongside a magnet (DynaMag-2, Invitrogen) for 10 
minutes, to allow attachment of beads and the collection of the flow-through 
fraction. Dynabeads were washed four times with wash buffer by vortexing, before 
a final 20-minute incubation with 25l of elution buffer (0.1 M citrate, pH 2-3). 
Five fractions were subsequently separated on a 4-12% gradient SDS gel and 
western blots conducted as has been described in section 2.4.2. These fractions 
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included: 1) the test IgG used in the immunoprecipitation experiments, 2) the 
culture supernatant containing immunogenic antigens 3) the flow-through following 
antigen-antibody binding, 4) four washes and 5) the eluates with the 
immunoprecipitated antigens. Having validated the immunoprecipitation protocol, I 
adapted it for use with parasite proteins extracted from merozoites with the 
following changes. Merozoite proteins were extracted using the radio 
immunoprecipitation assay (RIPA) buffer (150mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris, pH. 8.0) by gentle agitation at 4°C for 1 hour. 
The extracted proteins were collected in supernatant, after a centrifugation step at 
20000xg for 30 minutes at 4°C. Soluble merozoite proteins in the supernatant were 
incubated with purified immunoglobulins MIG and NEG at a final concentration of 
2500g/ml and immunoprecipitated as has been described above. 
 
2.4.6. Bi-dimensional gel electrophoresis coupled to fluorescent western blot 
 
An alternative method to identifying immunogenic merozoite antigens was tested. 
This was a two-step procedure in which merozoite proteins were first separated by 
2-dimensional gel electrophoresis and subsequently detected in a western blot 
performed using MIG and NEG (2DE-blot). Two-dimensional gels were made using 
labeled and unlabeled protein samples obtained from merozoites (3D7 strain and 
KIL9605 isolate). This involved protein separation in the first dimension by 
isoelectric focusing on a 13 cm long pH 3-10NL Immobiline Drystrip (GE 
Healthcare) using the Protean i12 IEF cell system (BioRad) followed by separation 
in the second dimension by SDS-PAGE gel electrophoresis. 
2.4.6.1. Separation in the first dimension by isoelectric focusing 
 
Prior to separation in the first dimension, merozoites were first resuspended in 
extraction buffer (6M Urea, 2M Thiourea, 4% CHAPS, 5mM Magnesium acetate, 
10mM Tris pH 8.5.) vortexed and sonicated and extracted proteins quantified using 
the RC DC protein assay (BioRad). For each 2D-gel, 80g of protein was Cy5 
labelled with 250 picomoles of Chromis 645 dye (Cyanagen, Italy) by incubation 
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for 30 minutes at room temperature and in the dark followed by a 10-minute 
incubation with 10mM lysine to quench the reaction. An equal volume of 2X 
sample buffer containing ampholytes (8M Urea, 4% CHAPS, 2% DTT, 2% IPG 
buffer 3-10NL GE Healthcare Life Sciences) was added and incubated for 15 
minutes in the dark followed by a top up to 250l with De-streak rehydration 
solution (GE Healthcare). The 13cm Immobiline DryStrips were rehydrated 
overnight with the protein solution in the dark after covering the strip with mineral 
oil to prevent dessication. Thereafter iso-electric focusing was done using a step 
voltage gradient (50V for 10 hours, 500V for 1 hour, 1000V for 1 hour and 8000V 
for 48000 volthours) using the Prtean i12 IEF Cell (BioRad).  
2.4.6.2. Separation in the second dimension by SDS gel electrophoresis 
 
The resolved proteins on the 13cm strip were reduced and alkylated prior to 
separation in the second-dimension by SDS-gel electrophoresis as follows. The 
resolved proteins on the 13cm strip were reduced for 15 minutes in equilibration 
reducing buffer (6M Urea, 75mM Tris pH 8.8, 30% glycerol, 2% SDS and 1% 
DTT). Thereafter the strip was alkylated for 15 minutes in alkylation buffer (6M 
Urea, 75mM Tris pH 8.8, 30% glycerol, 2% SDS and 2.5% iodoacetamide), and 
then separated in the second dimension on a 12% SDS-PAGE gel (13cm X 13 cm) 
using the Hoefer SE 600 vertical unit (GE Healthcare) at 20˚C, 20mA for 15 
minutes and 40mA until the dye front reached the bottom of the gel. The gel with 
the unlabeled protein was stained with silver, while those with Cy5 labeled proteins 
were scanned on a Typhoon 9400 laser scanner (GE healthcare) before transfer onto 
nitrocellulose membranes for probing with MIG and NEG IgG. 
2.4.6.3. Western blot detection of immunogenic antigens separated by 2D-gels 
 
To identify immunogenic antigens, merozoite proteins resolved in 2D-gels were 
transferred onto nitrocellulose membranes as has been described in section 2.4.2. 
The nitrocellulose membrane was blocked for 1 hour at room temperature with 5% 
non-fat milk/0.1%Tween 20 followed by incubation with MIG or NEG overnight at 
4°C at a 1:15000 and 1:5000 dilution respectively. Membranes were washed thrice 
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with 0.1%PBS/Tween 20 and incubated with goat anti-human IgG-Fc FITC 
conjugated secondary antibody at 1:500 dilution in the dark. Membranes were 
washed and scanned on a Typhoon 9400 laser scanner (GE healthcare).  
2.4.6.4. Identification and preparation of immunogenic antigens for mass-
spectrometry analysis 
 
Images of the scanned gels, membranes and silver-stained gels were analysed using 
SpotMap (Totallab) for alignment and MIG recognised spots were manually excised 
from the silver-stained gel for mass-spectrometry. Immunogenic spots were excised 
from 2D-gels, pooled and destained. The proteins were then reduced with 10mM 
TCEP for 30 minutes at 56°C and alkylated with 55mM iodoacetamide for 45 
minutes in the dark. Thereafter, proteins were subjected to enzymatic digestion with 
trypsin overnight at 37°C at a 1:30 enzyme-protein ratio. The peptides present in the 
supernatant following trypsin digestion were collected and an equal volume of 
100% acetonitrile (ACN) added. The supernatant was vacuum dried and 
resuspended in 50% acetonitrile/50% of 0.5% formic acid and stored at -20°C. Prior 
to mass-spectrometry analysis, peptides in supernatant were vacuum dried, 
resuspended in 65%acetonitrile/35%H20/0.1% formic acid, filtered and flow 
through vacuum dried and resuspended in 0.5% formic acid. 
 
2.4.7. LC-MS/MS analysis, database search and in-silico analysis of protein 
sequences 
 
Peptides obtained from excised 2D spots were resuspended in 40l of 0.5% formic 
acid and analysed using an Ultimate 3000 Nano/Capillary LC System (Dionex) 
coupled to an LTQ Orbitrap Velos hybrid mass spectrometer (Thermo Fisher) 
equipped with a nanospray source. The peptides were first loaded and desalted on a 
PepMap C18 trap column (0.1mm id x 20mm, 5m, Dionex) for 20 minutes using a 
10l/min flow rate prior to loading on the separation column (PepMap 75m id x 
25cm column with 5m particle size, Dionex). The samples were separated over a 
120-minute long-linear gradient changing from 100% ACN/0.1%v/v formic acid 
(FA) in water) to 5-45% of buffer B (80%ACN/0.1%FA) before a final elution 
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using 95% of buffer B. The Orbitrap mass spectrometer was operated in the “top 
15” data-dependant acquisition mode while the preview mode was enabled. The MS 
full scan was set at m/z of 380-1600 with a resolution at 30,000 and at m/z 400 and 
the automatic gain control (AGC) set at 1x106 with a maximum injection time of 
200 msec. The 15 most abundant multiply-charged precursor ions, with a minimal 
signal above 3000 counts, were selected for CID fragmentation (MS/MS) in the 
LTQ Velos ion trap, which has the AGC set at 5000 and a maximum injection time 
at 100ms. The raw files were processed in Proteome Discoverer (V1.4) (Thermo 
Fisher) using Mascot (V2.5) (Matrix Science) as the protein database search engine 
with the following parameters: Enzymatic digestion was set to trypsin with a 
maximum of 2 missed cleavages sites; peptide mass tolerance search was set at 20 
ppm; MS/MS fragment mass tolerance at 0.50 Da. Variable modifications for 
Acetyl (Protein N-term), Carbamidomethyl (C), Deamidated (NQ), and Oxidation 
(M).  The protein databases were downloaded from Uniprot (October 2014) plus the 
common contaminating database. FDR setting was based on PEP at 0.01 in 
Percolator, and proteins with high confidence peptides were reported. 
 
The proteins identified by the database search were subjected to in silico analyses 
using algorithms for detecting a predicted signal peptide and transmembrane 
domains http://www.cbs.dtu.dk/services/SignalP, 
http://www.cbs.dtu.dk/services/TMHMM/ respectively. The transcript levels of 
identified genes were derived from microarray transcriptome data available on 
PlasmoDB (http://plasmodb.org/plasmo/). Gene ontology cellular component 
enrichment analysis was performed using PlasmoDB where the frequency of 
occurrence of a particular cellular component term within the list of identified 
proteins is compared to the background frequency of occurrence in the entire 
organisms set of genes.  
 
2.4.8. Statistical analysis 
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Data analysis was performed using STATA 13 (StatCorp, TX, USA) and GraphPad 
Prism6 (GraphPad Software, San Diego, California, USA). The Mann-Whitney test 
was used to compare antibody levels to merozoite antigens in a pool of hyper-
immune sera (PHIS) and non-exposed sera.  The unpaired t-test was used to 
compare the mean dN/dS SNP ratio’s between parasite proteins identified in the 
Pf3D7 2DE-blots, KIL9605 2DE-blots or in both data sets. 
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2.5. Results 
2.5.1. Identifying potential immunogenic merozoite antigens using PlasmoDB 
 
I mined data from PlasmoDB to identify antigens that could be accessible to 
antibodies in circulation, either by being secreted or located on the surface of P. 
falciparum merozoites. I limited the list to parasite proteins whose microarray 
expression profiles indicated that maximum mRNA transcription occurs in the late-
trophozoite, early-late schizogony or merozoite stage of the erythrocytic life cycle 
[259, 260]. I used the stages of the erythrocytic life cycle as was defined and 
deposited on PlasmoDB by Le Roch et al [260]. In addition, I limited the list of 
genes to those with a predicted signal peptide and/or predicted transmembrane 
domains that would indicate the protein could potentially be: i) secreted ii) 
peripherally associated to or iii) an integral protein found on the merozoite surface. I 
identified a total of 796 proteins, 550 (69.1%) and 571 (71.7%) of which had a 
predicted N-terminal signal peptide and at least one predicted transmembrane 
domain respectively. The median predicted isoelectric point of the list of potential 
immunogenic merozoite antigens was 8.68 (range: 3.58-11.32) and the median 
predicted molecular weight was 55 KDa (range: 6-1206). As shown in Figure 2.1, of 
this list of potential immunogenic merozoite antigens, I identified 157 (19.7%) 
proteins that had been evaluated for immunogenicity (as of September 2016) using 
data that is publicly available from peer-reviewed publications [146, 147, 267, 271]. 
This preliminary analysis indicated that there were potentially many more 
immunogenic (over 600) merozoite antigens yet to be identified and evaluated. 
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Figure 2.1: Proportion of merozoite antigens assayed for immunogenicity. Pie chart showing the proportion 
of potentially immunogenic merozoite antigens assayed for immunogenicity as of 2013 and 2016. 
 
2.5.2. Visualization of the merozoites isolated from in vitro culture 
 
P. falciparum merozoites (3D7 strain) were obtained from in vitro culture and 
imaged under an electron microscope. This was done to confirm that the purification 
steps resulted in obtaining merozoites. In addition, I tested for reactivity with known 
merozoite antigen antisera that were readily available. As shown in Figure 2.2A, the 
characteristic shape of a circular merozoite with a protruding apical end was 
evident.  Similarly, known merozoite organelles were clearly visible including the 
micronemes located near the apical end, the large rhoptry and rhoptry neck toward 
the apical end of the merozoite. A large nucleus was also evident below the 
rhoptries. A panel of rabbit anti-sera that had previously been generated against 
specific merozoite antigens was used to validate the content of the merozoite pellet 
material obtained from in vitro culture. 
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Figure 2.2: Characterising purified P. falciparum merozoites. Characterisation of the purified P. falciparum 
merozoites obtained from in vitro culture by transmission electron microscopy and western blot A) 
Transmission electron microscopy of the apical end of a merozoite and the whole merozoite B) Western blot 
detection of known merozoite antigens on purified merozoite preparations separated on a SDS-PAGE, using 
anti-GAP45, anti-GAP50, anti-MAHRP1, anti-MTIP, anti-MyoA, anti-MSP3 and anti-EBA175 antisera. 
 
As shown in Figure 2.2B, all the available antigen-specific sera detected their 
respective antigens in the merozoite pellet using Western blots. These included anti-
GAP50, anti-MTIP, anti-MyoA, anti-MSP3 and anti-EBA175 at the expected 
molecular weights [326]. Anti-GAP45 showed reactivity at approximately 39kDa 
and between 64-97kDa while the predicted molecular weight was 45kDa.  
Reactivity with anti-GAP50, anti-MAHRP1, anti-MTIP, anti-MyoA, anti-MSP3 and 
anti-EBA175 sera was observed between 39-51, 28-39, 28, 64-97, 39-51 and 97-191 
kDa respectively, consistent with their predicted molecular weights. Anti-MAHRP1 
sera recognised a protein at the expected predicted molecular weight for MAHRP-1 
(29kDa).  This protein has been shown to localise to the Maurer’s clefts, a parasite-
derived vesicle structure in the infected erythrocyte cytosol, and is thought to play a 
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role in organising and sorting parasite proteins [329]. The presence of MAHRP-1 in 
the preparation suggests that the purified lysate contain some parasite material from 
schizonts as part of the debris obtained during filtration to collect merozoites. 
 
2.5.3. Validating the immunoglobulins from exposed and non-exposed individuals 
 
To ensure that the positive control immunoglobulins (MIG) recognised merozoite 
proteins and the negative controls were non-reactive to malaria antigens, I 
conducted the following tests: i) tested each individual negative control serum 
samples for reactivity with the immunodominant merozoite antigen AMA1 and 
schizont extract by ELISA and ii) tested whether purified merozoites would be 
recognised by the negative and positive control when using immunoelectron 
microscopy. 
 
As shown in Figure 2.3A, the presence of antibodies to AMA1 and schizont extract, 
was measured in the negative controls (the test sera), a second pool of non-exposed 
sera from adults resident in the United Kingdom (UK) and a pool of hyper-immune 
sera collected from adults living in the malaria-endemic region Kilifi in Kenya. I 
observed no differences in the levels of reactivity to both schizont extract and 
AMA1 in the two sets of negative controls. The pool of hyper-immune sera (PHIS) 
had significantly higher antibody levels to schizont extract compared to Swedish 
negative control sera (Mann-Whitney test: 1.226 versus 0.046; p-value=0.011). 
Similarly, reactivity to AMA1 was significantly higher in PHIS compared to 
Swedish sera (Mann-Whitney test: 1.880 versus 0.123; p-value=0.011). 
 
I then confirmed that purified merozoites were differentially recognised by the 
positive and negative control. Transmission electron microscopy was performed on 
purified merozoites incubated with purified immunoglobulins from negative and 
positive controls (Figure 2.3B). I observed higher reactivity in merozoites incubated 
with MIG compared to those incubated with negative pool of IgG as shown by dark 
spots on the surface of the merozoite. This reactivity was localised primarily on the 
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surface of the merozoites. A low level of reactivity was observed with the negative 
control IgG that was similarly primarily localised on the surface of the merozoites. 
 
Figure 2.3: Validating the pool of non-exposed and malaria-exposed purified immunogloblunins. A) 
Reactivity of individual Swedish adult samples (TEST) with Pf schizont extract and AMA1. A second pool of 
negative controls and a pool of hyper-immune sera from adults living in Kilifi (PHIS) were included for 
comparison.  B) Transmission electron microscopy image showing reactivity of purified Pf merozoites with 
purified immunoglobulins from non-malaria exposed adults (NEG) and malaria-exposed adults (MIG). 
M=micronemes. Rh=Rhoptries. N=Nucleus. Dg=Dense granules. PM=Plasma membrane. SC=Surface coat. 
 
2.5.4. Immunoprecipitation of MSP3 using parasite culture supernatant 
 
To optimise the immunoprecipitation protocol using magnetic beads coupled to 
protein G, I used spent culture supernatant into which parasite proteins were 
released following merozoite egress from schizonts. Prior to the 
immunoprecipitation experiment, I tested for the presence of known immunogenic 
merozoite antigens, released into culture supernatant following schizont rupture 
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(Figure 2.4). I detected MSP3 (Figure 2.4, lane 5) and EBA175 (Figure 2.4, lane 6) 
in spent culture supernatant using rabbit anti-MSP3 and anti-EBA175 sera. As 
expected, no reactivity was observed with anti-GAP50, anti-MAHRP1, anti-MTIP 
and anti-MyoA as shown in Figure 2.4 lanes 1, 2 and 3 respectively. Three of these 
antigens (GAP50, MTIP and MyoA) are glideosome proteins located on the inner 
membrane complex detectable in late schizonts and merozoites that form a complex 
involved in erythrocyte invasion [326], while MAHRP-1 is a protein localised to the 
Maurer’s Cleft within the infected erythrocytes. As a result of these locations, none 
of these antigens were expected to be secreted into the parasite culture supernatant 
following merozoite egress. Having confirmed the presence of the known 
immunogen MSP3 in the spent parasite culture supernatant, I tested the ability of the 
pool of purified immunoglobulins (MIG) to immunoprecipitate it alongside other 
immunogenic merozoite antigens. 
 
Figure 2.4: Detection of merozoite antigens in culture supernatant. Western blot detection of known 
merozoite antigens using spent culture supernatant separated on SDS-PAGE, using lane 1) anti-GAP50 2) anti-
MAHRP1 3) anti-MTIP 4) anti-MyoA 5) anti-MSP3 and 6) anti-EBA175 antisera. 
 
To test the ability of MIG to immunoprecipitate MSP3 (a known immunogen), I 
conducted pull-down experiments using parasite culture supernatant obtained 
following merozoite egress as the source of MSP3 and other immunogenic antigens. 
I monitored the experiment by SDS-PAGE (Figure 2.5A) and Western blots (Figure 
2.5B). As shown in Figure 2.5B, the MSP3 band at a size between 39-51 KDa was 
observed in the supernatant fraction, flowthrough as well as in the elution fraction 
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(as indicated by the arrow). No bands were detected in the fraction containing MIG 
antibodies or in the washes, implying immunoprecipitation of known immunogenic 
antigen MSP3 by the pool of immunoglobulins from immune adults.  
 
 
Figure 2.5: Detection of immunoprecipitated MSP3 from culture supernatant. Validation of 
immunoprecipitation protocol using spent culture supernatant. A) Coommassie stained SDS-PAGE showing the 
proteins present in all fractions collected from immunoprecipitation experiments. B) Western blot detection of 
MSP3 in the supernatant, flowthrough and elution fractions of the immunoprecipitation experiment shown using 
the arrow. The Coomassie stained bands at the molecular weights regions corresponding to 50 and 25 KDa are 
the heavy and light chains of human IgG while the other visible bands correspond to parasite proteins. 
 
I then conducted immuno-precipitation experiments using RIPA extracted merozoite 
protein using MIG and non-exposed IgG as a control. Prior to the 
immunoprecipitation, I confirmed that non-exposed IgG and MIG differentially 
recognised the merozoite proteins on a Western blot as shown in Figure 2.6A. 
Merozoite proteins were detected by MIG even at a dilution of 1:100,000 while no 
reactivity was evident with NEG at a dilution of 1:8000. Thereafter, I 
immunoprecipitated RIPA extracted merozoite proteins using NEG and MIG and 
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probed the elutions for the presence of known immunogenic antigens and the 
absence of non-immunogenic proteins by western blot. Figure 2.6B and C show 
Coomassie stained SDS-gels of fractions collected from immunoprecipitation 
experiments using NEG and MIG respectively. These gels confirmed that the RIPA 
extraction protocol was successful in extracting merozoite proteins of varying sizes. 
Similarly, proteins were evident in the eluates from NEG (Figure 2.6B) and MIG 
(Figure 2.6C) immunoprecipitation experiments including the heavy and light 
chains of the respective IgG’s at 50 and 25 KDa.  The binding of antibodies to 
Protein G is disrupted alongside immunoprecipitated proteins during the elution 
step, so elution of IgG bound to the column is expected. 
 
I tested the eluates for immunoprecipitation of known immunogenic merozoite 
antigens namely MSP3, MSP4 and EBA175.  I expected that these antigens would 
be detectable in the eluate fraction from MIG and absent in the NEG 
immunoprecipitation experiment. I also tested for the presence of ERD2, a non-
immunogenic internal merozoite antigen that would serve as a negative control and 
expected to be absent in both eluates. Surprisingly, as shown in Figure 2.6D and E, 
the known immunogenic merozoite antigen MSP4 was detected in elutions from 
both NEG and MIG immunoprecipitation experiments (Figure 2.6D and E, shown in 
the black squares). A third immunogenic antigen MSP3 was not detected in either of 
the eluates (Figure 2.6D and E, shown in the green squares). Lastly, the non-
immunogenic antigen ERD2 was detected in both elutions (Figure 2.6D and E, 
shown in the blue squares). EBA175 was present in the eluate from MIG 
immunoprecipitation and absent in the NEG experiment as was expected (Figure 
2.6D and E, shown in the red squares). These results indicated that there was some 
level of non-specific immunoprecipitation evidenced by ERD2 and MSP4. MSP3 
was not detected in eluates from both MIG and NEG immunoprecipitation 
experiments. 
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Figure 2.6: Immunoprecipitation of merozoite antigens. Immunoprecipitation of RIPA extracted merozoite 
proteins using non-exposed IgG (NEG) and malaria-immune IgG (MIG). A) Recognition of merozoite proteins 
by NEG at a dilution of 1:8000, 1:50000 and 1:100000. Recognition of merozoite proteins by MIG at a dilution 
of 1:32000, 1:50000 and 1:100000. B) Coommassie stained SDS gel of fractions obtained from 
immunoprecipitation of RIPA extract using NEG. C) Coommassie stained SDS gel of fractions obtained from 
immunoprecipitation of RIPA extract using MIG. Western blot detection of MSP3 (green squares), MSP4 (black 
squares), EBA175 (red squares) and ERD2 (blue squares) in elution’s following immunoprecipitation with NEG 
(D) and MIG (E). 
 
One possible explanation for not detecting MSP3 in either eluate would be that 
RIPA buffer did not extract and solubilise MSP3. However as shown in Figure 2.7, 
MSP3 was detectable using rabbit anti-MSP3 in merozoite proteins extracted with 
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RIPA and NP-40 buffer but not detected in extracts using 4% SDS-lysis or the 8M 
Urea buffer. 
 
Figure 2.7: Detection of MSP3 solubilised using different extraction buffers. Detection of MSP3 using 
rabbit anti-MSP3 sera in merozoite proteins extracted with 8M Urea, 4% SDS lysis buffer, RIPA buffer and NP-
40 buffer. 
 
The problems with background in the immunoprecipitation experiments, as well as 
the suggestion that the immunoprecipitation is not highly efficient, as evidenced by 
the absence of precipitation of MSP3, prompted me to explore bi-dimensional gel 
electrophoresis coupled to Western blotting as an alternative strategy. 
 
2.5.5. Identification of immunogenic merozoite antigens using 2DE-Western 
Blots: 3D7 strain 
 
P. falciparum merozoite antigens from the 3D7 strain were analysed by bi-
dimensional isoelectric focusing gel electrophoresis using a pH gradient ranging 
from pH 3-10 and silver-stained after the second dimension separation by SDS as 
shown in Figure 2.8A. Merozoite proteins that were recognised by MIG or NEG 
were detected using FITC conjugated anti-human antibody visible as green spots 
and shown in Figure 2.8B and C respectively.  As described in detail in section 
2.4.6.1, proteins extracted from merozoites were Cy5 labelled (red) prior to 
resolution by 2DE. These proteins were then probed for reactivity with MIG or 
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NEG and bound IgG were detected using a secondary antibody that was FITC 
labelled (green). As a result, scanning of the 2DE-Western blots revealed two 
colours, red spots indicated resolved merozoite proteins that did not react with IgG 
while green spots indicated proteins bound by IgG. The degree of Cy5 labelling is 
likely to reflect the quantity of lysine residues present in each protein as the dyes 
covalently attach to the free amine group on the N-terminal or lysine residues on 
proteins.   
 
Figure 2.8: Detection of immunogenic 3D7 antigens by 2DE. Bi-dimensional gel electrophoresis of 
P.falciparum 3D7 strain merozoite antigens and reactivity with MIG and NEG. A) Silver-stained image of 
merozoite antigens separated by two-dimensional gel electrophoresis (2D-gels). B). Fluorescent western blot 
image of MIG reactive merozoite antigens C) Fluorescent western blot detection of NEG reactive merozoite 
antigens. Antibody reactive proteins are shown as green spots while red spots are Cy5 labelled merozoite 
proteins that are not bound by antibodies. 
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Distinct green fluorescent spots were visible in western blot with MIG (Figure 2.8B 
and Figure 2.9A) and these were mapped using the SpotMap image analysis 
software onto the silver-stained gel (Figure 2.9B and C). A total of 69 spots or 
regions were mapped and manually excised from the silver-stained gel for 
identification by mass-spectrometry.  
 
 
 
Figure 2.9: Mapping immunogenic antigens on a 2DE gel. Mapping of immunogenic merozoite antigens onto 
silver-stained gel for manual excision and identification by mass-spectrometry. A) Western blot image of 
antigens recognised by MIG B) Mapping of spots recognised by MIG using SpotMap, image analysis tool C) 
Mapping of spots recognised by MIG onto the silver-stained gel image using SpotMap, image analysis tool. 
Antibody reactive proteins are shown as green spots. 
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2.5.6.  Protein characteristics (3D7 strain): signal peptides and transmembrane 
domains 
 
The proteins corresponding to regions of the Western blot recognised by MIG were 
excised from silver-stained gels and identified by mass-spectrometry. These yielded 
a list of 216 unique UniProt identifiers, which mapped onto 210 unique proteins in 
the PlasmoDB database (Appendix 2.1). I analysed the list of proteins obtained for 
their predicted isoelectric points and molecular weights, as I had used a pH gradient 
of limited to pH: 3-10 for separation in the first dimension and a 12% SDS-gel for 
the second dimension limited to separation of proteins between 10-250 KDa. 
 
As shown in Figure 2.10A and B, the identified proteins had a predicted median 
molecular weight of 51.0 KDa (range: 11.4-688.9) and a predicted median 
isoelectric point of 6.38 (range: 3.89-10.98). Searching the SignalP and TMHMM 
webservers revealed that forty-nine (20.5%) and 37 (17.6%) of the identified 
proteins were predicted to have a signal peptide and transmembrane domain(s), 
respectively. A known limitation of 2DE is the inability of the extraction buffers to 
solubilise membrane proteins. To evaluate whether membrane proteins were 
underrepresented in my findings, I compared the occurrence of features within my 
list and the total 3D7 predicted genes. The proportion of proteins with 
transmembrane domains identified by 2D-blot was statistically lower than their 
occurrence within protein coding genes in the 3D7 genome (genome versus 2D-
blots: 30.6% versus 17.6%; p-value=0.0001). No differences were observed with 
proteins predicted to have a signal peptide (genome versus 2D-blots: 19.3% versus 
20.5%; p-value=0.6712). Of those proteins with predicted transmembrane domains, 
33 (15.7%), 3 (1.43%) and 1 (0.48) were predicted to have one, two and seven 
transmembrane domains as shown in Figure 2.10C. 
 
 104 
 
 
Figure 2.10: Characteristic of proteins identified by mass-spectrometry spots picked from the 2DE-
Western Blots. Histograms showing the distribution of the predicted molecular weights (A), isoelectric points 
(B) and number of transmembrane domains (C) in the proteins identified by mass-spectrometry. 
 
2.5.7. Protein characteristics (3D7 strain): predicted cellular localization and 
transcriptional profiles 
 
To further analyse the characteristics of the proteins identified, I obtained data from 
PlasmoDB with information on the transcriptional profiles during the erythrocytic 
cycle and the predicted gene ontology for each of the antigens.  The transcriptome 
data collected indicated the maximal transcriptional timing across the 48-hour 
asexual cycle. The gene ontology analysis on PlasmoDB provides terms associated 
with each gene’s products that represent its predicted properties such as cellular 
location or the biological processes associated with the gene product 
(http://geneontology.org). A total of 24 predicted cellular GO terms were obtained 
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which were classified into four major subcellular localizations namely: nucleus-, 
cytoplasm-, mitochondrial- and membrane- associated localization as shown in 
Table 2.1.  
 
Table 2.1: Table showing the classification of the predicted cellular localization gene-ontology terms for 
proteins identified in the 2DE-Western Blots experiments: 3D7 strain 
The classification of the 24 cellular GO terms into 4 broad cellular localization terms 
Nucleus-associated PCNA complex 
 cytoplasm, nucleus 
 endoplasmic reticulum 
 eukaryotic translation elongation factor 
 intracellular, ribosome 
 nucleus 
 nucleosome, nucleus 
 ribosome 
 ribosome, small ribosomal subunit 
 small ribosomal subunit 
 eukaryotic translation elongation factor 1 complex 
Cytoplasm-associated cAMP-dependent protein kinase complex 
 cytoplasm 
 intracellular 
 intracellular, membrane 
 oxoglutarate dehydrogenase complex 
 phosphopyruvate hydratase complex 
 prefoldin complex 
 proteasome core complex 
 protein complex 
Mitochondrial-associated mitochondrial envelope 
 mitochondrial outer membrane 
Membrane associated membrane 
 myosin complex 
No predicted GO term  null 
 
As shown in Table 2.2, the majority of proteins identified 164 (75.9%) had no 
predicted localisation.  Twenty (9.3%) and 19 (8.8%) proteins, were predicted to be 
localised to the nucleus and the cytoplasm, respectively. Two proteins (0.9%) were 
considered mitochondrial-associated and five (2.3%) as membrane associated 
proteins.  The median maximal transcription hours post invasion (hpi) was 29 hours. 
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Proteins were classified as having their maximal transcription between 1-16 hpi, 17-
34 hpi and 35-48 hpi representing the ring, trophozoite and schizont stages of the 
erythrocytic life cycle. The majority (78.1%) of identified proteins showing elevated 
transcription levels in the 17-34 hpi and 35-48 hpi as shown in Table 2.2. 
 
Table 2.2:Table showing predicted gene-ontology terms and maximal transcription profiles for proteins 
identified in the 2DE-Western Blot experiments: 3D7 strain 
Number of proteins categorised into broad predicted cellular localization 
Predicted cellular location N (%) 
Nucleus associated 20 (9.3) 
Cytoplasm 19 (8.8) 
Mitochondria 2 (0.9) 
Membrane, extracellular 5 (2.3) 
Null 164 (75.9) 
Data not available 6 (2.8) 
P. falciparum maximal expression timing over the 48 hour erythrocytic cycle  
Hours post merozoite invasion (hpi) N (%) 
1-16  40 (19.1) 
17-34  83 (39.5) 
35-48  81 (38.6) 
Data not available 6 (2.9) 
 
2.5.8. Comparison of identified antigens in the 2DE-Western Blot (3D7 strain) 
and known immunogenic antigens 
 
Of the 210 proteins identified in the spots excised from 2DE gels, I found that 35 
(16.7%) of the targets had been previously shown to be immunogenic in peer-
reviewed publications [146, 147, 265, 267, 271, 292]. These include known 
immunogenic merozoite antigens such as Merozoite Surface Protein 1, 2, 3, 6, 7 and 
9, Apical Membrane Antigen 1 (AMA1), GPI-anchored Micronemal Antigen 
(GAMA), Glutamate Rich Protein (GLURP), High Molecular Weight Rhoptry 
Protein 3 (RhopH3) and Serine Repeat Antigen 4 and 5 (SERA 4 and 5). The full 
list of antigens identified in the 3D7 2DE-Western Blots and previously shown to be 
immunogenic is provided in Table 2.3. The proportion of the entire protein that was 
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identified by mass-spectrometry, as well as the number of unique peptides used to 
identify the protein, are shown in the columns labeled sequence coverage and 
unique peptides respectively. The majority of the antigens that I identified, 175 
(83.3%), do not appear to have been studied in the context of naturally acquired 
immunity to malaria.  
 
Table 2.3: Table showing proteins identified in the 2DE-Western Blot and previously shown to be 
immunogenic: 3D7 strain 
PlasmoDB 
identifier 
Product description Sequence 
Coverage 
Unique 
peptides 
Predicted 
signal peptide 
Predicted 
transmemb
rane 
domains 
PF3D7_0818200 14-3-3 protein (14-3-3I) 66.41 16 No No 
PF3D7_1232100 60 kDa chaperonin (CPN60) 15.74 8 Yes Yes 
PF3D7_0828800 GPI-anchored micronemal 
antigen (GAMA) 
5.96 3 Yes Yes 
PF3D7_1311800 M1-family alanyl 
aminopeptidase (M1AAP) 
0.92 1 No Yes 
PF3D7_0401800 Plasmodium exported protein 
(PHISTb)(PfD80) 
3.21 1 No Yes 
PF3D7_0801000 Plasmodium exported protein 
(PHISTc), unknown function 
0.74 1 No Yes 
PF3D7_1149000 Antigen 332, DBL-like protein 
(Pf332) 
0.34 2 No No 
PF3D7_1133400 Apical membrane antigen 1 
(AMA1) 
1.93 1 Yes Yes 
PF3D7_1014100 Conserved Plasmodium protein, 
unknown function 
0.39 1 Yes No 
PF3D7_1468100 Conserved Plasmodium protein, 
unknown function 
1.72 2 No No 
PF3D7_1320800 Dihydrolipoyllysine-residue 
succinyltransferase component of 
2-oxoglutarate dehydrogenase 
complex 
3.56 1 No No 
PF3D7_1401400 Early transcribed membrane 
protein 14.1 (ETRAMP14) 
12.15 1 Yes Yes 
PF3D7_0532100 Early transcribed membrane 
protein 5 (ETRAMP5) 
28.18 6 Yes Yes 
PF3D7_1222300 Endoplasmin, putative (GRP94) 21.07 13 Yes No 
PF3D7_1035300 Glutamate-rich protein (GLURP) 0.89 1 Yes No 
PF3D7_0818900 Heat shock protein 70 (HSP70) 71.49 71 No No 
PF3D7_0905400 High molecular weight rhoptry 
protein 3 (RhopH3) 
9.7 7 Yes No 
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PlasmoDB 
identifier 
Product description Sequence 
Coverage 
Unique 
peptides 
Predicted 
signal peptide 
Predicted 
transmemb
rane 
domains 
PF3D7_0532400 Lysine-rich membrane-
associated PHISTb protein 
(LyMP) 
2.27 1 No Yes 
PF3D7_0500800 Mature parasite-infected 
erythrocyte surface 
antigen,erythrocy 2 (MESA) 
8.86 9 No No 
PF3D7_0930300 Merozoite surface protein 1 
(MSP1) 
41.98 76 Yes Yes 
PF3D7_0206800 Merozoite surface protein 2 
(MSP2) 
22.06 4 No No 
PF3D7_1035400 Merozoite surface protein 3 
(MSP3) 
44.92 18 Yes No 
PF3D7_1035500 Merozoite surface protein 6 
(MSP6) 
32.35 13 No No 
PF3D7_1335100 Merozoite surface protein 7 
(MSP7) 
54.7 26 Yes No 
PF3D7_1228600 Merozoite surface protein 9 
(MSP9) 
1.62 1 Yes No 
PF3D7_1129100 Parasitophorous vacuolar protein 
1 (PV1) 
46.68 16 Yes No 
PF3D7_1467900 Rab GTPase activator, putative 0.66 1 No No 
PF3D7_0935900 Ring-exported protein 1 (REX1) 15.01 3 No Yes 
PF3D7_1149200 Ring-infected erythrocyte surface 
antigen 
1.1 1 No No 
PF3D7_0207700 Serine repeat antigen 4 (SERA4) 9.46 6 Yes No 
PF3D7_0207600 Serine repeat antigen 5 (SERA5) 19.66 16 Yes No 
PF3D7_1414400 Serine/threonine protein 
phosphatase PP1 (PP1) 
3.95 1 No No 
PF3D7_0702400 Small exported membrane 
protein 1 (SEMP1) 
17.89 2 No Yes 
PF3D7_1436300 Translocon component PTEX150 
(PTEX150) 
8.36 8 Yes No 
PF3D7_1008700 Tubulin beta chain 14.16 6 No No 
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2.5.9. Identification of immunogenic merozoite antigens using 2DE-Western 
Blots: KIL9605 isolate 
 
As long-term lab adapted isolates such as the 3D7 strain are known to undergo 
spontaneous gene deletions during in vitro culture [330, 331], and have not been 
exposed to immune pressure for a considerable period, I hypothesised that a recently 
lab-adapted isolate (KIL9605; obtained from a cerebral malaria patient admitted to 
Kilifi County Hospital, Kenya) might express a more diverse array of merozoite 
antigens.  
 
Purified P. falciparum merozoite antigens from KIL9605 were analysed by bi-
dimensional isoelectric focusing gel electrophoresis using a pH gradient ranging 
from pH 3-10 and silver-stained after the second dimension separation by SDS as 
shown in Figure 2.10A. and as described above for the 3D7 strain. Spots or regions 
recognised by MIG are shown in Figure 2.11B and C while the negative control IgG 
was not reactive as shown in Figure 2.11D. 
 
I mapped immunoreactive spots using the SpotMap image analysis software onto 
the silver-stained gel (Figure 2.12A, B and C). A total of 117 spots or regions were 
mapped and manually excised from the silver-stained gel and identified by mass-
spectrometry.  271 unique uniprot identifiers were identified that mapped to 262 
PlasmoDB unique identifiers and available in Appendix 2.2. As hypothesised, this 
was higher than the number of targets identified in the 3D7 immunoblot experiment. 
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Figure 2.11: Detection of immunogenic KIL9605 antigens by 2DE. Bi-dimensional gel electrophoresis of 
P.falciparum KIL9605 strain merozoite antigens and reactivity with MIG and NEG. A) Silver-stained image of 
merozoite antigens separated by two-dimensional gel electrophoresis (2D-gels). B). Fluorescent western blot 
image of MIG reactive merozoite antigens C) Western blot image of MIG reactive merozoite antigens D) 
Western blot image of NEG reactive merozoite antigens. Antibody reactive proteins are shown as green spots 
while red spots are Cy5 labelled merozoite proteins that are not bound by antibodies. 
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Figure 2.12: Mapping immunogenic antigens on a 2DE gel. Mapping of immunogenic merozoite (KIL9605 
strain) antigens onto silver-stained gel for manual excision and identification by mass-spectrometry. A) Western 
blot image of antigens recognised by MIG B) Mapping of spots recognised by MIG using SpotMap, image 
analysis tool C) Mapping of spots recognised by MIG onto the silver-stained gel image using SpotMap, image 
analysis tool. Antibody reactive proteins are shown as green spots. 
 
2.5.10. Protein characteristics (KIL9605 isolate): signal peptides, transmembrane 
domains and transcriptional profiles 
 
Similar to the 3D7 strain, identified proteins from KIL9605 isolate had a predicted 
median molecular weight of 53.0 KDa (range: 11.1-370.2) and a predicted median 
isoelectric point of 6.44 (range: 4.13-11.22). Searching the SignalP and TMHMM 
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webservers revealed that forty-two (16.03%) and 37 (14.1%) of the identified 
proteins were predicted to have a signal peptide and transmembrane domain(s) 
respectively.  The proportion of proteins with transmembrane domains identified 
was statistically lower than their occurrence within protein coding genes in the 3D7 
genome (genome versus 2D-blots: 30.6% versus 14.1%; p-value<0.0001). No 
differences were observed with proteins predicted to have a signal peptide (genome 
versus 2D-blots: 19.3% versus 16.0%; p-value=0.1891). Of those proteins with 
predicted transmembrane domains, 30 (11.45%), 2 (0.76%) were predicted to have 
one and two transmembrane domains. One antigen (0.38%) was predicted to have 
three, four, six, seven and eleven transmembrane domains. I used transcriptome data 
available on PlasmoDB where the maximal transcriptional timing across the 48-hour 
asexual cycle is available. Similar to the results with the 3D7 strain, the median 
maximal transcription hours post invasion (hpi) was 30 hours. Proteins were 
classified as having their maximal transcription between 1-16 hpi: 57 (21.03%), 17-
34 hpi: 95 (35.06%) and 35-48 hpi: 101 (37.27%) with the majority (72.3%) of 
identified proteins showing elevated transcription levels in the 17-34 hpi and 35-48 
hpi. Transcription profile over the 48-hour asexual life cycle was not available for 
18 (6.64%) of the identified antigens. 
 
2.5.11. Comparison between antigens identified in the 2DE-Western Blot from 
3D7 strain and KIL9605 isolate 
 
I had hypothesised that the antigenic determinants would vary between a recently 
lab-adapted clinical isolate obtained from a cerebral malaria patient and the lab-
adapted 3D7 strain that has been maintained in in vitro culture in the absence of the 
host’s immune system. I therefore compared the number of targets and their level of 
polymorphism between targets identified in the two parasite lines. 
 
More proteins were identified by MIG using the KIL9605 isolate compared to the 
3D7 strain (210 versus 262 proteins respectively). As shown in Figure 2.13, 133 
(39%) proteins were identified in both sets of experiments while 77 (23%) and 129 
(38.1%) were targets identified only with the 3D7 and KIL9605 isolate respectively. 
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Interestingly, targets found exclusively in the 3D7 2DE-blots had a higher level of 
polymorphisms compared to those found in the KIL9605 strain or both experiments.  
As shown in Figure 2.14, the ratio of non-synonymous /synonymous single 
nucleotide polymorphisms (dN/dS SNP ratio) was higher in the genes encoding 
antigens identified in the 3D7 blots (mean dN/dS SNP ratio in 3D7 versus KIL9605: 
2.533 versus 1.529: p-value=0.0165, unpaired t-test).   
 
 
Figure 2.13: Comparison of the number of antigens identified with the 3D7 and KIL9605 isolate. Venn 
diagram showing the overlap between proteins identified by mass-spectrometry in the 2D-blot from merozoite 
proteins extracted from 3D7 strain and KIL9605 clinical isolate. 
 
There were no significant differences in the mean dN/dS ratio between genes 
encoding antigens identified exclusively in the KIL9605 strain compared to those 
found in both data sets. Lastly, the mean dN/dS ratio was higher in the 3D7 dataset 
compared to antigens identified in both data sets (mean dN/dS SNP ratio in 3D7 
versus both: 2.533 versus 1.293: p-value=0.003, unpaired t-test).  
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Figure 2.14: Comparing the level of polymorphism in antigens identified using the 3D7 or KIL9605 
isolate. The ratio of non-synonymous/synonymous SNPs (dN/dS) in the genes encoding proteins identified by 
mass-spectrometry exclusively in the 2D-blot from merozoite proteins extracted from 3D7 strain and KIL9605 
clinical isolate were compared using the Mann-Whitney U test. *: p-value <0.05, **: p-value <0.001 
 
The following arguments represent plausible explanations for the differences 
observed between targets identified in the KIL9605 isolate and the 3D7 strain. The 
higher proportion of antigens identified exclusively in the KIL9605 dataset could 
represent: 1) identification of immunogenic targets lost following spontaneous 
deletions of segments of chromosomes in 3D7, resulting in a lower hit rate with the 
3D7 strain; 2) identification of immunogenic targets expressed in clinical isolates 
that serve as an immune evasion mechanism, by being a smoke screen that diverts 
antibody responses from “true” targets, expression of which are lost during long-
term in vitro culture in the absence of host immunity; 3) the similarities between the 
KIL9605 isolate and the Malawi isolates circulating at the time immunoglobulins 
were obtained from malaria-immune adults were higher that those between the 3D7 
strain and Malawi isolates. Of note, Malawi and Kenya are in East Africa while 3D7 
strain originated from West Africa. Differences between isolates from difference 
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geographical regions have been reported at several genetic loci [332-334]. 
Interestingly, I show that genes identified exclusively in the 3D7 dataset were 
significantly higher in their level of non-synonymous polymorphisms when 
compared to targets identified in both datasets. Encouragingly, this may indicate the 
presence of immunogenic targets of limited polymorphisms or with conserved 
epitopes that are found across isolates from different geographical regions and was 
therefore identified as immunogenic in both strains. The targets identified 
exclusively in the 3D7 isolate were highly polymorphic, it is therefore conceivable 
that they may induce strong strain specific antibodies such that the antibodies 
obtained from Malawian adults would not recognise the variant antigen expressed in 
a Kilifi isolate. 
 
Of the 339 proteins identified in the spots excised from 2DE-blots from both 
isolates, I found that a total of 59 (17%) proteins have been previously shown to be 
immunogenic. 26 were identified in both parasite isolates (Table 2.4) while 
additional 14 (Table 2.5) and 19 targets (Table 2.6) were identified in only the 3D7 
strain and KIL9605 2DE-blot respectively. Although I replicated the 2D-gel and 
western blotting steps for both the 3D7 and KIL9605 isolate and observed the spot 
pattern for recognition was similar, I excised spots from a single gel representing 
one biological replicate for each isolate. As such, the differences observed between 
the isolates could be due to primarily technical factors. Establishing that these are 
real biological differences would require confirmation with additional replicate data 
from mass-spectrometry. Despite this limitation, the majority of targets identified, 
280 (83%) had not been evaluated as targets of naturally acquired antibodies. 
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Table 2.4: Table showing proteins identified in the 2DE-blot from both 3D7 and KIL9605 and previously 
shown to be immunogenic. 
Known immunogenic antigens identified in both 3D7 strain and KIL9605 isolate 
PlasmoDB 
identifier 
Product description Predicted 
signal 
peptide 
Predicted 
transmembrane 
domains 
PF3D7_0207600 Serine repeat antigen 5 (SERA5) Yes No 
PF3D7_0207700 Serine repeat antigen 4 (SERA4) Yes No 
PF3D7_0401800 Plasmodium exported protein (PHISTb), unknown function 
(PfD80) 
No Yes 
PF3D7_0532100 Early transcribed membrane protein 5 (ETRAMP5) Yes Yes 
PF3D7_0702400 Small exported membrane protein 1 (SEMP1) No Yes 
PF3D7_0801000 Plasmodium exported protein (PHISTc), unknown function No Yes 
PF3D7_0818200 14-3-3 protein (14-3-3I) No No 
PF3D7_0818900 Heat shock protein 70 (HSP70) No No 
PF3D7_0905400 High molecular weight rhoptry protein 3 (RhopH3) Yes No 
PF3D7_0930300 Merozoite surface protein 1 (MSP1) Yes Yes 
PF3D7_1008700 Tubulin beta chain No No 
PF3D7_1014100 Conserved Plasmodium protein, unknown function Yes No 
PF3D7_1028700 Merozoite TRAP-like protein (MTRAP) Yes Yes 
PF3D7_1035400 Merozoite surface protein 3 (MSP3) Yes No 
PF3D7_1115400 Cysteine proteinase falcipain 3 (FP3) No Yes 
PF3D7_1129100 Parasitophorous vacuolar protein 1 (PV1) Yes No 
PF3D7_1133400 Apical membrane antigen 1 (AMA1) Yes Yes 
PF3D7_1149200 Ring-infected erythrocyte surface antigen No No 
PF3D7_1222300 Endoplasmin, putative (GRP94) Yes No 
PF3D7_1232100 60 kDa chaperonin (CPN60) Yes Yes 
PF3D7_1311800 M1-family alanyl aminopeptidase (M1AAP) No Yes 
PF3D7_1335100 Merozoite surface protein 7 (MSP7) Yes No 
PF3D7_1401400 Early transcribed membrane protein 14.1 (ETRAMP14) Yes Yes 
PF3D7_1436300 Translocon component PTEX150 (PTEX150) Yes No 
PF3D7_1467900 Rab GTPase activator, putative No No 
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Table 2.5: Table showing proteins identified in the 2DE-blot from 3D7 strain and previously shown to be 
immunogenic 
Known immunogenic antigens identified in the 3D7 strain 2DE-blots 
PlasmoDB 
identifier 
Product description Predicted 
signal 
peptide 
Predicted 
TMDs 
PF3D7_0206800 Merozoite surface protein 2 (MSP2) No No 
PF3D7_0500800 Mature parasite-infected erythrocyte surface antigen, erythrocyte 
membrane protein 2 (MESA) 
No No 
PF3D7_0532400 Lysine-rich membrane-associated PHISTb protein (LyMP) No Yes 
PF3D7_0828800 GPI-anchored micronemal antigen (GAMA) Yes Yes 
PF3D7_0935900 Ring-exported protein 1 (REX1) No Yes 
PF3D7_1035300 Glutamate-rich protein (GLURP) Yes No 
PF3D7_1035500 Merozoite surface protein 6 (MSP6) No No 
PF3D7_1121600 Circumsporozoite-related antigen, exported protein 1 (EXP1) Yes Yes 
PF3D7_1149000 Antigen 332, DBL-like protein (Pf332) No No 
PF3D7_1228600 Merozoite surface protein 9 (MSP9) Yes No 
PF3D7_1320800 Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 
No No 
PF3D7_1414400 Serine/threonine protein phosphatase PP1 (PP1) No No 
PF3D7_1420700 Surface protein P113 Yes Yes 
PF3D7_1468100 Conserved Plasmodium protein, unknown function No No 
TMDs: Transmembrane domains 
Table 2.6: Table showing proteins identified in the 2DE-blot from KIL9605 isolate and previously shown 
to be immunogenic. 
Known immunogenic antigens identified in the KIL9605 strain 2DE-blots 
PlasmoDB 
identifier 
Product description Predicted 
signal 
peptide 
Predicted 
TMDs 
PF3D7_0214100 Protein transport protein SEC31 (SEC31) No No 
PF3D7_0214900 Rhoptry neck protein 6 (RON6) Yes No 
PF3D7_0404900 6-cysteine protein (P41) Yes No 
PF3D7_0405900 Apical sushi protein (ASP) Yes Yes 
PF3D7_0407800 Conserved Plasmodium protein, unknown function No No 
PF3D7_0501100.1 Heat shock protein 40, type II (HSP40) No Yes 
PF3D7_0532300 Plasmodium exported protein (PHISTb), unknown function No No 
PF3D7_0730300 Transcription factor with AP2 domain(s) (AP2-L) No No 
PF3D7_0806800 Vacuolar proton translocating ATPase subunit A, putative No Yes 
PF3D7_0918900 Gamma-glutamylcysteine synthetase (gammaGCS) No No 
PF3D7_0922100 Ubiquitin-like protein, putative No Yes 
PF3D7_1003800 U5 small nuclear ribonuclear protein, putative No No 
PF3D7_1035700 Duffy binding-like merozoite surface protein (DBLMSP1) Yes No 
PF3D7_1123400 Translation elongation factor EF-1, subunit alpha, putative No No 
PF3D7_1252100 Rhoptry neck protein 3 (RON3) Yes Yes 
PF3D7_1335400 Reticulocyte binding protein 2 homologue a (RH2a) No Yes 
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2.5.12. Novel immunogenic merozoite antigens 
 
The majority of targets I identified in either the 3D7 or KIL9605 isolate had not 
been evaluated in the context of naturally acquired immunity. I analysed these 
targets further in the following ways. First, I investigated the overlap between the 
potentially novel targets (N=280) with a network of genes proposed to play a role in 
erythrocyte invasion by merozoites, based primarily on concurrent transcription on 
exposure to parasite growth inhibitory compounds [258]. Secondly, I compared the 
identified targets with those identified to be under balancing selection in a previous 
whole genome sequence study of 65 clinical isolates from the Gambia [253]. Genes 
under balancing selection are thought to be exposed to immune pressure in order to 
maintain different alleles in the population at intermediate frequencies [335]. Lastly, 
I tested for the overlap of the targets I identified with genes where genetic 
manipulation of rodent malaria orthologues (primarily P. berghei) had been 
attempted as of October 2016, using data deposited in these two databases: i) 
RMgmDB: (http://www.pberghei.eu/index.php) and ii) PlasmoGEM: 
(http://plasmogem.sanger.ac.uk/) [336].  These may provide valuable information on 
genes that may be essential for parasite growth during the asexual blood-stages of 
the life cycle. As shown in Table 2.7, genes termed as invasion-related or under-
balancing selection, were significantly higher in proportion within this 2D dataset 
than their occurrence within the genome. In contrast, P. berghei orthologues whose 
genetic modification classified the genes as either essential, resulted in reduced 
growth rate or dispensable over the asexual growth cycle, were significantly lower 
in proportion within the 2D-blot datasets obtained in my study. This may suggest 
that P. falciparum parasites may have evolved ways to shield proteins that are 
essential for growth and survival from protective antibody responses. 
 
Of the potential novel targets (N=280), 30 (11%) are considered to play important 
roles in erythrocyte invasion and 19 (7%) are considered to be under balancing 
selection as listed in Table 2.7 and 2.8 respectively. Attempts to genetically disrupt 
their rodent malaria orthologous have been reported for 49 (18%) and 162 (58%) of 
the novel targets identified on the RMgmDB and PlasmoGEM databases 
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respectively. Of these targets, 14 (Table 2.9) and 109 (Appendix 2.3) may represent 
essential blood-stage antigens as the disruption of their P. berghei orthologues have 
been attempted but were not successful. Several antigens I identified in this study 
were amenable to gene disruption (35 and 53 in the RMgmDB and PlasmoGEM 
databases, respectively). Interestingly, disruption of some of these genes showed 
significant differences in their asexual blood-stage growth rate when compared to 
wild-type parasites.  
 
In the context of naturally acquired immunity, antigens of interest for further 
evaluation would include: i) identified as immunogenic in my study but have not 
been evaluated as such ii) proposed to play a role in erythrocyte invasion 
(invadome) and iii) may play an essential role over asexual stage of the life cycle. 
For example, PF3D7_1455300, a target described as a “conserved Plasmodium 
protein, unknown function” on PlasmoDB, has been proposed to be a member of the 
core “invadome” [258] and shown to be under balancing selection (Tajima 
D=0.015) [253]. The P. berghei orthologue (PBANKA-1319000) is termed as an 
essential gene over the asexual stages of the life cycle in both the RMgmDB and 
PlasmoGEM databases. Thirteen targets shared similar features described above 
representing potential important targets of naturally acquired immunity whose 
evaluation and prioritization is warranted.  
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Table 2.7: Table showing a comparison between the occurrences of proteins of specific characteristics 
within the 2DE-blot data set and the genome. 
Feature Proportion found 
within the genome# 
N=5305 (%) 
Proportion found within 
entirea and novelb dataset 
P-value 
Member of the invadome 418 (7.88) a: 50 (14.8) 
b: 30 (11.0) 
0.0025 
0.0613 
Positive Tajima D* 337 (6.7) a: 35 (10.3) 
b: 19 (7.0) 
0.0115 
0.8452 
P. berghei phenotype suggests the 
genes play essential functions over 
asexual stages% 
1195 (46.4) a: 125 (36.9) 
b: 109 (38.9) 
0.0010 
0.0167 
P. berghei phenotype suggests 
modification of the gene results in a 
reduced growth rate over asexual 
stages% 
456 (17.7) a: 34 (10.0) 
b: 28 (10.0) 
0.0004 
0.0011 
P. berghei phenotype suggests the 
genes play dispensable roles over 
asexual stages% 
911 (35.4) a: 28 (8.3) 
b: 25 (8.9) 
<0.0001 
<0.0001 
 
 
#- Protein coding genes (excluding pseudogenes) on PlasmoDB. *-N=5056 genes were analysed. %- N-2575 
number of genes with a phenotype reported on PlasmoGEM. a:-N=339 and b:-N=280
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Table 2.8: Novel Nineteen (19) P. falciparum antigens identified as being under balancing selection. 
Plasmodium falciparum 
gene ID 
Product description Tajima D scores Additional notes 
PF3D7_0202100 liver stage associated protein 2 (LSAP2) 0.208 Proposed to be essential for invasion 
PF3D7_0318200 DNA-directed RNA polymerase II subunit RPB1 (RPB1) 0.72  
PF3D7_0424600 Plasmodium exported protein (PHISTb), unknown function 2.298  
PF3D7_0508800 single-stranded DNA-binding protein (SSB) 1.789  
PF3D7_0627800 acetyl-CoA synthetase, putative (ACS) 0.908  
PF3D7_0806500 DnaJ protein, putative 0.233  
PF3D7_0807800 26S proteasome regulatory subunit RPN10, putative (RPN10) 0.216  
PF3D7_0808300 ubiquitin regulatory protein, putative 0.062 Proposed to be essential for invasion 
PF3D7_0810800 Hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate 
synthase (PPPK-DHPS) 
0.155  
PF3D7_0831400 Plasmodium exported protein, unknown function 0.132  
PF3D7_1115300 cysteine proteinase falcipain 2b (FP2B) 0.062  
PF3D7_1134000 heat shock protein 70 (HSP70-3) 1.301  
PF3D7_1229500 T-complex protein 1 subunit gamma (CCT3) 2.016  
PF3D7_1343700 kelch protein K13 (K13) 0.084  
PF3D7_1347700 ethanolamine-phosphate cytidylyltransferase (ECT) 0.581 Mutant parasites showed a reduced asexual blood-stage growth rate when compared to 
wild-type parasites. 
PF3D7_1407800 plasmepsin IV (PM4) 0.656 Mutant parasites showed a slightly reduced growth rate and a virulence-attenuated 
phenotype in mice when compared to wild-type parasites[337]. 
PF3D7_1428300 proliferation-associated protein 2g4, putative 0.777  
PF3D7_1430300 acid phosphatase, putative 0.43  
PF3D7_1455300 conserved Plasmodium protein, unknown function 0.015 Proposed to be essential for invasion. Two attempts to disrupt the gene were not 
successful. 
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Table 2.9: Forty-nine P. falciparum genes in which genetic disruption their rodent malaria orthologues have been attempted 
Plasmodium 
falciparum gene ID 
Product description Proposed 
member of 
invadome 
Positive 
Tajima D 
RMgmID Rodent malaria 
gene ID 
Modification attempted in rodent malaria parasites 
Efforts to disrupt or knock-down the gene was not successful 
PF3D7_0305300 Conserved Plasmodium membrane 
protein, unknown function 
 0 RMgm-244 PBANKA_0403800 Two attempts to disrupt the gene were not successful* 
PF3D7_0422300 alpha tubulin 2  0 RMgm-4 PBANKA_0522700 Five attempts to disrupt the gene were not successful[338]. 
PF3D7_0503400 actin-depolymerizing factor 1 (ADF1)  0 RMgm-388 PBANKA_1103100 Four attempts to disrupt the gene were not successful[339]. 
PF3D7_0714000 histone H2B variant (H2B.Z)  0 RMgm-3838 PBANKA_1420600 Attempts to disrupt the gene were not successful*. Numbers of attempts 
were not reported. 
PF3D7_0919000 nucleosome assembly protein (NAPS)  0 RMgm-217 PBANKA_0819900 Four attempts to genetically disrupt the gene were not successful. Very 
small proportion of mature-schizonts showed GFP expression[340]. 
PF3D7_1023900 chromodomain-helicase-DNA-binding 
protein 1 homolog, putative (CHD1) 
 0 RMgm-507 PBANKA_0508100 Two attempts to disrupt the gene were not successful. 
PF3D7_1025300 conserved Plasmodium protein, 
unknown function 
 0 RMgm-80 PBANKA_0509500 Three attempts to disrupt the gene were not successful[341]. 
PF3D7_1145400 dynamin-like protein (DYN1)  0 RMgm-238 PBANKA_0903600 Three attempts to disrupt the gene were not successful*. 
PF3D7_1204300 eukaryotic translation initiation factor 
5A (EIF5A) 
 0 RMgm-1580 PBANKA_0603200 Two attempts to disrupt the gene were not successful[342]. 
PF3D7_1316600 choline-phosphate cytidylyltransferase 
(CCT) 
 0 RMgm-335 PBANKA_1415100 Two attempts to disrupt the gene were not successful[343]. 
PF3D7_1324900 L-lactate dehydrogenase (LDH)  0 RMgm-3592 PBANKA_1340100 Attempts to disrupt the gene were not successful 
PF3D7_1360800 falcilysin (FLN)  0 RMgm-804 PBANKA_1137000 Three attempts to disrupt the gene were not successful. 
PF3D7_1455300 conserved Plasmodium protein, 
unknown function 
1 1 RMgm-509 PBANKA_1319000 Two attempts to disrupt the gene were not successful. 
PF3D7_1454700 6-phosphogluconate dehydrogenase, 
decarboxylating, putative 
 0 RMgm-3494 PBANKA_1318400 Attempts to disrupt the gene were not successful. 
Efforts to disrupt or knock-down the gene was successful 
PF3D7_0309500 Asparagine synthetase, putative  0 RMgm-1872 PBANKA_0407600 Gene disruption successful. Significantly reduced growth rate when 
compared to wild-type parasites. Reduced ookinete, oocyst and sporozoite 
production[344]. 
PF3D7_0501600 rhoptry-associated protein 2 (RAP2) 1 0 RMgm-209 PBANKA_1101400 GFP-tagged RAP2 showed expression in maturing merozoites within 
schizonts and a two-dot staining[345]. Disrupted gene showed significantly 
reduced growth rate when compared to wild-type parasites. 
PF3D7_0502400 ring-stage membrane protein 
1,merozoite surface protein 8 (MSP8) 
 0 RMgm-225 PBANKA_1102200 P. berghei parasites expressing MSP8 lacking the GPI-anchor and C-
terminal EGF domains showed no difference in growth rate when compared 
to wild-type[346]. 
PF3D7_0507500 subtilisin-like protease 1 (SUB1) 1 0 RMgm-972 PBANKA_1107100 HA-tagged PbSUB1 showed expression in blood and liver stages. Plays 
essential role in merozoite egress from schizonts and parasite egress from 
hepatocytes[347, 348]. 
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Plasmodium 
falciparum gene ID 
Product description Invadome Positive 
Tajima D 
RMgmID Rodent malaria 
gene ID 
Modification attempted in rodent malaria parasites 
PF3D7_0608800 ornithine aminotransferase (OAT)  0 RMgm-1568 
RMgm-1642 
PY17X_0109000 
 
PBANKA_0107400 
GFP tagged P. yoelii showed internal localization. 
 
Genetic disruption of P.berghei gene showed no difference in asexual 
growth rate when compared to wild type. 
PF3D7_0903700 alpha tubulin 1  0 RMgm-1925 PBANKA_0417700 Gene disruption successful. No difference in growth rate between mutant 
and wild-type parasites.  
PF3D7_0904900 copper-transporting ATPase (CuTP)  0 RMgm-
960/1 
PBANKA_0416500 Gene disruption successful. No differences observed in asexual blood-
stages. Ookinete, oocyst and sporozoite formation reduced[349]. 
PF3D7_1003600 inner membrane complex protein 1c, 
putative (IMC1c) 
1 0 RMgm-1122 PBANKA_1202000 Significantly reduced growth rate in mutant parasites when compared to 
wild-type parasites. mCherry tagged PbIMC1c showed localization to the 
periphery of individual merozoites[350].  
PF3D7_1021600 deoxyribose-phosphate aldolase, 
putative 
 0 RMgm-1553 PY17X_0506900 PyGFP-tagged parasites showed localization to the cytoplasm. 
PF3D7_1033400 haloacid dehalogenase-like hydrolase 
(HAD1) 
 0  PY17X_0518300 Gene disruption was successful. No differences observed between asexual 
blood stage growth rate in mutant and wild-type parasites. 
PF3D7_1104000 phenylalanine--tRNA ligase beta 
subunit 
 0 RMgm-2690 PBANKA_0942900 Genetic disruption was successful. Growth rate phenotype has not been 
described. 
PF3D7_1113700 glyoxalase I (GloI)  0 RMgm-2649 PBANKA_0933900 Gene disruption was successful. No differences observed between asexual 
blood stage growth rate in mutant and wild-type parasites. 
PF3D7_1115600 peptidyl-prolyl cis-trans isomerase 
(CYP19B) 
 0 RMgm-253 PBANKA_0932200 Gene disruption was successful. Growth rate phenotype has not been 
described. 
PF3D7_1116700 cathepsin C, homolog,dipeptidyl 
aminopeptidase 1 (DPAP1) 
 0 RMgm-810 PBANKA_0931300 Gene disruption was successful. Reduced asexual blood-stage growth rate in 
mutant compared to wild-type parasites. 
PF3D7_1124600 ethanolamine kinase (EK)  0 RMgm-2590 PBANKA_0923700 Gene disruption was successful. Reduced asexual blood-stage growth rate in 
mutant compared to wild-type parasites. 
PF3D7_1130200 60S ribosomal protein P0 (PfP0)  0 RMgm-1561 PY17X_0919700 GFP-tagged Py parasites showed localization in the cytoplasm of asexual 
stages 
PF3D7_1135100 protein phosphatase 2C, putative  0 RMgm-1046 PBANKA_0913400 Pb∆ppm8 mutant parasites showed no differences from wild-type parasites 
in the asexual, sexual and liver stages. 
PF3D7_1138500 protein phosphatase 2C (PPM2)  0 RMgm-1041 PBANKA_0910200 Pb∆ppm2 mutant parasites showed no differences from wild-type parasites 
in the asexual blood stages. However, reduced numbers of macrogametes 
were observed and ookinete differentiation at stage II observed[351]. 
PF3D7_1222700 glideosome-associated protein 45 
(GAP45) 
1 0 RMgm-776 PBANKA_1437600 GAP45 is considered vital for merozoite invasion of erythrocytes. 
PbGAP45 zygotes failed to develop into ookinetes[352]. 
PF3D7_1229400 macrophage migration inhibitory factor 
(MIF) 
 0 RMgm-26 PBANKA_1444000 Pbmif-ko showed no differences in entire life-cycle growth rate or 
virulence. Rodent hosts infected with mutant parasite showed higher 
number of reticulocytes[353]. 
PF3D7_1235700 ATP synthase subunit beta, 
mitochondrial 
 0 RMgm-4000 PBANKA_1450300 Mutant parasites showed reduced asexual growth rate when compared to 
wild-type parasites. 
PF3D7_1246200 actin I (ACT1) 1 0 RMgm-678 PBANKA_1459300 GFP-tagging showed expression in all asexual blood stages, ookinetes, 
oocysts, sporozoites and liver stages[354]. 
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Plasmodium 
falciparum gene ID 
Product description Invadome Positive 
Tajima D 
RMgmID Rodent malaria 
gene ID 
Modification attempted in rodent malaria parasites 
PF3D7_1251200 coronin 1 0 RMgm-1497 PBANKA_1464100 Pb coronin- parasites showed reduced numbers of sporozoites in mosquito 
salivary glands, reduced liver stage development[355]. 
PF3D7_1342600 myosin A (MyoA) 1 0 RMgm-656 PBANKA_1355700 Pb mutant parasites showed no difference in asexual and gametes compared 
to wild-type. Ookinete motility was reduced and oocyst production was 
reduced[352]. 
PF3D7_1347500 DNA/RNA-binding protein Alba 4 
(ALBA4) 
 0 RMgm-3699 PBANKA_1360300 Mutant parasites showed a reduced asexual blood-stage growth rate when 
compared to wild-type parasites. 
PF3D7_1347700 ethanolamine-phosphate 
cytidylyltransferase (ECT) 
 1 RMgm-3701 PBANKA_1360500 Mutant parasites showed a reduced asexual blood-stage growth rate when 
compared to wild-type parasites. 
PF3D7_1361800 conserved Plasmodium protein, 
unknown function 
1 0 RMgm-
710/725 
PBANKA_1137800 mCherry tagged parasites showed localization to the cytoplasm of parasites. 
PF3D7_1404900 conserved Plasmodium protein, 
unknown function 
 0 RMgm-1482 PBANKA_1037300 GFP-tagged parasites generated. No phenotype has been described. 
PF3D7_1407800 plasmepsin IV (PM4)  1 RMgm-316 PBANKA_1034400 Mutant parasites showed a slightly reduced growth rate and a virulence-
attenuated phenotype in mice when compared to wild-type parasites[337]. 
PF3D7_1412500 actin II (ACT2)  0 RMgm-
632/633 
PBANKA_1030100 PbactII- showed no differences when compared to wild type, however 
reduced exflaggellation of male gametocytes and reduced ookinete and 
oocyst formation[356]. 
PF3D7_1438900 thioredoxin peroxidase 1 (Trx-Px1)  0 RMgm-206 PBANKA_1302800 PbPrx-KO showed no differences from wild-type parasites, however 
reduced production of gametocytes were observed[357, 358]. Reduced 
numbers of liver stage merozoites[359]. 
PF3D7_1446200 M17 leucyl aminopeptidase (LAP)  0 RMgm-814 PBANKA_1309900 Pb∆lap mutant parasites showed a strongly reduced growth rate of blood 
stages when compared to wild-type parasites. 
PF3D7_1454400 aminopeptidase P (APP)  0 RMgm-813 PBANKA_1318100 Pb∆aapa/b mutant parasites showed a reduced growth rate in mice and 
produces reduced levels of haemozoin when compared to wild type 
parasites. 
PF3D7_1460600 inner membrane complex sub-
compartment protein 3, putative (ISP3) 
1 0 RMgm-
962/964 
PBANKA_1324300 Pb∆isp3 showed no differences in asexual blood-stage when compared to 
wild type parasites. GFP-tagged parasites showed localization in schizonts 
and merozoites[360]. 
PF3D7_1466100 protein phosphatase containing kelch-
like domains (PPKL) 
 0 RMgm-785 PBANKA_1329500 Pbppkl- mutant parasites showed no difference in asexual blood stages 
however, aberrant developments of ookinetes were observed with reduced 
motility. No oocysts and sporozoites were formed in mutant parasites[361]. 
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2.6. Discussion 
Proteomic-serology approaches for the discovery of immunogenic merozoite 
antigens 
Comprehensive screening approaches such as the proteomic methods employed in 
this study have the potential to describe a greater range of specificities of immune 
responses to complex pathogens. Immunoprecipitation techniques using pathogen 
lysate material have been used widely to identify targets and protein-protein 
interacting partners. On the other hand, although it is labour-intensive, 2DE gels 
coupled to serology has been used to answer a range of biomedical research 
questions such as the identification of the targets of ‘self-antigen’ recognizing 
antibodies in autoimmune diseases, biomarker discovery or for vaccine discovery in 
infectious diseases [313]. For instance, the approach has been used to identify the 
targets of self-antibodies in autoimmune diseases such as the rare inflammatory 
Behcet’s disease [362-364] that results in damage to blood vessels, membranous 
glomerulonephritis that affects the kidneys[365] and type 1 diabetes [366]. 
Similarly, it has been successfully used to identify potential vaccine candidates for 
human diseases such as the bacterial infection by Chlamydia pneumonia[367] and 
Bordetella pertussis [368], or the parasitic infection by Leishmania donovani[369].  
 
Identifying immunogenic P. falciparum merozoite antigens: quality of reagents 
Mining data from PlasmoDB indicated that there were many P. falciparum 
merozoite antigens that were potentially immunogenic (639 potential targets) but 
had not been evaluated in this regard (see section 2.5.1). These could represent 
novel targets that elicit antibody responses that play a role in halting the erythrocytic 
life cycle of the malaria parasite. Therefore, I employed the two proteome-serology 
approaches to identify the targets of naturally acquired antibodies to merozoite 
antigens that could help prioritize a set of potential vaccine candidates. To confirm 
that my reagents were of high quality, I conducted a series of tests. First, I ensured 
that my method of merozoite extraction (adapted from Boyle et al, 2013) [370] 
yielded high quality merozoite preparations in multiple ways. I confirmed the 
presence of known merozoite antigens that vary in their function and localization. 
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These included peripherally associated surface protein MSP3, an erythrocyte 
invasion ligand located in the micronemes before invasion of erythrocytes, EBA175, 
members of the glideosome complex involved in driving erythrocyte invasion and 
located between the plasma membrane and the underlying inner membrane complex 
(IMC) such as GAP45, GAP50, MyoA and MTIP [326]. Secondly, I ensured the 
pool of negative sera was obtained from individuals with no previous exposure to P. 
falciparum malaria by confirming non-reactivity as measured by ELISA to the 
immunodominant merozoite antigen AMA1 and total P. falciparum schizont 
extract. Lastly, I confirmed by electron microscopy that the purified merozoites 
obtained following in vitro culture contained antigenic determinants. These were 
preferentially detected by the pool of purified immunoglobulins from malaria-
immune adults (MIG), and were primarily localised on the surface of the 
merozoites. The MIG preparation had been previously shown to bind to parasite 
derived surface antigens on erythrocytes in twenty-two clinical isolates from 
Malawi [328]. They further ascertained that the preparation contained antibodies 
with different specificities as the eluted antibodies, following adsorption with one 
isolate, recognised the homologous isolate but not heterologous ones. Lastly, the 
immunoglobulin preparation was also shown to be able to reverse the binding 
between infected erythrocytes and melanoma cells in an in vitro cyto-adherence 
reversal assay [328]. These observations provided the rationale for using MIG as a 
test immunoglobulin preparation whose target antigens would be of interest to 
identify. 
 
Identifying immunogenic merozoite antigens by 2DE western blots 
I coupled 2-dimensional gel electrophoresis (2DE) to western blotting using MIG to 
identify reactogenic P. falciparum merozoite antigens. This approach has been used 
in various infectious diseases to identify immunogenic targets. For example, thirty 
immunoreactive antigens against the causative agent of whooping cough, Bordetella 
pertussis, were identified using sera from ten children vaccinated with whole-cell 
pertussis vaccine (WCV) [368]. This represents 1% of the predicted protein coding 
genes (3456 genes) [371] in the entire B. pertussis genome. Similarly, the protozoan 
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Leishmania donovani that causes leishmaniasis has also been evaluated for 
antigenicity by 2DE-blots [369]. In this study, 330 immunogenic spots were 
observed representing 4% of the protein coding genes in the L. donovani genome 
(8336) [372]. Using a similar approach, I identified 210 and 262 putative 
immunogenic merozoite antigens from the lab-adapted Pf3D7 strain and a recently 
isolated and lab-adapted Kenyan clinical isolate respectively. This corresponds to 
only 3.8% and 4.7% of the entire protein coding genes in the P. falciparum genome. 
This particular approach has not been employed in the analysis of immunogenic P. 
falciparum antigens from any stages of the lifecycle, which has limited 
comparisons.  
 
Novel immunogenic P. falciparum targets 
I compared the targets I identified with published literature, and found fifty-nine 
antigens (17%) that have been previously shown to be immunogenic primarily 
through screening recombinant antigens by protein arrays or ELISA using sera from 
individuals with varying degrees of exposure and susceptibility to P. falciparum 
malaria [146, 147, 263, 265, 267, 292]. These include known merozoite antigens 
that are currently under evaluation as blood-stage vaccines AMA1, GLURP, MSP1, 
2, 3 and SERA 5 [305, 373, 374]. In addition, antigens that have been analysed 
more recently such as the peripherally associated merozoite surface antigens MSP 6, 
7, 9 [146, 147] and MSPDBL1 [292], cysteine proteases released following 
merozoite egress such as SERA4 and SERA5 [146], rhoptry neck proteins e.g. 
RON3 [267], the high molecular weight rhoptry proteins localised in the rhoptry 
bulbs e.g. RhopH3 [267] and the GPI-anchored Micronemal Antigen, GAMA [146].  
The identification of known immunogenic merozoite antigens gave me the 
confidence that this approach could lead to the discovery of novel antigens. There 
were merozoite antigens that are known to be targets of naturally acquired 
antibodies but were not identified in the 2D-blot experiments. These included 
MSP4, MSP5, MSP10, DBLMSP2, EBA-181 and EBA-175 [146, 147, 292]. These 
targets may have been missed due to the inability of 2D-blots to enrich for 
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hydrophobic or membrane proteins as is discussed in detail in the study limitations 
section on page 130. 
 
Interestingly, a large proportion of identified targets (83%) had not been evaluated 
in the context of naturally acquired immunity, representing potential novel antigens 
that should be analyzed further and evaluated as targets of protective antibodies. 
Encouragingly, some of these targets have been proposed to play important roles 
such as in erythrocyte invasion, or show interesting signatures such as evidence of 
balancing selection or a phenotype following genetic modification in several 
studies. Targets such as the conserved protein, PF3D7_1455300, has been proposed 
to be a member of the invadome and the attempts to disrupt the function of the P. 
berghei orthologue have been unsuccessful. This implies that the target plays an 
essential role over the asexual stage of the life cycle. It is therefore plausible that 
antibodies generated against this target may inhibit or halt parasite growth 
altogether warranting further evaluation of these targets as well as thirteen other 
targets that share similar features. 
 
Differences between immunogenic targets identified using a lab-adapted and 
clinical P. falciparum isolate 
I had hypothesised that the antigenic determinants would vary between merozoite 
antigens obtained from a lab-adapted parasite line (3D7) that was first adapted to in 
vitro culture in 1981 [375] and a clinical isolate from Kilifi, Kenya that was first 
isolated and put into in vitro culture on the 29th of July, 2009 (Abdirahman Abdi, 
personal communication). Differences between P. falciparum isolates have been 
documented before, that have had an effect on: i) parasite virulence or, ii) their 
susceptibility to drugs such as chloroquine [376] or iii) their ability to infect 
Anopheles gambiae mosquitoes [377] or iv) in their invasion phenotype and 
merozoite invasion ligand expression profiles [378]. In line with this hypothesis, we 
observed a higher number of antigens identified as immunogenic in the clinical 
isolate compared to the lab-adapted isolate. In addition, the targets identified in both 
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isolates were less polymorphic compared to targets identified exclusively in the 3D7 
isolate. Additional replicate data are required to confirm these findings. 
 
There are several plausible explanations for these differences that include: i) 
deletions of genomic regions or transcriptional repression that vary between isolates 
or ii) immune evasion mechanisms employed by different isolates or iii) similarities 
between circulating parasites from a similar geographical region.  For example, 3D7 
is known to delete sub-telomeric regions of its genome particularly on chromosome 
2 and 9 following long-term culture [330, 331]. Deletions in the sub-telomeric 
regions of chromosome two results in the loss of KAHRP (PF3D7-0202000), a 
protein involved in parasite cytoadherance. Interestingly, the gene PF3D7-0202100 
encoding liver stage associated protein 2 (LSAP2), which is adjacent to KAHRP, 
was identified as immunogenic exclusively in the clinical isolate’s immunoblots. 
Similarly, some genes have been shown to vary in their mRNA abundance between 
isolates when compared by microarray suggesting strain specific transcription 
regulation. For example, in a microarray analysis that compared mRNA levels 
between the lab-adapted isolates 3D7, HB3 and Dd2, they identified genes whose 
transcripts were highly abundant in a strain specific manner such as MSP2 that was 
highly abundant in the 3D7 isolate [257]. Similarly, in my study, MSP2 was 
identified as immunogenic in the 3D7 immunoblots only. Lastly, the expression of 
merozoite invasion ligands, have been shown to vary between isolates from the 
same [379] or varied geographical regions [378]. Interestingly, the invasion ligand, 
Reticulocyte Binding Protein 2 Homologue a (RH2a), was identified in the clinical 
isolate only. 
 
Although difficult to validate with the data available, it is plausible that the targets 
identified exclusively in the individual data sets could represent targets that serve as 
a “smoke screen” diverting antibody responses away from true targets. 
Encouragingly, I observed that targets identified in both isolates were less 
polymorphic compared to those identified in each of the isolates exclusively. This 
would suggest the presence of antigenic targets that are of limited polymorphism or 
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conserved and therefore likely to be immunogenic regardless of the geographical 
origin of the isolate. This has potential implications on vaccine design and efficacy. 
Previous work has shown that vaccine candidates based on highly polymorphic 
proteins such as MSP2 and CSP have elicited strain specific immunity [171, 222]. 
To circumvent this problem, approaches such as generation of a multi-valent 
vaccine (containing two or more alleles of the same antigen) that covers the 
majority of circulating alleles are being evaluated [380].  A second approach would 
be to focus on antigens that are targets of naturally acquired immunity and are of 
limited polymorphism as they are likely to be effective across diverse geographical 
regions [380]. 
 
Study limitations 
I observed a lack of specificity and reproducibility in the pull-down assays I 
conducted, which is common in this assay. This is often attributed to various 
sources that include: i) non-specific binding of parasite proteins with a high-affinity 
to Protein G and/or ii) high affinity protein-protein interaction present in a target 
bound by antibodies that are co-eluted [381]. For instance, a human monoclonal 
antibody with broad agglutinating activity of infected erythrocytes pulled down 
several targets evidenced by multiple bands on a western blot and multiple hits on 
mass-spectrometry identification of eluates [382].  Similarly, rabbit anti-P12 sera 
immunoprecipitated six targets from P. falciparum schizont lysates and only one 
target (P41) was subsequently validated as the true interacting partner [383]. The 
specificity of pull-down assays can be improved using stringent washing steps or 
pre-incubating extracted parasite proteins with Protein G before proceeding with the 
immunoprecipitation. While immunoprecipitation of antigens from P.falciparum 
parasite lysate material has been successfully used to identify antigens such as 
AMA1 [244], MSP1 [241] and MSP2 [242], it is worth noting that these 
experiments used either a monoclonal antibody or polyclonal sera against a single 
antigen. The quantities of antigen-specific antibodies in polyclonal sera obtained 
from animal immunization ranges from 200g/ml-3000g/ml (www.agrisera.com). 
This would be considerably higher in concentration, affinity and avidity than the 
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antigen-specific IgG present in a pool of immunoglobulins from adults whose 
malarial specific responses vary considerably between individuals, in addition to 
being exposed to a range of other pathogens [384, 385]. These may explain why the 
signal by western blot from MIG eluates did not differ from non-exposed controls.  
 
Although I have improved on the 2DE maps provided by Schmidt-Ullrich et al 
[317] and Gelhaus et al [315] whose maps were limited to a pH range of 4-7, I was 
limited to identifying immunogenic antigens whose isoelectric points lie between 3-
10. A total of 743 P. falciparum genes are predicted to having an isoelectric point 
above 10 (http://plasmodb.org/) and would have been missed by this approach. 
Similarly, high molecular weight proteins above 200 kDa were unlikely to be 
identified due to the resolution limits of a 12% SDS-gel. Three hundred and forty 
five (345) P. falciparum protein-coding genes are predicted to have molecular 
weights above 250 kDa, and would also have been missed by this approach. In 
addition, a known limitation of isoelectric focusing in the first dimension is its 
inability to solubilise and focus hydrophobic proteins, particularly membrane 
proteins that tend to precipitate [314, 386, 387]. As a result, proteins containing 
transmembrane domains are under represented in my 2DE maps. This was evident 
with my data where only 18% of identified targets had a transmembrane domain; 
significantly lower than proportions observed within the genome (section 2.5.6 and 
2.5.10). This is of particular concern given the observation that purified 
immunoglobulins from malaria-immune adults localised primarily on the surface of 
the merozoite as shown in section 2.5.3, suggesting they react to membrane-bound 
proteins. One possible solution that would aid in the enrichment and resolution of 
membrane proteins in a two-dimensional gel is the combination of a blue-native 
polyacrylamide gel electrophoresis (BN-PAGE) [388] coupled to SDS-PAGE. This 
technique differs with the method I used only at the protein extraction and 
separation in the first dimension. The blue-native polyacrylamide gel 
electrophoresis has the following modifications: i) proteins are extracted using non-
ionic detergents such as digitonin, that prevents disruptions of protein-protein 
interactions but efficiently solubilises lipophilic interactions such as those between 
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integral membrane proteins and the lipid-bilayer. ii) non-denaturing conditions are 
maintained in which SDS or urea is not present in any buffers and 3) the addition of 
an anionic dye in the extraction buffer that imparts an overall negative charge to aid 
migration during electrophoresis. Lastly, an additional limitation is that proteins 
separated by 2DE lose their native confirmation due to reduction and denaturation 
(in the second dimension separation) and as result, antigens that solely rely on 
conformation dependent epitopes for antibody recognition may be under-
represented. 
 
In summary, despite the limitations highlighted above, coupling bi-dimensional gel 
electrophoresis to fluorescent western blots has identified potential novel targets of 
naturally acquired immunity. These data indicate that there are many more 
immunogenic antigens that have not been evaluated for their utility as vaccine 
candidates.  This fits well with recently published work in which additional blood-
stage antigens that have not been studied before were evaluated as potential vaccine 
candidates and out-performed some of the candidates currently in clinical trials 
[146, 147, 389, 390].  Of the immunogenic targets I identified, a large proportion of 
them have not been studied particularly in the context of immunity. Interestingly, 
some of these targets have been proposed to be members of the “invadome” that 
may play a key role in erythrocyte invasion by merozoites [258]. Other antigens 
have encouraging phenotypes when their orthologue in the rodent malaria P. 
berghei is genetically modified[391], either leading to reduced asexual growth, or a 
simply not able to be deleted at all, suggesting they may be essential for growth. 
The targets I identified are a rich resource that should be further evaluated and 
validated as targets of protective immunity. In subsequent chapters, I selected a 
subset of these antigens and show that they are immunogenic and elicit varying 
antibody responses in adults living in a malaria endemic region of Tanzania. Some 
of these targets elicited antibody responses that were associated with protective 
immunity to P. falciparum malaria. Details of the down-selection procedures of the 
subset of antigens for further analysis and their subsequent evaluation in immuno-
epidemiological studies are presented in Chapter four and five of this thesis.  
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CHAPTER 3  
Describing the Plasmodium falciparum merozoite surface proteome 
using surface trypsinization and biotinylation 
3.0. Introduction 
 
The majority of infectious agents interact with the extracellular environment and the 
host’s immune system through their cell surface proteins [392]. Intracellular 
pathogens can use their surface proteins as ligands to bind to receptors on host cells 
thereby facilitating invasion [393], or as attachment and adherence factors during 
the colonization of tissues or organs [394], which can also enhance pathogenesis 
[395]. Alternatively, surface proteins may bind to soluble immune effector factors 
or cells to evade or modulate the hosts’ protective defences [394, 396]. Lastly, 
surface proteins can play key roles in sensing the chemical or physical cues of their 
external environment, and in the uptake of nutrients and molecules that are essential 
for pathogen survival. Due to their vital roles in pathogen tropism, survival and their 
interaction with the host’s immune defences, surface proteins often represent 
attractive drug and vaccine targets [395, 397].  
 
Several vaccines that are either commercially available or under development are 
based on surface-exposed pathogen proteins. One example is the 4CMenB 
multicomponent vaccine developed against the bacteria Neisseria meningitides 
serogroup B [398], which causes sepsis and meningitis in children and young adults 
and is often fatal. The 4CMenB vaccine is composed of three immunogenic antigens 
that are located on the surface of the bacteria namely Neisseria Adhesin A (NadA), 
Neisserial heparin binding antigen (NHBA) and factor H binding protein (fHbp) 
[399]. This multicomponent formulation induced antibodies in mice that were 
bactericidal against 35 (78%) of the tested meningococcal strains. Phase I, IIb and 
III clinical trials have been conducted showing immunogenicity in infants and 
adults, and which induced antibodies with bactericidal activity [398]. Similarly, a 
second vaccine candidate, Spy0416 antigen, is a membrane protein identified from 
surface shaving Streptococcus group A bacteria[400]. The recombinant form of the 
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identified antigen was subsequently shown to be protective in a mouse 
immunization, followed by challenge study where they used a virulent group A 
streptococcus bacteria [400].  
 
In the context of P. falciparum malaria, the majority of the vaccine candidates in 
clinical trials target antigens that localize to the surface of the sporozoite, merozoite 
or gametocyte stages of the parasite lifecycle [305]. These include the pre-
erythrocytic vaccine candidates RTS,S (the only malaria vaccine to pass phase III 
trials) [401, 402] and ME-TRAP [210, 403, 404] that are based on the 
circumsporozoite protein (CSP) and a string of epitopes fused to thrombospondin-
related adhesion protein (ME-TRAP) respectively. These proteins localise to the 
surface of the sporozoite and play a role in the gliding motility and hepatocyte 
infectivity of sporozoites [234, 405, 406]. Similarly, several blood-stage vaccine 
candidates are based on proteins with known merozoite surface localisation such as 
the FMP1/AS02 vaccine (based on MSP-142, the C-terminal fragment of MSP-1), 
combination B vaccine (based on a combination of MSP-1, -2 and RESA) and the 
GMZ2 vaccine formulations (based on a combination of MSP-3 and GLURP 
proteins) [305, 407, 408]. A transmission blocking vaccines based on Pfs25, a 
protein on the surface of gametocytes, is also under evaluation in phase I studies 
[229].  
 
While several surface exposed antigens are already under consideration as malaria 
vaccine candidates, only very few of the potential total number of candidates have 
been identified and investigated. The P. falciparum genome from the 3D7 strain 
contains 5398 protein-coding genes [206], excluding pseudogenes. Of these genes, 
1088 (20%) and 1754 (32%) are predicted to encode proteins with a signal peptide 
or at least one transmembrane domain respectively (http://plasmodb.org/plasmo/), 
and therefore could be potentially surface-associated proteins. As discussed in 
section 2.5.1, I mined data from PlasmoDB to identify merozoite antigens that could 
be potential vaccine candidates either by being secreted or located on the surface of 
P. falciparum merozoites. I limited the list to parasite proteins whose microarray 
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expression profiles indicated that maximum mRNA transcription occurs in the late-
trophozoite, early to late schizogony or merozoite stage of the erythrocytic life cycle 
[259, 260]. This profile is similar to that of known merozoite surface proteins such 
as the GPI-anchored MSP-1, -2, Pf92, Pf113 and Pf12. In addition, I limited the list 
of genes to those with a predicted signal peptide and/or predicted transmembrane 
domains that would indicate the protein could potentially be: i) secreted ii) 
peripherally associated to the merozoite surface or iii) an integral protein found on 
the merozoite surface. I found a total of 796 proteins with 550 (69.1%) containing a 
predicted signal peptide and 571 (71.7%) having at least one predicted 
transmembrane domain. These data indicate that there are potentially many novel 
merozoite surface proteins yet to be identified, that could be the target of protective 
antibodies. Furthermore, only 157 (20%) of these targets had been evaluated for 
antibody reactivity using sera from naturally exposed individuals (Figure 3.1). 
However, the evaluation of each of the remaining 639 antigens for their ability to 
elicit protective antibody responses would be a daunting task within the time 
constrains of a PhD.   
 
Membrane proteomics represents a potential approach to down-select the list of 
bioinformatically predicted surface proteins. These approaches have been employed 
to attempt to comprehensively identify surface proteins on P. falciparum 
erythrocytes [299] and on the surface of P. falciparum sporozoites, resident in 
mosquito salivary glands [300]. Biochemical purification and proteomics has also 
been used to identify novel antigens that are membrane or GPI-anchored to the 
surface of merozoites [294-296]. These approaches led to the identification of the 
novel GPI-anchored proteins such as Pf12, Pf92 and Pf113, as well as the cys6 
proteins Pf38 and Pf41 that are peripherally associated to the merozoite surface. 
Some of these targets were subsequently shown to be immunogenic using sera from 
individuals naturally infected with P. falciparum malaria [146, 147] and antibodies 
to these targets were associated with protection from clinical malaria individually in 
Kenyan and Papua new guinea children. Membrane proteomics therefore represents 
a validated mechanism to identify malaria vaccine antigens. In this section of my 
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PhD work, I employed a combination of proteomic approaches to describe the 
merozoite surface proteome and prioritize surface-exposed proteins for further 
characterization in the context of protective immunity against P. falciparum malaria.  
3.1. Rationale 
 
In this chapter, I sought to describe the merozoite surface proteome using two 
complementary techniques namely: i) a surface shaving and ii) surface biotinylation 
coupled to affinity purification. Mass spectrometry was used in combination with 
both approaches to identify targets. These two approaches have been successfully 
used to identify potential vaccine candidates, virulence factors and binding ligands 
in other infectious agents particularly bacterial organisms such as Enterococcus 
faecium [409], Staphylococcus aureus [410] and Streptococcus group A bacteria 
[400]. More recently, these approaches have been used to identify potential drug and 
vaccine targets in fungal organisms such as Candida parapsilosis and Candida 
tropicalis [411] and the parasites Trypanosoma cruzi [412] and Schistosoma 
mansoni [413]. In the context of P. falciparum malaria, the surface-shaving method 
has not been previously employed to elucidate surface proteins however; the surface 
biotinylation has been used to identify proteins on infected erythrocytes [299] and 
recently on sporozoites from mosquito salivary glands [300, 301]. 
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Figure 3.1: Potential P. falciparum merozoite targets predicted to be surface-embedded or exposed to 
antibodies. A small proportion 157 (19.7%) has been evaluated for immunogenicity as of September 2016. 
 
 
The surface shaving approach, also referred to as surfomics [414], is a rapid and 
direct method of identifying surface proteins in intact cells using proteolytic 
enzymes [415]. Target cells are incubated briefly with a proteolytic enzyme and the 
released proteins and peptides are then identified by mass-spectrometry as shown in 
Figure 3.2. Trypsin is the proteolytic enzyme chosen for the majority of surface 
shaving experiments because it specifically cleaves the carboxyl terminal of a lysine 
or arginine residues (positively charged amino acids) that are under-represented in 
hydrophobic domains. As a result, it is not thought to cleave peptides embedded 
within the hydrophobic lipid bilayer of membranes [392, 414]. 
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Figure 3.2: Cell surface trypsinization strategy. Workflow showing the general strategy employed when 
identifying surface-exposed proteins using the surface shaving approach coupled to mass-spectrometry 
identification of released targets [414]. 
 
The surface biotinylation approach relies on the use of a commercially available 
cell-membrane impermeable biotinylation reagent called EZ-link Sulfo-NHS-LC-
Biotin [416]. This water-soluble reagent reacts efficiently with -amino groups 
present on the N-termini of all proteins and the -amine group on lysine residues 
resulting in a biotinylated protein as shown in Figure 3.3.  The presence of the 
sulfonate group (-SO3) on the reagent serves two important roles; 1) it allows the 
reagent to be dissolved in water-based buffers that are common in biological 
experiments and 2) the negative charge does not allow the reagent to penetrate the 
plasma membrane, thereby only labeling proteins on the surface. Once biotinylated, 
labeled proteins can be purified by affinity purification using avidin-based reagents 
such as agarose beads conjugated to streptavidin. This affinity purification exploits 
the naturally occurring non-covalent interaction between avidin and biotin. Affinity 
purified biotinylated proteins can then be identified by mass-spectrometry [416]. 
 
These two approaches have the potential to down-select the number of potential 
surface proteins identified through bioinformatics to those that can be confidently 
expected to be surface-exposed and thus warrant further evaluation. An additional 
strength of these combined techniques would be the ability to identify atypical 
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surface proteins that lack the regular signals for extracellular localization. These are 
the so-called “moonlighting” proteins [417] that may have been overlooked if we 
relied solely on bioinformatic or predictive algorithms to identify potential surface-
proteins.  
 
 
Figure 3.3: Biotinylation of surface proteins: Addition of biotin to primary amine groups on the N-
terminal of proteins [416]. 
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3.2. Objective 
 
The overall objective was to identify the proteins located on the surface of P. 
falciparum merozoites using a combination of proteomic approaches 
 
3.3. Specific objectives 
 
• To identify proteins on the surface of P. falciparum merozoites using a 
surface shaving technique coupled to mass-spectrometry. 
• To identify proteins on the surface of P. falciparum merozoites using surface 
biotinylation, affinity purification and mass spectrometry. 
 
3.4. Laboratory methods 
3.4.0. P. falciparum merozoite purification 
 
I obtained merozoites from P. falciparum 3D7 strain using the same protocol I 
developed in section 2.4.1 with the modification that once merozoites were pelleted, 
they were washed thrice in ice-cold phenol-red free RPMI media to remove the 
excess bovine serum albumin used as a supplement in culture and resuspended in 
phenol-red free RPMI media. 
3.4.1. Merozoite surface trypsinization 
 
To identify the optimal conditions for cell surface trypsinization, I modified two key 
parameters that influence enzyme activity namely; 1) trypsin concentration and 2) 
incubation time for trypsin digestion. Cell surface trypsinization of merozoites was 
done as follows. Merozoites were washed twice in ice-cold phenol-free RPMI media 
and split into 6 equal fractions each containing 25µl of merozoites. As shown in 
Figure 3.4, in the first two fractions, 8.3g and 2.5g of trypsin was added and 
incubated at room temperature with rotation for 20 minutes. In the second set of two 
fractions, a similar trypsin concentration was added but with the incubation time 
increased to 60 minutes. The last two fractions served as controls in which one was 
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an untreated merozoite pellet (no trypsin added, no rotation, incubated at room 
temperature), while the second was a “mock-shaved” fraction, where no trypsin was 
added, but the merozoites were incubated at room temperature for 60 minutes with 
the same gentle rotation as the trypsin shaved fractions. After incubation periods 
were complete, treated merozoites were then pelleted by centrifugation at 5000 rpm 
for 4 minutes and supernatant (containing surface-shaved proteins and proteins that 
have either been shed or released due to cell lysis or damage) centrifuged further for 
20 minutes at 20238xg. The two concentrations were selected following 
observations made in earlier experiments where 10-100g of trypsin were used to 
treat merozoites resulting in a large degree of total protein cleavage as evaluated by 
Coomassie staining of the merozoite pellet material (data not shown). 
 
Figure 3.4: Optimisation of the merozoite cell surface trypsinization experiment. Schema of the 
optimisation protocol tested to optimise the trypsin concentration and the incubation time for P. falciparum 
merozoite cell surface trypsinization. 
 
To monitor the specificity of the surface-shaving protocol, shaved, untreated and 
mock-shaved pellet fractions were assessed by Western blot as described in section 
2.4.2. I used the assay to detect the following proteins in the treated merozoites: i) 
detection of the endoplasmic reticulum resident protein, ERD2, which was used as a 
loading and negative control as I expected that it would not be cleaved following 
treatment, as it is intracellular and ii) merozoite surface protein, MSP3, as I 
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expected it would be cleaved in the trypsinized merozoites and only present in the 
untreated and mock-shaved fractions. Briefly, the Western blot assay was performed 
as follows; trypsinized and control treated merozoite pellets were resolved on a 4-
12% gradient SDS gel (Invitrogen) and transferred onto a nitrocellulose membrane 
(Amersham Biosciences) overnight at 4C at 30V. Nitrocellulose membranes were 
then blocked for 1 hour at room temperature with 5% non-fat milk/0.1% Tween 20 
followed by incubation with anti-MSP3 or anti-ERD2 for 3 hours at room 
temperature at a 1:1000 dilution. Membranes were then washed three times in 
PBS/0.1% Tween 20 followed by incubation with anti-rabbit-HRP secondary 
antibody at a 1:10000 dilution (Sigma Aldrich) for 2 hours at room temperature. 
Membranes were washed three times in PBS/0.1% Tween 20 followed by a final 
wash in PBS. Detection of parasite protein was observed by developing the 
membrane using the ECL substrate (Amersham Biosciences) according to 
manufacturer’s instructions’ and visualized using autoradiography.  
 
Once the trypsinization protocol was optimised, two independent biological 
replicates were generated for mass-spectrometry analysis as follows. Merozoites 
were resuspended in phenol-free RPMI media and split into 2 equal fractions. The 
sample to be trypsin-shaved was supplemented with 1g of trypsin (proteomics 
grade, Sigma Aldrich), while the mock-shaved fraction was supplemented with 1l 
of RPMI buffer; both fractions were then incubated for 20 minutes with rotation at 
room temperature. Treated merozoites were then pelleted by centrifugation at 5000 
rpm for 4 minutes and the supernatant (containing surface-shaved proteins) 
centrifuged further for 20 minutes at 20238xg.  Collected supernatants were stored 
in low protein binding Eppendorf tubes and 1g of trypsin was added to the 
supernatant collected from the mock-shaved fraction to generate peptides. 
Thereafter, 2mM of the reducing agent TCEP was added to each supernatant 
fraction and stored at -20C before identification by mass-spectrometry. The 
remaining pellets were immediately resuspended in sample buffer and heated at 
95°C for characterization by Western blotting with anti-MSP3 and anti-ERD2.  
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3.4.2. Merozoite surface biotinylation and affinity purification 
 
A second approach was employed to identify merozoite surface proteins, which 
relied on the biotinylation of surface proteins using the cell membrane impermeable 
reagent EZ-link Sulfo-NHS-LC-Biotin (Thermo-Scientific). Several protocols were 
attempted to identify the best-suited protocol for extraction of biotinylated surface 
proteins for analysis by mass-spectrometry. In the first protocol, purified P. 
falciparum merozoites were washed once with ice-cold 1XPBS and incubated with 
2mM EZ-link Sulfo-NHS-LC-Biotin for 30 minutes at room temperature. The 
biotinylation reaction was stopped and excess biotin quenched by adding 100mM 
glycine.  Biotinylated merozoites were washed thrice in ice-cold 100mM glycine 
before extraction of proteins with different extraction buffers to solubilize 
biotinylated membrane proteins. These buffers included a 4% SDS lysis buffer, 8M 
Urea buffer, RIPA buffer and NP-40 buffer.  Following extraction, proteins in the 
supernatant were incubated with streptavidin agarose beads (Pierce) (1ml of packed 
agarose resin for 3mg of biotinylated protein) for 1 hour at 4°C to allow non-
covalent binding to biotinylated proteins. Prior to binding, agarose beads are washed 
thrice in ice-cold PBS to remove the storage buffer that contains ethanol. The resin 
was packed into a column and washed five times with ice-cold 1XPBS and 
biotinylated proteins eluted using various elution buffers for the ability to disrupt the 
strong non-covalent bond between biotinylated proteins and streptavidin. The 
elution buffers tested included sample buffer (lithium dodecyl sulphate, pH.8.4 
containing 50mM dithiothreitol or 8M Guanidine HCL, pH 1.5. 
 
In a second protocol, purified P. falciparum merozoites were similarly washed with 
ice-cold PBS, incubated with 2mM Biotin and quenched with 100mM glycine as 
has been previously described. To extract biotinylated proteins, merozoites were 
resuspended in distilled water containing protease inhibitors and lysed by 3 freeze-
thaw steps using liquid nitrogen. After lysis, merozoite pellets were washed twice 
with protease inhibitors diluted in water and resuspended in 2% Triton X-100 then 
vortexed and left on ice for 1 hour. The extracted proteins in the supernatant were 
incubated with washed streptavidin agarose beads overnight at 4°C for affinity 
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purification. Following binding, agarose beads were packed onto a column and 
washed thrice with 1% Triton X-100/PBS followed by 3 additional washes with 1% 
Triton X-100 in 1M NaCl. Biotinylated proteins were eluted by incubating with 5ml 
of 8M Guanidine HCL, pH 1.5 for 1 hour at room temperature and then neutralised 
with 5ml of 250mM Tris, pH. 7.4. Proteins were then concentrated using a 3K 
MWCo concentrator (Pierce, Thermo Scientific). To monitor the biotinylation 
experiments, the following fractions were collected i) the biotinylated merozoite 
proteins, ii) flowthrough following binding, iii) washes to release unbound proteins 
and iv) eluates containing biotinylated proteins. Western blotting as has been 
described in section 2.4.2 was used to test the fraction collected. Briefly, the 
fractions were resolved on a 4-12% gradient SDS gel and transferred onto 
nitrocellulose membrane and probed with either streptavidin conjugated to HRP, 
anti-MSP3 or anti-ERD2. 
3.4.3. LC-MS/MS analysis, database search and in-silico analysis of protein 
sequences 
 
Peptides obtained following the surface-shaving experiments were analysed using 
an Ultimate 3000 Nano/Capillary LC System (Dionex) coupled to an LTQ Orbitrap 
Velos hybrid mass spectrometer (Thermo Fisher) equipped with a nanospray source. 
Supernatant containing surface-shaved and mock-shaved trypsin digested peptides 
were desalted using the C18-stage tips and acidified to a final concentration of 1% 
trifluoroacetic acid. The samples were then loaded and desalted on a PepMap C18 
trap column (0.1mm id x 20mm, 5µm, Dionex) for 20 minutes at a 10µl/min flow 
rate prior to loading on the separation column (PepMap 75µm id x 25cm column 
with a 5µm particle size, Dionex). The samples were separated over a 120-minute 
long-linear gradient changing from 100%ACN/0.1%v/v formic acid (FA) in water 
to 5-45% of buffer B (80%ACN/0.1%FA) before a final elution using 95% buffer B 
to release the hydrophobic peptides. The Orbitrap mass spectrometer was operated 
in the “top 15” data-dependant acquisition mode while the preview mode was 
enabled. The MS full scan was set at m/z of 380-1600 with a resolution at 30,000 at 
m/z 400 and the automatic gain control (AGC) set at 1x106 with a maximum 
injection time of 200 msec. The 15 most abundant multiply-charged precursor ions, 
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with a minimal signal above 3000 counts, were selected for CID fragmentation 
(MS/MS) in the LTQ Velos ion trap, which has the AGC set at 5000 and a 
maximum injection time at 100ms. The raw files were processed in Proteome 
Discoverer (V1.4) (Thermo Fisher) using Mascot (V2.5) (Matrix Science) as the 
protein database search engine with the following parameters: Enzymatic digestion 
was set to trypsin with a maximum of 2 missed cleavages sites; peptide mass 
tolerance search was set at 20 ppm; MS/MS fragment mass tolerance at 0.50 Da. 
Variable modifications for Acetyl (Protein N-term), Carbamidomethyl (C), 
Deamidated (NQ), and Oxidation (M).  The protein databases were downloaded 
from Uniprot (October 2014) plus the common contaminating database. False 
Discovery Rate (FDR) setting was based on PEP at 0.01 in Percolator, and proteins 
with high confidence peptides were reported. Eluates from two biological replicates 
of the surface-biotinylation experiment were reduced to disrupt disulfide bonds 
using 20mM TCEP at 56C for 1 hour. Thereafter, alkylation of cysteine to prevent 
reformation of disulfide bonds was performed by addition of 40mM iodoacetamide 
(IAA) for 45 minutes in the dark followed by addition of trypsin at a 1:40 E: S ratio 
at 37C overnight. The peptides obtained were analysed as has been described 
above for the surface-shaving experiments. 
 
The proteins identified by the database search were subjected to in silico analyses 
using publicly available algorithms for detecting a predicted signal peptide and 
transmembrane domains http://www.cbs.dtu.dk/services/SignalP, 
http://www.cbs.dtu.dk/services/TMHMM/ respectively. The transcript levels of 
identified genes were derived from microarray transcriptome data available on 
PlasmoDB (http://plasmodb.org/plasmo/). Gene ontology cellular component 
enrichment analysis was performed using PlasmoDB where the frequency of 
occurrence of a particular cellular component term within the list of identified 
proteins is compared to the background frequency of occurrence in the total 
proteome.  
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3.5. Results 
3.5.1. Optimising the merozoite cell surface trypsinization protocol 
 
As a first step, I optimised the merozoite cell surface trypsinization protocol by 
varying the concentration of trypsin and the incubation time. As shown in Figure 
3.5A (blue arrows), pellets obtained from short-term trypsin treatment contained 
proteins of varying sizes, which were not visible in the respective supernatant 
fractions (red arrows), suggesting that trypsin was not resulting in large scale lysis. I 
monitored the specificity of the trypsinization protocol by detecting the retention of 
the internal protein ERD2 and the loss of the peripherally associated merozoite 
surface protein, MSP3. As shown in Figure 3.5B, ERD2 was detected in all the 
pellets, including merozoites incubated with either 8.3g or 2.5g of trypsin, 
suggesting as expected, trypsin was not cleaving intracellular proteins. The MSP3 
protein was detected in the merozoite pellet that was untreated and in the mock-
shaved pellet fraction. Most pellet fractions to which trypsin had been added lacked 
MSP3, showing surface shaving had been successful. The exception was the 2.5g 
of trypsin/20 minute’s fraction, where the intensity of the MSP3 band was reduced 
relative to the mock-shaved fraction, indicating some loss of merozoite surface 
proteins, but not completely absent.  
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Figure 3.5: Optimising the P. falciparum merozoite cell surface trypsinization protocol. A) Silver-stained 
gel of the pellet and supernatants from the different treated merozoite fractions. Blue arrows show pellet 
material with proteins of varying sizes while red arrows are supernatant material in which fewer proteins were 
detected. B) Western blot results of the detection of MSP3 and ERD2 in pellets obtained from merozoites 
treated with trypsin, or mock-treated or left untreated.  
 
3.5.2. Putative merozoite surface proteins identified by cell surface trypsinization 
 
To identify merozoite surface proteins, I performed two independent biological 
replicates of the merozoite trypsinization experiment and proteins released into the 
supernatant were identified by mass-spectrometry. Prior to protein identification, I 
confirmed the specificity of the trypsinization by detecting the presence of ERD2 in 
both fractions and the loss of MSP3 in the trypsin treated fraction as shown in 
Figure 3.6A. In one biological replicate, a total of 1857 proteins were identified 
from supernatant obtained from trypsin shaved and mock-shaved merozoites. I 
eliminated proteins that were not P. falciparum specific (N=33), often referred to as 
contaminants i.e. keratin, trypsin, proteins from Bos Taurus (bovine origin) or 
Homo sapien (human origin). I also eliminated proteins that were identified when 
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peptides were mapped onto a decoy database (database derived from reversing the 
P. falciparum database) (N=25) or proteins in which information on intensity (a 
measure of the quantity) was absent (N=353). Similarly, for the second biological 
replicate, I eliminated contaminant proteins (N=33), proteins that mapped onto the 
decoy database (N=11) and proteins in which information on intensity was absent 
(N=453). Therefore, the total number of P. falciparum specific proteins identified 
from supernatants obtained from the mock-shaved and trypsin treated merozoites in 
the two independent biological replicates was 1431 and 1331 respectively. 
 
As shown in Figure 3.6B, 485 (33.9%) of proteins identified in the first experiment 
were uniquely identified in supernatant from trypsin-shaved merozoites while 184 
(12.9%) were identified in the mock-shaved supernatant. The majority of proteins 
identified, 762 (53.2%) were detected in both fractions. In the second experiment, 
549 (41.2%) and 158 (11.9%) were uniquely identified in the trypsin treated and 
mock shaved fractions respectively and 624 (46.9%) were identified in both 
fractions (Figure 3.6C). The list of proteins identified in the trypsin shaved, mock 
shaved and present in both fraction for the two biological replicates are found in 
Appendix 3.1 and 3.2 respectively. In both cases, relatively few proteins were 
specifically released upon trypsin treatment. These results were similar to findings 
from cell surface trypsinization experiments on the extracellular stage 
(trypomastigotes) of the blood-borne pathogen Trypanosoma cruzi. In this study, 
surface shaving identified 1245 targets of which 566 (46%) were found exclusively 
in the treated cells and 483 (39%) in both shaved and control trypomastigotes [412].  
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Figure 3.6: Identification of putative merozoite surface proteins by cell surface trypsinization. A) Western 
blot detection of retention of ERD2 and loss of MSP3 in trypsin treated merozoites. P.falciparum specific 
proteins identified in supernatant from trypsin treated and mock shaved merozoites in B) biological replicate 1 
and C) biological replicate 2. 
3.5.3. Defining potential P. falciparum merozoite surface proteins from surface 
shaving 
 
The two biological replicates were analysed independently and only merged after 
defining a putative surface protein list from each experiment as is described below 
in section 3.5.6. To obtain a list of putative surface merozoite proteins, several 
analyses were performed as follows. Proteins identified only in the trypsin-shaved 
fractions were all considered to be surface proteins. However, some proteins in the 
overlap between both the shaved and mocked fraction in the two replicates (Figure 
3.6B and C; 762 and 624, respectively) could also be surface proteins. Several 
proteins present on the merozoites are shed prior to or at the point of invasion of 
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erythrocytes (e.g. MSP1 and AMA1) [408, 418], meaning that they would be found 
in both the shaved and mock-shaved samples. However, I hypothesized that trypsin 
treatment should accelerate the surface shedding process, and therefore cleaved 
surface proteins would be more abundant in the trypsin treated compared to mock 
shaved merozoites.  I compared the relative abundance of the proteins in each of the 
fractions by calculating the intensity ratio (IR) as follows: RI = intensity of protein 
in trypsin treated merozoites/ intensity of protein in mock treated merozoites. A RI 
greater than 1 would indicate that the protein identified was more abundant in the 
trypsin treated supernatant compared to the mock shaved merozoites. I then used a 
set of genes predicted to be intracellular to generate a cut-off ratio such that any 
protein with an RI value greater than the cut-off would be considered putative 
surface proteins.  
 
Figure 3.7: Relative abundance of proteins identified in both the mock treated and trypsin treated 
merozoites in: A) the first and B) the second biological replicate. 
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Proteins considered intracellular had been designated terms such as ‘Nuclear’, 
‘Transcription’, ‘DNA’, ‘Helicase’, ‘Proteasome’, ‘Ribosomal’ and ‘Heat shock’. A 
total of 126 (16.5%) and 96 (15.4%) proteins were considered intracellular and 
resulted in a RI cut-off of 3.96 (log10 (RI)=0.59) and 9.56 (log10 (RI)=0.98). As 
shown in Figure 3.7A and B, a total of 225 and 163 proteins had an RI ratio above 
this cut-off point in the two biological replicates. This resulted in a set of 710 
(225+485=710) and 712 (163+549) designated as putative surface proteins from the 
two biological replicates (Figure 3.8A and B, respectively). The remaining proteins, 
721 and 619 targets were considered mock proteins. On searching the PlasmoDB 
database with the unique uniprot IDs, the 710 and 712 targets that were designated 
as putative surface proteins, mapped to 681 and 684 targets respectively. The list of 
proteins designated as putative surface proteins is available in Appendix 3.3. 
 
 
Figure 3.8: A summary of the number of targets re-classified at putative surface proteins or mock 
(intracellular) proteins. Data from the first (A) and second (B) biological replicate of the surface-shaving 
experiments is presented. 
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3.5.4. Comparing the predicted gene ontology and level of polymorphism between 
putative surface and mock proteins 
 
Having defined the set of proteins likely to be on the surface of the merozoite, I 
evaluated which cellular component terms were enriched within my list when 
compared to their occurrence in the entire 3D7 protein coding genes. This gene 
ontology cellular component enrichment analysis was performed using PlasmoDB, 
and it compares the frequency of occurrence of a particular cellular component term 
within my list of putative surface proteins compared to the background frequency of 
occurrence in the entire organisms set of genes. As shown in Figure 3.9 A and B, 
the two top cellular component terms that were enriched in the surface protein list 
from the first biological replicate was ‘cell periphery’ (p-value=0.0087) and ‘plasma 
membrane’ (p-value=0.0090), fitting in with the expectation of enriching for surface 
proteins. However, for the second biological replicate the two enriched component 
terms were ‘endoplasmic reticulum’ (p-value=0.0412) and ‘macromolecular 
complex” (p-value=0.0481), which were borderline significant. This may indicate 
that a higher degree of merozoite lysis occurred during the second replicate 
experiment. 
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Figure 3.9: Gene ontology cellular component enrichment analysis in proteins designated surface 
proteins. Data presented in the first A) and B) second biological replicate experiments. The enriched gene-
ontology terms are arranged in order of descending significance. In A) significantly enriched terms are “cell 
periphery” and “plasma membrane” while in B) it was “macromolecular complex” and  “endoplasmic 
reticulum” were borderline significant. 
 
I hypothesized that proteins on the surface of the merozoite would be more 
polymorphic compared to mock proteins due to exposure to the host immune’s 
system. I therefore compared the number of non-synonymous SNPs (single 
nucleotide polymorphisms that result in an amino acid change) in genes classified as 
surface proteins and mock proteins. As shown in Figure 3.10A, putative surface 
proteins had a significantly higher number of non-synonymous SNPs compared to 
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mock proteins. The mean log10 non-synonymous SNPs between surface and mock 
proteins were 1.764 versus 1.386 (p-value <0.0001: Unpaired t test) and 1.690 
versus 1.460 (p-value<0.0001: Unpaired t test). Similarly, the mean log10 ratio of 
non-synonymous /synonymous SNPs per gene (dN/dS ratio) was significantly 
higher in the surface proteins when compared to mock proteins.  As shown in Figure 
3.10B, the mean log10 dN/dS ratio between surface and mock proteins was 0.2385 
versus 0.0357 (p-value <0.0001: Unpaired t test) and 0.1849 versus 0.0653 (p-value 
<0.0001: Unpaired t test). 
 
Figure 3.10: Comparison of the number of non-synonymous SNPs per gene and the ratio of non-
synonymous to synonymous SNPs in mock and putative surface proteins. The number of non-synonymous 
SNPs (A) and the ratio of non-synonymous to synonymous SNPs (B) in genes encoding putative surface 
proteins were significantly higher than compared to mock proteins. The Mann-Whitney U test was used for 
comparisons. ****: p-value < 0.0001 
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3.5.5. Comparing the protein features represented in putative surface and mock 
proteins 
 
To analyse further the characteristics of the proteins I identified (N=1651) in both 
biological replicates, I obtained data from PlasmoDB with information on the 
predicted gene ontology for each of the antigens as well the presence of a predicted 
signal peptide or transmembrane domains. In addition, I used data from a peer-
reviewed publication [258] in which changes in gene expression following exposure 
to 20 parasite growth inhibitory compounds were analysed over the asexual 
erythrocytic cycle. A set of genes termed the “invadome” that may be important for 
erythrocyte invasion were proposed from this article. I then compared the 
occurrence of these features in the following ways: i) between different fractions 
within my dataset i.e. compared occurrence in putative surface versus mock proteins 
and ii) between the different fractions within my dataset and their occurrence within 
the entire genome. 
3.5.5.1. Comparison of features between putative surface and mock proteins 
 
As shown in Figure 3.11, features characteristic of surface-exposed proteins such as 
a predicted N-terminal signal peptide and/or transmembrane domains were 
generally enriched in proteins classified as putative surface proteins (the blue bars 
are longer than the grey bars). Similarly, the proportion of proteins predicted to be 
cytosolic, mitochondrial or vesicle located was larger in mock proteins (the grey 
bars are longer than the blue bars)  
 
For example, as shown in Figure 3.11, 197 (12%) of the proteins I identified (in 
both mock and putative surface proteins) were proposed to be genes encoding 
proteins essential for merozoite invasion of erythrocytes [258]. Of these targets, 115 
(58%) were identified in biological replicate 1 and 97 (49%) were identified in 
biological replicate 2, as putative surface proteins. These included the 6-cys proteins 
Pf38 and Pf41, the GPI-anchored micronemal antigen (GAMA), glideosome-
associated protein 40, 45 and 50 (GAP40, GAP45 and GAP50) and MSP-1, 9, 10 
among others [258].  A small proportion of “invadome” genes were identified in 
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mock proteins in both biological replicates (67 (34%) and 56 (28%) respectively). 
These included proteins and enzymes that may play important roles prior to 
merozoite egress or invasion but are not surface-located. These include enzymes 
such as CDPK4, putative protein kinases, putative phosphatases, and subtilisin-like 
proteases 2 (SUB2) among others. Similarly, 487 (29%) of all the proteins identified 
(in both mock and putative surface proteins) were predicted to have a signal peptide 
and/or transmembrane domains which are features that suggest a protein localisation 
may be extracellular or on the surface of a cell. Of these targets, 276 (56%) were 
identified in biological replicate 1 and 237 (49%) were identified in biological 
replicate 2 as putative surface proteins.  A small proportion of all identified proteins 
were predicted to be cytosolic 119 (7%), nucleus-associated 93 (6%) and 
mitochondrial 3 (0.2%). Interestingly, for the majority of targets 1325 (80%) I 
identified, there was no predicted sub-cellular localisation. 
 
Figure 3.11: Predicted cellular localisation and representation of protein features putative surface and 
mock proteins. Data presented are proteins identified as putative surface proteins or the mock proteins in the 
first (A) and second (B) biological replicate. Features suggesting surface localisation such as signal peptide 
and/or transmembrane domains were represented to a higher proportion in putative surface proteins. Proteins 
predicted to be cytoplasmic located were enriched in mock proteins. 
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3.5.5.2. Comparison of features between putative surface/mock proteins and 
occurrence in the genome 
 
 I compared the occurrence of proteins with features suggesting surface localisation 
or roles in merozoite invasion of erythrocytes within the dataset obtained and in the 
genome. As shown in Table 3.1, proteins that were proposed to be members of the 
invadome were significantly enriched within the putative surface protein list when 
compared with occurrence within the entire genome. No differences were observed 
between the proportion of proteins with a signal peptide or transmembrane domains 
in the putative surface proteins when compared with the genome. However, the 
proportions of these proteins were significantly lower in mock proteins when 
compared to the genome. This validated the methods I used to differentiate between 
putative surface and mock proteins. 
 
Table 3.1: Table showing the proportion of proteins proposed to be members of the invadome or have a 
signal peptide and/or transmembrane domain found within the genome and datasets obtained from 
merozoite trypsinization 
Features Proportion found within different datasets  
Biological replicate 1 
 Proportion found 
within the genome# 
N=5305 (%) 
Putative surface 
proteins 
N=710 
P-value Mock 
proteins 
      N=721 
P-value 
Member of the 
invadome 
418 (7.88%) 115 (16.19) 0.0001 67 (9.29%) 0.1917 
Presence of a SP 
and or TMDs 
1979 (37.3%) 276 (38.87) 0.4591 134 (18.59) 0.0001 
Biological replicate 2 
 Proportion found 
within the genome# 
N=5305 (%) 
Putative surface 
proteins 
N=712 
P-value Mock 
proteins 
      N=619 
P-value 
Member of the 
invadome 
418 (7.88%) 97 (13.62) 0.0001 56 (9.05) 0.3100 
Presence of a SP 
and or TMDs 
1979 (37.3%) 237 (33.29) 0.0563 125 (20.19) 0.0001 
#- Protein coding genes on PlasmoDB excluding pseudogenes. SP: Signal peptde. TMDs: 
Transmembrane domains 
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3.5.6. Putative surface proteins identified in both biological replicates 
 
To increase the likelihood of identifying true merozoite surface proteins, I narrowed 
down to the targets classified as putative surface proteins in both biological 
replicates, N=374. Of these targets, 157 (42%) were predicted to have an N-terminal 
signal peptide and/or atleast one transmembrane domain. I then investigated the 
overlap between these putative surface proteins and the invadome [258] as well as 
with genes for which genetic manipulation had been attempted in their P. berghei 
orthologues, as of October 2016. Phenotypes obtained from these experiments have 
been deposited on the RMgmDB (http://www.pberghei.eu/index.php) and 
PlasmoGEM (http://plasmogem.sanger.ac.uk/phenotypes). A summary of the 
overlap between proteins identified in my study, the invadome and P. berghei 
genetic modification database is shown as Figure 3.12. These represent additional 
information that could be considered when selecting potential vaccine candidates for 
evaluation from a list of putative merozoite surface proteins. 
 
Among the putative surface proteins I identified in both biological replicates, 70 
(19%) of them are considered members of the proposed invadome, as shown in 
Figure 3.12 and Table 3.2. These are genes whose transcriptional profiles were up or 
down-regulated during the asexual erythrocytic cycle following exposure to parasite 
growth inhibitory compounds. As shown in Table 3.3, the proportion of genes 
termed as invasion-related were significantly higher when compared to the 
occurrence within the genome: 18.7% versus 7.9% p-value <0.0001. Among these 
were known merozoite surface proteins under evaluation as potential blood-stage 
vaccine candidates such as the MSP-9 and 10, the 6-cys proteins P41 and P38 [294-
296] and GAMA [419]. Additional proteins that have been shown to localise to the 
surface of free merozoites, and are considered essential for invasion that were 
identified as putative surface proteins in my study included, 1) PF3D7-0217500, 
also known as calcium-dependent protein kinase 1 (PfCDPK1) that was shown to 
co-localise with MSP1 in indirect immuno-fluorescent assays [420], 2) PF3D7-
0210700, also known as syntaxin (PfStx1), has been shown to co-localise with 
PfMSP3 and 3) PF3D7-0206200 also known as the pantothenate transporter (PAT), 
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showed localisation to the surface of individual merozoites within schizonts [421]. 
None of these antigens have been evaluated in the context of naturally acquired 
immunity. In addition, 28 (40%) of proteins that are considered to be members of 
the invadome and that I identified as putative surface proteins in this study, were 
termed as “conserved plasmodium protein, unknown function” or “conserved 
plasmodium membrane protein, unknown function”.  These represent potential 
targets of protective antibodies that have thus far not been evaluated. 
 
 
Figure 3.12: Publicly available data on the putative surface proteins identified. Figure shows the overlap 
between putative surface proteins and a proposed set of invadome genes and P. berghei orthologues in whom 
genetic modification has been attempted.  Examples of known and the number of understudied targets identified 
in each group in presented. 
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Table 3.2: P. falciparum putative surface proteins identified in my study and are part of the invadome 
genes proposed by Hu et al [258].  
Plasmodium 
falciparum gene 
ID 
Product description No. of 
TMDs 
Presence 
of SP 
PF3D7_0204100 conserved Plasmodium protein, unknown function 0 1 
PF3D7_0206200 pantothenate transporter (PAT) 11 0 
PF3D7_0210600 conserved Plasmodium protein, unknown function 0 1 
PF3D7_0210700 syntaxin, Qa-SNARE family (SYN17) 1 0 
PF3D7_0217500 calcium-dependent protein kinase 1 (CDPK1) 0 0 
PF3D7_0303200 HAD superfamily protein, putative 0 0 
PF3D7_0308300 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0308700 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0321100 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0321400 protein kinase, putative 1 0 
PF3D7_0403800 alpha/beta hydrolase, putative 0 0 
PF3D7_0404900 6-cysteine protein (P41) 0 1 
PF3D7_0407800 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0418600 regulator of chromosome condensation, putative 0 0 
PF3D7_0420300 transcription factor with AP2 domain(s) (ApiAP2) 0 0 
PF3D7_0423500 glideosome associated protein with multiple membrane 
spans 2 (GAPM2) 
6 0 
PF3D7_0423700 early transcribed membrane protein 4 (ETRAMP4) 2 1 
PF3D7_0501600 rhoptry-associated protein 2 (RAP2) 0 1 
PF3D7_0503600 myosin B (MyoB) 0 0 
PF3D7_0506900 rhomboid protease ROM4 (ROM4) 6 0 
PF3D7_0508000 6-cysteine protein (P38) 1 1 
PF3D7_0515700 glideosome-associated protein 40, putative (GAP40) 10 0 
PF3D7_0522600 inner membrane complex protein 8 1 
PF3D7_0525800 inner membrane complex protein 1g, putative (IMC1g) 0 0 
PF3D7_0528400 palmitoyltransferase (DHHC7) 4 0 
PF3D7_0613900 myosin E, putative (myoE) 0 0 
PF3D7_0618000 conserved Plasmodium membrane protein, unknown 
function 
4 0 
PF3D7_0620400 merozoite surface protein 10 (MSP10) 2 1 
PF3D7_0722200 rhoptry-associated leucine zipper-like protein 1 (RALP1) 1 1 
PF3D7_0730400 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0802600 adenylyl cyclase beta (ACbeta) 0 0 
PF3D7_0805300 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0813100 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0817700 rhoptry neck protein 5 (RON5) 0 0 
PF3D7_0822900 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0828800 GPI-anchored micronemal antigen (GAMA) 2 1 
PF3D7_0903600.1 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0908000 P1 nuclease, putative 2 0 
PF3D7_0911100 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0913800 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0914400 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0918700 conserved Plasmodium protein, unknown function 0 0 
PF3D7_0920500 ADP-ribosylation factor, putative 0 0 
PF3D7_0930500 diacylglycerol kinase, putative (DGK1) 2 0 
PF3D7_0935800 cytoadherence linked asexual protein 9 (CLAG9) 2 1 
PF3D7_1014100 conserved Plasmodium protein, unknown function 0 1 
PF3D7_1017500 conserved Plasmodium protein, unknown function 0 0 
PF3D7_1023000 conserved Plasmodium membrane protein, unknown 
function 
5 0 
PF3D7_1031200 MORN repeat-containing protein 1 (MORN1) 0 0 
PF3D7_1035300 glutamate-rich protein (GLURP) 0 1 
PF3D7_1037500 dynamin-like protein (DYN2) 0 0 
PF3D7_1113000 conserved Plasmodium protein, unknown function 0 0 
PF3D7_1146600 CCAAT-box DNA binding protein subunit B (NFYB) 0 0 
PF3D7_1222700 glideosome-associated protein 45 (GAP45) 0 0 
PF3D7_1228600 merozoite surface protein 9 (MSP9) 0 1 
PF3D7_1229300 conserved Plasmodium protein, unknown function 1 1 
PF3D7_1250200 conserved Plasmodium membrane protein, unknown 9 1 
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Plasmodium 
falciparum gene 
ID 
Product description No. of 
TMDs 
Presence 
of SP 
PF3D7_1308000 conserved Plasmodium membrane protein, unknown 
function 
4 0 
PF3D7_1332200 conserved Plasmodium protein, unknown function 0 0 
PF3D7_1343800 conserved Plasmodium protein, unknown function 2 0 
PF3D7_1351700 inner membrane complex protein 1f, putative (IMC1f) 0 0 
PF3D7_1410400 rhoptry-associated protein 1 (RAP1) 0 1 
PF3D7_1414500 atypical protein kinase, ABC-1 family, putative (ABCk2) 0 0 
PF3D7_1452000 rhoptry neck protein 2 (RON2) 1 1 
PF3D7_1455300 conserved Plasmodium protein, unknown function 0 0 
PF3D7_1460600 inner membrane complex sub-compartment protein 3, 
putative (ISP3) 
0 0 
PF3D7_1461400 conserved Plasmodium protein, unknown function 0 0 
PF3D7_1463900 conserved Plasmodium membrane protein, unknown 
function 
7 1 
PF3D7_1467900 rab GTPase activator, putative 0 0 
PF3D7_1476300 Plasmodium exported protein (PHISTb), unknown 
function 
1 0 
TMDs: Transmembrane domains. SP: Signal peptide 
 
In a second analysis, I searched the rodent malaria genetic modification databases 
RMgmDB and PlasmoGEM to identify genes in which the P. berghei orthologue 
had either been tagged, disrupted/mutated or knocked down, or for which attempts 
to knock down were unsuccessful. I found a total of 210 of the putative merozoite 
surface proteins in these databases (67 (18%) and 184 (49%) in the RMgmDB and 
PlasmoGEM databases, respectively). Of these 210 targets, 41 of them have also 
been proposed to be essential for invasion as has been described above such as 
PfPAT, CDPK1, P41, P38, MSP10 and GAMA among others.  
3.5.6.1. Overlap with targets with a phenotype reported in RMgmDB database 
 
Of the 67 targets with a phenotype deposited on RMgmDB, three targets namely 
PfPAT [421], ISP3 and CDPK1 [420] have been shown to localise to the periphery 
of merozoites (Table 3.4), and therefore potentially accessible to circulating 
antibodies. In twenty-four (36%) of the 67 targets identified on RMgmDB database, 
efforts to knock down the gene have been unsuccessful despite several attempts as 
shown in Table 3.4. This includes 4 proteins namely PF3D7_0305300, 
PF3D7_1463900, PF3D7_1455300 and PF3D_1468100 that are described as 
“conserved Plasmodium (membrane) proteins, unknown function”. Eight targets had 
their P. berghei orthologues genetically disrupted, which resulted in a defect in 
merozoite membrane biogenesis formation or a reduced parasite growth rate over 
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the asexual blood stage. These targets included skeleton binding protein 1 (SBP1), 
Phosphatidylinositol 4-kinase (PI4K), Zn2+ or Fe2+ permease, Tyrosine kinase-like 
protein, putative (TKL4), Plasmodium exported protein (PHISTc), CCR4-associated 
factor 1 (CAF1), Heat shock protein 101 (HSP101), a putative transporter 
(PF3D7_1129900) and Thioredoxin 2 (TRX2). 
3.5.6.2. Overlap with targets with a phenotype reported in PlasmoGEM database 
 
One hundred and eighty-four targets have had their P. berghei orthologue 
phenotypes reported on PlasmoGEM [336] (Appendix 3.4). These were targets 
identified from a high throughput reverse genetic screen using barcoded gene 
knockout vectors. Large pools of barcoded vectors were co-transfected 
simultaneously and a growth rate phenotype over the asexual stage of the life cycle 
assigned to genes. As a result, for a subset of the P. berghei genome, genes have 
been assigned as either essential, dispensable or result in a slow parasite growth rate 
over the erythrocytic stage [336]. As shown in Table 3.3, 104 targets are termed as 
essential and 38 as resulting in a reduced growth rate.  
 
Table 3.3: Table showing a comparison between the occurrences of proteins of specific characteristics 
within the putative surface protein data set and the genome. 
Feature Proportion found 
within the 
genome# 
N=5305 (%) 
Proportion found 
within the putative 
surface protein list 
N=374 (%) 
P-value 
Member of the invadome 418 (7.88) 70 (18.7) <0.0001 
P. berghei phenotype suggests the genes play 
essential functions over asexual stages% 
1195 (46.4) 104 (27.8) <0.0001 
P. berghei phenotype suggests modification 
of the gene results in a reduced growth rate 
over asexual stages% 
456 (17.7) 38 (10.2) 0.0003 
P. berghei phenotype suggests the genes play 
dispensable roles over asexual stages% 
911 (35.4) 41 (11.0) <0.0001 
 
#- Protein coding genes (excluding pseudogenes) on PlasmoDB. *-N=5056 genes were analysed. %- 
N-2575 number of genes with a phenotype reported on PlasmoGEM. 
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Table 3.4: P. falciparum putative surface proteins for which genetic manipulation has been attempted in P. berghei orthologues and phenotypes reported on RMgmDB.  
Plasmodium 
falciparum gene 
ID 
Product description  Invadome RMgmid Rodent malaria gene 
ID 
Modification attempted in rodent malaria parasites. *No publication.  
Efforts to disrupt or knock-down the gene was not successful 
 
PF3D7_0305300 Conserved Plasmodium membrane protein, 
unknown function 
 RMgm-244 PBANKA_0403800 Two attempts to disrupt the gene were unsuccessful* 
PF3D7_0321400 Protein kinase, putative 1 RMgm-575 PBANKA_1217100 Five attempts to disrupt the gene were unsuccessful[422]. 
PF3D7_0506900 Rhomboid protease ROM4 (ROM4) 1 RMgm-764 PBANKA_1106500 Three attempts to disrupt the gene were unsuccessful. M-cherry tagged ROM4 shows 
expression in schizonts and gametocytes[423]. 
PF3D7_0515700 Glideosome-associated protein 40, putative  1 RMgm-1402 PBANKA_1115300 Two attempts to disrupt the gene were unsuccessful[424].   
PF3D7_0523000 Multidrug resistance protein (MDR1)  RMgm-1158 PBANKA_1237800 Three attempts to disrupt the gene were unsuccessful[425]. 
PF3D7_0628200 Protein kinase PK4 (PK4)  RMgm-737 PBANKA_1126900 Four attempts to disrupt gene were unsuccessful. Shown to be essential during the blood-stage 
of the life cycle[426]. 
PF3D7_0709000 Chloroquine resistance transporter (CRT)  RMgm-612 PBANKA_1219500 Four attempts to disrupt the gene were unsuccessful[427]. 
PF3D7_0904700 Bacterial histone-like protein (HU)  RMgm-266 PBANKA_0416700 Three attempts to disrupt the gene were unsuccessful[428]. 
PF3D7_0935800 Cytoadherence linked asexual protein 9 
(CLAG9) 
1 RMgm-248 PBANKA_0836300 Five attempts to disrupt the gene were unsuccessful*. 
PF3D7_1007700 Transcription factor with AP2 domain(s) 
(ApiAP2) 
 RMgm-1130 PBANKA_1205900 Attempts to disrupt the gene were unsuccessful*. Number of attempts have not been reported 
PF3D7_1037500 Dynamin-like protein (DYN2) 1 RMgm-765 PBANKA_0520400 Three attempts to disrupt the gene were unsuccessful. 
PF3D7_1309200 Protein phosphatase 2c-like protein, putative  RMgm-1080 PBANKA_1407700 Five attempts to disrupt the gene were unsuccessful. GFP-tagged gene showed expression in 
asexual stages, gametocytes and oocysts[351]. 
PF3D7_1316600 Choline-phosphate cytidylyltransferase (CCT)  RMgm-339 PBANKA_1415100 Two attempts to disrupt the gene were unsuccessful.  GFP-tagged CCT showed expression in 
the cytoplasm of blood-stages[343]. 
PF3D7_1320000 Rhoptry protein 2, putative (PRP2)  RMgm-215 PBANKA_1418300 Three attempts to disrupt the gene have been unsuccessful. GFP-tagged mature merozoites 
within schizonts showed two-dot staining characteristic of rhoptry-organelle localisation[345]. 
PF3D7_1323500 Plasmepsin V (PMV)  RMgm-881 PBANKA_1338700 Three attempts to disrupt the gene were unsuccessful*. 
PF3D7_1340700 Ras-related protein Rab-11B (RAB11b)  RMgm-823 PBANKA_1354100 Two attempts to disrupt the gene were unsuccessful*. 
PF3D7_1410400 Rhoptry-associated protein 1 (RAP1) 1 RMgm-1134 PBANKA_1032100 Attempts to disrupt the gene were unsuccessful*. Number of attempts have not been reported 
PF3D7_1436300 Translocon component PTEX150 (PTEX150)  RMgm-1331 PBANKA_1008500 Three attempts to disrupt the gene were unsuccessful. HA-tagged PTEX150 showed 
localization to the parasitophorous vacuolar membrane (PVM)[429]. 
PF3D7_1450000 Serine/threonine protein kinase, putative  RMgm-541 PBANKA_1313700 Four attempts to disrupt the gene have been unsuccessful[422]. 
PF3D7_1452000 Rhoptry neck protein 2 (RON2) 1 RMgm-213 PBANKA_1315700 Three attempts to disrupt the gene were unsuccessful. mCherry tagged parasites showed apical 
localisation on merozoites[345]. 
PF3D7_1455300 Conserved Plasmodium protein, unknown 
function 
1 RMgm-509 PBANKA_1319000 Two attempts to disrupt the gene were unsuccessful*. 
PF3D7_1463900 Conserved Plasmodium membrane protein, 
unknown function 
1 RMgm-190 PBANKA_1327100 Three attempts to disrupt the gene were unsuccessful. 
PF3D7_1464600 Phosphatase, putative  RMgm-1364 PBANKA_1328000 Two attempts to disrupt the gene in the blood-stages have been unsuccessful[430]. 
PF3D7_1468100 Conserved Plasmodium protein, unknown   RMgm-510 PBANKA_1331400 Two attempts to disrupt the gene were unsuccessful* 
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Efforts to disrupt or knock-down the gene was successful 
Plasmodium 
falciparum gene 
ID 
Product description  Invadome RMgmid Rodent malaria 
gene ID 
Modification attempted in rodent malaria parasites  
PF3D7_0206200 Pantothenate transporter (PAT) 1 RMgm-1098 
RMgm-1372 
PY17X_0304500 
PBANKA_0303900 
Gene disruption was successful resulting in no mature oocysts or sporozoite [424, 431]. P.berghei 
male and female gametes fail to egress from host erythrocytes after induction of 
gametogenesis[432]. 
PF3D7_0217500 Calcium-dependent protein kinase 1 (CDPK1) 1 RMgm-772 PBANKA_0314200 P. berghei GFP tagged CDPK1 shows expression in schizonts, gametocytes, ookinetes, oocysts 
and sporozoites[352] 
PF3D7_0312500 Transporter, putative  RMgm-1383 PBANKA_0410500 Gene disruption showed reduced P. berghei sporozoite numbers in vivo[424]. 
PF3D7_0317100 6-cysteine protein (B9)  RMgm-929 PBANKA_0808100 Gene disruption resulted in arrested development of sporozoites within hepatocytes[433]. 
PF3D7_0320800 ATP-dependent RNA helicase DDX6 (DOZI)  RMgm-1583 PBANKA_1217700 Gene disruption showed no significant difference in growth rate with wild type parasites 
PF3D7_0404900 6-cysteine protein (P41) 1 RMgm-480 PBANKA_1002600 Gene disruption showed no difference in growth rate compared to wild-type parasites[434]. 
PF3D7_0501300 Skeleton-binding protein 1 (SBP1)  RMgm-1452 PBANKA_1101300 C57B/6 mice infected with Pbsbp1 parasites did not develop cerebral malaria compared to those 
infected with wild type parasites. Reduced sequestration of schizonts in Pbsbp1 compared to 
wild-type[435]. 
PF3D7_0501600 Rhoptry-associated protein 2 (RAP2) 1 RMgm-209 PBANKA_1101400 GFP tagged parasites showed two-dot staining in merozoites within schizonts and in oocyst and 
salivary gland sporozoites[345]. 
PF3D7_0502400 Ring-stage membrane protein 1,merozoite 
surface protein 8 (MSP8) 
 RMgm-225 PBANKA_1102200 P. berghei parasites expressing truncated MSP8 showed no difference in growth rate when 
compared to wild-type parasites[346]. 
PF3D7_0503600 Myosin B (MyoB) 1 RMgm-1230 PBANKA_1103300 GFP tagged MyoB showed expression on the extreme apical end of merozoites within 
schizonts[436]. 
PF3D7_0508000 6-cysteine protein (P38) 1 RMgm-354 PBANKA_1107600 Pbp38 showed no differences from wild type across the complete life cycle[437]. 
PF3D7_0509800 Phosphatidylinositol 4-kinase (PI4K)  RMgm-969 PBANKA_1109400 Mutated gene showed that inhibition affects merozoite formation interfering with membrane 
biogenesis around developing merozoites[438]. 
PF3D7_0528400 Palmitoyltransferase (DHHC7) 1 RMgm-901 PBANKA_1243000 Gene disruption successful, however the growth rate comparison with wild type has not been 
determined[439]. 
PF3D7_0609100 Zn2+ or Fe2+ permease  RMgm-1143 PBANKA_0107700 Gene disruption was successful resulting in a reduced parasite multiplication rate over the asexual 
blood stage when compared to wild type parasites. Reduced numbers of female gametocytes, no 
male gametocytes, no ookinetes, oocyst or sporozoites develop within mosquitoes[424]. 
PF3D7_0614300 Organic anion transporter  RMgm-1395 PBANKA_0112500 Gene disruption successful and no differences observed across the asexual blood stage when 
compared to wild-type parasites[424]. 
PF3D7_0620400 Merozoite surface protein 10 (MSP10) 1 RMgm-416 PBANKA_1119600 No phenotype presented[434]. 
PF3D7_0623800 Tyrosine kinase-like protein, putative (TKL4)  RMgm-533 PBANKA_1122700 Gene deletion was successful resulting in a reduced parasite growth rate over the asexual blood 
stage[336]. 
PF3D7_0629500 Amino acid transporter, putative  RMgm-832 PBANKA_1128300 Gene disruption successful however the phenotype has not been described*. 
PF3D7_0715800 Drug/metabolite exporter, drug/metabolite 
transporter 
 RMgm-1388 PBANKA_1422100 Gene disruption successful and no differences were observed when compared to wild type[424]. 
PF3D7_0715900 Zinc transporter, putative  RMgm-1373 PBANKA_1422200 Gene disruption successful, no differences observed over asexual blood stage, reduced 
exflaggellation, reduced ookinete numbers, reduced sporozoite numbers, delayed transmission in 
vivo[424]. 
Plasmodium Product description  Invadome RMgmid Rodent malaria Modification attempted in rodent malaria parasites  
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falciparum gene 
ID 
gene ID 
PF3D7_0801000 Plasmodium exported protein (PHISTc), 
unknown function 
 RMgm-708 PBANKA_1229000 C57BI/6 mice infected with knockout parasites showed longer survival rates and a mild reduction 
in the growth rate of the asexual blood-stages when compared to wild type parasites[440]. 
PF3D7_0805300 Conserved Plasmodium protein, unknown 1 RMgm-444 PBANKA_1225300 Gene disruption was successful however no phenotype has been described[434]. 
PF3D7_0811200 Conserved protein, unknown function  RMgm-780 PBANKA_1426300 mCherry tagged parasites, however the localization has not been reported*. 
PF3D7_0811300 CCR4-associated factor 1 (CAF1)  RMgm-318 PBANKA_1426200 P. berghei disruption was not successful 
The number of merozoites per schizont did not differ between Pfcaf1 and wild type parasites, 
however the growth rate was reduced. Pfcaf1 parasites resulted in aberrant expression of 
merozoite proteins such as SUB1, SERA5, EBA175 and GAP45[441] 
PF3D7_0824400 Nucleoside transporter 2 (NT2)  RMgm-1392 PBANKA_0706200 Gene disruption successful, no differences observed over asexual blood stage[424]. 
PF3D7_0828800 GPI-anchored micronemal antigen (GAMA) 1 RMgm-95 PBANKA_0701900 P. falciparum orthologue is refractory to gene knockout[442]. Pbpsop9 showed reduced numbers 
of oocysts and reduced number of salivary gland sporozoites[341]. 
PF3D7_0830500 Tryptophan/threonine-rich antigen (TryThrA)  RMgm-1252 PBANKA_0701000 Assigning orthology between genes of different species is difficult as multiple genes near/in sub-
telomeric regions encode them.  
PF3D7_1027800 60S ribosomal protein L3 (RPL3)  RMgm-1567 PY17X_0513000 GFP-tagged protein shows expression in the cytoplasm and the periphery of the parasite[443]. 
PF3D7_1033200 Early transcribed membrane protein 10.2 
(ETRAMP10.2) 
 RMgm-726 PBANKA_0517000 Gene disruption successful, no differences observed over asexual blood stage. 
PF3D7_1113000 Conserved Plasmodium protein, unknown  1 RMgm-105 PBANKA_0934600 Gene disruption attempts were successful, however a phenotype has not been described* 
PF3D7_1116800 Heat shock protein 101, (HSP101)  RMgm-1327 PBANKA_0931200 P. berghei parasites with mutant HSP101 showed reduced growth rate (parasetemia) in mice[444]. 
PF3D7_1129900 Transporter, putative  RMgm-1368 PBANKA_0918300 Gene disruption resulted in a reduction in the parasite multiplication rate at the asexual blood stage 
of infection[424]. 
PF3D7_1222700 Glideosome-associated protein 45 (GAP45) 1 RMgm-776 PBANKA_1437600 GAP45 is considered vital for merozoite invasion of erythrocytes. PbGAP45 zygotes failed to 
develop into ookinetes[352]. 
PF3D7_1228600 Merozoite surface protein 9 (MSP9) 1 RMgm-1536 PY17X_1445800 GFP-tagged MSP9 shown to be expressed in the cytoplasm of infected erythrocytes[443]. 
PF3D7_1249800 THO complex subunit 2, putative (THO2)  RMgm-443 PBANKA_1462700 Gene disruption was successful however; a phenotype has not yet been reported* 
PF3D7_1320600 Ras-related protein Rab-11A (RAB11a)  RMgm-298 PBANKA_1418900 GFP-tagged Rab-11A showed an apical localisation in merozoites partially co-localising with 
MSP1[445]. 
PF3D7_1345100 Thioredoxin 2 (TRX2)  RMgm-918 PBANKA_1358000 PbTRX2 parasites showed delayed blood-stage growth in mice[429]. 
PF3D7_1349300 Tyrosine kinase-like protein (TKL3)  RMgm-1221 PBANKA_1362100 Gene disruption was successful and no difference in growth rate was observed between transgenic 
parasites and wild type[336]. 
PF3D7_1447900 Multidrug resistance protein 2 (heavy metal 
transport family) (MDR2) 
 RMgm-1165 PBANKA_1311700 mCherry tagged MDR2 showed weak localisation in blood-stages and ookinetes and the plasma 
lemma of merozoites. Reduced oocyst and sporozoite formation in PbMDR2[425]. 
PF3D7_1460600 Inner membrane complex sub-compartment 
protein 3, putative (ISP3) 
1 RMgm-962 PBANKA_1324300 Gene disruption was successful and showed no difference in asexual blood stage or gametocyte or 
ookinete/oocyst or liver stage when compared to wild type parasites. GFP-tagging of ISP3 showed 
localisation to schizonts and merozoites[360]. 
PF3D7_1466400 Transcription factor with AP2 domain(s) 
(ApiAP2) 
 RMgm-398 PBANKA_1329800 Gene disruption was successful resulting in oocysts development that lacked sporozoites. GFP 
tagged ApiAP2 showed expression in nuclei of oocyst and salivary gland sporozoites[446]. 
PF3D7_1471100 Exported protein 2 (EXP2)  RMgm-921 PBANKA_1334300 PbEXP2 showed reduced hepatocyte infectivity of sporozoites and unable to result in a blood-
stage infection in mice[447]. 
PF3D7_1474900 Trailer hitch homolog, putative (CITH)  RMgm-358 PBANKA_1301300 GFP-tagged CITH showed expression in blood stage parasites. No difference in asexual blood 
stages growth rate between PbCITH and wild-type parasites[448]. 
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A total of 239 (64%) targets were either considered members of the invadome or for 
which genetic manipulation of their P. berghei orthologues attempted. These 
represent additional information that could be considered when selecting targets for 
further evaluation as potential vaccine candidates. Interestingly, a small subset of 
these targets, N=59 (25%) was described as “conserved targets” of unknown 
function. I compared the degree of polymorphism between these targets and the 
current blood stage vaccine candidates under evaluation in clinical trials. These 
were MSP-1, -2, -3, AMA1, EBA175, RESA, GLURP, SERA-5, RH5 and 
PFF0165c. As shown in Figure 3.13, the blood stage vaccine candidates had a 
significantly higher dN/dS ratio when compared to these 59 targets (median dN/dS 
in vaccine candidates (N=10) versus conserved targets (N=59): 7.675 versus 2.360; 
p-value <0.0001). 
 
 
Figure 3.13: A comparison of the ratio of non-synonymous to synonymous SNPs (dN/dS) in vaccine 
candidate and unstudied targets identified as putative surface proteins. Comparison of the dN/dS ratio in 
the genes encoding 10 blood stage vaccine candidates (blue) and targets described as being conserved and of 
unknown function. 
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The list of the remaining 135 (36%) (Figure 3.12) putative surface merozoite 
antigens identified in both biological replicates is available in Appendix 3.5. In this 
list, 10 (7%) are predicted to have an extracellular/membrane localisation and the 
majorities 118 (87%) have no predicted localisation. Among those predicted to have 
an extracellular or membrane localisation included transporters such as: triose 
phosphate transporter (PF3D7_0508300), inorganic anion antiporter 
(PF3D7_1471200;SulP), sodium-dependent phosphate transporters 
(PF3D7_1340900:PiT) and CorA-like Mg2+ transporter (PF3D7_1304200.2). 
Interestingly, 67 (50%) of these targets are termed as “conserved plasmodium 
protein, unknown function” or “conserved plasmodium membrane protein, unknown 
function”. A small proportion of the targets were predicted to localise to the nucleus 
and cytoplasm, 2 (1.5%) and 4 (3%) respectively. This list may also contain 
potential novel targets of protective antibodies or anti-malaria drug targets. 
 
3.5.7.  Optimising the merozoite surface-biotinylation experiments 
 
A second approach was attempted to identify merozoite surface proteins that relied 
on the following steps: 1) a cell-membrane impermeable reagent was added to 
merozoites to covalently attach biotin to the N-terminus of a protein or the free 
amine group on lysine residues of proteins on the surface, 2) biotinylated proteins 
were extracted and 3) affinity purified using a streptavidin column.  Several 
protocols were attempted and I monitored the specificity of the reaction by probing 
the fractions and eluates using the following primary antibodies: streptavidin 
conjugated to HRP, anti-ERD2 and anti-MSP3 antibodies.  
 
The streptavidin-HRP antibody was used to monitor the biotinylation reaction and 
to confirm affinity purification of biotinylated proteins. Anti-MSP3 sera was used as 
a positive control as MSP3, a peripherally associated merozoite surface protein, 
should ideally be biotinylated and detectable in the eluate. Anti-ERD2 was used as a 
negative control as it is an endoplasmic reticulum resident protein and therefore 
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ideally inaccessible to the biotinylation reagent and therefore absent in the eluate 
following affinity purification. As shown in Figure 3.14A and B, biotinylated 
merozoite proteins were present in the eluate following extraction with 8M Urea or 
4% SDS lysis buffer when probed with streptavidin-HRP. However, as shown in 
Figure 3.14C, known merozoite surface or membrane proteins such as MSP3 and 
MSP2 were not evident in any of the eluates. This indicated that merozoite proteins 
were biotinylated, however it was not possible to confirm whether these were 
surface or internal proteins. I therefore attempted a second protein extraction 
protocol aimed at enriching for membrane proteins. 
 
 
Figure 3.14: Merozoite surface biotinylation, extraction and western blot. Biotinylated merozoite proteins 
extracted with A) 8M Urea and B) 4% SDS lysis buffer and probed with streptavidin-HRP. C) Probing of 
eluates from affinity purification using streptavidin column with the merozoite surface/membrane protein sera 
anti-GAP45, anti-MSP2 and anti-MSP3 and the internal negative control anti-ERD2. Figure A) and B) confirm 
the presence of biotinylated proteins. However on probing with positive and negative control sera, no antigen-
specific bands were visible (C, limiting the ability to confirm the specificity of the biotinylation reaction. 
 
Due to the absence of known merozoite surface proteins in the eluate from 
extraction with 8M urea and 4% SDS buffer, I attempted a second extraction buffer, 
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the non-ionic detergent 2% Triton X-100 that is commonly used to lyse cells and 
permeabilize cell membranes. As shown in Figure 3.15A, the PfMSP3 positive 
control was detected in the eluate following affinity purification as expected. 
Similarly, PfERD2 the internal protein was absent in the elution and present in the 
flow through as shown in Figure 3.15B. The eluate from two biological replicates of 
the surface biotinylated merozoites in which PfMSP3 was detectable and PfERD2 
was absent was submitted for mass-spectrometry identification. 
 
Figure 3.15: Successful merozoite surface biotinylation, extraction and western blot. Biotinylated 
merozoite proteins extracted with 2% Triton X-100. Probing of eluates from affinity purification using A) anti-
MSP3 and B) the internal negative control anti-ERD2. As expected, MSP3 was detected in the eluate while 
ERD2 was detected in the flowthrough. 
 
Despite detecting MSP3 in the eluate it was not subsequently identified by mass-
spectrometry. As shown in Figure 3.16A, the MS-spectra from analysis of the 
eluates showed an abundance of “peptides” with a single positive charge (z=1), 
suggesting that these were actually Triton X-100. These abundant ions likely 
masked the ability to detect the less abundant protein peptides that were of interest. 
Trypsin treated proteins generate peptides with at least two charges (z=2) from the 
N-terminal end of a peptide and the positive charge from either the lysine or 
arginine residue that determines the specificity of the cleavage site. This feature is 
 170 
used as a filter to select peptides for mass-spectrometry identification. I attempted to 
remove the excess detergent using the commercially available HiPPR (High Protein 
and Peptide Recovery) detergent removal spin column kit. As shown in Figure 
3.16B, the mass-spectra profile obtained after detergent removal attempt was 
identical to the original sample. Therefore no data on merozoite surface biotinylated 
proteins was available for analysis. These experiments were not continued further 
due to time constraints. 
 
 Figure 3.16: The MS-spectra obtained from analysis of eluates from merozoite surface biotinylation 
experiments. A) The MS-spectra shows an abundance of peptides with a single charge (z=1), as opposed to 
multiple charges (Z > 2) that are characteristic of trypsin generated peptides. B) Efforts to remove contaminating 
Triton X-100 from eluate were unsuccessful as the mass spectra profiles are similar after HiPPR treatment (blue) 
when compared to untreated samples (black). HiPPR: High Protein and Peptide Recovery. 
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3.6. Discussion 
 
The merozoite proteome is largely under-studied in the context of NAI 
Although protective antibodies to blood-stage antigens are acquired following 
natural exposure to P. falciparum malaria [127], a surprisingly small portion of the 
merozoite proteome has been evaluated in this context. Mining data obtained from 
PlasmoDB indicated the presence of many potential merozoite surface proteins. As 
discussed in section 3.1 of this chapter, 550 and 571 genes whose transcriptional 
profiles are elevated in the late trophozoite-schizont stage of the erythrocytic life 
cycle are predicted to encode antigens with an N-terminal signal peptide or at least 
one transmembrane domain respectively. These represent potential surface-exposed 
antigens that may be targets of protective antibodies. Only a small proportion 
(N=157, (20%)) of these targets have been evaluated as potential targets of 
protective immunity. Thus the potential of most of these proteins as vaccine 
candidates is unknown[146, 263, 265, 267, 271, 292]. I therefore employed 
complementary proteomic approaches to comprehensively identify proteins on the 
surface of merozoites in order to generate a rich resource of potential targets of 
protective humoral immunity for further analysis.  
 
Identification of novel putative merozoite surface proteins 
Surface biotinylation was attempted but was abandoned due to difficulty with 
protein solubilization. In contrast, surface shaving combined with multiple 
bioinformatic analyses identified a total of 374 proteins that are likely to be either 
on or associated with the surface of the merozoite. The validity of this list as a 
source of potential targets is supported by multiple observations. First, it included 
multiple known merozoite surface proteins such as the GPI-anchored 6-cys proteins 
Pf12 [294] and Pf38 [294], the peripherally associated surface proteins such as 
GLURP, MSP-8, -9, -10 [407] and Pf41 [294] and plasma membrane embedded 
proteins such as ROM1 and ROM4 [407]. Second, I identified an overlap between 
the identified proteins and the invadome (Figure 3.12), which is a list of genes, 
proposed to be important/essential for merozoite invasion of erythrocytes based on 
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coordinated transcriptional patterns. Lastly, I observed that the putative surface 
proteins I identified were significantly more polymorphic when compared to 
intracellular proteins, suggesting that they were under immune selection[290-292]. 
Interestingly, a subset of these proteins’ orthologues has been identified in rodent 
malaria and genetic disruption of these genes in P. berghei had a negative impact on 
parasite growth (Figure 3.12 and Table 3.3). 
 
However, only 16% (N=59) of the 374 proteins I identified as likely surface proteins 
have been analysed either in population studies to identify correlates of immunity or 
progressed to testing in clinical trials. These included the 6-cys proteins Pf41, Pf38 
and Pf12, and the surface proteins MSP-9, -10, GLURP that have been tested for 
antibody reactivity with sera from Kenyan [146] and Papua New Guinean children 
[147]. One of the identified targets, GLURP, is a component of the multi-subunit 
GMZ2/alum vaccine alongside MSP3 that has undergone phase I and II clinical 
trials showing good safety, tolerability and immunogenicity in naïve adults [449], 
malaria-exposed adults [450] and children [216]. As expected, 84% (N=315) of the 
targets I identified have not been tested in the context of NAI, and no information is 
available on the function or cellular localisation for most of these proteins (N=135 
(36%). This list therefore represents a rich resource of novel potential targets of 
protective antibodies or anti-malarial drugs. My analysis ultimately yielded two lists 
of putative merozoite surface proteins; 1) targets for which some published 
literature is available (e.g. roles in erythrocyte invasion or a phenotype in the rodent 
malaria orthologues) the majority of which have not yet been evaluated as potential 
vaccine candidates and 2) targets for which no known information is available 
representing true novel potential targets. Both sets of proteins warrant further 
evaluation for reasons outlined below. 
 
Putative surface proteins with potential as vaccine or drug targets based on 
literature 
Sixty four percent (N=239) of the putative merozoite surface proteins that I 
identified have either been proposed to play important roles in erythrocyte invasion 
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and parasite survival, either as members of the invadome [258] or based on genetic 
disruption experiments in P. berghei orthologues’.  
 
Members of the invadome: Seventy (19%) of proteins I identified are encoded by 
genes whose transcriptional profiles showed differential expression on exposure to 
20 parasite growth inhibitory compounds and are thought to be essential for 
erythrocyte invasion (termed the invadome) [258]. Antibodies against some of these 
targets could therefore be predicted to reduce or halt parasite growth altogether 
making them potential vaccine candidates. For example, the pantothenate 
transporter (PfPAT: PF3D7-0206200) plays a role in the uptake of vitamin B, a 
precursor for coenzyme A, which functions as an enzyme activator in metabolism of 
fatty acids, carbohydrates and amino acids [451]. This protein localises to the 
periphery of merozoites within schizonts [421] and P. falciparum blood-stage 
parasites grown in the absence of pantothenate were not viable [451, 452]. In 
addition, genetic studies where the P. berghei orthologue of PAT was disrupted, a 
defect in forming mature oocysts was observed as the female and male gametes 
failed to egress from host erythrocytes[431, 432]. As a result, naturally acquired or 
vaccine induced antibodies against PfPAT may have the potential to inhibit blood 
and transmission stages of the parasite. Additional examples of potential vaccine or 
drug targets include PfCDPK1 (PF3D7_0217500) that co-localises with MSP-
1[420]. PfCDPK1 phosphorylates two members (MTIP and GAP45) of the actin-
myosin motor complex that drives merozoite entry into erythrocytes. Inhibition of 
PfCDPK1 resulted in the inability of merozoites to egress from schizonts halting 
erythrocyte invasion[420]. These may represent a new target of anti-malarial 
protective antibodies or chemical inhibitors.  
P. berghei orthologues: Data was available on the P. berghei or P. yoelii 
orthologues of 210 of the putative surface proteins I identified (Figure 3.12 and 
Table 3.3). These included proteins in which attempts to knockdown the gene were 
not successful implying essential roles in the erythrocytic stage of the lifecycle [343, 
345, 351, 422-426, 428, 429]. Interestingly, four of these are described as P. 
falciparum conserved membrane proteins of unknown function. In addition, for 
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some proteins for which genetic disruption was successful, a phenotype suggesting 
that targeting these proteins could reduce or halt parasite growth was reported [336, 
341, 431, 432, 435, 438, 440, 441]. For example, genetic disruption of P. falciparum 
CCR4-associated factor 1 (CAF1), resulted in a reduced parasite growth rate, 
defects in merozoite egress from schizonts and aberrant localisation of EBA175 and 
GAP45 [441] among others. Due to these potential essential roles in parasite 
survival, antibodies or drugs against these targets are likely to have potent growth 
inhibitory activity making these potentially attractive vaccine or antimalarial drug 
targets. There was an overlap of 41 proteins that are proposed members of the 
invadome and for which genetic disruption in P. berghei has been attempted (Figure 
3.11). These include proteins such as PfPAT and PfCDPK1 that have been 
described above. Similarly, these are potential targets for therapeutic intervention.  
 
Conserved proteins of unknown function: Encouragingly, 59 (25%) (Figure 3.12 & 
3.13) of the proteins proposed to be members of the invadome and/or with P. 
berghei orthologues are referred to as conserved proteins of unknown function on 
PlasmoDB. Based on this PhD thesis, these might be proteins located on the surface 
of the merozoite. Interestingly, these targets were significantly less polymorphic 
than the current blood-stage vaccine candidates in clinical trials (Figure 3.13). These 
may represent ideal targets that may overcome the challenge of designing a vaccine 
that would be effective against genetically diverse parasites [453] and warrant their 
evaluation further as targets of protective antibodies. For example, clinical trials 
using the following candidates, RTS’S (CSP) and Combination B (MSP-1, -2 and 
RESA), have been shown to induce strain-specific responses that ultimately resulted 
in low vaccine efficacy [171, 222]. This was attributed to clinical episodes of 
malaria in vaccinated individuals resulting from parasites that were diverse at the 
candidate proteins’ genetic loci. For these and other polymorphic vaccine 
candidates, a multivalent (vaccine consisting of multiple alleles of the same antigen) 
or a multi-subunit (vaccine consisting of multiple distinct antigens) approach may 
be better and is under evaluation [380]. An alternative approach would be to target a 
relatively conserved antigen with the expectation that vaccine-induced responses 
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would be effective across diverse parasite isolates. This has been demonstrated for 
the conserved target reticulocyte binding protein homologue 5 (RH5), in which only 
5 non-synonymous SNPs have been reported at over a 10% frequency in 290 
clinical isolates from diverse geographical locations [454]. Antibodies raised against 
the 3D7 variant of RH5 showed broad inhibitory activity against diverse P. 
falciparum lab isolates and strains [454, 455] in growth inhibition in vitro assays. In 
subsequent vaccination followed by challenge studies, Aotus monkeys vaccinated 
with the Pf3D7 variant of RH5 and challenged with the virulent heterologous FVO 
strain showed reduced parasetemia and ability to self-cure when compared to 
control animals[456]. This demonstrated the in vivo vaccine induction of responses 
that were protective against heterologous strains, showing the utility of using a 
conserved vaccine candidate. 
 
Novel putative surface proteins for therapeutic intervention 
A large proportion of the P. falciparum protein coding genes have unknown 
functions on PlasmoDB and not surprisingly, 18% (N=67) of putative surface 
proteins I identified fall within this category (Figure 3.12). These include predicted 
transporters whose functions have not been confirmed and proteins described as 
being conserved and of unknown function. Additional studies are needed to begin to 
understand the functional roles of these proteins. These could include studies that 
evaluation the transcriptional profiles of these proteins in parasite exposed to the 
400 diverse drug-like molecules available in the Malaria box (available from 
Medicines for Malaria Venture, MMV) [457, 458]. Similarly, high-throughput 
screening of these novel targets for naturally acquired antibody responses could be 
evaluated. For example, the use of a phage-display library [459, 460] expressing all 
the proteins of unknown function that I identified could subsequently be screened 
for recognition using sera from individuals exposed to P. falciparum. 
 
Study limitations 
The above approaches have various limitations shared by all proteomic studies, the 
most common of which is the identification of contaminant proteins. I monitored the 
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specificity of the surface-shaving experiment by observing the release of the 
peripherally associated protein MSP3 in the enzyme treated merozoites while the 
internal protein ERD2 was retained. Despite this, I observed the presence of a small 
proportion of proteins (less than 10%) predicted to be nucleus-associated, 
cytoplasmic or mitochondrial. These are likely to have been detected due to 
merozoite lysis or damage during the schizont filtration or incubation steps resulting 
in the release of intracellular targets. Additional replicate data would have been 
beneficial in differentiating between true targets and contaminant proteins. 
 
Contaminants in proteomic studies are common as illustrated in a recent review on 
the application of the surface-shaving technique to bacterial and eukaryotic 
pathogens, which showed a range of between 6-80% of proteins identified as being 
localised to the cytoplasm [414]. Nevertheless, I cannot exclude the possibility that 
the predicted intracellular targets I identified are in fact “moonlighting proteins” 
[417]. These proteins, which are often enzymes, lack the typical motifs that 
determine their extracellular localization such as N-terminal signal peptides or 
transmembrane domains. However, they have been shown to be present on the cell 
surface of pathogens and play dual roles that include their intracellular enzymatic 
function as well as a non-catalytic role when they translocate to the cell surface. 
Examples include the intracellular enzyme GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) that was shown to be highly immunogenic in systematic candidiasis 
and subsequently shown to be also located on the surface of Candida albicans as a 
ligand binding to fibronectin and laminin [461]. Although difficult to validate in this 
study, this is a potential explanation for the observation that intracellular or 
cytosolic enzymes or proteins were classified as surface proteins in my study. 
Interestingly, antibodies against intracellular proteins have been reported to be 
associated with protection from malaria in some studies [265].  A second limitation 
was the inability to generate useful data from the complementary merozoite surface 
biotinylation approach. As I observed that the non-ionic detergent Triton X-100, 
was capable of extracting the surface protein PfMSP-3, attempts with similar 
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detergents that are compatible with mass-spectrometry identification should be 
evaluated [462]. 
 
Despite the above limitations, my study provides strong evidence for a set of novel 
proteins that are potentially located on the surface of merozoites. Additional 
experimental approaches would help to further validate these observations. 
Confirmatory assays could involve generating recombinant forms of the novel 
antigen, raising polyclonal sera and conducting immuno-fluorescent assays (IFAs), 
to map their localisation [294, 419, 421, 463]. This approach has been successfully 
used to show co-localisation of Pf12 and Pf41 with MSP-119 on the surface of free 
merozoites [383].  Alternatively, transgenic parasite lines could be generated in 
which an epitope tag such as the c-myc or HA-tag, or a fluorescent proteins such as 
the green fluorescent protein (GFP) or mCherry is added to the C-terminus of the 
protein of interest, in order to enable localisation using fluorescent microscopy. 
These approaches have been used to localise a putative sugar transporter (PY17X-
0823700;ortholog of PF3D7-0919500) to the surface of sporozoites [301]. 
Similarly, the localisation of P. berghei RAP2/3 to the rhoptry organelles on 
merozoites and sporozoites was achieved using a c-myc tagged transgenic line 
[345].  
 
Conclusion 
In summary, I identified 374 putative surface proteins using merozoite surface 
shaving, the majority of which have unknown functions and have not been studied 
in the context of naturally acquired immunity. Data on the 30% of proteins for 
which some published information is available suggest that these proteins may have 
important roles in erythrocyte invasion or be essential for parasite survival. This 
provides a rich resource for further study for the identification of novel drug and 
vaccine candidates. In line with evaluating their utility as targets of protective 
antibodies, I have since selected a subset of these proteins and shown that they are 
reactogenic in serum collected from adults living in a malaria endemic region of 
Tanzania. In addition, antibody levels to some of these targets such as PfPAT 
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(PF3D7-0206200) and a putative amino acid transporter (PF3D7-0629500) are 
associated with a reduced number of clinical episodes of P. falciparum malaria. The 
details of the down-stream selection criteria of a subset of these antigens for further 
analysis, and their subsequent analysis in immuno-epidemiology studies are 
presented in Chapter four and five of this thesis. 
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CHAPTER 4  
Novel Plasmodium falciparum merozoite antigen selection and 
 characterization for antibody reactivity 
 
4.0 . Introduction 
 
The -omics era has enabled the rapid generation of large data sets that provide an 
unprecedented opportunity for the discovery of novel vaccine candidates, drug 
targets or essential host or pathogen determinants of infection and survival. 
However, the subsequent systematic evaluation required for the large numbers of 
newly identified candidates can be labour intensive and daunting. Down-selection 
criteria can help to focus attention on targets with the highest probability of utility. 
For example, recently a forward genetic screen employing RNA interference 
(RNAi) was used to identify host determinants of malaria infection [464]. Although 
over 350 proteins that appeared to be involved in erythrocyte invasion by P. 
falciparum were identified in the initial screen, subsequent validation experiments 
were focused on the 42 proteins that shared similarities with known invasion 
receptors (members of the human blood group antigens). This analysis led to the 
identification of CD55 as an essential receptor for P. falciparum invasion [464]. 
 
In the context of drug and vaccine identification in P. falciparum, comparative 
genomics [253], proteomics [254, 255] and transcriptional profiling [256-258] of 
parasites have provided valuable information to use as down-selection criteria for 
new malaria vaccine targets. Datasets that are currently publicly available include; 
1) the genome sequences of 2512 P. falciparum isolates under the Pf3K project 
[465] to provide gene diversity data, 2) population genomic analyses of 65 Gambian 
isolates for the identification of genes under balancing selection [253] and hence 
may be exposed to the human immune system, 3) proteomic analyses of sporozoites, 
trophozoites, merozoites and gametocytes obtained from the 3D7 and NF54 strains 
[254, 255] and 4) transcriptional profiling of the 3D7 and HB3 strains in the 
intraerythrocytic developmental stages [259, 260], gametocytes and mosquito 
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salivary gland sporozoites stages [260] to identify the stages in which candidates are 
expressed. These data sets continue to be harnessed when selecting targets for 
laboratory evaluation. For example, to identify P. falciparum genes with important 
roles during the erythrocytic life cycle, changes in gene expression throughout the 
asexual stages was measured following exposure to 20 chemical compounds known 
to inhibit parasite growth [258], in order to identify co-regulated genes that may 
function in the same pathways. A total of 3125 genes showed over a three-fold 
increase or decrease in gene expression compared to uninhibited parasites. From this 
datasets, targets likely to play a role in merozoite invasion of erythrocytes were 
identified by; 1) comparing the sequence homology between newly identified 
targets and orthologue genes in 210 sequenced genomes involved in conserved 
functional pathways, 2) predicting protein-protein interactions using available yeast-
two hybrid interactome data and 3) utilizing transcriptional profiling data on lab and 
field isolates to identify genes up-regulated during the late blood stages. 
Probabilistic networks were generated from this data to cluster the identified targets 
[258]. Thereafter, the authors selected the targets that clustered around 27 known 
merozoite targets involved in erythrocyte invasion. This resulted in a list of 418 
targets (termed invadome or invasion-related genes), 263 (63%) of which were 
described as hypothetical proteins of unknown function. A subset of predicted 
invasion-related genes were selected for sub-cellular localization and they 
demonstrated for the first time, the surface localisation of PF3D7_1036000 now 
known as MSP11, and two conserved Plasmodium proteins namely 
PF3D7_0308300 (PFC0355c) and PF3D7_1115800 (PF11_0166) [258].  
 
These publicly available datasets have been harnessed for the identification of 
potential vaccine candidates in five other studies. These include two studies that 
selected targets for evaluation only from publicly available datasets [263, 264] and 
three studies that generated additional proteomic data from sporozoite [301] and 
asexual stages [299, 316] prior to evaluation using available datasets. In each of 
these studies one or more of the following criteria were used to prioritize targets for 
laboratory evaluation: 1) elevated mRNA transcription at the schizont stage (40-48 
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hpi) or 2) identified as a member of the invadome as has been described above[258] 
or 3) presence of a signal peptide or 4) one or more transmembrane domains or GPI-
anchor and 5) have homologues present in different organisms of known function. 
In the two non-proteomic studies, a total of 113 unique targets were selected. One 
study subsequently identified 7 proteins, MSP3.5, MSRP2, ETRAMP11.2, 
ETRAMP14.1, RALP1, StAR-related lipid transfer protein and a conserved 
membrane protein (PF3D7_1459900) as immunogenic for the first time [263]. The 
second study characterised the rhoptry associated adhesin (RA) as a protein that 
translocates to the merozoite surface and interacts with erythrocytes [264]. 
Antibodies generated against this target showed modest invasion inhibitory activity 
[264]. The three large-scale proteomic studies identified between 33 and 423 sets of 
proteins. They subsequently applied a range of one or more of the criteria described 
above and narrowed down to 2-4 proteins per study, for further laboratory 
evaluation. These resulted in identifying novel proteins on the surface of parasite-
infected erythrocytes namely PF3D7_0310400 (PFC0435w) and PF3D7_0501200 
(PFE0060w), now known as PIESP1 and 2 (parasite-infected erythrocyte surface 
protein 1 and 2) respectively [299]. Similarly, an uncharacterised antigen, 
PF3D7_0919500 (a sugar transporter) was shown to localise to the surface of 
salivary gland sporozoites and for the first time, provided evidence that some 
components of the inner membrane complex (IMC) are surface exposed [301]. The 
last study demonstrated the secretion of four novel proteins during the erythrocytic 
stages of the life cycle with potential roles in immune evasion and host-pathogen 
interactions [316]. 
 
In this chapter, the target lists I generated in the previous chapters using proteomic 
approaches were evaluated and down-selected using publicly available databases, 
peer-reviewed publications and in-silico prediction algorithms in order to prioritize 
novel targets for further characterisation. However, it differs from previous efforts 
to identify potential targets of naturally acquired antibody responses in the 
following ways. I focused on generating a list of immunogenic merozoite targets as 
well as proteins localised to the surface of merozoites using proteomic approaches 
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prior to employing a down-selection criteria. This is in contrast to selecting targets 
directly from the published P. falciparum genome based on the same criteria as has 
been employed in studies by Fan et al [263] and Crompton et al [265].  This was 
expected to result in a higher rate of target identification compared to the average 
rate of 20% obtained with the previous efforts [263, 265, 271]. Secondly, the 
majority of targets I selected were either conserved or of limited polymorphism. 
This has potential implications on vaccine efficacy across different geographical 
locations where genetically diverse parasites isolates are present. Similarly, previous 
large-scale studies did not consider the level of polymorphism at each gene loci 
selected as a criterion for inclusion or exclusion. 
 
4.1. Rationale 
 
Using the proteomic approaches described in chapter 2 and 3 of this thesis, I 
identified a set of antigens that are potential targets of naturally acquired antibodies 
(N=210) and putative surface merozoite proteins (N=374) respectively.  I then used 
several selection criteria to narrow down on antigens for further laboratory 
characterisation as potential targets of protective humoral immunity. These included 
selecting targets common to both experimental approaches and predicted to have an 
N-terminal signal sequence and/or a transmembrane domain(s). In addition, I 
compared the selected targets with publicly available data on: i) balancing selection; 
ii) potential roles in erythrocyte invasion, iii) have orthologues in rodent malaria 
species for which genetic disruption has been attempted and iv) studies of naturally-
acquired immunity, in order to identify those poorly or never previously studied.  
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4.2. Objective 
 
The overall objective was to select and evaluate a set of novel P. falciparum 
merozoite antigens as targets of naturally acquired antibody responses. 
4.3. Specific objectives 
 
• To select a sub-set of novel antigens identified in proteomic studies for 
further characterisation as targets of naturally acquired immunity (NAI). 
• To express recombinant forms of the novel antigens selected above for 
evaluation of reactivity with human antibodies obtained from naturally 
exposed individual. 
4.4. Methods 
4.4.1. Selection of novel antigens 
 
Using the proteomic approaches described in chapter two and three of this thesis; I 
identified 210 antigens in the 3D7 immunoblot assays and 374 targets in two 
biological replicates of 3D7 merozoite surface shaving experiments. To narrow 
down on which of these targets to evaluate in the context of NAI, the following 
down-selection procedures were applied. In the first step, targets that were identified 
in all the three data sets that I had generated, 2D-immunoblots and the two 
biological replicates of the surface-shaving experiments were selected.  In the 
second step, targets identified in the 2D-immunoblots that had a predicted N-
terminal signal peptide and/or at least one transmembrane domain were further 
shortlisted. Similarly, in the third step, targets identified in both surface-shaving 
biological replicates and that had a predicted N-terminal signal peptide and/or at 
least one transmembrane domain were chosen. Within this subset (N=222), I down-
selected further using the following criteria 1) candidates that had been evaluated 
for reactivity with naturally acquired antibodies in less than 3 studies or not at all, 2) 
those with elevated maximum transcriptional profiles in the late trophozoite or 
schizont stages 3) those with evidence of balancing selection and 4) those that had a 
phenotype following genetic disruption in the respective P. berghei orthologue 
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(RMgmDB database). At the time of protein selection, phenotypic data on P. 
berghei reverse genetic studies now deposited on PlasmoGEM, was not publicly 
available.   
 
4.4.2. Design of selected antigens for recombinant protein expression 
 
A total of 27 antigens were selected for recombinant protein expression using the 
Expi293 mammalian expression system (ThermoFisher) that is commercially 
available. This system is designed for scalable transient transfection of high-density 
cultures of human embryonic kidney 293 (HEK293) cells for recombinant protein 
expression[466]. For each of the 27 antigens selected, I obtained the Pf3D7 protein 
sequences from PlasmoDB and submitted these to signal peptide and 
transmembrane domain prediction using the 
(http://www.cbs.dtu.dk/services/SignalP/) & 
(http://www.cbs.dtu.dk/services/TMHMM/), algorithms respectively.  To obtain 
only the predicted extracellular domains of the selected antigens, amino acids 
representing the N-terminal signal peptides and the transmembrane domains were 
excluded. In proteins with multiple transmembrane domains, the regions predicted 
to be extracellular were selected for recombinant protein expression. All potential 
N-linked glycosylation sites (NXS/T) were predicted using the 
(http://www.cbs.dtu.dk/services/NetNGlyc/) algorithm. The serine and threonine 
residues in predicted N-glycosylation sites were substituted with an alanine to 
prevent addition of glycans, which are thought to be absent in native P. falciparum 
proteins [467]. In proteins with no predicted N-terminal signal peptide, the first 
methionine was removed, as it was present in the final expression vector. Final 
amino acid sequences were submitted for gene synthesis and codon-optimisation for 
expression in human cells by GeneartAG, with, unique Not1 and Asc1 restriction 
sites inserted at the 5’ and 3’ end of the protein sequence respectively. This was 
done to clone each gene into a derivative of the pTT3 expression vector, in between 
a leader sequence to drive secretion of antigen and a rat Cd4 domains 3 and 4 tag 
followed by hexa histidine tag for protein purification. The leader sequence was the 
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N-terminal signal peptide that drives secretion of the mouse variable kappa light 
chain [468, 469]. The expression vector was obtained from the non-profit plasmid 
repository (https://www.addgene.org/). A schema of the sub-cloning strategy and 
the features of the expression vector is shown in Figure 4.1. 
4.4.3. Sub-cloning and recombinant protein expression of novel antigens 
 
Codon-optimised gene constructs obtained from GeneartAG were received as a 
lyophilised plasmid vector with either the ampicillin or kanamycin resistance gene. 
To clone each gene into the expression vector, the following steps were taken: 1) 
excision of gene of interest (GOI) from backbone Geneart vector, 2) ligation of the 
GOI to expression vector and E.coli colony screening, 3) transfection of expi293F 
cells for recombinant protein expression and 4) protein purification from culture 
supernatant using the hexa-histidine tag. Prior to experimental procedures, in silico 
digestion was simulated using the Geneious R.9 software. This was used to predict 
the expected product size following restriction digestion and the expected protein 
sequence following successful cloning into expression vector. For each Geneart 
construct, I confirmed that in silico prediction of the expected protein matched the 
amino acid sequences requested.  
4.4.3.1. Excision of GOI from the backbone GeneartAG vector 
 
Five micrograms (5µg) of lyophilised constructs from GeneartAG were resuspended 
using 50µl of TE buffer (10mM Tris, pH 8.0, 1mM EDTA) to a final concentration 
of 100ng/µl. These vectors also contain either a kanamycin or ampicillin resistance 
gene. To propagate these constructs, the plasmids were transformed (introduction of 
foreign DNA to bacterial cells) into competent Top 10 E.coli cells (Invitrogen) as 
follows: Top 10 cells stored at -80°C were thawed on ice and 2µl of resuspended 
plasmids added to 25µl of cells, gently mixed and incubated on ice for 30 minutes. 
Thereafter, cells were heat-shocked by incubation at 42ºC for 30 seconds followed 
by incubation on ice for 2 minutes. Cells were resuspended in 250µl of SOC media 
at 37ºC for 1 hour while shaking at 225 rpm before being resuspended in 300ml of 
LB broth supplemented with respective antibiotic overnight at 37ºC. The heat-
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shocking step is thought to change the fluidity of the cell membrane creating pores 
that allow exogenous DNA to enter cells[470]. After overnight incubation in LB-
broth, E.coli cells were pelleted and the plasmid DNA extracted using the Qiagen 
maxiprep kit according to manufacturer’s instruction. To excise the gene of interest 
flanked by Not1 and Asc1, a double digest using the respective enzymes was 
performed as follows: 0.5µl of Asc1 and Not1 (New England Biolabs (NEB) were 
added to 2µl of the 10X cutsmart buffer (NEB), 10µl of respective plasmid DNA 
and top-up to 20µl using DNAse/RNAse free water. This reaction was incubated 
overnight at 37ºC and then separated on a 1% agarose gel supplemented with red 
safe DNA dye at 100V until the loading dye line was 90% down the gel. 
Hyperladder I (Bioline) was used as the molecular size marker as it showed the 
separation of DNA whose sizes ranged 200-10000 base pairs. Separation of the GOI 
from backbone vector was visualised under UV light using the ChemiDoc MP 
system (Bio-Rad). Thereafter, the genes of interest that migrated at the expected 
base pair size were excised from the gel using a scalpel and forceps under 
observation using a UVP Chromato-vue transilluminator. The GOI was extracted 
using the QIAquick gel extraction kit (Qiagen) according to manufacturer’s 
instruction. Extracted DNA was resuspended in 20µl in TE buffer and quantified 
using the NanoDrop 2000 UV-Vis spectrophotometer (Thermo Scientific). 
 
 
 187 
 
Figure 4.1: A schema of the in silico experiment in which the GeneartAG vector is double-digested to obtain gene of interest (GOI) and sub-cloned into expression 
vector. The Geneart vector contains the Not1 and Asc1 sites flanking the GOI. The same restriction sites were used to sub-clone the GOI downstream of the leader sequence and 
upstream of the Cd4-hexa histidine tag in the expression vector
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4.4.3.2. Ligation of the GOI to expression vector 
 
The NEBiocalculator (http://nebiocalculator.neb.com) was used to design the 
parameters for ligation of the GOI to the expression vector using the formulae 
below.  
 
Required mass insert (ng)= (desired insert/vector molar ratio) X (mass of vector 
(ng)) X (ratio of insert to vector lengths). 
 
For example, using 50ng of the expression vector whose size was 6678 base pairs 
(bp) and a GOI of length 2191 bp at the recommended insert/vector molar ratio of 
3:1, the quantity of insert DNA required was 49.21 ng. The ligation was done as 
follows: I combined 50ng of expression vector with 3 fold molar ratio of GOI and 
adjusted the volume of reaction to 10µl using distilled water.  10µl of 2X quick 
ligation buffer (NEB) was added to vector-DNA mix and 1µl of quick T4 DNA 
ligase was added and vortexed. The mix was allowed to incubate for 5 minutes at 
room temperature and stored at -20ºC. This mix was then used to transform 
competent Top 10 E.coli cells as has been described in section 4.4.3.1 with the 
following changes. Instead of growing transformed cells in LB broth, these cells 
were plated on an LB-Agar plate supplemented with 100µg/ml of ampicillin and 
incubated overnight at 37ºC. Following incubation, 8 colonies from each plate 
(corresponding to one GOI) were randomly selected and inoculated into 3ml of LB-
ampicillin broth and grown overnight at 37ºC. Plasmids were extracted from 1.5ml 
of each clone using the plasmid miniprep extraction kit (Promega) according to 
manufacturer’s instructions. Extracted plasmids were digested using the Not1 and 
Asc1 restriction enzymes as was described in section 4.4.3.1. Two results were 
expected; 1) If the GOI were absent from expression vector, a single high molecular 
weight band at 6678 bp would be observed and 2) If the GOI was ligated into the 
vector, two bands were anticipated corresponding to the backbone vector and the 
GOI. Colonies showing the presence of the GOI were selected and grown in 400ml 
of LB-Broth to obtain sufficient quantity of target expression vector for transfection 
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of expi293F cells. These plasmids were extracted from E.coli using the Qiagen maxi 
prep kit (Qiagen), resuspended in TE buffer and quantified by NanoDrop. 
 
 4.4.4. Recombinant protein expression using Expi239F mammalian expression 
system 
 
To obtain target recombinant protein, expi293F cells were transfected with the 
expression vector using the commercially available expi293 expression system 
[466]. Expi293F cells stored in liquid nitrogen were thawed rapidly in a water bath 
at 37ºC for 2 minutes with gentle agitation and resuspended in 30ml of pre-warmed 
expi293 expression media in 125ml Erlenmeyer flasks with vented caps. These cells 
were incubated at 37ºC and 8% CO2 in a humidified orbital shaker platform, 
rotating at 125rpm. The viability and total cell count was determined using an 
automated cell counter and monitored until the cell density was between 0.5-1 x 106 
cells/ml. The culture was diluted to 3-5 x 105 viable cell/ml and monitored every 
two days until a maximal density of 4-6 x106 viable cells/ml. Cell viability was 
monitored and cultures whose viability was lower than 90% was discarded. In 
addition, cells maintained in culture for longer than 3 months were discarded and a 
new batch of cells thawed. Prior to transfection, cell count and viability was 
determined and cells diluted to a 2.0 x 106 cells/ml with Expi293 media. For each 
antigen, a 25.5ml suspension culture at a 2.0 x 106 cells/ml density was transfected 
with 30µg of expression vector as follows. 30µg of DNA was diluted with 1.5ml of 
the Opti-MEM media and mixed gently. In a separate tube, 81µl of the cationic-lipid 
transfection reagent expifectamine 293 was diluted in 1.5ml of Opti-MEM media 
and incubated for 5 minutes at room temperature. The two reagents were then gently 
mixed making a total volume of 3ml and incubated for 20 minutes at room 
temperature. Thereafter, this was gently added to cells while swirling and incubated 
at 37ºC and 8% CO2 in an orbital shaker at 125rpm. After 16 hours of incubation, 
150µl of enhancer 1 and 1.5ml of enhancer 2 was added and cells incubated for an 
additional 4 days. Thereafter, the cells were pelleted and the culture supernatant, 
which contained secreted recombinant protein, was stored at 4ºC prior to 
purification. 
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4.4.4.1. Purification of recombinant hexa-histidine tagged proteins 
 
Hexa-histidine tagged recombinant proteins were purified from culture supernatant 
using the Ni-NTA purification system.  This system uses an agarose matrix cross-
linked to nitrilotriacetic acid (NTA) that binds four Ni2+ per molecule, which has a 
high affinity (Kd=10
-13M) for the hexa-histidine tag on recombinant proteins. Prior 
to purification, 30µl of 1mM of nickel chloride was added to supernatant, before 
binding to 1ml of Ni-NTA agarose overnight at 4ºC while rotating. Following 
incubation, the agarose resin was pelleted and resuspended in native wash buffer 
(50mM NaH2PO4, 0.5M NaCl, 20mM imidazole, pH.8.0) and placed in a column 
for batch purification. The resin was washed five times with the wash buffer before 
elution using the native buffer (50mM NaH2PO4, 0.5M NaCl, 250mM imidazole, 
pH.8.0).  Four-1ml eluted fractions were collected following incubation of resin 
with native elution buffer. These were pooled and concentrated to between 500-
1000µl prior to separation on an SDS gel and quantification using the BCA kit 
according to manufacturer’s instruction.  
4.4.5. Evaluation of the immunogenicity of novel antigens by standard ELISA 
 
Once purified recombinant proteins were obtained and quantified, I evaluated 
immunogenicity of these antigens by standard ELISA. For each antigen, 100µl of 
recombinant antigen was coated at a two-fold serial dilution of ranging from 
128µg/ml to 0.06µg/ml on the wells of a Dynex 4HBX Immunolon plates. 
Recombinant antigen was diluted in coating buffer (15mM Na2CO3, 35mM 
NaHCO3, pH 9.4) and coated overnight at 4˚C. After overnight incubation, plates 
were washed four times in 1X PBS containing 0.05% Tween-20 (wash buffer) and 
blocked for 5 hours at room temperature with 1% skimmed milk (Marvel) diluted in 
PBS Tween 20 (Blocking buffer). Thereafter, plates were washed four times in wash 
buffer and 100µl of a pool of hyper-immune sera (PHIS) obtained from adults living 
in the malaria endemic region of Kilifi, Kenya and a pool of non-exposed sera from 
adults in Sweden (NEG) at a 1:1000 dilution were added as positive and negative 
controls respectively. Following an overnight incubation at 4˚C, well were washed 
and incubated for 3 hours at room temperature with 100µl of HRP conjugated to 
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polyclonal rabbit anti0human IgG (Dako) at a 1:5000 dilution using block buffer. 
The wells were then washed four times and incubated at room temperature with 
100µl of substrate development buffer (0.1M citric acid, 0.2M Na2HPO4, 4mg o-
phenylenediamine dihydrochloride tablets (Sigma), 8µl hydrogen peroxide and 5ml 
distilled water). After 20 minutes of incubation in the dark, the reaction was stopped 
with 25µl H2SO4 and absorbance read at 492nm. 
4.4.6. Statistical analysis 
 
The non-parametric Mann-Whitney T-test was used to compare the Tajima D scores 
between selected antigens and non-selected targets.  Graphpad Prism was used to 
generate the dose response immunogenicity curves for each antigen. 
4.5. Results 
4.5.1. Selection of novel merozoite targets for immunoprofiling 
 
I used several criteria to select 27 novel P. falciparum antigens for immunoprofiling 
using the datasets I generated from the 2D immunoblots (N=210) and putative 
merozoite surface proteins (N=374). A summary of the selection procedure 
employed is shown in Figure 4.2, and is described in detail below. 
 
To narrow down on the set of antigens from which to select targets for 
immunoprofiling, I first identified the proteins that were identified in all the three 
proteomic datasets I had generated. These were the targets identified in the 3D7 2D-
immunoblot (N=210) and proteins defined as surface proteins from the two 
biological replicates (N=681 and 684 respectively). As shown in Figure 4.2 and 4.3, 
34 targets were identified in all three data sets. These included known immunogenic 
targets such as GLURP, GAMA, KAHRP, MSP-8, MSP-9, PTEX150, RAP2 and 
MESA. In this subset of antigens, 8 (24%) were proteins described as conserved 
Plasmodium proteins of unknown function.  
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Figure 4.2: An overview of the down-selection process employed to select 27 targets for immunoprofiling  
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 Figure 4.3: Figure showing the overlap between targets identified in the 3D7 2D immunoblots (green 
circle) and the two putative surface protein data sets (dark and light blue circles). 
 
In a second and third selection, targets identified in the immunoblot or both surface 
shaving experiments that had a predicted signal peptide and or at least one 
transmembrane domain were selected and these corresponded to 59 and 157 
antigens respectively (Figure 4.4 A & B, respectively). Fourteen of these targets had 
been previously selected in the first criteria. This resulted in a total of 222 antigens 
from which to select novel antigens from (Appendix 4.1). Additional criteria were 
used to select the targets for recombinant protein expression. From this list, 23 
candidates were eliminated as they had already been selected for expression and 
analysis as part of a larger multi-centre cohort study. These targets included MSP-1, 
-3, -7, -8, -9 & -10, the SERA-3, -4 & -5 antigens, the 6-cys proteins Pf41, Pf38, 
Pf12 & Pf113, AMA1, GAMA, MTRAP, GLURP, the rhoptry proteins RAP-1, -2 
& RhopH3, PTEX150, ETRAMP10.2 & PF3D7_0210600. An additional 40 targets 
were excluded as they have been/or are currently under evaluation in various groups 
as targets of naturally acquired immunity [265, 267]. The presence of these genes in 
the initial down-selection list is a useful validation of the initial gene list as potential 
sources of novel antigens. 
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These resulted in a list of 159 targets which I then compared against publicly 
available data on: i) evidence of balancing selection as indicated by a positive 
Tajima D score, when the genomes of 65 isolates in the Gambia were analysed 
[253], ii) proposed to be involved in erythrocyte invasion by merozoites 
(“invadome”) [258] and iii) displayed a phenotype in P. berghei orthologue 
disruption that suggested an important role over the asexual blood stages. At the 
time of target selection (September-December 2015), data from PlasmoGEM was 
not yet publicly available. As a result, the rodent malaria phenotypes evaluated were 
genes deposited in the RMgmDB database. Of these targets, 14 (8.8%), 26 (16.4%) 
and 31 (19.5%) had a positive Tajima D score, were member of the “invadome” and 
had a rodent malaria phenotype reported (RMgmDB database), respectively. 
 
 
 
Figure 4.4: The number of targets predicted to have a signal peptide or transmembrane domains. Figure 
showing proteins predicted to have a predicted N-terminal signal peptide and/or transmembrane domains 
(TMDs) in the A) 3D7 2D-immunoblots data set and B) 3D7 putative surface proteins. 
 
First, I selected seven targets from the 14 with a positive Tajima D, primarily 
because their transcriptional profiles suggested an elevated transcriptional profile in 
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the late trophozoite and schizont stages of the life cycle (4 targets: 32-48 hpi, 2 
targets 3-8 hpi). In addition, although they were under balancing selection [253] 
they had a lower median Tajima D score when compared to non-selected targets 
(N=7) (selected versus non-selected: 0.324 versus 0.7200, p-value=0.3829) 
representing less polymorphic candidates (Table 4.1). Second, 26 (16.4%) of the 
159 targets have been proposed to be members of the invadome [258] (merozoite 
genes essential for erythrocyte invasion). I therefore selected ten under-studied 
targets as they may potentially make good immune targets.  
 
Lastly, 31 (19.5%) of the 159 targets had rodent malaria orthologues in which 
genetic modification has been attempted (using data from the RMgmDB database). 
Some of the phenotypes reported either showed no differences in parasite growth 
rate and survival when compared to wild-type parasites. I therefore selected eleven 
targets whose attempts to genetically disrupt the P. berghei orthologues resulted in 
the following phenotypes; 1) had been attempted but were unsuccessful (N=4; 
PF3D7_1455300, PF3D7_1468100, PF3D7_1025300 & PF3D7_1105800). These 
may represent targets whose functions are essential and indispensable for parasite 
growth or survival or 2) targets whose phenotypes showed a reduced growth rate 
over the asexual blood stages of the lifecycle (N=2; Plasmepsin IV & Thioredoxin 
2) or localised to the periphery of merozoites (N=2; PfPAT & ISP3), and therefore 
accessible to circulating antibodies. Three of the eleven selected targets encode the 
6-cys (B9) antigen, a putative amino acid transporter and a tryptophan/threonine rich 
antigen. These were selected for the following reasons: The disruption of the P. 
berghei B9 protein resulted in arrested development of sporozoites within 
hepatocytes [433] and B9 contains the 6-cys domains which are thought to be 
involved in protein-protein interactions [407]. The identification of B9 in my 
proteomic studies, as well as in mass-spectrometry analysis of synchronous 
merozoites by Florens et al [254] may therefore represent a potential target of both 
pre-erythrocytic and blood-stage immunity. The second target, PF3D7-0629500, 
encodes a putative amino acid transporter, however its phenotype following 
disruption has not been reported yet. P. falciparum obtains the majority of its amino 
 196 
acids from haemoglobin degradation, with the exception of isoleucine that is likely 
obtained from plasma via a transporter [471]. Blocking the function of this 
transporter through antibodies may therefore be detrimental for parasite survival, 
representing an attractive target. Lastly, PF3D7_0830500 encoded a tryptophan-
threonine rich antigen. The P. vivax members of the tryptophan-rich antigen family 
have been shown to immunogenic [472] while one of P. falciparum orthologues of a 
protective P. yoelii antigen (pyAg-1) was shown to be a tryptophan rich antigen 
associated with the merozoite surface [473]. As expected, there was some overlap 
between selected targets as shown in Figure 4.2 and Table 4.1. For example, of the 
10 invasion-related targets selected, 2 also had a phenotype described for their P. 
berghei orthologues. Similarly, two targets that had a positive Tajima D had a 
phenotype described in the RMgmDB database. 
 
The last, five targets were selected as they were described as “conserved 
Plasmodium proteins, unknown function” whose maximum mRNA transcription 
was observed at the late schizont stage (N=1), merozoite stage (N=1) or was 
unknown (N=3). The selection of conserved proteins may be beneficial in 
downstream vaccine development, on the premise that protective immune responses 
elicited against this targets should be effective against diverse parasite strains from 
different geographical locations. This is of particular concern for P. falciparum 
vaccinology as the majority of the candidates are polymorphic and induce strain-
specific responses [171, 222, 380]. A summary of the protein features and the 
available peer-reviewed literature of the 27 targets I selected for immunoprofiling 
are shown in Table 4.1. Included in this summary are phenotypes available on 
PlasmoGEM that are now publicly available.  
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Table 4.1: A summary of the 27 antigens selected for immuno-profiling. 
Plasmodium 
falciparum gene ID 
Product description TMDs Signal 
peptide 
Timing of max. 
Transcription 
Additional information on P. berghei genetic modification, role in erythrocyte invasion, 
evidence of balancing selection and studies on a naturally acquired immunity 
PF3D7_0206200 Pantothenate transporter (PAT) 11 0 43 Plasmodium falciparum parasites are not viable over the asexual blood stages in the absence 
of pantothenic acid. PfPAT localises to the periphery of individual merozoites within 
schizonts. Genetic disruption of PfPAT was not successful and down-regulation of its 
expression resulted in parasite death in vitro [421]. Proposed to be essential for erythrocyte 
invasion[258]. 
P. yoelii gene disruption resulted in no mature oocysts or sporozoites[431]. In P. berghei gene 
disruption resulted in male and female gametocytes failing to egress from host 
erythrocytes[432].  
PF3D7_0317100 6-cysteine protein (B9) 0 1 8 P. berghei gene disruption resulted in arrested development of sporozoites within 
hepatocytes[433](RMgmDB). 
Termed as dispensable on PlasmoGEM. 
PF3D7_0525800 Inner membrane complex protein 1g, putative (IMC1g) 0 0 41 Proposed to be essential for erythrocyte invasion[258]. 
Termed as essential on PlasmoGEM. 
PF3D7_0629500 Amino acid transporter, putative 9 0 45 P. berghei gene disruption was successful however the phenotype has not been described 
(RMgmDB). 
PF3D7_0722200 Rhoptry-associated leucine zipper-like protein 1 (RALP1) 1 1 39 P. falciparum RALP1 has been refractory to gene knockout attempts[474] (RMgmDB) 
Proposed to be essential for erythrocyte invasion[258]. 
Shown to be recognised by a sera from asymptomatic adults in Thailand and Mali in one 
study[463] and China in a second study[263]. 
Termed as essential on PlasmoGEM. 
PF3D7_0730800.2 Plasmodium exported protein, unknown function 0 1 48  
PF3D7_0822900 Conserved Plasmodium protein, unknown function 0 0 Unknown Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_0823800 DnaJ protein, putative 3 0 32 Evidence of balancing selection (Tajima D=0.324)[253]. 
Termed as resulting in a slow growth rate on PlasmoGEM following gene knockout. 
PF3D7_0831400 Plasmodium exported protein, unknown function 1 1 Unknown Evidence of balancing selection (Tajima D=0.132)[253] 
PF3D7_0830500 Tryptophan/threonine-rich antigen (TryThrA) 1 0 3 P. berghei orthologues were successfully disrupted, however P. falciparum expresses multiple 
proteins encoded near subtelomeric regions therefore assigning orthology is not clear. 
Evidence of balancing selection (Tajima D=1.019)[253] 
PF3D7_0925900 Conserved Plasmodium protein, unknown function 0 1 Unknown  
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Plasmodium 
falciparum gene ID 
Product description TMDs Signal 
peptide 
Timing of max. 
Transcription 
Additional information on P. berghei genetic modification, role in erythrocyte invasion, 
evidence of balancing selection and studies on a naturally acquired immunity 
PF3D7_1014100 Conserved Plasmodium protein, unknown function 0 1 41 Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1025300 Conserved Plasmodium protein, unknown function 0 1 31 Three attempts to disrupt the gene were not successful (RMgmDB). 
Termed as essential on PlasmoGEM. 
PF3D7_1105800 Conserved Plasmodium protein, unknown function 1 1 39 Attempts to disrupt the gene were not successful (RMgmDB). 
Termed as essential on PlasmoGEM. 
PF3D7_1137300 Conserved Plasmodium membrane protein, unknown function 6 0 8 Evidence of balancing selection (Tajima D=1.015)[253]. 
Termed as resulting in a slow growth rate on PlasmoGEM following gene knockout. 
PF3D7_1229300 Conserved Plasmodium protein, unknown function 1 1 Unknown Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1237900 Conserved Plasmodium protein, unknown function 1 1 Unknown  
PF3D7_1252300 Conserved Plasmodium protein, unknown function 1 0 Unknown  
PF3D7_1308000 Conserved Plasmodium membrane protein, unknown function 4 0 Unknown Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1343700 Kelch protein K13 (K13) 0 0 47 Evidence of balancing selection (Tajima D=0.084)[253]. 
PF3D7_1345100 Thioredoxin 2 (TRX2) 0 1 43 P. berghei gene disruption showed a delayed blood-stage growth rate in mice[429]. 
Termed as resulting in a slow growth rate on PlasmoGEM following gene knockout. 
PF3D7_1401600 Plasmodium exported protein (PHISTb), unknown function 1 0 39 Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1407800 Plasmepsin IV (PM4) 1 0 48 P. berghei gene disruption showed a reduced growth rate and a virulence attenuated 
phenotype in mice[337] (RMgmDB). 
Evidence of balancing selection (Tajima D=0.656)[253]. 
Termed as resulting in a slow growth rate on PlasmoGEM following gene knockout. 
PF3D7_1455300 Conserved Plasmodium protein, unknown function 0 0 42 Two attempts to disrupt the P. berghei orthologues were not successful (RMgmDB) 
Termed as essential on PlasmoGEM. 
Proposed to be essential for erythrocyte invasion[258]. 
Evidence of balancing selection (Tajima D=0.015)[253]. 
PF3D7_1460600 Inner membrane complex sub-compartment protein 3, putative 
(ISP3) 
0 0 41 P. berghei GFP tagged parasites showed localisation to schizonts and merozoites[360]. 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1462300 Conserved Plasmodium protein, unknown function 3 1 1  
PF3D7_1468100 Conserved Plasmodium protein, unknown function 0 0 15 Two attempts to disrupt the P. berghei orthologues were not successful (RMgmDB) 
Termed as essential on PlasmoGEM. 
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4.5.1. Editing protein sequences for gene synthesis by GeneartAG 
 
The amino acid sequences for selected antigens were obtained from PlasmoDB and 
edited as described in section 4.4.2. The P. falciparum endogenous N-terminal 
signal peptides were replaced with the rat Cd4 domain 3 and 4 leader sequence had 
been shown to result in increased protein yields [469]. In addition, the predicted N-
glycosylation sites were mutated to prevent addition of glycans to these sites. This is 
because the degree of N-linked glycosylation in native P. falciparum genes is 
controversial. Early studies on native immunoprecipitated MSP-1 and -2 proteins 
indicated that these antigens had no affinity for lectin nor were they sensitive to 
PNGase F treatment which suggested the absence of N-linked glycans [475]. 
Thereafter, bioinformatic analysis of the genome indicated that the parasite lacked 
most of the glycosyltransferases involved in this process [467] suggesting this 
glycosylation did not occur. However, three enzymes within this pathway are 
present, and it is has been recently shown that P. falciparum synthesises a shorter 
version of N-glycans than those in mammalian cells [476, 477]. Lastly, the yield of 
recombinant protein increased following mutation of these glycosylation sites [469]. 
As a result, to avoid inappropriate addition of these glycans, the sites on the protein 
sequences were mutated prior to recombinant expression. 
 
An example of the editing of a protein sequence (e.g. RALP1) is shown in Figure 
4.5. The protein sequence for RALP1 (PF3D7_0722200) is predicted to have a 22 
amino acid N-terminal signal peptide and a transmembrane domain ranging between 
amino acids 3 and 20, as well as five predicted N-glycosylation sites. As shown in 
Figure 4.5, the protein sequence sent to GeneartAG excluded the predicted signal 
peptide and transmembrane domain (shown in red) and at predicted N-glycosylation 
sites (shown in yellow), the serine or threonine residues were replaced with alanine. 
The edited protein sequences that were submitted for codon-optimization and gene 
synthesis for each of the 27 selected antigens are available in Appendix 4.2. 
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Figure 4.5: Editing of protein sequences prior to GeneartAG gene synthesis. Figure showing the protein 
sequence for RALP1 (A) in which the predicted N-terminal signal peptide (red) was excluded and N-
glycosylation sites edited (yellow) (B). 
 
4.5.2. Successful sub-cloning of codon-optimised constructs into expression vector 
 
I received 26 out of the 27 GeneartAG constructs I requested for synthesis. For the 
27th target, PF3D7_0822900, 20 attempts to synthesise the gene by GeneartAG were 
unsuccessful. Synthesis problems often occur in sequences that either have 
repetitive sequences, have a high (>80%) or low (<20%) GC content or have long 
polypurine or polypyrimidine runs (https://www.thermofisher.com/ke/en/home/life-
science/cloning/gene-synthesis/geneart-gene-synthesis/geneart-standard-and-xxl-
genes.html). The PF3D7_0822900 gene construct had several complexities that may 
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have contributed to the inability to synthesize it, including; 1) a window of 100 
bases with a GC content of 19% and 2) multiple 8 base pair repeats were present 
between position 299 and 764. This construct was eliminated from subsequent 
study. For the 26 constructs I received, a summary of the expression pipeline and 
screening is summarised in Figure 4.6 and described in details below. 
 
 
 Figure 4.6: A summary of the selected and subsequently cloned and expressed antigens. 
 
For the 26 constructs I received, the genes of interest (GOI) were first excised using 
restriction digestion using Not1 and Asc1, and separated on a 1% agarose gel. As 
shown in Figure 4.7, the expected GOI migrating at the in silico predicted size was 
obtained for 23 of the constructs. In the 23 targets in which restriction digestion was 
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successful, I gel purified the GOI, ligated them to the expression vector and 
transformed E.coli cells with the ligation product. For each target, I screened 8 
randomly selected colonies for the presence of my GOI.  As shown in Figure 4.8, 
4.9 and 4.10, a successfully ligated construct was observed in at least one of the 8 
colonies screened in all 23 cases. Successfully cloned constructs were then 
expanded to obtain sufficient quantity of expression vector for transient transfection 
of expi293F cells. Figure 4.11 shows all the expression vectors for the 23 successful 
targets. These were used for subsequent recombinant protein expression.  
 
Three of the twenty-six constructs received from GeneartAG were not successfully 
cloned to the expression vector. As shown in red in Figure 4.7, in the three targets, 
namely PF3D7_0317100 (B9), PF3D7_0722200 (RALP1) and PF3D7_1468100, a 
clear separation of the GOI from backbone vector was not clear. In one target, 
PF3D7_1343700 (KELCH), a clear separation was not observed however 
subsequent attempts were successful as shown in Figure 4.8 and 4.11. The genes 
encoding KELCH, RALP1 and B9 were expected to be 2188bp, 2857bp and 2191bp 
and migrated similarly to the backbone vector, which was 2400bp in size. The last 
GOI, PF3D7_1468100 was expected migrate at 768bp. No product at this size was 
observed following restriction digestion. Due to the time constraints of my PhD, 
additional attempts to clearly separate the vector from the GOI have not yet been 
attempted.  One approach to circumvent the problem would involve identification of 
additional restriction enzyme sites within the backbone vector downstream of the 
gene of interest. A triple digest should release the GOI at the expected size while 
cleaving the backbone vector into two fragments that would both be smaller in size 
and thus would separate more clearly from the GOI. An alternative approach would 
be to design vector-specific primers flanking my GOI, PCR amplify the GOI and 
restriction digest the PCR product and proceed with the ligation steps described 
above.  
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Figure 4.7: Double digest of GeneartAG construct to release the GOI for subsequent sub cloning steps. Figure showing a 1% agarose gel resolving the codon-optimised gene 
of interest excised from the backbone geneart vector.  The GOI highlighted in red were not successfully separated from the geneart backbone vector as they migrated at similar 
sizes. White arrows shows the expected GOI following double digestion. 
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Figure 4.8: E.coli colony screening to identify successfully ligated expression vector. Screening 8 colonies per GOI for successful sub-cloning of target to each expression 
vector. Target labelled in red shows a colony screen that was not successful. In the remainder, a GOI at the expected base pair size (shown in brackets) was evident in at least one 
of the eight colonies. 
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Figure 4.9: E.coli colony screening to identify successfully ligated expression vector.  Screening 8 colonies per GOI for successful sub-cloning of target to each expression 
vector. The GOI at the expected base pair size (shown in brackets) was evident in at least one of the eight colonies. 
 
 
 206 
 
Figure 4.10: E.coli colony screening to identify successfully ligated expression vector. Screening 8 colonies per GOI for successful sub-cloning of target to each expression 
vector. In the remainder, a GOI at the expected base pair size (shown in brackets) was evident in at least one of the eight colonies. 
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Figure 4.11: A summary of successfully cloned geneart constructs to the expression vector
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4.5.3. Recombinant protein expression 
 
To obtain recombinant proteins, I transfected expi293F cells with the 
successfully sub-cloned Geneart constructs as shown in Figure 4.11. The 
recommended starting cell cultures for transfection were 30ml at a cell density 
of 2.0 x 106 cells/ml (total cell density=6.0 x 107 cells), and 30µg of expression 
vector is recommended. For each of the 22 targets, varying concentration of 
protein was obtained ranging from 150µg/ml to 1490µg/ml. The expi293F 
expression system is scalable allowing transfection of upto 1.0 x 109 cells, 
meaning that sufficient quantities of protein are able to be generated for all 
targets. One target, PF3D7_1014100 was not used for transfection, as sufficient 
quantity of DNA for transfection had not been obtained. As shown in Figure 
4.12, 4.13 and Table 4.2, purified recombinant proteins were obtained and 
migrated at the expected predicted molecular weights when separated on a 
reducing SDS-page gel following purification using the Ni-NTA system 
(Invitrogen). 
 
Figure 4.12: Coommassie stained SDS gels showing recombinant proteins. Three Coomassie stained 
SDS gels showing eleven purified recombinant proteins. The numbers in bracket indicate the predicted 
molecular masses (in KDa) for each protein. Protein in red indicates the same target expressed and purified 
in two independent experiments. 
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Figure 4.13: Coommassie stained SDS gels showing recombinant proteins. Two Coomassie stained 
SDS gels showing four additional purified recombinant proteins. The numbers in bracket indicate the 
predicted molecular masses (in KDa) for each protein. Protein in red indicates the same target expressed 
and purified in two independent experiments. 
 
4.5.4. Identifying reactogenic targets using ELISA 
 
A total of 27 antigens were selected for immunoprofiling and 22 targets were 
tested for immunogenicity using a pool of hyper immune sera (PHIS) from 
adults living in the malaria endemic region, Kilifi. Kenya. A pool of sera from 
adults living in Sweden who have not been exposed to malaria was used as a 
negative control. For the 22 antigens for which recombinant protein was 
obtained, reactogenicity was measured by measuring a two-fold serial dilution of 
recombinant antigen at a fixed dilution (1:1000) of a positive and negative serum 
samples. As shown in Figure 4.14, 4.15 and 4.16, 19 (86%) of the selected 
targets showed a dose response curve with the positive control sera. No response 
to these antigens was observed with the Swedish non-exposed sera even at the 
highest protein concentration tested. Sixteen (73%) of selected and expressed 
antigens displayed a dose response curve that reached saturation as shown in 
Figure 4.14, 4.15 and 4.16A. AMA1 recombinantly expressed using the same 
system was included as a comparator. As shown in Figure 4.14A, AMA1 titres 
with the positive control reached the highest optical density measurements 
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observable (OD=4).  The selected targets were less reactogenic than AMA1, 
with none of them attaining an optical density of 4. However, AMA1 is known 
to be a highly immunodominant antigen and the differences do not necessarily 
reflect on the vaccine potential of the new targets. 
 
A second approach, in which the optimal ELISA well coating concentration was 
determined for each antigen (shown as a green line in Figure 4.14, 4.15 and 
4.16) also indicated that these targets were less immunogenic compared to the 
AMA1. In all examples, the coating concentration was over 2 fold above the 
0.05µg/ml concentration determined for AMA1. In Figure 4.16 (D, F and G), 3 
of the 22 antigens that were immunogenic showed evidence of a dose response 
curve however this did not reach saturation. Three antigens (14%) showed no 
evidence of immunogenicity: these were PF3D7_0525800 (IMC1g), 
PF3D7_0831400 and PF3D7_1343700 (KELCH13) (Figure 4.16 B, C and E). 
As expected, the CD4 tag present in each antigen was not immunogenic as 
shown in Figure 4.14B. Table 4.2 provides a summary of the selected proteins 
and indicates the immunogenic, non-immunogenic and targets that were not 
tested because they dropped out at different stages in the synthesis, cloning and 
expression pipeline. 
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Figure 4.14: Immunogenicity of recombinant antigens measured by ELISA. Figure showing the immunogenicity of 7 of the 22 selected recombinant proteins. For comparison 
AMA1 (A) was recombinantly expressed and assayed similarly to the novel antigens. The CD4 tag present on each antigen was not immunogenic (B).  The black line shows the 
coating concentration selected for AMA1 while the green line indicates the coating concentration for each antigen. 
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Figure 4.15: Immunogenicity of recombinant antigens measured by ELISA. Figure showing the immunogenicity of the 9 of the 22 selected recombinant proteins. The black 
line shows the coating concentration selected for AMA1 while the green line indicates the coating concentration for each antigen. 
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Figure 4.16: Immunogenicity of recombinant antigens measured by ELISA. Figure showing the immunogenicity of the 7 of the 22 selected recombinant proteins. The black 
line shows the coating concentration selected for AMA1 while the green line indicates the coating concentration for each antigen. 
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Table 4.2: Table showing novel immunogenic targets identified from screening by ELISA and the sections of the protein evaluated. 
Plasmodium 
falciparum gene ID 
Region expressed 
(Number of 
amino acids) 
Predicted 
molecular 
weight* 
Product description Additional information on P. berghei genetic modification, role in erythrocyte invasion, evidence of 
balancing selection & studies on a naturally acquired immunity 
PF3D7_0206200 D241-K319 
(79) 
38 Pantothenate transporter (PAT) Plasmodium falciparum parasites are not viable over the asexual blood stages in the absence of pantothenic 
acid. PfPAT localises to the periphery of individual merozoites within schizonts. Genetic disruption of 
PfPAT was not successful and down-regulation of its expression resulted in parasite death in vitro [421]. 
Proposed to be essential for erythrocyte invasion[258]. 
P. yoelii gene disruption resulted in no mature oocysts or sporozoites[431]. In P. berghei gene disruption 
resulted in male and female gametocytes failing to egress from host erythrocytes[432].  
PF3D7_0525800 C2-A300 
(299) 
63 Inner membrane complex protein 1g, putative 
(IMC1g) 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_0629500# Q331-R391: 
G451-N544 
(61:94) 
36,40 Amino acid transporter, putative P. berghei gene disruption was successful however the phenotype has not been described. 
PF3D7_0730800.2 S20-F293 
(274) 
60 Plasmodium exported protein, unknown function  
PF3D7_0823800 Y93-K605 
(513) 
90 DnaJ protein, putative Evidence of balancing selection (Tajima D=0.324)[253]. 
PF3D7_0831400 K29-I302 
(274) 
62 Plasmodium exported protein, unknown function 
 
Evidence of balancing selection (Tajima D=0.132)[253] 
PF3D7_0830500 K55-V675 
(621) 
103 Tryptophan/threonine-rich antigen (TryThrA) P. berghei orthologues were successfully disrupted, however P. falciparum expresses multiple proteins 
encoded near subtelomeric regions therefore assigning orthology is not clear. 
Evidence of balancing selection (Tajima D=1.019)[253] 
PF3D7_0925900 S21-D217 
(197) 
51 Conserved Plasmodium protein, unknown 
function 
 
PF3D7_1025300 Y18-F922 
(908) 
135 Conserved Plasmodium protein, unknown 
function 
Three attempts to disrupt the gene were not successful 
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Plasmodium 
falciparum gene ID 
  Product description Additional information on P. berghei genetic modification, proposed to be essential for erythrocyte 
invasion, evidence of balancing selection, studies on a naturally acquired immunity 
PF3D7_1105800 D26-Y266 
(241) 
57 Conserved Plasmodium protein, unknown 
function 
Attempts to disrupt the gene were not successful 
PF3D7_1137300 L582-D689 
(108) 
42 Conserved Plasmodium membrane protein, 
unknown function 
Evidence of balancing selection (Tajima D=1.015)[253]. 
 
PF3D7_1229300 K21-S890 
(870) 
132 Conserved Plasmodium protein, unknown 
function 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1237900 E27-S1188 
(1162) 
167 Conserved Plasmodium protein, unknown 
function 
 
PF3D7_1252300 S2-L51 
(50) 
34 Conserved Plasmodium protein, unknown 
function 
 
PF3D7_1308000 P341-K602 
(262) 
60 Conserved Plasmodium membrane protein, 
unknown function 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1343700 E2-I726 
(725) 
112 Kelch protein K13 (K13) Evidence of balancing selection (Tajima D=0.084)[253]. 
PF3D7_1345100 T24-L157 
(134) 
45 Thioredoxin 2 (TRX2) P. berghei gene disruption showed a delayed blood-stage growth rate in mice[429]. 
PF3D7_1401600 K69-I478 
(410) 
77 Plasmodium exported protein (PHISTb), 
unknown function 
Proposed to be essential for erythrocyte invasion [258]. 
PF3D7_1407800 S63-L449 
(387) 
73 Plasmepsin IV (PM4) P. berghei gene disruption showed a reduced growth rate and a virulence attenuated phenotype in 
mice[337]. 
Evidence of balancing selection (Tajima D=0.656)[253]. 
PF3D7_1455300 D2-R609 
(608) 
98 Conserved Plasmodium protein, unknown 
function 
Two attempts to disrupt the P. berghei orthologues were not successful 
Proposed to be essential for erythrocyte invasion[258]. 
Evidence of balancing selection (Tajima D=0.015)[253]. 
PF3D7_1460600 G2-A148 
(147) 
46 Inner membrane complex sub-compartment 
protein 3, putative (ISP3) 
P. berghei GFP tagged parasites showed localisation to schizonts and merozoites[360]. 
Proposed to be essential for erythrocyte invasion[258]. 
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Plasmodium 
falciparum gene ID 
  Product description Additional information on P. berghei genetic modification, proposed to be essential for erythrocyte 
invasion, evidence of balancing selection, studies on a naturally acquired immunity 
PF3D7_1462300 I19-F1155 
(1137) 
164 Conserved Plasmodium protein, unknown 
function 
 
 
 
Antigens in which recombinant forms were not obtained 
 
PF3D7_0317100 G22-F969 
(948) 
141 6-cysteine protein (B9) P. berghei gene disruption resulted in arrested development of sporozoites within hepatocytes[433]. 
PF3D7_0722200 S23-F749 
(726) 
114 Rhoptry-associated leucine zipper-like protein 1 
(RALP1) 
P. falciparum RALP1 has been refractory to gene knockout attempts[474]. 
Proposed to be essential for erythrocyte invasion[258]. 
Shown to be recognised by a sera from asymptomatic adults in Thailand and Mali in one study[463] and 
China in a second study[263]. 
PF3D7_0822900$ E2-K1176 
(1175) 
$ Conserved Plasmodium protein, unknown 
function 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1014100 E22-P1455 
(1433) 
200 Conserved Plasmodium protein, unknown 
function 
Proposed to be essential for erythrocyte invasion[258]. 
PF3D7_1468100 S2-I2558 
(2557) 
324 Conserved Plasmodium protein, unknown 
function 
Two attempts to disrupt the P. berghei orthologues were not successful 
 
 
Key: *- Predicted molecular weight in kilodaltons including the CD4-hexahistidine tag on the C-terminal end of protein. #- Two extracellular loops were 
predicted and expressed as segment 1 and 2. $-Geneart construct was not available. 
Blue: immunogenic and achieved saturation. Purple: evidence of immunogenicity. Orange: not immunogenic. White- not tested.
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4.6. Discussion 
 
Nineteen novel potential vaccine candidates identified 
I have identified a set of 19 novel antigens as targets of naturally acquired antibody 
responses and therefore potential vaccine candidates. These included six targets 
proposed to play essential roles in merozoite invasion of erythrocytes [258], four 
targets considered to be under balancing selection [253] but had not previously been 
evaluated for naturally acquired antibody responses and five targets whose functions 
are unknown. These represent a pool of ideal targets for pre-clinical evaluation as 
potential blood-stage vaccine candidates. Within this set, particularly interesting 
targets that warrant further evaluation include the conserved targets that have been 
proposed to be essential for invasion of erythrocytes such as the three antigens, 
PF3D7_1229300, PF3D7_1308000 and PF3D7_1455300. Identifying conserved 
targets is important because they may overcome the hurdle of parasite genetic 
diversity that has contributed to the low efficacy of previous vaccine candidates 
such as RTS’S [171], AMA1 [172] and MSP-2 [222]. Additional targets of interest 
include the transporters PfPAT and a putative amino acid transporter that have been 
shown to be immunogenic in this study for the first time. Not only has PfPAT been 
shown to localise to the periphery of individual merozoites [421], attempts to 
disrupt the P. falciparum gene were unsuccessful [421] and it has been proposed to 
be essential for invasion [258] suggesting it may play an indispensible role in 
parasite biology. Similarly, blocking the active in-take of essential amino acids such 
as isoleucine may prove detrimental to P. falciparum warranting further evaluation 
of the amino-acid transporter as a target of protective antibodies. 
 
Stringent selection criteria results in a high immunogenicity hit rate 
Encouragingly, 86% of the selected antigens showed evidence of immunogenicity. 
This hit rate was higher than has been observed in studies that solely mined 
PlasmoDB for potential blood-stage immunogenic antigens. For example, in a study 
that selected 138 antigens prioritized on the presence of a signal sequence and/or 
transmembrane domains and elevated transcription profile in the schizont stages, 
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only 21.7% of them were found to be immunogenic [263].  Similarly, rapid in vitro 
transcription/translation expression systems have allowed the large-scale 
recombinant expression of P. falciparum open reading frames [265, 269]. However, 
the hit rate on immunogenic targets in these studies is low. For instance, in one 
study, 2320 P. falciparum protein fragments were screened by protein arrays using 
sera from Malian children and adults. Only 491 (21%) targets were found to be 
immunogenic [265]. In a second study, an analysis of 824 P. falciparum proteins 
identified 163 (20%) targets as being immunogenic when measured using sera from 
Kenyan immune adults [268]. The higher hit rate in my study can be attributed to 
focusing on proteins obtained from merozoites, and identified following reactivity 
with a pool of hyper-immune sera and likely to be located on the surface of the 
merozoite. In addition, it has been recognised that RNA levels may not always 
correlate to protein levels due to different rates of mRNA translation and/or protein 
degradation that influences a proteins half-life [478, 479]. Therefore focusing on 
proteomic data as opposed to transcription levels ensured the presence of target 
protein during blood-stages of P. falciparum infection. In addition, employing 
stringent down selection criteria increased the likelihood of identifying true targets 
of naturally acquired antibodies by eliminating false positives hits common to 
proteomic analyses.  
 
Comparative immuno-reactivity of novel proteins with known blood-stage vaccine 
candidate 
The merozoite antigen AMA1 is a well-studied immunogenic blood-stage antigen 
that demonstrated low efficacy (less than 10%) in a phase 2 trial involving children 
in Mali over a 2-year follow-up period[172], largely due to the fact that strain-
specific antibodies appear to dominate anti-AMA1 responses. The full-length 
ectodomain of AMA1 expressed at similar levels to the novel antigens, and was 
used as a comparator to determine the relative immunogenicity of newly identified 
targets. In general, the nineteen targets identified in these analyses were less 
immunogenic than AMA1, evidenced by the lower optical density observed at 
saturation and the higher coating concentration required to observe antibody 
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reactivity. These findings were expected, as the majority of them are conserved 
targets and only 7 (32%) of selected targets had evidence of balancing selection as 
indicated by a positive Tajima D [253]. Highly polymorphic targets often result 
from being under strong immune pressure and are evident in immunodominant 
targets[253]. Furthermore, these scores were on average lower than the scores for 
AMA1 and other known immunogenic merozoite targets. Nevertheless, two targets 
namely PF3D7_073800.2 (Plasmodium exported protein, unknown function) and 
PF3D7_1025300 (conserved Plasmodium protein, unknown function) achieved 
relatively high optical density values on saturation when compared to the other 
novel targets.  
 
Three targets showed no evidence of antibody reactivity. These included 
PF3D7_0525800 (IMC1g), a putative member of the inner membrane complex 
(IMC). As the IMC is located beneath the plasma membrane, it is plausible that this 
target is not exposed to circulating antibodies.  The other targets that were not 
immunogenic included PF3D7_0831400 and PF3D7_1343700 whose functions 
have not been elucidated. Interestingly, while these targets had a positive Tajima D 
score, the score was low, 0.132 and 0.084 respectively[253]. RALP1 was the only 
target selected in my study that has been previously evaluated in the context of 
naturally acquired immunity using sera from asymptomatic adults in Thailand[463], 
Mali[463] and China[263]. However, I was unable to express this target, meaning I 
could not compare my data with available literature. 
 
Conserved targets are potential ideal vaccine candidates 
Fifteen (79%) of the reactogenic novel targets examined in this study were 
identified as conserved or of limited polymorphism (and therefore not under 
balancing selection) in a genome-wide population genetic analysis of Gambian 
isolates[253]. In addition, the majority of these targets are described as conserved 
proteins of unknown function on PlasmoDB, representing ideal targets that may 
overcome one of the major obstacles hindering vaccine development. Parasite 
antigenic diversity has contributed to the low effectiveness observed in the majority 
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of multi-subunit vaccine candidates tested in phase 2 and 3 trials[380, 480]. Clinical 
trials using the following candidates, RTS’S (CSP)[171], combination B (MSP-1, -2 
and RESA)[373] and AMA1[172] have been shown to induce strain-specific 
responses and ultimately resulted in low vaccine efficacies against heterologous 
strains. Multivalent (vaccine consisting of multiple alleles of the same antigen) or a 
multi-subunit (vaccine consisting of multiple distinct antigens) approaches may be 
better and are under evaluation. An alternative approach would be to target a 
relatively conserved antigen with the expectation that vaccine induced responses 
would be effective across diverse parasite isolates. This has been demonstrated for 
the conserved target reticulocyte binding protein homologue 5 (RH5), in which only 
5 non-synonymous SNPs have been reported at over a 10% frequency in 290 
clinical isolates from diverse geographical locations[454]. Antibodies raised against 
the Pf3D7 variant of RH5 showed broad inhibitory activity against diverse P. 
falciparum lab isolates and strains[454, 455] in growth inhibition in vitro assays. In 
subsequent vaccination followed by challenge studies, Aotus monkeys vaccinated 
with the Pf3D7 variant of RH5 and challenged with the virulent heterologous FVO 
strain showed reduced parasitaemia and ability to self-cure when compared to 
control animals[456]. This demonstrated the in vivo vaccine induction of responses 
that were protective against heterologous strains, showing the utility of using a 
conserved vaccine candidate. This similar protection against homologous and 
heterologous P. falciparum strains has yet to be demonstrated in human clinical 
trials. Nevertheless, a pool of conserved blood-stage targets of naturally acquired 
antibody responses warrants further pre-clinical evaluation as vaccine candidates. 
 
Recombinant expression of functionally relevant antigens 
I successfully obtained soluble recombinant full-length extracellular domains that 
ranged from 34-167 kDa in size (Table 4.2), for 16/26 proteins that either lacked or 
had a single transmembrane domain. In an additional six antigens that were multi-
transmembrane proteins: the longest predicted extracellular loops were similarly 
obtained in soluble form. This resulted in an 84% success rate in the heterologous 
expression of soluble P. falciparum proteins which was similar to the rates observed 
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in studies that expressed P. falciparum [469] and P. vivax [481] merozoites proteins. 
This were considerably higher than efforts using the E.coli system by Mehlin et al 
[482], Aguiar et al [483] and Vedadi et al [484], that obtained soluble proteins for 
6.3% and 7.3% and 20.9% of selected targets respectively. My success rate is 
attributed to several factors: I selected a mammalian expression system using 
commercially available Exp293F cells and codon-optimised my gene constructs to 
facilitate expression in human cells. In addition, I mutated the N-glycosylation sites 
preventing inappropriate addition of N-glycans and replaced the native P. 
falciparum signal peptide with an exogenous peptide that drives mouse antibody 
secretion. These modifications had been shown to increase the protein yield 
obtained using HEK293E cells[468, 469]. The mammalian expression system was 
selected over bacterial or the cell-free systems available within our laboratory for 
the following reasons. Although bacterial expression systems are relatively easy to 
handle and cost-effective, soluble proteins are seldom obtained [482-484] and they 
are limited to proteins less than 50 kDa[485] (74% of selected targets were >50 
kDa; Table 4.2). This has subsequently resulted in expression of fragments of 
proteins by E.coli as opposed to full-length proteins that can be obtained with 
mammalian cells [468]. The cell-free systems such as the eukaryotic wheat germ 
cell-free protein synthesis system (WGCFS)[269] have been used successfully to 
obtain soluble P. falciparum proteins [269]. However, an inverse correlation was 
also observed between soluble proteins and size [269] resulting in the expression of 
segments of proteins separately [265, 269, 271, 486]. Plasmodium proteins >200 
kDa in size have been successfully expressed in mammalian cells, and have 
recapitulated known biochemical activity such as the MSP1-MSP7 and P12-P41 
protein-protein interactions[469]. Although the yields using mammalian systems are 
lower when compared to E.coli expression systems, the system is scalable and 
antibody detection assays have improved from the ELISA to luminex and protein 
arrays that require over 100-fold less antigen for detection in cohort studies.  
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Conclusion 
 In summary, I identified 19 novel antigens that were reactogenic with a pool of 
hyper-immune sera from adults naturally exposed to P. falciparum infection. The 
majority of these targets are of unknown function, of limited polymorphism and 
may play essential roles in merozoite invasion of erythrocytes. They represent ideal 
candidates for pre-clinical evaluation as potential vaccine candidates. These would 
include evaluating the prevalence and titres of antibody responses to these targets in 
individuals living in malaria endemic areas and their correlation with immunity or 
susceptibility to clinical episodes of P. falciparum malaria. In addition, identifying 
the protective mechanisms by which antibodies to each individual target function 
and the extent to which this function is strain transcending would provide valuable 
information for vaccine target prioritization. In line with this, a subset of the 
nineteen antigens has been evaluated using sera from a longitudinally monitored 
cohort of immune adults. In chapter 5, I present data on associations between 
antibody responses and clinical immunity. In chapter 6, I present data on the 
correlation between antibody responses to novel targets and protective antibody 
effector functions.  
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CHAPTER 5  
Antibodies against novel targets in a longitudinally monitored 
cohort of adults 
5.0. Introduction 
 
Adults living in an area with a high intensity of malaria transmission are known to 
be immune to clinical episodes of malaria even in the presence of detectable 
parasites [11, 76], and when infected often have lower parasite densities than 
children [119, 487, 488]. Landmark passive transfer studies have shown that 
immunoglobulin G purified from adults living in a malaria-endemic area can 
successfully treat children admitted to hospital with severe malaria[127], suggesting 
that the mediators of immunity in adults are also functional in children. Identifying 
the targets and mechanisms by which this anti-disease and anti-parasite immunity is 
mediated in adults is therefore important and could guide the selection of suitable 
malaria vaccine candidates.  
 
Immuno-epidemiological studies aimed at identifying the targets of protective 
immunity against malaria use cohorts typically comprised of children, primarily 
because they are in the process of acquiring immunity, and can be classified into 
“protected” and “susceptible” groups, allowing comparison of immune profiles 
between groups. In contrast, adults in high transmission regions are generally all 
immune to clinical malaria, and thus of limited value for this kind of approach. 
However, studying such adults does offer some advantages over studying children. 
Immunity to clinical episodes in adults is known to be stable in the presence of 
continuous intense exposure (i.e. there are no outbreaks of clinical malaria reported 
in adults under these conditions) with exceptions in pregnancy associated malaria 
[16] and/or immuno-compromised individuals [489, 490]. Similarly, immune 
responses in adults have been shown to be stable in longitudinally monitored 
cohorts [491, 492]. By contrast, responses in children can be unstable [491] and 
have been shown to be short-lived [493], meaning they may be functionally 
different to adult responses. In addition, retrospective studies on the epidemiological 
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and clinical manifestations of imported malaria suggest that the clinical immunity 
gained in adults living in a malaria-endemic area may be long-lived[494]. Thus, 
unlike children, immune adults are thought to provide a stable clinical and 
immunological phenotype. I reasoned therefore that a cohort of longitudinally 
monitored adults living in a highly endemic area of Tanzania was an ideal platform 
for the identification of potential targets of protective immunity, and used this to 
monitor responses to the antigens identified in the proteomic studies in Chapters 2-
4, as well as previously studied control antigens. 
5.1. Rationale 
 
Prospective cohort studies in children are used widely to identify the targets of 
protective antibodies. This relies on examining antibody responses (sero-positivity 
or high antibody titers) to a range of antigens in relation to observed clinical 
episodes of malaria in cohorts of children followed over time.  However, the results 
from such studies have often been contradictory, with protective associations 
against a given antigen being reported in some studies and contradicted in others 
from the same or different regions [302].  Many factors could account for this, 
including differences in i) malaria transmission intensities, ii) methodology and 
analytical approaches used, iii) the target antigens used given the variations due to 
antigen polymorphisms. Additional factors specific to the use of serum samples 
taken from children in these types of analyses contribute further to the 
discrepancies. Firstly, antibody responses in children have been shown to be short-
lived[493] and unstable[491] and therefore a measurement taken before a long 
follow-up period may not be adequately predictive of protective efficacy. Second, 
children can easily be misclassified as immune when in reality they were not 
exposed to infectious mosquitoes during the period of observation. This undermines 
the ability to clearly distinguish “truly immune” from “susceptible” children and 
further compromises analyses in cohort studies[495]. Third, even if exposure could 
be confirmed, children who are immune during one malaria transmission season 
may be susceptible to malaria during a subsequent season (personal communication, 
F. Osier). 
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Examining antibody responses in adults may overcome some of the above 
limitations, as it is known that almost all adults are immune to clinical episodes of 
malaria despite living in an area of high transmission intensity. This minimizes the 
misclassification bias that occurs when defining an immune or susceptible 
individual. Adult immunity is thought to be stable over time; therefore 
measurements taken at any time point are likely to be informative with regards to 
protective immunity. Immune responses measured in longitudinally monitored 
adults are stable[491, 492], and therefore protective responses should be identifiable 
at multiple sampling points. I therefore hypothesized that a protective immune 
response would be detectable in the majority of clinically immune adults 
(conservative estimate of approximately 50%) at multiple time points.  
In addition, studies have shown that the magnitude (titre) of antibody responses 
[496] as well as the breadth (the number of antigens recognized) [496, 497] is 
predictive of protection from clinical episodes of malaria in children.  I therefore 
hypothesized further that immune adults living in malaria endemic areas would have 
high titers of antibodies to a subset of important malaria antigens, and that these 
titers would be maintained over time.  
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5.2. Objective 
 
To use sera from a cohort of longitudinally monitored adults to establish an 
analytical framework for the identification of antigens associated with protective 
immunity.  
 
5.3. Specific objectives 
 
• Describe the epidemiology of malaria within a cohort of longitudinally 
monitored immune adults in Nyamisati, Tanzania. 
• Identify antibody responses to novel antigens associated with protective 
immunity in adults 
5.4. Methods 
5.4.1. Study population: Nyamisati Cohort 
 
The study was conducted in a longitudinally monitored population in Nyamisati 
village situated in Rufiji District, coastal Tanzania. Malaria transmission is 
perennial with seasonal fluctuations and the area is considered to be holoendemic, 
with a parasite prevalence of > 75 % in 2-9 year olds at the time the cohort was 
established in 1985 [498-500]. A research team was set up in the village to study the 
epidemiology of malaria in 1985. Since then, annual cross-sectional surveys have 
been conducted between March and May before the rainy season and continue to 
date.  The work presented here includes data collected during the 1993, 1994 and 
1995 surveys that comprised of 558, 793 and 722 individuals respectively (Figure 
5.1). These years were selected as they were conducted during a period of high 
malaria transmission and both epidemiological data and serum samples were readily 
available for analysis. During the cross-sectional surveys, venous blood samples 
were collected and clinical assessments conducted for each individual. All 
participants were monitored passively for clinical episodes of malaria throughout 
the year at a single health centre that served the entire village. A malaria episode 
was defined as a fever (axillary temperature of  > 37.5oC), detectable parasites by 
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microscopy and the absence of clinical findings related to other infections. 
Individuals who met these criteria were given anti-malarial treatment as per the 
national guidelines. Plasmodium parasites were identified using thick and thin blood 
films stained with Giemsa. Parasite densities were determined by counting parasites 
against leucocytes assuming 8000 leucocytes per µl. One hundred oil immersion 
fields were examined for microscopy analysis[501]. Data on merozoite surface 
protein 1 and 2 (MSP1 and MSP2) genotyping [502] as well as a multiplexed real-
time polymerase chain reaction (PCR) assay for the detection of the 18S gene [503] 
was also available for the 1994 cross-sectional survey and for individuals who were 
16 years and younger at the 1995 cross-sectional survey. I analyzed the 
epidemiology of malaria within this cohort and selected individuals who were 15 
years and older and asymptomatic at each of the survey (i.e. having no record of 
malaria at the time of the survey, 4 weeks before or 1 week after) as the adults 
whose antibody responses would be analyzed. In the individuals in whom a serum 
sample was available for antibody detection, I also detected the 18S gene in their 
corresponding packed red cell pellets to provide data on parasite status at the time of 
the cross-sectional survey. 
5.4.2.  Adult immuno-epidemiology: measuring antibody responses to merozoite 
antigens 
5.4.2.1. Recombinant merozoite antigens 
 
Recombinant merozoite antigens used for adult immuno-assays included a panel of 
well-studied antigens and a subset (11/19, 60%) of the novel antigens described in 
Chapter 4. The well-studied antigens included; AMA1 (3D7 and FVO alleles), 
MSP1 (19 kilodalton of the Wellcome strain), MSP2 (CH150/9 and DD2 alleles), 
MSP3 (3D7-like and K1-like alleles) and RH2 (2030 fragment). These antigens 
were expressed and purified as has been previously described in the references listed 
in Table 5.1 with the exception of AMA1. Dr. Ed Remarque of the department of 
Parasitology Biomedical Primate Research Centre, Netherlands, kindly provided the 
AMA1 recombinant proteins. The subset of novel antigens identified in this work 
was selected based on the availability of sufficient quantities of protein to measure 
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responses in the entire cohort by indirect ELISA. The details of the recombinant 
antigens expressed and tested in this study are shown in Table 5.1. Full-length 
AMA1 and MSP2 expressed using the same Expi293 mammalian system used for 
the novel antigens were included as comparators. Altogether, antibody responses to 
21 recombinant proteins were measured in a cohort of longitudinally monitored 
adults in the Nyamisati cohort, Tanzania. 
 
Table 5.1: Details of the recombinant P. falciparum antigens used in this study 
Recombinant antigen Region of 
protein 
expressed 
Purification 
Tag 
Expression 
system 
Immunological assay 
MSP-119[504] 1631-1726 GST E.coli  
 
 
Luminex assay 
MSP-2 (Dd2)[505] 22-248 GST E.coli 
MSP-2 (CH150/9)[505] 1-184 GST E.coli 
MSP-3 (3D7)[170] 2-354 MBP E.coli 
MSP-3 (K1)[170] 2-379 MBP E.coli 
AMA-1 (3D7)[506] 83-531 His P. pastoris 
AMA-1 (FVO)[507] 25-544 His P. pastoris 
PfRH2 (2030 fragment)[283] 2030-2528 GST E.coli 
Antigens expressed in-house using the Expi293 expression system (all are based on the Pf3D7 strain) 
AMA-1 25-541  
 
 
 
 
His 
 
 
 
 
 
Expi293 cells 
 
 
 
 
 
Indirect ELISA 
MSP-2 20-246 
PF3D7_0206200(PfPAT) 241-319 
PF3D7_0629500 (SEG2) 451-544 
PF3D7_0730800.2 20-293 
PF3D7_0823800 93-605 
PF3D7_0830500 55-675 
PF3D7_0925900 21-217 
PF3D7_1025300 18-922 
PF3D7_1252300 2-51 
PF3D7_1308000 341-602 
PF3D7_1345100 24-157 
PF3D7_1401600 69-478 
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5.4.2.2.  Indirect ELISA to measure antibody responses to novel antigens  
 
For the eleven novel antigens, a coating concentration for the ELISA was 
determined as follows: 100µl of recombinant antigen was coated at a two-fold serial 
dilution of ranging from 128µg/ml to 0.06µg/ml in Dynex 4HBX Immunolon 
ELISA plates. These were tested with a pool of hyperimmune sera and a negative 
control as has been described in section 4.4.4. An optimal coating concentration was 
determined for each antigen. The optimal coating concentration for each antigen 
was subsequently plated at 100µl per well, diluted in coating buffer (15mM 
Na2CO3, 35mM NaHCO3, pH 9.4) and left overnight at 4˚C. After overnight 
incubation, plates were washed four times in 1X PBS containing 0.05% Tween-20 
(wash buffer) and blocked for 5 hours at room temperature with 1% skimmed milk 
(Marvel) diluted in PBS Tween 20 (Blocking buffer). Thereafter, plates were 
washed four times in wash buffer and 100µl of individual sera at a 1:1000 dilution 
were tested in duplicate. Positive and negative controls were included in each plate 
as well as a serial dilution of malaria immune globulin (MIG) as a standard positive 
control and to allow for the conversion of optical density values to relative antibody 
concentrations in arbitrary units. MIG is a reagent that contains purified 
immunoglobulin G (98% IgG) from the plasma of 834 healthy Malawian 
adults[328]. It was originally manufactured to test its potential role as an adjunct 
therapy for the treatment of cerebral malaria in Malawian children[328]. Following 
an overnight incubation at 4˚C, wells were washed and incubated for 3 hours at 
room temperature with 100µl of HRP conjugated to polyclonal rabbit anti-human 
IgG (Dako) at a 1:5000 dilution using block buffer. The wells were then washed 
four times and incubated at room temperature with 100µl of substrate development 
buffer (0.1M citric acid, 0.2M Na2HPO4, 4mg o-phenylenediamine dihydrochloride 
tablets (Sigma), 8µl hydrogen peroxide and 5ml distilled water). After 20 minutes of 
incubation in the dark, the reaction was stopped with 25µl H2SO4 and absorbance 
read at 492nm. As a comparator, responses to AMA1 and MSP2 expressed using the 
same Expi293 expression system were measured as described above. A coating 
concentration of 0.05µg/ml was used for these antigens [496, 508]. 
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5.4.2.3. Luminex assay to measure antibody responses to the well-studied antigens  
 
An optimized multiplex bead-based antibody assay that was available in-house 
[509, 510], was used to measure responses to previously studied merozoite antigens, 
with the exception of Expi293 expressed MSP2 and AMA1, whose responses were 
measured by ELISA. Each antigen was coupled to magnetic microsphere beads 
(Luminex corp) using the Bioplex amine coupling kit (Biorad) according to 
manufacturer’s instructions. I coupled the antigens at a concentration of 1.0 
µg/million beads for AMA1 (3D7 and FVO allele) and 0.5 µg/million beads for the 
other antigens namely MSP1-19, MSP2 (DD2 and CH150/9 allele), MSP3 (3D7 and 
K1 allele) and RH2-2030. These coating concentrations were determined by 
performing a checkerboard titration in which both the antigen and serum 
concentrations were serially diluted to identify optimal assay conditions (Appendix 
5.1, Figure 1 and 2). To test for the presence of plasma IgG to the different antigens, 
the following protocol was used. Antigens coupled to magnetic beads of unique 
spectral addresses were diluted to a final concentration of 100 beads/µl (b/µl) using 
1% BSA/PBS. 50µl of diluted beads (5000 beads) were added to Bio-Plex Pro flat 
bottom plates (Bio-Rad Laboratories) and 50µl of sera diluted 1:1000 in 1% 
BSA/PBS was added. The plate was incubated for 1 hour on a microplate shaker 
(rotation 500 rpm) at room temperature and in the dark. The plate was then washed 
four times using 0.05% PBS/Tween 20 and 50µl of R-phycoerythrin-conjugated, 
F(ab’)2 fragment-specific, goat anti-human immunoglobulin G (Jackson 
ImmunoResearch Laboratories) was added to each well and the plate incubated for 
30 minutes at room temperature on the microplate shaker. The plates were washed 
four times using 0.05% PBS/Tween 20 and each well resuspended in 100µl of 
1%BSA/PBS. Each well was then analysed on the MAGPIX using the xPONENT 
software. The fluorescence intensity was read from at least 100 microspheres per 
spectral address (corresponding to a single antigen) and reported as mean 
fluorescence intensity (MFI). Similar to the indirect ELISA controls, a serial 
dilution of malaria immune globulin were included in each plate as a standard 
positive control and to allow for the conversion of MFI values to relative antibody 
concentrations in arbitrary units. A pool of hyper-immune sera (PHIS) drawn from 
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malaria immune adults in Kenya was also used on each plate to correct for plate-to-
plate variations and sera from 30 non-malaria exposed adults were included as 
negative controls. 
5.5. Statistical analysis 
 
All analysis was done using STATA (StataCorp, version 13.1) and Graphpad 
PRISM (version 6.0h). The Kruskal-Wallis H test for trend was used to analyze the 
trend between parasite density and age. The Mann-Whitney U test was used to 
compare median parasite density levels between 0-14 year olds and > 14 year olds 
treated at the health centre for clinical episodes of malaria. I examined the 
relationship between antibody responses and age, parasite prevalence and parasite 
density. Antibody levels were determined from interpolation from the non-linear 5-
parameter standard curve made by a tripling dilution of purified malaria-immune 
IgG that was included in each plate. Antibody levels and parasite densities were log 
transformed to normalize the data. The cohort of adults was split into two age 
groups, 15-29 year and > 30 years. The Mann-Whitney U test was used to model 
associations between antibody levels and age, antibody levels and parasite status 
(PCR positive versus negative individuals) and antibody levels and clinically 
symptoms. The Mann-Whitney U test was used to compare median parasite density 
levels between individuals with a stable versus non-stable antibody response. An 
individual’s breadth score was determined by adding up the number of antigens to 
which an individual had high antibody titres (above median antibody levels of the 
cohort). The Kruskal-Wallis test for trend was used to model the breadth score 
against age and parasite density. The Mann-Whitney U test was used to compare the 
median breadth score between individual who experienced a clinical episode of 
malaria versus those who did not. 
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5.6. Results 
5.6.1. Description of the Nyamisati cohort and selection of clinically immune 
adults 
5.6.1.0. Nyamisati cohort description 
 
I used data collected from three cross-sectional surveys conducted in the years 1993, 
1994 and 1995 to describe the epidemiology of malaria in adults living in Nyamisati 
village, a malaria-endemic region in Tanzania. The epidemiological data that was 
available at each cross-sectional survey included the year of birth, sex, parasitaemia 
by microscopy, a description of each individual’s house and roofing material, the 
results of an HIV rapid serology test and confirmatory HIV viral detection assay.  
PCR data for parasite detection and genotype (as described above) was available for 
all samples collected at the 1994 survey and for the under 16 year olds in the 1995 
survey. PCR data was not available for the 1993 survey. The axillary temperature 
measurements were conducted for each individual but only recorded in the 1995 
survey.  Data on the pregnancy status of the females were available for the 1995 
survey only.  
 
There were 558, 793 and 722 individuals surveyed at the 1993, 1994 and 1995 
surveys respectively (Figure 5.1). These included adults and children whose ages 
ranged from less than 1 year to 85 years. The data available to calculate the age was 
the year of birth and therefore an individual’s age in months could not be 
determined. The parasite prevalence in the entire cohort by microscopy was 46.2%, 
38.9% and 36.1%, respectively, for each of the three consecutive annual surveys. 
Plasmodium falciparum infection accounted for over 93% of infections in all three 
surveys with Plasmodium malariae accounting for 0.4, 3.3 and 2.4% of infection in 
the 1993, 1994 and 1995 surveys. There was one case of a mixed Plasmodium 
falciparum and Plasmodium malariae infection recorded at the 1993 survey and five 
(1.7%) cases at the 1994 survey. There were no mixed infections recorded at the 
1995 survey. The overall HIV prevalence was low at each of the surveys with an 
average of 5.1%. 
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Figure 5.1: Schema showing the three cross-sectional surveys conducted in the Nyamisati village and 
follow-up period for the cohort of individual’s analyzed in this thesis. 
5.6.1.1. Parasite prevalence in the Nyamisati cohort 
 
Plasmodium falciparum transmission intensity is often estimated using either the 
Plasmodium falciparum parasite rate (PfPR) in children aged 2-10 years (PfPR2-10), 
which refers to the proportion of the population found to be carrying asexual blood 
stage parasites in this age group, or the entomological inoculation rate (EIR) that 
estimates the number of infectious mosquito bites per person per unit time [511]. 
Data on the EIR was not available for this population and so I used the PfPR2-10 to 
estimate the transmission intensity in this region at each of the three surveys. The 
PfPR2-10 was 74%, 62% and 58% as determined by microscopy in the 1993, 1994 
and 1995 cross-sectional surveys. The PfPR2-10 estimated using PCR data was 78% 
and 71% at the 1994 and 1995 surveys respectively. Based on this data, this area 
would be classified as a region with hyperendemic malaria transmission [511]. 
 
A clinical assessment was conducted for all study participants at the time of the 
cross-sectional survey. Data was available on symptomatic individuals, defined as 
those who had been on treatment four weeks before, during or one week after the 
survey. There were 8, 64 and 57 individuals at the 1993, 1994 and 1995 cross-
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sectional surveys who were symptomatic. The majority of these individuals were 
under the age of 10 years: 7 (87.5%), 62 (97.0%) and 52 (91.2%) individuals in the 
1993, 1994 and 1995 surveys. To describe the epidemiology of malaria in the 
cohort, I used data that both included or excluded the symptomatic individuals at 
each of the cross-sectional surveys. The data presented below excludes the 
individuals who were symptomatic. As shown in Figure 5.2, the parasite prevalence 
(microscopy) rose with age reaching a peak of between 65 and 80% at about seven 
years of age and declining gradually thereafter.  The lowest parasite prevalence by 
microscopy ranged between 7 and 13% and was observed in older adults aged 30 to 
85 years. The parasite prevalence estimated by PCR data showed overall higher 
parasite prevalence in all age groups when compared to microscopy. This was 
particularly striking for the older age groups (over 6 years olds) as seen in the 1994 
(Figure 5.1B) and 1995 (Figure 5.1C) data. For example, using data from the 1994 
survey in adults aged between 30-35 years, microscopy underestimated the 
prevalence of asymptomatic parasitaemia by 48% when compared to the prevalence 
estimated by PCR data.  
 
Figure 5.2: The parasite prevalence by age in the Nyamisati cohort. The parasite prevalence by age in 
asymptomatic individuals using data collected at A) 1993 B) 1994 and C) 1995 cross-sectional survey. Blue bars 
show parasite prevalence determined by microscopy. Purple bars represent parasite prevalence determined by 
PCR. PCR data is not available for the 1993 survey or for the over 16 year olds in the 1995 survey. 
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The parasite prevalence in the entire cohort including both symptomatic and 
asymptomatic individuals is shown in Appendix 5.1, Figure 3. 
5.6.1.2. Parasite densities in the Nyamisati cohort 
 
The median parasite density dropped gradually with age in asymptomatic 
individuals. This decline was statistically significant for the 1993 and 1994 surveys 
(Figure 5.3A and 5.2B respectively). The highest median parasite densities were 
recorded in children aged 3-4 years in the 1993 survey (560 parasites/µl, range 8-
104,000) and in children aged 5-6 years in the 1994 and 1995 surveys (400 
parasites/µl: range 8-7516 and 8-4160 in the 1994 and 1995 surveys respectively). 
The lowest median parasite densities recorded were 8 (range: 8-32), 8 (range: 8-
160) and 100 (range: 8-560) parasites/l in adults aged 39-51, 36-45 and 46-85 
years in the three consecutive surveys.  
 
Figure 5.3: The parasite densities by age in the Nyamisati cohort. Parasite densities decline with age in 
asymptomatic individuals. The log10 parasite density by age using data collected at the A) 1993 B) 1994 and C) 
1995 cross-sectional survey. The Kruskal-Wallis H test for trend was used to compare media parasite density 
levels with age. 
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The data presented exclude 8, 64 and 57 individuals at the 1993, 1994 and 1995 
cross-sectional surveys who were symptomatic at the respective surveys. While the 
decline in parasite density with age was evident in the 1993 cross-sectional survey, 
this trend was not observed in the 1995 survey. This may suggest a rapid decline in 
transmission intensity in the Nyamisati cohort over a 3-year period resulting in 
concomitant loss of immunity in the population. However, while the PfPR2-10 over 
the three years dropped from 74-58%, the area would still be classified as 
experiencing hyperendemic transmission therefore the loss in trend with age is 
unexpected and loss of immunity within the population is unlikely. An alternative 
explanation would be that the data collected was not sufficient to make conclusions. 
The data presented includes parasite densities as measured by microscopy in 46% of 
the cohort population. Retrospective detection and quantification of parasite 
densities by PCR would strengthen these findings, however this data was 
unavailable for analysis at the time of writing this thesis. 
5.6.1.3. Clinical episodes of malaria in the Nyamisati cohort 
 
Episodes of malaria defined as a fever, detectable parasitaemia by microscopy and 
the absence of clinical findings related to other infectious diseases were recorded at 
the health centre. As shown in Figure 5.4, the majority of malaria episodes occurred 
in children under the age of 8 years, with an average of 83% of all episodes 
occurring in children aged 0 to 7 years of age.  Only 4.6%, 6.1% and 9.2% of 
recorded malaria episodes occurred in individuals over 14 years in the 1993, 1994 
and 1995 respectively. The number of cases varied in each of the cross-sectional 
surveys resulting in 151, 279 and 455 cases reported at the health centre in the 1993, 
1994 and 1995 cross-sectional survey. This probably reflected improvements in 
diagnosis of malaria as well as data collection and recording in the subsequent years 
rather than a drop in transmission intensity and immunity that would result in an 
increase in the clinical episode observed as has been discussed in section 5.6.1.2. 
For example, while axillary temperature was not available in the 1993 and 1994 
data, these data were collected in the 1995 follow-up period. Similarly, data on 
pregnancy status of the females within the cohort were reported in 1995. 
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Figure 5.4: Clinical episodes of malaria decline with age. The count of episodes by age recorded at the health 
centre over the A) 1993, B) 1994 and C) 1995 calender year. Numbers at the top of the column represent the 
proportion of total episodes. 
 
Multiple episodes per individual were also recorded at the health centre, the 
majority of which occurred in children under the age of 7 years as shown in Figure 
5.5. No individuals over the age of 14 had more than one episode of malaria 
recorded in the years 1993 (Figure 5.5A) and 1994 (Figure 5.5B). In the year 1995, 
a total of 7 individuals who were 15 years and older had two or more episodes of 
malaria recorded at the health centre (Figure 5.5C), and three of these were pregnant 
women. Five individuals had two recorded episodes of malaria and two individuals 
had three documented episodes of malaria recorded at the health centre. 
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Figure 5.5: Multiple clinical episodes of malaria are rarely experienced in older individuals. The count of 
multiple episodes by age recorded at the health centre over the A) 1993, B) 1994 and C) 1995 calendar and D) 
log10 parasite densities of individuals treated at the health centre for malaria categorised by age. 
 
The median parasite density of individuals over 14 years and treated for malaria at 
the health centre ranged between 3000 to 4320 parasites/µl. Interestingly, this 
parasite density was lower than that observed in children 14 years and younger 
presenting with clinical malaria at the health centre (6400-14000 parasites/µl) 
(Figure 5.5D and Table 5.2). This implies that although adults are generally 
immune, the few who become symptomatic do so at a lower parasite density 
compared to children. A summary of the demographic characteristics of individuals 
who were older than 14 years and treated at the health centre for malaria is shown in 
Table 5.2.  
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Table 5.2: Table showing the demographic characteristics of the individuals over 14 years treated at the 
health centre for a clinical episode of malaria 
Characteristics 1993 1994 1995 
No. of episodes recorded 151 279 456 
No. of episodes in > 14 year old (%) 7 (4.6) 17 (6.1) 42 (9.2) 
Median age in years (min-max) 35 (20-82) 30.5 (16-44) 29 (15-60) 
Female 3 8 25 
No. pregnant 0 2 5 
Median parasite density in > 14 years 
(min-max) 
3200 
(400-91200) 
3000 
(320-54000) 
4320 
(320-6400) 
Mean axillary temperature (min-max) nd nd 37.5 
(36.0-40.20) 
Plasmodium falciparum infection 6 17 42 
Mixed infections 1 (Pf + Pv) 0 0 
Median parasite density in < 15 year old 
(min-max) 
14000 
(240-19800) 
6400 
(40-660000) 
11600 
(80-400000) 
 
Based on these data, I selected individuals who were over 14 years and 
asymptomatic at the time of the 1993 survey (i.e. those who had not been on 
treatment four weeks before, during or one week after) for immuno-epidemiology 
assays. As it was a longitudinal study spanning three years, I limited analysis to 
adults with a sample available in all three cross-sectional surveys, and who were 
asymptomatic at the time of sampling at all three time points. A summary of the 
demographic details of these selected adults at each cross-sectional survey is shown 
in Table 5.3.  
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Table 5.3: Table showing the demographic characteristics of the individuals over 14 years whose antibody 
responses were measured. 
Characteristics 1993 1994 1995 
Total number of individuals 558 793 722 
Number of individuals aged over 14 years  283 388 353 
Number of samples available (%) 77 
Median age in years (Min-Max) 33 (15-78) 34 (16-79) 35(17-80) 
Females (%) 46(59.7) 
Pregnant (%) nd* nd* 5(10.8) 
HIV positive (%) 0 
Parasite prevalence (Microscopy) 20#(26.3) 12#(15.8) 8#(10.5) 
Parasite prevalence (PCR) 28&(41.2) 40%(54.8) 31@ (43.7) 
Median parasite density (p/µl) (Min-Max) 
in parasite positive individuals by microscopy 
16 (8-1200) 16 (8-240) 24(8-640) 
*: No data available. #: N=76. &: N=68. %: N=73. @: N=71 
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5.6.2. Antibody responses in a longitudinally monitored cohort of adults 
 
I measured antibody responses to 21 recombinant antigens, which were obtained 
using different expression systems as shown in Table 5.1. Antibody responses to a 
subset of the antigen were measured using the Luminex assay and the remainder by 
indirect-ELISA for logistical reasons. 
5.6.2.1. Comparison between antibody responses to antigens recombinantly 
expressed using multiple systems 
 
The majority of the previously studied antigens analysed in this study were obtained 
using the E.coli or P. pastoris heterologous expression while the novel antigens 
were expressed using an Expi293 mammalian expression system as has been 
described in Chapter 4. In addition, antibody responses to well-studied antigens 
were measured using the Luminex assay at the beginning of the study while 
responses to novel antigens were measured using an indirect ELISA (Table 5.1). 
Therefore it was important to see that antigens expressed in the different systems 
gave comparable results and were positively correlated. 
 
To compare the ELISA and Luminex immuno-assays, I tested 72 serum samples for 
the presence of IgG antibodies to the same antigens namely: AMA1-3D7 and 
MSP2-CH150/9, using a well established in-house ELISA assay [496] and an 
optimized multiplex Luminex assay based on the parameters described in section 
5.4.2.3 and Appendix 5.1, Figure 1 and 2. A standard curve made from a tripling 
dilution of purified IgG from adults in Malawi [328] was included in each plate and 
used to interpolate antibody concentrations for each tested sample. As shown in 
Appendix 5.1, Figure 5, a strong positive Pearson correlation coefficient was 
observed for each antigen indicating that the optimised multiplex Luminex assay 
and the monoplex ELISA assay were comparable. Next, I compared antibody 
responses in the same serum samples to AMA1-3D7 and MSP2-CH150/9 expressed 
in different expression systems (Table 5.1). The full-length ecto-domains of AMA1 
and MSP2 were expressed using the Expi293 mammalian expression system 
described in Chapter 4. These were compared to responses measured against AMA1 
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expressed using P. pastoris and MSP2 expressed in E. coli that were available in-
house.  As shown in Appendix 5.1, Figure 6, a strong positive Pearson correlation 
coefficient was observed for antibody responses to AMA1. Responses to MSP2 
were also positively correlated, albeit to a lesser extent than for AMA1, perhaps 
indicating differences in folding efficiencies between the two systems (Appendix 
5.1. Figure 6 C and D).  
5.6.2.2. Prevalence of antibodies to known and novel antigens defined by 
seropositivity 
 
To determine the prevalence of antibody responses to merozoite antigens, a 
seropositivity cut-off was determined using 30 non-exposed sera from Swedish 
adults. A sample with an MFI or OD value greater than the cut-off defined as the 
mean + 3 standard deviation values of the 30 serum samples from non-exposed 
adults was interpreted as being positive. As shown in Figure 5.6, the prevalence of 
antibodies to the novel antigens ranged from as low as 10% to 100% across each of 
the three cross-sectional surveys. The prevalence of antibodies to 
PF3D7_0730800.2, PF3D7_1025300, PHISTb and PF3D7_1308000 were over 80% 
across all three cross-sectional surveys, similar to the prevalence of antibodies to 
previously studied merozoite antigens AMA1, MSP2 and -3. Antibody prevalence 
to PF3D7_0925900 and PF3D7_1252300 were over 70% while those to 
PF3D7_1345100, PfPAT and PF3D7_0830500 was less than 55%. The prevalence 
of antibodies to PF3D7_0925900 ranged between 58-72% while those to 
PF3D7_0823800 ranged between 38-61%. The antibody prevalence to 
PF3D7_0830500 was the lowest and ranged from 13 in 1993 to 28% in the 1994 
cross-sectional surveys. 
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Figure 5.6: Antibody prevalence to novel antigens. Antibody prevalence and polymorphism levels to five 
known merozoite antigens (blue bars) and eleven novel antigens (purple bars) at the A) 1993, B) 1994 and C) 
1995 cross-sectional survey. D) A comparison of the non-synonymous/synonymous SNP ratio (dN/dS) between 
previously studied antigens (blue circles) and novel antigens (purple squares).  
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5.6.2.4. Antibody responses to known and novel antigens by age and parasite status 
 
I measured antibody responses to adults whose ages ranged from 15 years to 80 
years (Table 5.3). I categorized the individuals into two age categories, those 
between 15 to 29 years and those 30 years and older. As shown in Table 5.4, 
antibody responses did not vary with age for all tested antigens. This is in contrast to 
responses in children whose levels are known to increase with increasing age. 
However, antibody levels were generally higher in PCR positive individuals 
compared to PCR negative individuals for all tested antigens (Table 5.5) suggesting 
that antibody levels were boosted in the presence of parasites.  
 
Table 5.4: Association between antibody levels and age  
Antigen 1993# 1994% 1995* 
 Z-score P-value Z-score P-value Z-score P-value 
MSP-119 0.218 0.8273 -0.355 0.7222 -0.360 0.7188 
MSP-2 (Dd2)  0.748 0.4545 0.323 0.7466 0.883 0.3773 
MSP-2 (CH150/9)  1.330 0.1837 0.592 0.5536 0.105 0.9167 
MSP-3 (3D7)  -0.664 0.5196 -0.657 0.5111 -0.523 0.6011 
MSP-3 (K1)  1.039 0.2990 -0.786 0.4317 -0.105 0.9167 
AMA-1 (3D7)  1.662 0.0965 1.266 0.2056 0.534 0.5931 
AMA-1 (FVO)  1.402 0.1608 1.260 0.2076 nd 
PfRH2 (2030 fragment)  0.862 0.3886 0.571 0.5681 0.372 0.7101 
Antigens expressed in-house using the Expi293 expression system (all are based on the Pf3D7 strain) 
AMA-1 1.413 0.1578 0.937 0.3487 0.395 0.6929 
MSP-2 1.002 0.3162 0.679 0.4974 0.523 0.6011 
PF3D7_0206200(PfPAT) -0.987 0.3281 -1.497 0.1343 -0.592 0.5535 
PF3D7_0629500 (SEG2) -0.156 0.8762 -0.765 0.4444 0.761 0.4467 
PF3D7_0730800.2 -0.327 0.7435 -0.856 0.3918 -0.511 0.6092 
PF3D7_0823800 -0.374 0.7084 -0.097 0.9228 0.523 0.6011 
PF3D7_0830500 0.977 0.3288 -0.657 0.5111 1.197 0.2315 
PF3D7_0925900 -0.426 0.6702 -0.631 0.5285 0.651 0.5153 
PF3D7_1025300 -0.561 0.5749 -0.673 0.5008 -1.336 0.1816 
PF3D7_1252300 1.698 0.0894 0.485 0.6287 1.162 0.2454 
PF3D7_1308000 -0.805 0.4208 -1.734 0.0829 -0.883 0.3773 
PF3D7_1345100 0.473 0.6365 -0.668 0.5042 0.732 0.4643 
PF3D7_1401600 0.769 0.4421 -0.991 0.3217 0.232 0.8163 
#: 1993: Individuals 30 years and older =46 (60%). %: 1994: Individuals 30 years and older =51 (66%). *: 1995: 
Individuals 30 years and older =57 (74%). 
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Table 5.5: Association between antibody levels and parasite status at the cross-sectional survey 
Antigen 1993# 1994% 1995* 
 Z-score P-value Z-score P-value Z-score P-value 
MSP-119 -1.620 0.1053 -0.299 0.7647 -0.267 0.7897 
MSP-2 (Dd2)  -2.617 0.0089 -2.339 0.0194 -1.507 0.1318 
MSP-2 (CH150/9)  -0.860 0.3899 -1.452 0.1465 -1.113 0.2657 
MSP-3 (3D7)  -1.545 0.1223 -0.344 0.7311 -0.904 0.3658 
MSP-3 (K1)  -1.470 0.1415 -0.732 0.4644 -2.133 0.0329 
AMA-1 (3D7)  -1.034 0.3010 -1.208 0.2270 -0.487 0.6263 
AMA-1 (FVO)  -1.470 0.1415 -1.164 0.2445 nd 
PfRH2 (2030 fragment)  -1.445 0.1483 -0.599 0.5495 -0.580 0.5620 
Antigens expressed in-house using the Expi293 expression system (all are based on the Pf3D7 strain) 
AMA-1 -0.386 0.6993 -1.097 0.2726 -0.243 0.8076 
MSP-2 -1.271 0.2037 -2.361 0.0182 -0.580 0.5621 
PF3D7_0206200(PfPAT) -0.847 0.3968 -0.111 0.9117 -0.046 0.9630 
PF3D7_0629500 (SEG2) -3.022 0.0025 -1.319 0.1872 -0.985 0.3244 
PF3D7_073800.2 -1.707 0.0878 -1.906 0.0566 0.012 0.9907 
PF3D7_0823800 -2.729 0.0064 -1.097 0.2725 -0.151 0.8802 
PF3D7_0830500 -2.237 0.0253 -0.449 0.6535 -0.603 0.5466 
PF3D7_0925900 -0.966 0.3341 0.011 0.9911 -0.475 0.6345 
PF3D7_1025300 -1.863 0.0625 -0.233 0.8159 -1.264 0.2063 
PF3D7_1252300 -1.751 0.0800 -2.411 0.0159 -0.394 0.6934 
PF3D7_1308000 -2.374 0.0176 -0.964 0.3349 0.185 0.8528 
PF3D7_1345100 -2.773 0.0056 -0.410 0.6817 0.603 0.5466 
PF3D7_1401600 -1.371 0.1704 -2.178 0.0294 -0.707 0.4794 
#: 1993: Individuals who were parasite positive (PCR detection of 18S gene)=28(41.2%). %: 1994: Individuals 
who were parasite positive (PCR detection of 18S gene)=40(54.8%). *: 1995: Individuals who were parasite 
positive (PCR detection of 18S gene) =31(43.7%). Significant differences are shown in bold. 
5.6.2.5. Association between antibody responses to novel antigens and clinical 
episodes of malaria 
 
As shown in Figure 5.4 and Table 5.2, the majority of clinical episodes of malaria 
recorded over the follow-up period were reported in children under the age of 7 
years. Less than 10% of the episodes recorded occurred in individuals 15 years and 
older. In the 77 individuals whose antibody responses were measured, 3 of them 
experienced a clinical episode in 1994 and 9 individuals experienced an episode in 
1995. No episodes of malaria were recorded in the year 1993 in these 77 
individuals. The age and haemoglobin levels between individuals who had a febrile 
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malaria episode did not differ from those who did not, as shown in Appendix 5.1, 
Figure 7. I then compared the total IgG antibody titres to each antigen in individuals 
who did or did not experience a clinical episode of malaria in the 1995 follow-up 
period (68 versus 9 individuals, respectively). In general, antibody titres were higher 
in clinically immune individuals and the difference was statistically significant for 
five of the novel antigens tested.  RH2 was the only exception in which titres were 
higher in the individuals who experienced a clinical episode of malaria (Table 5.6, 
Appendix 5.1, Figure 8). As shown in Figure 5.7 and Table 5.6, antibody levels to 5 
(45%) novel antigens were significantly higher in adults who did not experience a 
clinical episode of malaria compared to those who did. These antibodies were 
collected in Mar-May, 1995 prior to the occurrence of the clinical episodes 
evaluated.  These antigens were PfPAT, PF3D7_0629500, PF3D7_0830500, 
PF3D7_1345100 and PF3D7_1401600(PHISTb). This was similar to results 
observed with MSP2 (Figure 5.7A). 
 
Figure 5.7: Antibody levels to novel antigens were lower in adults who experienced a clinical episode of 
malaria. Lower antibody levels to five novel antigens in adults who experienced a clinical episode of malaria. A 
comparison of the antibody levels in individuals who experienced a clinical episode of malaria versus those who 
did not to A) MSP2 B) PF3D7_0206200 C) PF3D7_0629500 D) PF3D7_0830500 E) PF3D7_1345100 and F) 
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PF3D7_1401600. Blue circles represent antibody levels in individuals who did not experience a clinical episode 
while purple circles represents individuals who did. 
 
I then analyzed the association between antibody responses to individual antigens 
defined as seropositivity and clinical episodes of malaria.  Antibody seropositivity 
was fitted as the independent variable in a logistic regression model separately for 
each individual antigen. The dependent variable was whether or not a clinical 
episode was experienced over the 1-year follow-up period. Antibody responses to 
all the novel antigens measured were associated with reduced odds of experiencing 
a clinical episode (Table 5.6).  
Table 5.6: Association between antibody levels and protection from clinical episodes of malaria over the 
1995 follow-up period. 
Antigen Median antibody levels Associations with the risk of malaria 
No clinical 
episode 
N=68 
Clinical 
episode 
N=11 
P-value$ Prevalence 
N (%) 
Odds ratio  
(95% CI)# 
P-value# 
MSP-119 2909 1086 0.0551 63(81.8) 0.33 (0.07-1.60) 0.170 
MSP-2 (Dd2) 3129 1443 0.1582 77 (100) nd 
MSP-2 (CH150/9) 824.9 595.4 0.9494 76 (98.7) nd 
MSP-3 (3D7) 597.7 303.8 0.5259 69 (89.6) 0.38 (0.06-2.28) 0.289 
MSP-3 (K1) 514.5 233.1 0.3496 71 (92.2) 0.58(0.06-5.85) 0.647 
AMA-1 (3D7) 4526 2426 0.1320 74 (96.1) nd 
PfRH2 (2030 fragment) 416.2 613.3 0.6686 37(48.1) 2.60 (0.59-11.43) 0.207 
AMA-1 2.424 2.147 0.2104 74 (96.1) 0.21 (0.02-2.85) 0.243 
MSP-2 0.871 0.488 0.0298 69 (89.6) 0.93 (0.10-8.68) 0.946 
PF3D7_0206200(PfPAT) 0.314 0.114 0.0350 37 (48.1) 0.48 (0.11-2.11) 0.331 
PF3D7_0629500 (SEG2) 0.231 0.069 0.0048 55 (71.4) 0.16 (0.03-0.70) 0.015 
PF3D7_0730800.2 0.705 0.427 0.1320 77 (100) nd 
PF3D7_0823800 0.133 0.163 0.5953 29 (37.7) 0.48 (0.08-2.29) 0.329 
PF3D7_0830500 0.130 0.049 0.0390 17 (22.1) 0.39 (0.04-3.39) 0.395 
PF3D7_0925900 0.116 0.057 0.1881 59 (76.6) 0.33 (0.08-1.42) 0.137 
PF3D7_1025300 1.030 0.267 0.1491 74 (94.8) 0.10 (0.01-0.88) 0.038 
PF3D7_1252300 0.220 0.104 0.1165 54 (70.1) 0.29 (0.07-1.25) 0.097 
PF3D7_1308000 0.372 0.407 0.3578 62 (80.5) 0.45 (0.09-2.08) 0.309 
PF3D7_1345100 0.214 0.115 0.0085 39 (50.7) 0.10 (0.01-0.89) 0.038 
PF3D7_1401600(PHISTb) 0.460 0.132 0.0311 72 (93.5) 0.06 (0.01-1.45) 0.006 
$=Mann-Whitney U test was used to compare antibody titres in individuals who experienced a clinical episode 
versus those who did not. #=Associations between responses to individual antigens and the odds of malaria were 
analyzed using a logistic regression model. Seropositivity was used for analysis. Odds ratios are adjusted for 
age. nd= odds ratio not computed as seropositivity for this antigen was > 96%. Statistically significant 
associations are shown in bold. 
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These associations were statistically significant for four antigens namely 
PF3D7_0629500, PF3D7_0830500, PF3D7_1345100 and 
PF3D7_1401600(PHISTb). Interestingly, although the numbers are small, 
significant associations were not observed for the previously studied antigens (Table 
5.6). To adjust for multiple comparisons in the above analysis, the Bonferroni 
correction was applied resulting in a readjusted statistical significance level of P-
value=0.0025. Based on this criterion, the presence of antibodies to 
PF3D7_1401600 (PHISTb) remained significantly associated with reduced odds of 
clinical episodes of malaria. 
 
5.6.2.6. Stability of antibody responses to novel antigens 
 
The antibody prevalence to novel targets ranged from as low as 13% 
(PF3D7_0830500) to as high as 100% (PF3D7_0730800.2). I therefore explored the 
stability of a seropositive or seronegative response to the novel antigens in immune 
individuals in order to test the hypothesis that antigens likely to be important for 
immunity were stable in a majority of adults. I excluded 11 individuals who 
experienced a clinical episode of malaria in the entire 3-year follow-up period.  As 
shown in Figure 5.8, responses in individuals were generally stable i.e. individuals 
who were seropositive at one time point tended to remain seropositive at subsequent 
time points for most antigens. This was particularly evident in PF3D7_0206200, 
PF3D7_0629500, PF3D7_0823800, PF3D7_0830500 and PF3D7_1345100, where 
the same individuals tended to be positive at measurements made in subsequent 
surveys. Antibody seropositivity to previously studied merozoite antigens AMA1, 
MSP-2, -3 and RH2 were also stable in the three crossectional surveys (Appendix 
5.1, Figure 9). 
 
I then compared the parasite densities measured at each of the three cross-sectional 
surveys in individuals with stable responses versus non-responders. These two 
categories were defined as follows for novel antigens; a) stable responders were 
defined as individuals with a seropositive response in at least two of the three 
crossectional surveys and b) non-responders were individuals who were 
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seronegative at all three cross-sectional surveys or had a seropositive response in 
only one of the surveys. For two of the novel antigens namely PF3D7_0730800.2 
and PF3D7_1401600, the stable seropositivity rate was over 95% limiting 
comparisons between responders and non-responders (Table 5.7). For these 
antigens, the median antibody titres were used as a second cut-off. Stable responders 
to these two antigens were defined as individuals with a response above the median 
titre in at least two of the three crossectional surveys and non-responders were 
individuals in whom the titres were below median levels at all three cross-sectional 
surveys or had an high-titre response in only one of the surveys. As a comparison, I 
compared parasite densities to previously studied antigens (AMA1, MSP-119, -2, -3 
and RH2) using the same criteria as above based on both seropositivity and median 
antibody levels as the cut-off. As shown in Appendix 5.1, Figure 10, responses to 
AMA1 (3D7 and FVO alleles) and MSP3 (3D7 and K1 alleles) were highly 
correlated and suggesting cross-reactivity, while MSP2 induced a more obvious 
allele-specific response. I therefore used only the 3D7 allele for AMA1 and MSP3 
and included both alleles of MSP2 in the analyses below. 
 
The prevalence of stable responders (seropositivity or above median levels) varied 
greatly between antigens ranging from a low of 18% to PF3D7_0830500 to a high 
of 92% to PF3D7_1025300. Over 50% of the adults tested had stable responses to 
six of the novel antigens tested in this study. There was a modest but statistically 
significant lower median parasite densities in individuals with a stable seropositive 
response to PF3D7_1308000 compared to those who were not stable (Table 5.7). 
Median parasite densities were also lower in individuals with a stable seropositive 
response to most novel antigens with the exception of PF3D7_1252300, although 
none of these differences were statistically significant. Interestingly, parasite 
densities (as determined by microscopy) were higher in individuals with a stable 
high titre (above median responses) to AMA1 (Table 5.5). 
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Table 5.7: Association between stable antibody responses and parasite densities. 
  Median parasite densities 
(parasites/l) 
  
Antigen Proportion of 
stable 
responders 
N (%) 
Non- 
responders 
Stable 
responders 
Z-score$ P-value$ 
MSP-119 b 38 (49.4) 32 32 0.584 0.5589 
MSP-2 (Dd2) b 35 (45.5) 32 32 -0.963 0.3354 
MSP-2 (CH150/9) b 36 (46.8) 32 24 0.863 0.3882 
MSP-3 (3D7) b  39 (50.7) 16 32 0.549 0.5832 
AMA-1 (3D7)      b  40 (52) 16 88 -2.622 0.0087 
PfRH2 (2030 fragment) b 38 (49.4) 16 32 -0.524 0.6003 
AMA-1 a 75 (97.4) nd 
b 41 (53.3) 14 96 -2.660 0.0078 
MSP-2 a 72 (93.5) nd 
b 36 (46.8) 32 32 0.261 0.7942 
PF3D7_0206200(PfPAT) 38 (49.4) 28 32 0.484 0.6286 
PF3D7_0629500 (SEG2) 55 (71.4) 88 32 0.986 0.3244 
PF3D7_073800.2 a 75 (97.4) nd 
b 36 (46.8) 80 16 1.707 0.0878 
PF3D7_0823800 37 (48.1) 51 32 0.8606 0.4202 
PF3D7_0830500 14 (18.2) 32 32 0.484 0.6286 
PF3D7_0925900 60 (77.9) 24 32 0.164 0.8700 
PF3D7_1025300 71 (92.2) 49 32 0.163 0.8703 
PF3D7_1252300 61 (79.2) 25 32 -0.449 0.6534 
PF3D7_1308000 65 (84.4) 604 32 2.286 0.0223 
PF3D7_1345100 27 (35.1) 32 32 0.528 0.5972 
PF3D7_1401600(PHISTb) a 73 (94.8) nd 
b 39 (50.7) 51 32 0.644 0.5198 
$=Mann-Whitney U test was used to compare log10 parasite densities recorded in all three cross-sectional survey 
in individuals who were defined as stable responders or non-responders. a=Stable responders were defined as 
individuals with a seropositive response in atleast two of the three crossectional surveys. b= stable responders in 
these cases, were defined as individuals with a response above the median titre in atleast two of the three 
crossectional surveys. Statistically significant differences are shown in bold. 
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Figure 5.8: Stability of seropositive response in adults. The majority of immune adults have stable seropositive response to novel antigens. Plot matrix showing the 
seropositive response to AMA1, MSP2 and eleven novel antigens, in 66 clinically immune individuals with samples collected at the 1993, 1994 and 1995 cross-sectional survey. 
Each row on the Y-axis represents an individual while the X-axis shows responses to each antigen grouped together and arranged in consecutive years. For example, for AMA1, 
the three consecutive columns represent 1993,1994 and 1995 seropositive response.
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5.6.2.7. Breadth of antibody responses to novel antigens 
 
The breadth of antibody response, defined as the sum of high titer responses to 
individual merozoite antigens has been previously shown to be a strong predictor of 
immunity against clinical episodes of malaria in children [496]. To determine the 
breadth of antibody response in each individual, a single allele was included in the 
analysis for all antigens, resulting in a total of 16 measurements considered (five 
previously studied targets and eleven novel antigens). A stable response for the 
previously studied targets and two novel antigens (PF3D7_1401600 & 
PF3D7_0730800.2) was defined as a response above the median titre in at least two 
of the three crossectional surveys. For the remaining targets (9/11 novel targets) a 
stable response was defined as having a seropositive response in atleast two of the 
three crossectional surveys. I then determined the breadth score by adding up the 
number of antigens to which an individual had a stable seropositive response. For 
example, an individual with a breadth score of 16 would have had a stable 
seropositive response for 9 of the antigens tested and a high titre response (above 
median antibody levels) to PF3D7_073800.2, PF3D7_1401600 and the 5 previously 
studied antigens (9+2+5=16).  
 
Using this definition, no adult had a breadth score of 0. The lowest score obtained 
was 2 in 3 (4%) of the individuals tested. Similarly 3 individuals had a stable 
response to all antigens measured resulting in a breadth score of 16 (Appendix 5.2). 
I categorized the individuals into 4 groups based on their breadth score (2-4, 5-8, 9-
12 & 13-16). As shown in Figure 5.9A, a trend of an increase in breadth score with 
increase in age was observed although this was not statistically significant. 
Interestingly, the median breadth score was higher in clinically immune adults 
compared to those who experienced a clinical episode over the three year follow-up 
period (no clinical episode versus clinical episode breadth score: 10 versus 6: p-
value=0.047)(Figure 5.9B). 
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Figure 5.9: The breadth of stable antibody responses in adults by A) age and B) clinical status. 
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5.7. Discussion 
 
Novel targets of naturally acquired humoral responses 
The main aim of this study was to identify novel antigens associated with protective 
immunity that could feed into the malaria vaccine development pipeline. Although 
the numbers of serum samples tested are small, the work in this chapter provides 
evidence that suggests these novel antigens are targets of naturally acquired humoral 
responses and six of them appear to be associated with protection from clinical 
episodes of malaria in adults. The antibody prevalence to the panel of eleven novel 
antigens varied from a low of 13% to 100%, the majority of which were lower than 
the prevalence observed for previously studied merozoite antigens that are under 
evaluation as leading vaccine candidates. Encouragingly, the prevalence to the 
previously studied merozoite antigens tested in this panel was similar to those 
observed in adults living in high malaria transmission settings such as Senegal[512], 
western[513] and coastal Kenya[163, 168]. While antibody levels did not increase 
with age, they were boosted in the presence of parasites as has been observed in 
children[496, 510, 514]. The responses to previously studied and novel antigens in 
adults were stable when measured in the same individuals in subsequent surveys 
similar to observations in Gambian and Kenyan adults[491, 492].  
 
Novel antigens associated with protection from clinical episodes of malaria 
Antibody responses to six (66%) of the novel antigens tested were individually 
associated with protection from clinical episodes of malaria in adults. For the 
majority of these targets (4/6), the responses were defined as 
seropositive/seronegative suggesting that a low antibody concentration may be 
sufficient for protection. Over 50% of adults had stable responses to four of the 
targets namely PfPAT, PF3D7_0629500, PF3D7_1025300 and 
PF3D7_1401600(PHISTb) across three surveys. The breadth of antibody responses 
has also been shown to be associated with protection from clinical malaria in 
children [496, 510]. I observed that in adults, the breadth score increased with age, 
and immune individuals had a higher median breadth score compared to the few 
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adults who developed a clinical episode of malaria over the three-year follow-up 
period. Interestingly, all the adults evaluated in this study had a response to at least 
one of the novel antigens.  This is in contrast to responses in children in which 
breadth scores of zero have been reported albeit to a different panel of merozoite 
antigens [496, 510, 515]. Taken together, these results are encouraging and warrant 
further evaluation in classic cohort studies involving children and adults from 
regions of varying transmission intensities. Similarly, these targets should be 
evaluated further using samples that are available in-house from controlled human 
malaria infection studies to identify responses associated with protection [151, 152]. 
 
Novel antigens associated with lower asymptomatic parasite densities 
A trend towards lower parasite densities measured at the cross-sectional surveys 
was observed in individuals who had a stable response to a majority of novel 
antigens (6/11 antigens; Table 5.7). This was significant for PF3D7_1308000 and 
the trend was evident for three other novel antigens that were also associated with 
protection from clinical episodes of malaria: PF3D7_0629500, PF3D7_1025300 and 
PF3D7_1401600(PHISTb). Additional studies are required to elucidate the role of 
these antigens in controlling parasite densities in both children and adults.  
 
Unanswered questions 
While I demonstrate that antibody responses to a subset of these novel antigens 
appear to be associated with protection from malaria, the mechanisms by which they 
mediate their protection have yet to be elucidated. Antigen-specific functional 
responses monitored in either naturally exposed individuals or immunized animal 
models would provide valuable information to guide selection of new vaccine 
candidates. This would include evaluating the degree to which responses to these 
targets are effective against diverse parasite isolates. As antigenic polymorphisms 
have been a major obstacle in vaccine efficacy for antigens such as AMA1 and 
MSP-2, focusing on targets of limited polymorphisms is thought to be one way of 
overcoming this hurdle. Interestingly, the majority of novel targets evaluated (9/11: 
Figure 5.6) had a lower non-synonymous/synonymous SNP ratio compared to the 
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known merozoite antigens evaluated suggesting that they contained limited 
polymorphisms and were potentially attractive vaccine candidates.  
 
Little is known about the temporal dynamics of humoral responses to malarial 
antigens in adults with the exception of MSP1 [491, 492] and MSP2 [491]. I show 
that antibody responses to a panel of known and novel antigens were stable over 
time in adults living in a hyperendemic village of Tanzania where malaria 
transmission was sustained throughout the study period. However, the longevity and 
stability of these responses in the absence of exposure or in the context of 
decreasing transmission intensity has yet to be elucidated. Recently, clinical 
episodes of malaria have been reported increasingly in adults living in endemic 
areas such as Senegal[516, 517] and Gabon[518], following reductions in malaria 
transmission due to introduction of control measures such as insecticide treated 
bednets[10, 516, 517]. The ideal effective vaccine should elicit a long-lived 
response following vaccination that would sustain protection even in the absence of 
exposure.  
 
Study limitations 
The study had several limitations, largely due to the nature of the samples and data 
that were available. A major limitation was that the numbers of clinical episodes in 
the cohort of adults were few, limiting the potential to detect true effects in the 
association studies. Secondly, temperatures were not routinely recorded during the 
cross-sectional surveys and at the health centre, although fevers were reported 
(personal communication, A. Farnert). As such, the definition of a clinical episode 
of malaria is less stringent than that typically used in immuno-epidemiology studies. 
However, this is mitigated by the fact that our study was focused on adults widely 
known to be clinically immune. In addition, data on identification of pregnant 
individuals within the cohort in the 1993 and 1994 survey is not available. This 
leaves open the possibility that a proportion of the few clinical cases observed at 
these time points were attributable to pregnancy-associated malaria. Fortunately, the 
numbers are small and would have minimal impact on the study. Lastly, due to the 
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time constraints of a PhD, I analysed antibody responses to only the 3D7 allele 
(originally from West Africa) of each antigen. Using this sequence may under-
estimate responses to more regionally representative sequences from East Africa. 
This also limited my ability to evaluate the effect of antigenic diversity on humoral 
responses and immunity.  
 
Epidemiology of malaria in Nyamisati, Tanzania 
Little is known on the contribution of antigen-specific antibody responses on the 
clinical immunity observed in adults living in a region of high transmission 
intensity. I therefore analysed the available epidemiological data from a cohort of 
longitudinally monitored individuals living in rural Tanzania so as to select a 
population of adults whose antibody responses would be analysed. Based on the 
PfPR2-10, the Nyamisati village would be classified as an area with a hyperendemic 
malaria transmission[511]. This classification would have remained unchanged had 
the parasitaemia been detected by microscopy or the more sensitive PCR method. 
Although microscopy is known to underestimate the parasite prevalence [519], the 
magnitude of this difference was particularly striking in the older age groups as has 
been reported before[519]. This has important implications for control programs 
aimed at reducing transmission, that rely on microscopy to monitor progress as the 
undetected low-density parasitaemia in adults may sustain larger than expected 
reservoirs for malaria transmission.  
 
The epidemiology of malaria in Nyamisati was similar to that described in other 
areas that are subject to a high malaria transmission intensity [11, 76, 119].  The 
majority (over 90%) of adults were clinically immune with a large proportion (over 
40%) carrying asymptomatic infections, consistent with the observation that sterile 
immunity is not achieved. Parasite prevalence rose in the youngest children, 
reaching a peak in older children and gradually declined with age in adulthood. 
Parasite densities also declined with age, in keeping with observations from other 
studies showing that adults living in a malaria-endemic area have the ability to 
control parasite densities upon P. falciparum infection [119] [487, 488]. Few 
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clinical episodes of malaria were observed in individuals older than 14 years of age, 
in agreement with reports of the acquisition of anti-disease immunity in older age-
groups [520]. This clinical immunity appears to be stable as the prevalence of 
clinical malaria remained low over the three years of observation. Multiple clinical 
episodes of malaria were rare in adults and the few that occurred did so 
predominantly in pregnant women who are known to be susceptible [16].  
 
Interestingly, I observed that the few adults treated at the health centre had three-
fold lower median parasite densities (3500 p/µl) compared to the under 15 years 
olds treated at the health centre (10666 p/µl). Similar findings were reported from a 
treatment re-infection study in adults living in a holo-endemic village in Ghana 
where symptomatic adults had mean parasite densities of less than 500 parasites/µl 
[521], although a comparison with symptomatic children was not provided. 
Similarly in Mali, although fewer episodes of malaria were observed in adults (15-
25 years), in these individuals, the median parasite densities were three fold lower 
than those reported in children (4-6 years)[487]. This would suggest that protection 
against clinical episodes of malaria in adults is at least in part mediated through 
mechanisms that control parasite density. On the other hand, one could argue that 
among susceptible adults, the threshold of parasetemia that results in a clinical 
episode is significantly lower than that observed in children. However, given the 
observation that asymptomatic parasite densities are also lower in adults compared 
to children, the most plausible explanation is that adults are better able to suppress 
parasite densities than children. 
 
In conclusion 
I present data identifying six novel antigens with limited polymorphisms whose 
humoral responses appear to be associated with protection from malaria in adults. 
These responses appear to be stable in adults over the three years. In chapter 6, I 
investigate the protective mechanisms by which antibodies to these novel antigens 
may function. 
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CHAPTER 6  
Antibody mediated effector functions against merozoites in immune 
adults 
6.0. Introduction 
 
Identifying the targets of protective antibodies and the mechanisms by which they 
mediate protection is important for vaccine development. While naturally acquired 
P. falciparum antibodies have been shown to be effective by limiting blood stage 
replication and reducing parasite densities [127], little is known about the specific 
mechanisms by which they achieve this against the merozoite stage of the life-cycle. 
In vitro assays that are aimed at identifying the vaccine induced and naturally 
acquired immune correlates of protection to malaria continue to be developed and 
validated [136]. To date, most have focused on two proposed mechanisms against 
the merozoite stage of the life-cycle: 1) direct neutralization and thereby inhibiting 
merozoite invasion of erythrocytes and subsequently parasite growth or 2) 
interaction with leucocytes releasing effector functions that leads to parasite death. 
 
The in vitro growth inhibitory assay (GIA), which measures the ability of antibodies 
alone to inhibit P. falciparum growth, has been the most widely used method for 
evaluating naturally-acquired and vaccine induced antibody effector functions 
against P. falciparum blood stages. For example, the GIA has been used to 
demonstrate the antigen specific activity for the potential merozoite vaccine targets 
MSP1-19 [522], RH4 [282] and RH5 [523] using affinity purified immunoglobulins 
from pools of malaria immune adults. In addition, it has been used to evaluate whole 
serum samples from children in prospective cohort studies albeit with conflicting 
results [136]. A second assay developed in the early 1990s demonstrated that 
naturally-acquired [150] and vaccine induced antibodies interacted with monocytes 
via their FcII receptors releasing a soluble factor that resulted in parasite growth 
inhibition. This antibody-dependent cellular inhibition (ADCI) assay was 
subsequently used to demonstrate parasite inhibitory activity in sera from vaccinees 
that received the MSP2-C1 (containing the 3D7 and FC27 alleles of MSP2)[524] 
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and GMZ2 (containing the N-terminal of GLURP and the C-terminal of MSP3) 
vaccines[525]. Little is about the contribution of ADCI to naturally acquired malaria 
immunity in both children and adults. More recently, several new in vitro assays 
have been developed to elucidate the interaction between antibodies and 
monocytes/macrophages, neutrophils and soluble complement factors to trigger 
anti-merozoite (and other blood stages) responses. These assays included: 1) the 
direct phagocytosis of merozoites by monocytes opsonized by antibodies [139, 526] 
2) interaction of merozoite specific antibodies with neutrophils resulting in the 
release of reactive oxygen species (ADRB) [140, 141, 527] and 3) the ability of 
antibodies to fix complement soluble factors onto the surface of merozoites 
resulting in cell lysis [138]. Similar assays had previously evaluated these immune 
effector mechanisms with more readily available stages of the parasite life cycle 
such as the opsonic and non-opsonic phagocytosis of P. falciparum infected 
erythrocytes[148], mature schizonts[528] and mature gametocytes[529]. However, 
the recently developed ability to purify viable merozoites [370] has facilitated the 
evaluation of these effector mechanisms specifically in anti-merozoite immunity for 
the first time. 
 
Each of these assays has been evaluated in prospective cohort studies in children to 
elucidate their contribution to naturally acquired immunity. For example, opsonic 
phagocytosis of merozoites has been associated with protection from clinical 
episode and high parasite densities in Kenyan [139] and Papua New Guinea children 
[149, 530]. Similarly, opsonisation of merozoites with antibodies that result in 
neutrophil respiratory burst has been associated with clinical protection from 
malaria in Senegalese children [140] and protection from severe malaria in Kenyan 
infants when analysed in combination with growth inhibitory antibodies [515, 531]. 
Lastly, pools of antibodies from Kenyan and Papua New Guinean adults were 
shown to be able to fix complement factor C1q onto the surface of free merozoites 
leading to the formation of a membrane attack complex and presumably lysis of the 
merozoites. This ability was subsequently shown to be associated with protection 
from high-density parasitaemia and clinical episodes in Papua New Guinea children 
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[138]. It is notable that all of these studies to date have focused on responses in 
children, and consequently, the contribution of these effector functions to mediating 
immunity in adults has not been evaluated. In addition, little is currently known 
about whether the same individuals are able to produce multiple effector functions, 
or how stable or long-lived these functions are. Finally, the specific merozoite 
targets that elicit these protective functional responses are not currently known, and 
is critical for vaccine target prioritization. 
6.1. Rationale 
 
With the exception of the use of adult sera in the development and validation of 
these in vitro assays, little is known about the role of these new protective 
mechanisms in immune adults. For example, pools of sera collected from adults 
living in malaria endemic regions of Kenya, Papua New Guinea and Senegal were 
used in the optimization of the opsonic phagocytosis [139], C1q-fixing [138] and 
the ADRB [140] assays respectively, but nothing is known about the prevalence, 
levels and contribution to immunity of each of these mechanisms, either on their 
own or in combination. I reasoned therefore that a cohort of longitudinally 
monitored adults living in a highly endemic area of Tanzania was an ideal platform 
for the evaluation of potential mechanisms of protective immunity. In particular, I 
measured three immune effector mechanisms namely 1) opsonic phagocytosis of 
merozoites, 2) antibody-dependent respiratory burst and 3) antibody-dependent 
recruitment of C1q onto merozoites in serum from adults collected at three 
consecutive time points. I evaluated: 1) the contribution of each of these 
mechanisms to immunity to clinical episodes, 2) the stability of these responses over 
a three year period, 3) the breadth of effector functions in adults and 4) correlations 
with antibody responses to the new antigens described in the preceding chapters. 
 262 
6.2. Overall Objectives 
To use sera from a cohort of longitudinally monitored adults to study antibody 
mediated effector responses, test for association with protective immunity and test 
the role of specific antigens in these functional responses.  
6.3. Specific Objectives 
• Describe antibody mediated effector mechanisms associated with protective 
immunity in adults. 
• Identify merozoite antigens associated with protective antibody mediated 
effector functions. 
6.4. Methods 
6.4.1. Isolation of P. falciparum merozoite and RBC membrane enclosed 
merozoites 
 
I obtained merozoites and RBC membrane enclosed merozoites from P. falciparum 
3D7 or D10 strains using the same protocol described in section 2.4.1 with the 
following modifications. Segmented schizonts (approximately 44hpi) were 
incubated with 10µM of E64, (trans-Epoxysuccinyl-L-leucylamido (4-guanidino) 
butane), for 6-8 hours. E64 is a protease inhibitor, which prevents merozoite egress 
from schizonts[370]. Treated schizonts were pelleted by centrifugation and 
resuspended in fresh media, counted using a haematocytometer and stored at -80°C 
as PEMS. To obtain merozoites, resuspended schizonts were filtered through a 
1.2m Acrodisc filter to release merozoites. Pelleted merozoites were resuspended 
in 1ml of RPMI media and quantified by flow-cytometry and used immediately in 
subsequent assays. Merozoites were stained with 100µg/ml of ethidium bromide for 
10 minutes and incubated with Count-bright absolute counting Beads (Invitrogen) at 
a 1:10 dilution before data acquisition and quantification by flow cytometry. The 
formulae below was used for quantification: 
 
Merozoite concentration= (count of merozoite (EtBr+ population) X  (volume of beads)  X  (Concentration of beads/ml) 
          (Count of beads)                             (volume of merozoites) 
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6.4.2. Antibody-mediated opsonisation and phagocytosis of P. falciparum 
merozoites assay (OPA) 
 
An optimised assay was used to measure the ability of sera from adults to opsonize 
merozoites for phagocytosis by monocytes[139]. Briefly, THP-1, a human 
monocytic leukemic cell line[532], was grown at 37°C in 5% carbon dioxide in 
RPMI media that was supplemented with 10mM HEPES, 1% penicillin 
streptomycin, 2mM L-glutamine and 10% fetal calf serum. The cells were 
maintained at a total density of between 105 and 106 prior to phagocytic assays. 30µl 
of merozoites/well at a concentration of 5x107 merozoites/ml were incubated with 
individual sera at a 1:2500 dilution in a 96-well U bottom plate pre-coated with 1% 
casein for 1 hour at room temperature. Wells were washed thrice using RPMI media 
and merozoites resuspended in THP-1 culture media.  Phagocytosis of opsonized 
merozoites was performed by incubating 100µl of THP-1 cells at a cell density of 
5x105/ml with 50µl of opsonized merozoites for 10 minutes at 37°C. Phagocytosis 
was stopped by centrifugation at 4°C and cells washed once with FACS buffer (1% 
Fetal bovine serum/0.05% sodium azide in PBS) and fixed with 2% ice-cold 
paraformaldehyde before data acquisition by flow cytometry, where a minimum of 
4000 events was collected for each sample. The population of THP-1 cells that 
stained ethidium bromide positive indicated phagocytosis of P. falciparum 
merozoites. In each plate, several control samples were employed that included: a) 
unopsonised THP1 cells where no sera was added, positive control samples where 
b) a pool of hyper-immune sera (PHIS), c) purified immunoglobulins from immune 
adults (MIG) and d) negative control sera from non-malaria exposed adults living in 
Sweden. The relative phagocytosis index (RPI) for each serum sample was 
calculated as follows using reading obtained with PHIS sera as the benchmark: 
 
RPI= (% EtBr+ population of THP1 cells opsonized with sample sera) X 100 
           (% EtBr+ population of THP1 cells opsonized with PHIS sera) 
 
All serum samples were assayed in duplicate and the mean RPI of duplicate 
readings calculated. The prevalence of antibodies mediating phagocytosis was 
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calculated using the mean RPI plus 3 standard deviation values of non-malaria 
exposed sera from Swedish adults (N=14) as the cut-off point 
6.4.3. Antibody mediated C1q fixation by P. falciparum merozoites 
 
I used a recently developed and published ELISA-based C1q fixation assay[138] to 
measure the ability of merozoites to recruit the complement factor C1q. To optimize 
PEMS coating concentration to use in the C1q fixation assay, PEMS were serially 
diluted to determine and tested against a pool of immune sera from malaria-exposed 
adults and non-exposed adults as a negative control. Thereafter, 100µl of PEMS at a 
concentration of 10x105 PEMS/ml was used for all serum samples. PEMS were 
coated on a 96-well flat-bottomed immulon 4HBX plates overnight at 4°C. Wells 
were then washed thrice with PBS and blocked with 200µl of 10% skimmed milk 
for 2 hours at 37°C. This was followed by incubation with 50µl of sera at a 1:200 
dilution in 5% skimmed milk for 2 hours at room temperature.  Wells were washed 
and incubated with recombinant human C1q (Calbiochem) at a 10µg/ml 
concentration for 30 minutes at room temperature. This was followed by incubation 
with 50µl of rabbit anti-C1q antibodies at a 1:2000 dilution for 1 hour at room 
temperature. Wells were washed thrice as before and incubated with 50µl of anti-
rabbit conjugated to horseradish peroxidase at a 1:2000 dilution for 1 hour at room 
temperature. Wells were then washed and incubated with 100µl of O-
phenylenediamine (OPD) for 15 minutes at room temperature and reaction stopped 
by adding 25µl of 2M H2SO4 and the absorbance read at 492nm using the Biotek 
Synergy 4 plate reader and Gen5 acquisition software. All serum samples were 
assayed in duplicate. 
6.4.4. Antibody-dependent respiratory burst (ADRB) 
 
I measured ADRB activity in serum samples using an optimised assay that had been 
set up in-house[515, 531]. The serum samples were measured in duplicate using 
freshly isolated neutrophils obtained from two healthy adults. 
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6.4.4.1. Neutrophil isolation from healthy donors 
 
Forty (40) ml of whole blood was collected from healthy individual donors in 
heparin vacutainer tubes and mixed with an equal volume of Hanks buffered salt 
solution (HBSS; Sigma Aldrich) with NaHCO3 and layered over ficoll (Ficoll-paque 
Plus; Sigma Aldrich) and centrifuged for 15 minutes to separate blood components. 
Serum, peripheral blood mononuclear cells and ficoll layers were carefully removed 
and the remaining red blood cells that contained granulocytes resuspended in HBSS 
buffer. This was then gently mixed with 3% dextran solution at a 1:3 dilution and 
incubated at room temperature for 1 hour in the dark. The supernatant that contained 
neutrophils was carefully collected and pelleted and the red blood cell contaminants 
lysed by sequential treatment with ice-cold 0.2% and 1.6% NaCl solutions 
respectively. Pelleted neutrophils were resuspended in sterile-filtered 
polymorphonuclear cell buffer (PMN buffer: 0.1% bovine serum albumin, 1% D-
(+)-Glucose, HBSS) and counted using a hemocytometer observed under x400 
magnification using the formulae below, before readjustment to a concentration of 
10X106 neutrophils/ml. 
Neutrophil concentration/ml = (count of neutrophils in 25 squares) X  (dilution factor) X  (104)= cells/ml 
             
6.4.4.2. ADRB assay 
 
PEMS stored at -80°C were serially diluted to determine the coating concentration 
for subsequent assays and tested against a pool of immune sera from malaria-
exposed adults and non-exposed adults as a negative control. After optimization, 
100µl of RBC membrane ec at concentration of 15x105 PEMS/ml were coated on a 
96-well flat-bottomed white polystyrene fluorescence maxisorp plates overnight at 
room temperature in the dark. Wells were washed 3 times with PBS and blocked 
with 200µl of 10% casein in PBS for 1 hour at room temperature. Following a 
second wash step with PBS, 50µl of sera diluted at 1:50 in PBS was added for 1 
hour at 37°C before an additional wash with PBS and the addition of 50µl of 
neutrophils at a 10 X 106 neutrophils/ml concentration per well.  50µl of isoluminol 
at 0.04mg/ml concentration was rapidly added to each well and luminescence 
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measured in each well every 2 minutes over a duration of 60 minutes using the 
Biotek Synergy 4 plate reader and Gen5 acquisition software. The maximal RLU 
measured in each serum was obtained. All serum samples were assayed in duplicate 
using neutrophils obtained from two different healthy donors. The relative light 
units (RLU) for each serum sample was calculated as follows using responses 
obtained from the MIG positive control included on each plate as the benchmark: 
RLU =   Maximum light units in the sample 
              Mean maximum light units of 4 MIG samples included in each plate 
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6.5. Results 
Serum samples collected from the same 77 individuals in three consecutive cross-
sectional surveys were available for functional assays resulting in a total of 231 samples. 
The samples were used to measure the ability to opsonize and phagocytosis of 
merozoites, interact with neutrophils for ADRB activity and antibody-dependent 
recruitment of C1q onto merozoites.  
6.5.1. Opsonic-phagocytosis of merozoites by sera from adults  
 
Serum samples were tested for the presence of antibodies that mediate opsonic 
phagocytosis of P. falciparum merozoites (OPA). The relative phagocytosis index 
was calculated for each adult sample, using hyper-immune sera as the benchmark 
sample as described in section 6.4.2. As shown in Figure 6.1A, merozoites 
opsonized with hyper-immune sera (PHIS) were phagocytosed to a greater extent 
compared to non-malaria exposed sera or unopsonised THP-1 cells evidenced by a 
higher proportion of ethidium positive THP1 population (36% in PHIS compared to 
0.68% and 2% in negative and unopsonised samples respectively (Figure 6.1A)). 
The relative phagocytosis indices computed for individuals varied from as low as 
1.7 to as high as 321.7. As shown in Figure 6.1B, C and D, the median (min-max) 
RPI value of Nyamisati adult sera was 61.8 (4.6-150.6), 68.3 (1.7-321.7) and 56.3 
(8.2-196.4) using samples collected at the 1993, 1994 and 1995 surveys 
respectively. The prevalence of antibodies mediating phagocytosis was determined 
based on a cut-off generated by calculating the mean plus 3 standard deviation RPI 
of sera from non-exposed Swedish adults. Opsonizing antibodies were detectable in 
the majority of adults tested resulting in prevalence’s of 90.9%, 93.5% and 96.1% in 
the 1993, 1994 and 1995 cross-sectional surveys respectively. As the serum samples 
were not heat-inactivated to remove the effect of complement, the above assay 
would measure opsonisation by antibodies alone, complement alone or both these 
factors if present in the serum sample. 
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Figure 6.1: Antibodies mediating phagocytosis of P. falciparum merozoites by opsonisation and interaction with THP-1 cells in adults of the Nyamisati cohort. (A) A flow 
cytometry histogram overlay contrasting phagocytosis in THP-1 monocytic cell lines in freshly isolated merozoites opsonized with PHIS (blue), non-malaria exposed sera (red) 
and unopsonised THP-1 cells (orange).  A comparison of the relative phagocytosis index (RPI) calculated for each individual samples collected at the 1993 (B), 1994 (C) and 1995 
(D) crossectional survey with indices obtained in control serum samples. The RPI values were higher in adults (blue box and whisker plots) compared to the negative control that 
was serum from non-exposed adults from Sweden. The box shows the median and interquartile RPI for the 77 individuals/survey while the whiskers show the minimum and 
maximum RPI measured.
 269 
6.5.1.0. Association between opsonic-phagocytosis, age and asymptomatic 
parasitaemia in adults 
 
I measured OPA in adults whose ages ranged from 15 years to 80 years. I 
categorized the individuals into two age categories, those between 15 to 29 years 
and those 30 years and older at each survey. I then pooled the data from individuals 
who fell within these age categories and compared their RPI. As shown in Figure 
6.2A, the median relative phagocytosis indices were significantly higher in the older 
age group: median RPI between 15-29 years versus > 30 years was 54.81 versus 
62.07, p-value=0.0497. A weak positive correlation of an Rpearson=0.1251, p-
value=0.058 was observed between age and the phagocytosis indices. A similar 
trend was observed when data from each cross-sectional survey was analysed 
independently as shown in Appendix 6.1, Figure 1A. 
 
 
Figure 6.2: Relative phagocytosis indices in adults grouped by age and parasite status.  (A) A comparison 
of the median phagocytosis indices in adults 30 years and older (white box and whisker plots) compared to 15-
29 year olds. (B) Median phagocytosis indices in adults with asymptomatic parasitaemia (as measured by qPCR 
of the 18S gene) compared to those who were parasite negative (black box and whisker plots). Data presented is 
pooled from the three cross-sectional surveys. 
 
Similarly, the phagocytosis indices were compared in individuals who were parasite 
positive or negative at any of the three cross-sectional surveys as measured by 
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qPCR detection of the 18S ribosomal RNA gene (Figure 6.2B). These indices were 
elevated in PCR positive individuals, which was statistically significant: median 
RPI in parasite negative adults compared to parasite positive individuals were 55.03 
versus 64.87, p-value=0.0196. A similar trend was observed when data from each 
cross-sectional survey was analysed independently as shown in Appendix 6.1, 
Figure 1B. 
6.5.1.1. Association between opsonic-phagocytosis and clinical immunity in adults 
 
All participants in the annual cross-sectional surveys were monitored for clinical 
episodes of malaria throughout the year at the single health centre that serves the 
entire village. A malaria episode was defined as a fever (axillary temperature of > 
37.5oC), detectable parasites by microscopy and the absence of clinical findings 
related to other infections. Of the 77 individuals, none of them experienced a 
clinical episode in the 1993 follow-up period, while 3 (3.9%) and 9 (11.7%) 
individuals experienced a clinical episode in the 1994 and 1995 follow-up periods 
respectively. I compared the phagocytosis indices in individuals who did and did not 
experience a clinical episode of malaria. As shown in Figure 6.3, although the 
numbers are small, in the 1994 follow-up period the median phagocytosis indices at 
the cross-sectional survey were lower in individuals who experienced a clinical 
episode compared to those who did not although this was not statistically significant 
(Mann-Whitneys U test: 64.87 versus 67.65; p-value=0.718). Similarly, in the 1995 
follow-up period, median indices were lower in individuals who experienced a 
clinical episode compared to those who did not (37.51 versus 55.36; p-
value=0.053), which was borderline significant. 
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Figure 6.3: Relative phagocytosis indices in adults who experienced a clinical episode of malaria 
compared to those who did not in the 1994 and 1995 follow-up period. Blue circles represent adults who did 
not experience a clinical episode while red circles represent those who did. 
6.5.2. C1q-fixing antibodies in sera from adults 
 
I used an established protocol to measure C1q-fixing antibodies in sera from adults 
in the Nyamisati cohort [138]. I optimised the coating concentration of PEMS for 
subsequent assays by testing a serial dilution of merozoites against a pool of hyper-
immune sera and non-exposed sera as a negative control. As shown in Appendix 
6.1, Figure 2, I selected a coating concentration of 10 x 105 PEMS/ml for all 
subsequent assays, as this was within the linear range and showed differential 
activity between the positive and the negative control samples. As shown in Figure 
6.4, the median optical density (min-max) measured for C1q-fixing antibodies in 77 
adults were 0.65(0.25-2.40), 0.62(0.21-1.87) and 0.61(0.27-2.79) in samples 
collected at the 1993, 1994 and 1995 surveys respectively. These levels were higher 
than responses measured in serum from non-exposed individuals. The prevalence of 
C1q-fixing antibodies was determined by calculating the proportion of individuals 
with responses above the mean plus 3 standard deviation of 12 non-exposed serum 
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samples and were as follows: 59 (76.6%), 64 (83.1%) and 65 (84.4%) at the 1993, 
1994 and 1995 surveys respectively. 
 
Figure 6.4: C1q-fixing antibodies in adults of the Nyamisati cohort. C1q-fixing antibodies in sera samples 
from adults of the Nyamisati cohort collected at the1993, 1994 and 1995 crossectional surveys. Green box and 
whisker plots represent OD values in serum samples from 12 non-exposed serum samples from Swedish adults. 
Blue box and whisker plots represent the median and minimum/maximum OD values in serum samples from 
adults at each cross-sectional survey. 
6.5.2.0. Association between C1q-fixing antibodies by age and parasites status 
 
I compared the levels of C1q-fixing antibodies in adults by age and their parasite 
status determined at the cross-sectional surveys. As shown in Figure 6.5A, C1q-
fixing antibody levels increased with age with the median antibody levels in 15-29 
year olds compared to 30 year olds being 0.5210 versus 0.6515; p-value=0.0113. A 
positive correlation of an Rpearson=0.2989, p-value=0.0001 was observed between 
age and the C1q-fixing antibody levels. Similarly, C1q-fixing antibodies were 
elevated in adults with asymptomatic parasitaemia (parasite positive) compared to 
those who were not, although this was not statistically significant (Figure 6.5B 
respectively). Similar trends were observed when data from each cross-sectional 
survey was analysed independently as shown in Appendix 6.1, Figure 3. 
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Figure 6.5: C1q-fixing antibodies in adults of the Nyamisati cohort by age and parasite status. (A) Median 
anti-C1q fixing antibodies were higher in adults 30 years (white box and whisker plots) and older compared to 
15-29 year olds (black box and whisker plots). (B) Median anti-C1q fixing antibodies were higher in adults with 
asymptomatic parasitaemia (as measured by qPCR of the 18S gene) than in those who were parasite negative 
(black box and whisker plots). Data presented is pooled from the three cross-sectional surveys. 
6.5.2.1. Association between C1q-fixing antibodies and clinical immunity in adults 
 
I compared the levels of C1q-fixing antibody in individuals who did or did not 
experience clinical episodes of malaria in the 1994 and 1995 follow-up periods. 
These were 3 and 9 individuals respectively. The median levels of C1q-fixing 
antibodies were significantly lower in the adults who experienced a clinical episode 
over the 1995 follow-up period. The median antibody levels were 0.608 versus 
0.622; p-value=0.853 and 0.632 versus 0.449; p-value=0.013 in the 1994 and 1995 
follow-up period as shown in Figure 6.6.  
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Figure 6.6: C1-q fixing antibodies in adults who experienced a clinical episode of malaria compared to 
those who did not in the 1994 and 1995 follow-up period. Blue circles represent adults who did not 
experience a clinical episode while red circles represent those who did. 
 
6.5.3. Antibody-dependent respiratory bursts (ADRB) of merozoites by sera from 
adults 
 
I used an optimised protocol to measure ADRB activity in serum sample from a 
cohort of immune adults. Prior to conducting the assays, a new batch of PEMS 
stored at -80°C were serially diluted to optimize the coating concentration for 
subsequent assays using a pool of hyper-immune sera and non-exposed sera as a 
negative control. As shown in Appendix 6.1, Figure 4, I selected a coating 
concentration of 10x105 PEMS/ml per well as this was within the linear range and 
showed differential activity levels between the positive and the negative control 
samples. The relative light units (RLU) were calculated for each sample as has been 
described in section 6.4.4.2.  As expected, the median (min-max) RLU in the adult 
sera samples were higher than non-exposed adults and were 1.092 (0.241-2.364), 
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1.142 (0.165-2.072) and 1.122(0.268-2.031) for samples collected at the 1993, 1994 
and 1995 cross-sectional surveys respectively (Figure 6.7). I used the mean plus 3 
standard deviation RLU calculated from 15 non-exposed sera from Swedish adults 
as a cut-off for seropositivity. The prevalence of antibodies mediating ADRB 
activity was high at 76 (98.7), 74 (96.1) and 76 (98.7) adults at the 1993, 1994 and 
1995 cross-sectional survey respectively.   
 
Figure 6.7: ADRB activity in adults of the Nyamisati cohort. ADRB in sera samples from adults of the 
Nyamisati cohort collected at the1993, 1994 and 1995 crossectional surveys. Red box and whisker plots show 
the RLU values obtained in a pool of hyper immune sera samples from Kenyan adults (positive control), the 
green box and whisker plots represent RLU values in serum samples from 15 non-exposed serum samples from 
Swedish adults. Blue box and whisker plots represent RLU values in serum samples from adults. 
6.5.3.0. Association between ADRB activity by age and parasite status 
 
I did not observe an increase in ADRB activity with age or parasite status as shown 
in Figure 6.8A and B respectively. Median RLU in 15-29 year olds compared to 
over 30 year olds were 1.106 versus 1.135, p-value=0.2761. A weak positive 
correlation of an Rpearson=0.1927, p-value=0.0033 was observed between age and the 
adrb relative light units reported. Similarly, no trend with asymptomatic parasetemia 
was observed. ADRB activity in adults with asymptomatic parasetemia (parasite 
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positive) compared to negative individuals was not significantly different. Similar 
trends were observed when data from each cross-sectional survey was analysed 
independently as shown in Appendix 6.1, Figure 5. 
 
Figure 6.8: ADRB in adults of the Nyamisati cohort by age and parasite status. (A) Median relative light 
units were not significantly different in adults 30 years and older (white box and whisker plots) compared to 15-
29 year olds. (B) Median relative units were not significantly different in adults with asymptomatic parasetemia 
(as measured by qPCR of the 18S gene) than in those who were parasite negative (black box and whisker plots). 
Data presented is pooled from the three cross-sectional surveys. 
6.5.3.1. Association between ADRB and clinical immunity in adults 
 
I compared the ADRB activity in individuals who did or did not experience clinical 
episodes of malaria. No differences were observed in the ADRB levels between 
these individuals. As shown in Figure 6.9, the median relative light units did not 
differ in those who experienced a clinical episode of malaria as follows; median 
RLU were 1.072 versus 1.163; p-value=0.2659 and 1.085 versus 1.137; p-
value=0.178 in the 1994 and 1995 follow up periods respectively. 
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Figure 6.9: ADRB in adults who experienced a clinical episode in the 1994 and 1995 follow-up period.  
 
6.5.4. Stability and breadth of immune effector mechanisms in adults of the 
Nyamisati cohort 
 
The prevalence of the three measured immune effector mechanisms were high in 
this cohort of adults ranging from 77% to 98% in the three cross-sectional surveys. 
As a result, I categorized these individuals as having either high or low levels of 
measured effector functions, if they had an above or below median levels measured 
at each respective survey. I then determined the stability of these levels over the 
three years. The majority of adults had stable ADRB and C1q-fixing antibodies over 
the three years. For instance, as shown in Table 6.1, 66% had stable ADRB levels 
measured, with 34% of them having above median ADRB responses and 32% 
below the median levels in all three cross-sectional surveys. Similarly, 62% of the 
adults had stable C1q-fixing antibody levels with 29% and 34% having above and 
below median levels in all three surveys respectively. 
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Table 6.1: The stability of antibody effector responses in adults in the Nyamisati cohort.  
Classification I Opsonic-
phagocytosis 
N (%) 
C1q-fixing 
antibodies 
N (%) 
ADRB 
levels 
    N (%) 
Classification 
II 
Above median levels in all three 
surveys 
18 (23.4) 22 (28.6) 25 (32.5) Stable high 
responders 
Above median levels in 2/3 surveys 22 (28.6) 20 (26.0) 13 (16.9) 
Above median levels in 1/3 surveys 16 (20.8) 9 (11.7) 13 (16.9) Non-
responders Below median levels in all three 
surveys 
21 (27.3) 26 (33.8) 25 (32.5) 
The proportion of individuals classified as having above or below median levels of immune effector responses 
in each of the three surveys. In brackets is the proportion of adults who fell within the category. 
 
I then compared the parasite densities measured at each of the three cross-sectional 
surveys in individuals with stable responses versus non-responders. As shown in 
Table 6.1, stable high responders were defined as individuals with an antibody 
effector response above the median level in at least two of the three crossectional 
surveys and non-responders were individuals in whom the levels were below 
median levels at all three cross-sectional surveys or had an high-titre response in 
only one of the surveys. As shown in Table 6.2, no significant differences were 
observed in the parasite densities recorded in individuals who had a stable response 
to any of the 3 immune effector mechanisms measured. 
 
Table 6.2: The relationship between the stability of antibody effector responses and parasite densities (as 
determined by microscopy) in adults in the Nyamisati cohort. 
Immune effector functions Median log10 parasite densities (95% confidence intervals) 
Non responders Stable responders P-values 
Opsonic-phagocytosis 1.50(0.99-1.90) 1.50(0.90-2.20) 0.6589 
C1q-fixing antibodies 1.50(0.96-2.35) 1.50(0.90-1.75) 0.3882 
ADRB levels 1.20 (0.90-2.20) 1.51 (0.91-1.98) 0.5190 
Breadth scores 0 3  
 
Lastly, I calculated the breadth of antibody effector responses by adding up the 
number of stable responders or non-responder in each assays. This resulted in 
individuals having one of the four possible breadth scores that ranged from 0-3. A 
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breadth score of 3 indicated that the individuals were categorized as a stable 
responder (Table 6.2) in all three functions. Using this classification, 15(19.5%), 
22(28.6%), 21(27.3%) and 19(24.7%) had a breadth score of 0, 1, 2 and 3 
respectively as shown in Figure 6.10. The breadth score increased with age as 
shown in Figure 6.10A, while individuals who experienced a clinical episode had a 
lower breadth score than immune individuals, although this was not statistically 
significant (median breadth score: 2 versus 1: p-value 0.1866). I also observed a 
strong positive correlation between the breadth of immune effector responses and 
the breadth of antibody responses to individual antigens (Figure 6.10B). 
 
Figure 6.10: The breadth of antibody effector function in adults. The breadth increases with age  (A) and 
with the breadth of antibody responses (B) in adults of the Nyamisati cohort. The breadth score of antibody 
responses to 16 antigens was correlated to the breadth of immune effector mechanisms measured in the same 
adults of the Nyamisati cohort. 
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6.5.5. Correlation between immune effector mechanisms and antibody levels to 
novel antigens 
 
Cumulatively, I measured antibody responses (total IgG) to 16 antigens that 
included 5 previously studied merozoite antigens and 11 novel antigens described in 
Chapter 5 of this thesis. I then determined the correlation between antibody levels to 
these antigens and the three immune effector mechanisms measured in the same 
individuals. As shown in Table 6.3, strong positive Pearson correlations (above 0.5: 
blue squares) were observed between MSP1-19 and MSP-3 with C1q-fixing 
antibodies and MSP-2 with both ADRB and C1q-fixing antibodies. In the panel of 
11 novel antigens, strong positive correlations were consistently observed in the 
three surveys between PfPAT and both ADRB and C1q fixing antibodies. Similarly, 
a strong positive correlation was observed consistently between antibody levels to 
PF3D7_073800.2 and C1q-fixing antibodies. Antibody levels to PF3D7_1252300 
were strongly correlated to C1q-fixing antibody levels in all surveys, while 
PF3D7_1308000 were strongly correlated to ADRB and C1-fixing levels in at least 
one survey. PF3D7_1401600(PHISTb) showed a strong correlation with C1q-fixing 
antibodies. Four antigens did not show a strong positive correlation to any of the 
three immune effector mechanisms measured.
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Table 6.3: Correlation between antigen-specific antibody responses and the levels of ARDB, C1q-fixing and opsonic-phagocytosis mediating antibodies 
 1993 1994 1995 
Antigens 
 
ADRB 
 
C1-q fixing 
antibodies 
Opsonic 
phagocytosis 
ADRB C1-q fixing 
antibodies 
Opsonic 
phagocytosis 
ADRB C1-q fixing 
antibodies 
Opsonic 
phagocytosis 
MSP1-19 0.2301 0.5607 0.2892 0.2402 0.5418 0.1788 0.3027 0.4565 0.2591 
AMA-1 0.3426 0.2293 0.1847 0.4589 0.2587 0.3254 0.2570 0.2403 0.1258 
MSP-2 0.5532 0.6013 0.1298 0.4900 0.5970 0.1220 0.5637 0.5661 0.0862 
MSP-3 (3D7 allele) 0.2149 0.4647 0.2746 0.3657 0.5646 0.0182 0.2767 0.5623 -0.0933 
RH2b 0.0776 0.1432 0.2089 0.2381 0.1564 0.2433 0.2586 0.2870 0.0137 
PF3D7_0206200(PfPAT) 0.6236 0.5966 0.3154 0.5649 0.6655 0.0518 0.5156 0.5506 -0.1367 
PF3D7_0629500 (SEG2) 0.3135 0.4225 0.1584 0.3427 0.4994 -0.0196 0.2338 0.5212 0.0284 
PF3D7_073800.2 0.3624 0.6766 0.2409 0.4590 0.7006 0.1487 0.4669 0.6627 -0.0083 
PF3D7_0823800 0.1812 0.2605 0.0839 0.3385 0.3778 0.0296 0.2633 0.3794 0.0077 
PF3D7_0830500 0.3384 0.3911 0.0539 0.2734 0.3611 -0.0743 0.2719 0.4639 0.0914 
PF3D7_0925900 0.2708 0.3116 0.2136 0.4033 0.4570 0.0969 0.4407 0.2829 -0.1430 
PF3D7_1025300 0.2273 0.4342 0.1632 0.4369 0.4668 0.2141 0.3874 0.4829 0.0492 
PF3D7_1252300 0.3180 0.5384 0.0253 0.3416 0.6322 0.0391 0.4009 0.6431 0.0802 
PF3D7_1308000 0.4188 0.5225 0.2333 0.5416 0.6592 0.0786 0.4528 0.4543 -0.1017 
PF3D7_1345100 0.3138 0.3990 -0.0239 0.3358 0.5152 -0.0185 0.3373 0.5307 -0.0554 
PF3D7_1401600(PHISTb) 0.2763 0.5137 0.0325 0.2789 0.4756 0.1941 0.3364 0.6136 0.0864 
Pearson correlation coefficients between antigen-specific antibody responses (optical density values) and ADRB activity (RLU), C1-fixing antibody levels 
(optical density values) and opsonic-phagocytosis (Relative phagocytosis indices).  Squares highlighted in blue indicate a strong positive correlation coefficients 
> 0.5. 
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6.6. Discussion 
 
Immune effector mechanisms in adults 
The main aim of this study was to describe immune effector mechanisms in a cohort 
of longitudinally monitored adults and test whether they are correlated with 
responses to the novel antigens identified in this thesis. A high prevalence (greater 
than 90%) of antibodies that opsonized merozoites resulting in phagocytosis and 
respiratory burst by neutrophils was observed in adults of the Nyamisati cohort. 
C1q-fixing antibodies were also detected in this population but to a lesser extent 
with a prevalence that ranged from 77-84% in the three surveys. The levels of these 
effector functions varied greatly between individuals and a trend of an increase with 
age and asymptomatic parasitaemia for opsonic-phagocytosis and C1-fixing 
antibody levels was observed. In contrast, age and parasite status did not seem to 
influence ADRB levels in this cohort of adults. These findings are similar to those 
from two cohorts in Senegal (age range in years: 3.4-76.9) in which ADRB levels 
were lower in the individuals with circulating parasites[140] compared to those who 
were parasite free. They differ however, from findings following experimental 
human infections with P. falciparum in malaria-exposed adults in which ADRB 
levels increased significantly following challenge[152]. It is worth noting that 
antibody levels to individual antigens in this cohort also did not vary with age 
(Chapter 5). 
 
Immune effector mechanisms are associated with protection from clinical 
episodes of malaria 
Opsonic-phagocytosis and C1q-fixing antibodies appeared to be associated with 
protection from malaria in adults as individuals who developed clinical episodes had 
significantly lower levels of these antibodies, although the numbers were small and 
strong conclusions cannot be made. Much larger studies will be needed to 
rigorously test these associations. Interestingly, ADRB activity was not associated 
with protection, although the caveat about sample size of symptomatic malaria in 
this study should be clearly noted. This is in contrast to results obtained in 
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prospective cohorts of children in Kenya [531] and Senegal [140] in which ADRB 
activity was associated with protection from malaria. In a second study involving 
Kenyan children, ADRB activity in combination with growth inhibitory activity 
(GIA) was associated with protection from severe malaria [515].  The majority of 
adults (81%) had stable high levels of effector functions (above median) to at least 
one of the three assays resulting in a minimum breadth score of one. The breadth of 
immune response increased with age and individuals who experienced a clinical 
episode had a lower median score than those who were malaria-free, although this 
was not statistically significant. The trend towards a protective effect from malaria 
with increased breadth of effector functions has been observed in studies with 
Kenyan children where a combined GIA and ADRB activity was associated with 
protection from severe malaria [515]. No studies have looked at multiple effector 
functions in the same adults; however, it has been observed that the breadth and 
magnitude of antibody responses is associated with the protection from malaria in 
adults. These have primarily been in studies that evaluated the protection observed 
in adults in the context of; 1) the sterile protection achieved following experimental 
controlled human infection with sporozoites [271, 272, 533, 534], 2) semi-immune 
adults following natural exposure [268, 271, 535] and 3) the genetic resistance 
observed in the adults of the Fulani ethnic group [536]. It is likely that responses to 
multiple antigens resulted in an increased ability to elicit multiple effector functions, 
which is supported by the strong positive correlation (r=0.6) between the breadth of 
antibody and immune effector responses (Figure 6.10B). 
 
Antibodies to novel antigens are strongly correlated with immune effector 
mechanisms 
Identifying the merozoite targets that elicit protective immune effector functions 
would aid in prioritizing antigens for vaccine pre-clinical evaluation and identifying 
the quality of vaccine-induced responses. In line with this, I evaluated the 
correlation between antigen specific levels and immune effector functions in the 
same individuals. A strong positive correlation (greater than 0.5) was observed 
between antibody levels to six novel antigens namely PF3D7_0206200(PfPAT), 
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PF3D7_073800.2, PF3D7_1252300, PF3D7_1308000, PF3D7_1345100 and 
PF3D7_1401600(PHISTb) and C1q-fixing antibodies suggesting a possible 
mechanism by which these antibodies function. Encouragingly, a similar strong 
positive correlation was observed between the well-studied antigens MSP1-19 and 
MSP-2 antibodies and the levels of C1q-fixing antibodies, which fits well with the 
following published observations [138]: 1) rabbit polyclonal sera raised against 
recombinant MSP1-19 and MSP2 (FC27 allele), 2) affinity purified antibodies 
against MSP-1 and -2 from Kenyan adults and 3) antibodies from MSP2-C1 
vaccinee’s [524] all demonstrated C1q-fixing ability [138]. In contrast, no C1q-
fixing ability was observed using rabbit polyclonal sera against AMA1, MSP-3 and 
MSP-4 [138]. Similarly, a weak correlation was observed between antibody levels 
to these antigens and C1q-fixing ability.   
 
ADRB levels were strongly correlated with antibody levels to MSP-2, 
PF3D7_0206200 (PfPAT) and PF3D7_1308000. Little is known about the 
contribution of antigen-specific antibodies to ADRB levels with the exception that 
depletion of MSP1-19 specific antibodies in serum from Senegalese individuals 
showed a slight reduction in ADRB activity [537]. Similarly, a weak positive 
correlation (Rho values of less than 0.5) between anti-MSP5 antibodies and ADRB 
activity was observed in a cohort of Senegalese individuals [538]. Lastly, no 
correlations were observed between antibodies to any of the 21 antigens evaluated 
and opsonic-phagocytosis levels. Although not directly comparable, these findings 
contrast with data in which anti-MSP2 and MSP3 affinity-purified immunoglobulins 
from Kenyan adults showed strong opsonic phagocytosis activity in a dose-
dependent manner [139]. Interestingly, it has been suggested that opsonic-
phagocytosis of merozoites is strain transcending and therefore targeted at 
conserved antigens or domains in merozoite antigens [530]. No differences were 
observed between opsonic-phagocytosis of wild-type parasites and those deficient 
of MSP3, MSP4, DBLMSP1 and MSP1-19 when measured in children, suggesting 
that these were not the dominant targets for opsonic-phagocytosis [530]. 
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Unanswered questions 
Although immune effector mechanisms were detectable in the majority of adults in 
all three surveys, the longevity and stability of these responses in the absence of 
exposure or in the context of decreasing transmission intensity has yet to be 
elucidated. More importantly, the immune effector functions elicited by antibody 
responses to novel antigens identified in this study require to be evaluated 
specifically. Although strong positive correlations suggest mechanisms by which 
these antibodies may function, these findings need confirmation. This would include 
evaluating antigen-specific responses obtained either from animal immunization 
studies or affinity-purified antibodies from humans. These antigen-specific 
antibodies can then be tested against the panel of assays that are available to 
evaluate antibody function. Furthermore, as the novel antigens have limited 
polymorphism in global isolates (Chapter 5), the degree to which these functional 
responses are effective against diverse parasite isolates require evaluation.  Lastly, 
the contribution of the invasion/growth inhibition assay and the antibody-dependent 
cellular inhibition was not evaluated in this cohort due to the limited serum volumes 
available and the difficulty in setting up the ADCI assay. Testing these assays in the 
context of different studies where larger sample volumes are available is a clear 
priority. 
   
Summary 
I provide evidence that opsonic-phagocytosis and recruitment of C1q to merozoites 
is associated with protection from clinical episodes of malaria in adults, although 
conclusions are limited by sample size. Secondly, I show strong positive 
correlations between antigen specific antibody levels and recruitment of soluble 
C1q, particularly for three novel antigens whose antibody levels were associated 
with protection from clinical episodes in malaria. These targets include PfPAT, 
PF3D7_1345100 and PF3D7_1401600(PHISTb). These data provide supportive 
evidence that suggest the mechanisms by which antibodies to novel antigens 
mediate protection.  
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CHAPTER 7  
 
Conclusions and recommendations 
7.0. Summary of findings 
Antibodies are a major component of a host’s natural defence against most 
pathogens including Plasmodium parasites. One major bottleneck to malaria vaccine 
discovery is identifying the specific targets of naturally acquired immunity in the 
>5400 proteins predicted to be encoded by the P. falciparum genome. The 
experiments and analyses presented in this thesis were aimed at addressing the 
above knowledge gap and I summarise the findings below. 
 
First, I identified a set of merozoite proteins that were reactogenic with a pool of 
immunoglobulins from malaria immune adults. Second, I identified another set of 
proteins that may potentially be located on the surface of merozoites and therefore 
accessible to circulating antibodies. The data from these experiments were 
combined with bioinformatic predictions resulting in a list of potential targets of 
protective humoral responses. As predicted, the overwhelming majority of these 
targets had not been evaluated in the context of naturally acquired immunity to 
malaria. Of those that had been previously studied, several interesting features were 
noted: 
i. Known immunogenic antigens. Over a quarter of the proteins I identified 
had been evaluated in previous studies and shown to be targets of naturally 
acquired antibody responses. The identification of these proteins validated 
the overall approach, and added confidence that the unstudied proteins 
within the list were potential targets of protective immunity. 
ii. Roles in erythrocyte invasion. Previous transcriptional studies that evaluated 
the gene expression patterns during the P. falciparum intra-erythrocytic 
developmental stages following exposure to growth-inhibitory compounds, 
identified a set of >400 genes with a potential role in erythrocyte invasion 
[258].  Interestingly, 16.4% of the proteins I identified that had not been 
evaluated in the context of naturally acquired immunity were also identified 
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in this past work to be invasion-related. I subsequently demonstrated that 
antibodies to some of these targets were associated with protective immunity 
in adults, in line with their potential role in erythrocyte invasion. 
iii. Essentiality for asexual growth. A proportion of the targets I identified have 
P. berghei orthologues in which attempts to disrupt the genes were not 
successful [261]. These findings suggest that these targets may have 
essential roles in parasite growth or survival during the asexual stages, 
although essentiality cannot be confirmed without a conditional genetic 
approach. The findings from my analyses indicating that antibody responses 
to some of these essential targets were associated with protection from 
malaria warrant their further evaluation in pre-clinical studies. 
 
Lastly, I used a cohort of longitudinally monitored adults living in a region that 
experiences perennial malaria transmission, to evaluate antibody responses to a set 
of potential vaccine candidates identified by my mass spectrometry and 
bioinformatics approaches. Antibody levels to six antigens appear to be associated 
with protective immunity, as adults who experienced a malaria episode had 
significantly lower levels of antibodies to these antigens. To examine potential 
protective mechanisms, I studied antibody effector functions that have previously 
been associated with protection from clinical episodes of malaria, namely 
interaction with neutrophils and recruitment of soluble complement proteins. These 
two mechanisms were strongly correlated with antibody levels to some of the novel 
vaccine candidates presented in this thesis, providing a potential mechanistic 
explanation for protection. 
 
7.1. Recommendations for future studies 
This work could be extended in the future in two main ways: i) additional pre-
clinical evaluation of the nineteen proteins presented in this thesis as potential 
vaccine candidates (19/22 proteins I obtained were found to be immunogenic and I 
evaluated only 11 antigens in the cohort studies) and ii) evaluating the remainder of 
the long list of identified proteins for their potential as targets of naturally acquired 
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antibody responses (I prioritized 27 of the 159 potential vaccine candidates 
identified using the down-selection criterion described in chapter 4). 
7.1.1. Further pre-clinical evaluation of antigens studied in this thesis 
 
The antigens evaluated in this thesis as targets of protective immunity in adults 
should be evaluated further in the following ways:  
i. Examining antibody responses in other cohorts of adults exposed to P. 
falciparum transmission to confirm the findings from this work. These 
should include measuring the longevity of antibody responses to these 
antigens as well as effector functions using samples obtained either from 
adults living in highly seasonal malaria transmission settings or whom have 
travelled to non-endemic regions. In Kilifi, Kenya this analysis may be 
possible due to a unique “natural experiment” that has occurred over the past 
ten years. Two ethnically and culturally similar cohorts of children and 
adults with historically similar exposure to P. falciparum malaria have 
experienced a marked difference in their levels of exposure to malaria over 
the last 9 years [539, 540]. Analysing antibody responses in these 
individuals may provide insight into their dynamics particularly in the 
absence of exposure. In addition, experimental human malaria challenge 
facilities have been set up in Kilifi, Kenya, which will now facilitate the 
evaluation of both antibody responses and effector functions in adults, and 
correlate these with parasite growth rates and the development of clinical 
symptoms following experimental challenge with sporozoites. Similar 
studies should be conducted in individuals from varying geographical 
regions including West Africa and South-East Asia where P. falciparum 
transmission also occurs. 
ii. These targets should also be evaluated by measuring antibody responses in 
children from regions with varying transmission intensities to identify 
targets consistently associated with protection from severe, uncomplicated 
malaria and high parasite densities. 
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iii. The antigen specific antibody effector functions elicited by the targets 
presented in these studies should also be evaluated further. The degree to 
which these responses are effective against a diverse set of parasite isolates 
will be crucial in selecting which of these targets should be prioritized for 
vaccine development. 
iv. Further analysis within individual antigens could be conducted to identify 
the epitopes that are important for protection. Short linear epitopes can be 
readily obtained as synthetic peptides and WHO has published guidelines for 
the production and quality control of synthetic peptides for use as vaccine 
constructs [541].  
v. Analyses to identify the role of polymorphisms within the newly 
characterised antigens and assess their potential effect on protective 
immunity should be conducted. 
vi. Animal models of Plasmodium infection also offer an approach to evaluate 
the immunogenicity and protective efficacy of potential vaccine candidates 
prior to clinical studies in humans[542]. This may include evaluation in 
either rodent malaria infections (P. berghei or P. yoelii) or using the recently 
developed humanised P. falciparum mouse models. In rodent malaria 
infection, vaccine efficacy can be evaluated by vaccinating mice with 
recombinant protein (the P. berghei/P. yoelii orthologue of the P. falciparum 
target), followed by P. berghei/P. yoelii parasite challenge and monitoring 
disease progression [543]. Alternatively, where applicable, mice may be 
vaccinated with the P. falciparum antigen and challenged with a chimeric 
rodent malaria parasite that expresses the P. falciparum protein [544, 545]. 
In a second approach, humanised mouse models continue to be developed 
that support P. falciparum blood stage growth and development [546-548]. 
While vaccination may not yet be possible in these immunosuppressed mice, 
the role of antibodies generated against a vaccine candidate can be evaluated 
using passive transfer studies of immunoglobulins followed by challenge 
with P. falciparum in these mice [549, 550]. Obtaining sufficient 
recombinant protein may occasionally represent an obstacle to the above 
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approaches. As an alternative, immunization of mice with expression 
libraries may represent a simple vaccination tool to quickly evaluate the 
protective efficacy of each of the identified targets [551].  Briefly, selected 
exons or open reading frames from parasite genomes e.g P. berghei 
orthologue of P. falciparum targets are cloned into eukaryotic expression 
vectors and directly used as DNA vaccines. Direct immunisation with DNA 
can generate both cellular and humoral responses and their protective 
efficacy can be evaluated by challenging immunised mice with the pathogen, 
in this case P. berghei [552]. 
vii. Approaches have been developed to analyse the roles of genes across the P. 
falciparum life cycle. These include conditional approaches that can regulate 
the expression of a gene at the genomic, transcription or protein level 
providing information on the functions of these genes. These approaches 
could be applied to the antigens identified in this thesis to elucidate the roles 
of these antigens in erythrocyte invasion and/or parasite growth over the 
asexual stages of the life cycle. Several approaches are currently in use in P. 
falciparum to elucidate phenotype following regulation of expression of a 
gene that include: a) gene deletion by double crossover homologous 
recombination [553], b) gene editing using the CRISPR/Cas9 (Clustered 
Regularly Interspaced Short Palindromic Repeats/CRISPR-associated 
protein-9 nuclease), c) gene editing using zinc-finger nucleases, d) 
conditional control of a gene using the dimerizable Cre recombinase (DiCre) 
system [554, 555] and d) use of the destabilisation domains (DD) to degrade 
target proteins after protein expression. These options should be evaluated 
and employed to elucidate the potential roles of the genes identified in this 
thesis. 
 
7.1.2. Evaluation of proteins identified but not analysed further. 
 
Due to the time constraints of my PhD, I selected 27 antigens for evaluation in the 
context of naturally acquired immunity. A total of 159 targets had been identified 
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using the selection criterion described in Chapter 4, leaving a set of 132 proteins 
that have not been evaluated for their role in protective immunity. Of these 132 
targets, 92% are predicted to have an N-terminal signal peptide or at least one 
transmembrane domain indicating that they may potentially be secreted or located 
on the surface of merozoites and therefore accessible to antibodies. In addition, 12% 
of these targets are proposed to be invasion-related genes warranting their further 
evaluation as targets of protective antibodies. Lastly, 41% of these targets have P. 
berghei orthologues whose genetic disruption has been achieved and a phenotype 
following disruption deposited on the PlasmoGEM website [336]. Interestingly, 33 
targets are classified as being essential for asexual growth while disruption of 9 
targets resulted in a reduced growth rate over the blood stages. The P. falciparum 
orthologues of these targets represent attractive candidates for pre-clinical 
evaluation as targets of protective immunity. Below, I highlight experiments that 
may allow high-throughput screening of these targets: 
i. A Plasmodium falciparum expression library can be generated for these 
specific targets and used to screen for reactivity with carefully selected 
serum samples from individuals resistant to malaria infection and disease. 
ii. Alternatively, as highlighted above, expression library immunization may 
offer a rapid approach to testing the potential protective efficacy of these 
targets using animal models. These could be initially tested in pools 
consisting of 10-20 DNA vaccines and down-selected in a systematic 
manner. 
 
Thereafter, targets with a positive phenotype can be evaluated further using the pre-
clinical evaluation studies proposed in section 7.1.1. 
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APPENDICES 
Appendix 2.1. Immunogenic P. falciparum antigens identified by 2DE using 
3D7 lab isolate 
 
https://www.dropbox.com/s/kfkme00hskte2m9/Appendix%202.1.xlsx?dl=0 
 
Appendix 2.2. Immunogenic P. falciparum antigens identified by 2DE using 
KIL9605 clinical isolate 
 
https://www.dropbox.com/s/vsgpeui32lc69x9/Appendix%202.2.xlsx?dl=0 
 
Appendix 2.3. List of targets identified in 2D-immunoblots with phenotypic 
data available on PlasmoGEM 
 
https://www.dropbox.com/s/gckhfsu84yzdfbp/Appendix%202.3.xlsx?dl=0 
 
Appendix 3.1. List of P. falciparum antigens identified in the 1st biological 
replicate of the surface shaving experiment. 
 
https://www.dropbox.com/s/ro0cykoyh3bw9qo/Appendix%203.1.xlsx?dl=0 
 
Appendix 3.2. List of P. falciparum antigens identified in the 2nd biological 
replicate of the surface shaving experiment. 
 
https://www.dropbox.com/s/zaz48063ofxkhjs/Appendix%203.2.xlsx?dl=0 
 
Appendix 3.3. List of P. falciparum antigens classified as putative surface 
proteins 
 
https://www.dropbox.com/s/d70nbcl136gzbms/Appendix%203.3.xlsx?dl=0 
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Appendix 3.4. List of targets identified in surface shaving experiments with 
phenotype available on PlasmoGEM 
 
https://www.dropbox.com/s/g7ktqe1raor2ydu/Appendix%203.4.xlsx?dl=0 
 
Appendix 3.5. List of P. falciparum putative merozoite surface proteins whose 
role in NAI, merozoite invasion or essentiality is unknown 
 
https://www.dropbox.com/s/ohdulwpxj986jqc/Appendix%203.5.xlsx?dl=0 
 
Appendix 4.1. Subset of targets used to select novel antigens for 
immunoprofiling (N=222) 
 
https://www.dropbox.com/s/irawmfvegcbf2va/Appendix%204.1.xlsx?dl=0 
 
Appendix 4.2.  The protein sequences for the 27 antigens selected for 
immunoprofiling. 
 
Glossary 
 
Red= predicted N-terminal signal peptide and transmembrane domains or start 
methionine residue 
Yellow- predicted N-glycosylation sites 
Green= internal helices 
 
1. 
>PF3D7_1105800 
MNWKKALSLAGGAAAVVALTYMLMKDEDNHDDNDDENDKKKKKDNKLSKDSNRIIKGDSMTREDLLQLLNEML
KLQSDMKNIVKDLIVVAKNNNYDFMAVYNVAKTYNTIDPLGKYQIEMPEFDKVVESYHFDPEVKETVSKLMSSQEN
YYSNMSETTLSVDKIIEIHHFMLNELYKIDPEFKKIPNKNELDPKLIALVIQSIVSAKVEEEFNLTSEDVEASIANQQYAL
TSNMEFARV NIQMQTIMNKFMGDHFKFMCDKEGAY 
 
>>PF3D7_1105800 sent to GeneartAG 
DEDNHDDNDDENDKKKKKDNKLSKDSNRIIKGDSMTREDLLQLLNEMLKLQSDMKNIVKDLIVVAKNNNYDFMA
VYNVAKTYNTIDPLGKYQIEMPEFDKVVESYHFDPEVKETVSKLMSSQENYYSNMAETATLSVDKIIEIHHFMLNEL
YKIDPEFKKIPNKNELDPKLIALVIQSIVSAKVEEEFNLASEDVEASIANQQYALTSNMEFARV 
NIQMQTIMNKFMGDHFKFMCDKEGAY 
 
2. 
>PF3D7_0722200_RALP1 
MNFFFFFIIVYCFISSFYLIKSSSNDKNKINKNNMPLQRGASNLKDINIHNVEKKSNMESVNNNINNTTCSKNLNANKV
PNVAHTGVNKKGETKNEEVEKEENENEEIEKEEIENEENQQNEEDENEENQQNEEDENEENQQMNVNVDVSAEKKN
KELPEEKKELQKNSEKNINKEVIKDSNKDNTFNFHKNINTSFNKNKNIYNNNNNNNNNNKTFIEKKEEAIDMKKTHC
SNNNKMCKYNNMNNHMSTNKNNNQIFEESKQNVNKPIYNLKSLGNNTFKNDEKYNENDYKNNHDDDKKKYTDDS
NEENIYEERNQKILLIHLLKNIKELLNRQRQNFNNFLSFLSENYQSYEKFYKSQKYQNGKNYIDKLDQQGELKNVSVV
THSFLDMSKAANGKKDKNGVFVKLMNDQNDDGDDTK 
DGDDTKDEDDHKNEDDHKNEDDHKNEDDHKNEDDHKNGDDNKNGDDHKNGDDNKNGDDDN 
GKKSHDISDIKNIIDTILQSDDITDEQKKYLEIIKKILDLEEDVLNKEKEQLQLNKNIIEVLMGKSDELRNIAVNLKNGN
GDNESSQRVDLAQNIVSNLLNFSVQLKNTGNIVYNNIQGQGELLQSIEKNIDKAENDLKKSTSVNTTFTPKNVPNTEQ
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NDQETQTDDDINDSDIDENNNTNDKNNCHMYKKNNCHMYKKNNCKKYFLNSHYNNYLCKKQKKYNKNDMGNK
QKDNKKFKLNESMKNHFYNIFVKETVMLKKLYKVLFELF 
 
>PF3D7_0722200_RALP1 sent to GeneartAG 
SSNDKNKINKNNMPLQRGASNLKDINIHNVEKKSNMESVNNNINNTACSKNLNANKVPNVAHTGVNKKGETKNEE
VEKEENENEEIEKEEIENEENQQNEEDENEENQQNEEDENEENQQMNVNVDVSAEKKNKELPEEKKELQKNSEKNIN
KEVIKDSNKDNTFNFHKNINTSFNKNKNIYNNNNNNNNNNKAFIEKKEEAIDMKKTHCSNNNKMCKYNNMNNHMS
TNKNNNQIFEESKQNVNKPIYNLKSLGNNTFKNDEKYNENDYKNNHDDDKKKYTDDNEENIYEERNQKILLIHLLK
NIKELLNRQRQNFNNFLSFLSENYQSYEKFYKSQKYQNGKNYIDKLDQQGELKNVAVVTHSFLDMSKAANGKKDK
NGVFVKLMNDQNDDGDDTKDGDDTKDEDDHKNEDDHKNEDDHKNEDDHKNEDDHKNGDDNKNGDDHKNGDD
NKNGDDDNGKKSHDISDIKNIIDTILQSDDITDEQKKYLEIIKKILDLEEDVLNKEKEQLQLNKNIIEVLMGKSDELRNI
AVNLKNGNGDNEASQRVDLAQNIVSNLLNFAVQLKNTGNIVYNNIQGQGELLQSIEKNIDKAENDLKKSTSVNTTFT
PKNVPNTEQNDQETQTDDDINDSDIDENNNTNDKNNCHMYKKNNCHMYKKNNCKKYFLNSHYNNYLCKKQKKY
NKNDMGNKQKDNKKFKLNESMKNHFYNIFVKETVMLKKLYKVLFELF 
 
3. 
>PF3D7_1014100 
MNRIFYFCLFTILFWLSLVSGENVNNKNCNEKNRKAILLALLKNSLVDNKDYNNSEELKYALEHIQNSELYPKDSKKF
DKFIDEFFSYYNIHVNFTDEEKRILHISGVFKEFYVDVDNLNKDEMKEYFKKNYEKGLSLINLIVHSNLIIQQFDHDIID
KKKVHEQNTNTNKTLEYISDNLNDLINFKNIHLNNNSTGDFIIKLYTNYVNYINPYQTNPLPNTPHYYEHKNFHTKEH
YIYDEEIVNPNMDNINTHTEEDNVYVSATKGNQKEETEKKENHENNNAINPKYMNYETYYKKIFNAIFEQIDKLNKT
LFEIKNKNNSETNENISESNSGNPELNNENSYSVKLSSSSPNSTNKESLIFPYTYYNPYYMFRLTNNFKENDEGLKNEN
NINNNEDNQNDNMNIVLGKIHNILKDFNINENIMTNKMSAPLIMTIILNFFKKYMAENKFNLPMSSEVENKINKSNNK
ALLQQSNKDTPIHKKKEIRNKKIQTKVDVIDEKTKKKIANTIYVNVGQSGINGFFNFFDFREKSIDSNIFDLLHVMEDM
KIFDIFQTIIFIQKFTENVCASYCMNITDVLELSHYDMIFYDKMVFHFSKDGMMIKTDKKYLYNLKEFENILNLLNINA
NTIALNCTCKFYVDVNYTYSEQYKMHLKGYLHKMNEFDYINNFSASYLLNQLIIFQDKFNYIKMNGKLPIDDPKNIY
NMNNVHDTAYYHNSRYFPTKDMPSLEDNFYEHLKYPDINTIHIYYNASPVKLNEVNDLKTIIIDEIKSKIFYINSYRVG
DQFFPTYSNLGKDDHDLEHSAKNFYNISNENGDNTFNNNNNNMDNKKRMYNYNKHKDNDSRYTDNSNKNRDNSN
KNRDNYNRNKDKNNTNRDNYNRYKDNNYYYNNSDNNNYNERKRYIRKKTYNKLSYFNLPSLKSIYNNKIKGNSEE
FSFDNELPEQTESFPLNKPQDHEAFYNLKKHHTNVYEPNDEEKQNEQKLKDQIKITSDILYKDIEENKNTEDVLLIETIT
INNGTTSNTIENNKDSNKEAENSNTEQNDNNNNDNNNNINNNNNNNDNKEEDMNENNNNSKVTGDSVENINEQTN
NNQYPNTEYNTIQRSINAKYLIFFFKNLHVWKTDLFCQNINYMNNYLNSIQYNKTLTFDINYDTNAVTIYFTDNITYT
VKVNLEYLVFLLEKISLITFVEDLCSLFDTDKKRNYKNLTEFLENTERINTFVRNHMMLSNEQFINKNKYAKELAEIST
SNLFYPKKDIILRSTPYNNIILDEKDIYQTIFIYMDDMLTEKMVNDTWITPYAFVVYSKSKKDMQGNNIKIEQNKNITK
YSRSAIDKYVHYEYKRISENLNRFFMESNSNAPQFNENYKEYTIIIYNDNPSMPNIVLTTTINVFNVSFLQSIMEMLLNI
KANQQFFSYKGKFIPINAFITLENKINYIFFNYIPL ENYVNNGDALDFRNP 
 
>PF3D7_1014100 sent to GeneartAG 
ENVNNKNCNEKNRKAILLALLKNSLVDNKDYNNAEELKYALEHIQNSELYPKDSKKFDKFIDEFFSYYNIHVNFADE
EKRILHISGVFKEFYVDVDNLNKDEMKEYFKKNYEKGLSLINLIVHSNLIIQQFDHDIIDKKKVHEQNTNTNKALEYIS
DNLNDLINFKNIHLNNNSAGDFIIKLYTNYVNYINPYQTNPLPNTPHYYEHKNFHTEHYIYDEEIVNPNMDNINTHTEE
DNVYVSATKGNQKEETEKKENHENNNAINPKYMNYETYYKKIFNAIFEQIDKLNKALFEIKNKNNAETNENIAESNS
GNPELNNENSYSVKLSSSSPNSTNKESLIFPYTYYNPYYMFRLTNNFKENDEGLKNENNINNNEDNQNDNMNIVLGKI
HNILKDFNINENIMTNKMSAPLIMTIILNFFKKYMAENKFNLPMSSEVENKINKANNKALLQQSNKDTPIHKKKEIRN
KKIQTKVDVIDEKTKKKIANTIYVNVGQSGINGFFNFFDFREKSIDSNIFDLLHVMEDMKIFDIFQTIIFIQKFTENVCAS
YCMNIADVLELSHYDMIFYDKMVFHFSKDGMMIKTDKKYLYNLKEFENILNLLNINANTIALNCACKFYVDVNYAY
SEQYKMHLKGYLHKMNEFDYINNFSASYLLNQLIIFQDKFNYIKMNGKLPIDDPKNIYNMNNVHDTAYYHNSRYFPT
KDMPSLEDNFYEHLKYPDINTIHIYYNASPVKLNEVNDLKTIIIDEIKSKIFYINSYRVGDQFFPTYSNLGKDDHDLEHS
AKNFYNIANENGDNTFNNNNNNMDNKKRMYNYNKHKDNDSRYTDNSNKNRDNSNKNRDNYNRNKDKNNTNRD
NYNRYKDNNYYYNNSDNNNYNERKRYIRKKTYNKLSYFNLPSLKSIYNNKIKGNSEEFSFDNELPEQTESFPLNKPQ
DHEAFYNLKKHHTNVYEPNDEEKQNEQKLKDQIKITSDILYKDIEENKNTEDVLLIETITINNGTTSNTIENNKDSNKE
AENSNTEQNDNNNNDNNNNINNNNNNNDNKEEDMNENNNNAKVTGDSVENINEQTNNNQYPNTEYNTIQRSINAK
YLIFFFKNLHVWKTDLFCQNINYMNNYLNSIQYNKALTFDINYDTNAVTIYFTDNIAYTVKVNLEYLVFLLEKISLITF
VEDLCSLFDTDKKRNYKNLAEFLENTERINTFVRNHMMLSNEQFINKNKYAKELAEISTSNLFYPKKDIILRSTPYNNI
ILDEKDIYQTIFIYMDDMLTEKMVNDAWITPYAFVVYSKSKKDMQGNNIKIEQNKNIAKYSRSAIDKYVHYEYKRISE
NLNRFFMESNSNAPQFNENYKEYTIIIYNDNPSMPNIVLTTTINVFNVSFLQSIMEMLLNIKANQQFFSYKGKFIPINAFI
TLENKINYIFFNYIPLENYVNNGDALDFRNP 
 
4. 
>PF3D7_1455300 
MDKCRNSSRKYKLSAGDSTFGKPTVRGSVTNDNLSDDGEIEFEGWVEFVTKNGNDDTNLSQEKKKRHGRNRNHTV
SLCNIAKDDIVFNKSRKRDKQSRRDSKKGNEMNTDYMYSNNNNNIYANYVFKQPNEISNGSILYTLRNNNNNNNYN
NNNNVVTPLYINNQTKTNDNLINILSPNYVDPAPPIVLKNQQVLPQLYIRQPPTVIVTNEPRPPLVINPPPANIIFKNKSP
QPIYVNSTRPNIIIKNDPPVVQNPINMDTTPVQLDMPTENITINKETINYPYVMNIKKDSFLDNRNVYLKGSVSSTNASV
SPTNVIYVESNNNNNNMNDINQQNIPNFYMMNNNQTPHLHQTTNAYATIPPINNHQIQTQPTNTVQYIQPNYEQVITQ
VDQNRNLFNQQLVGSTVMQNMTPQGVNTLNYPATINTVCVPQTISNTNNTTSQQVQYIPQTQAYAPYNNVQNTTIY
ERNYVPQIAQNTMTNNVVQQYVPSTTTMVQENVQNTPSSQYRILVPNNDNIQSPNIIRHYNNISNTKNNVNKAIVQPT
YNSSEILPSCSPSGCASRNKVTHVQNVRRNSYINPHSHSMHECPKKVQIIARPMHDQNLRTYSLCR 
 
>PF3D7_1455300 send to GeneartAG 
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DKCRNSARKYKLSAGDSTFGKPTVRGSVTNDNLADDGEIEFEGWVEFVTKNGNDDTNLAQEKKKRHGRNRNHAVS
LCNIAKDDIVFNKARKRDKQSRRDSKKGNEMNTDYMYSNNNNNIYANYVFKQPNEISNGAILYTLRNNNNNNNYN
NNNNVVTPLYINNQAKTNDNLINILSPNYVDPAPPIVLKNQQVLPQLYIRQPPTVIVTNEPRPPLVINPPPANIIFKNKSP
QPIYVNSARPNIIIKNDPPVVQNPINMDTTPVQLDMPTENIAINKETINYPYVMNIKKDSFLDNRNVYLKGSVSSTNAS
VSPTNVIYVESNNNNNNMNDINQQNIPNFYMMNNNQTPHLHQTTNAYATIPPINNHQIQTQPTNTVQYIQPNYEQVIT
QVDQNRNLFNQQLVGSTVMQNMTPQGVNTLNYPATINTVCVPQTISNTNNTTSQQVQYIPQTQAYAPYNNVQNTAI
YERNYVPQIAQNTMTNNVVQQYVPSTTTMVQENVQNTPSSQYRILVPNNDNIQSPNIIRHYNNIANTKNNVNKAIVQ
PTYNSAEILPSCSPSGCASRNKVTHVQNVRRNSYINPHSHSMHECPKKVQIIARPMHDQNLRTYSLCR 
 
5. 
>PF3D7_1460600_ISP3 
MGNLCCSNNDIKNSKSNIDIFQDNEIYGDNENWTLENWINKYKSGNSIKVAFPDGNEIQCNFRIFFKEKYFELSLDNK
VRVIKFNDINCILHRNSCETLLESEQNLLKSPKVIGIRLIST LKAIAFSMDSPGEARIFNDFLQKYCLNA 
 
>PF3D7_1460600_ISP3 sent to GeneartAG 
GNLCCSNNDIKNSKSNIDIFQDNEIYGDNENWALENWINKYKSGNSIKVAFPDGNEIQCNFRIFFKEKYFELSLDNKVR
VIKFNDINCILHRNSCETLLESEQNLLKSPKVIGIRLIST LKAIAFSMDSPGEARIFNDFLQKYCLNA 
 
6. 
>PF3D7_1468100 
MSKINGTNIDEMNHIENQLNSSNNQLNDDNYNASKNFSLSNYNLDLIKCLQDDSGIYFILDPSKAINEKKQSDVYDIFV
PEDTEGVTLHVQKMNDEYKCIGVSITKKGIDINSGTRIFNSKISDWLEQLFVFNKNLINNGLQMNEKMKKIPNNTSVL
NTNNVNSGASFMNGDINGNINIPINAINYKNDKFINKGSNINIINEGSNLTHSKNTNYNNMKRASGTSNLQDTTTTNLI
KNKYNNLEYFENKEKNNLMLPNNNNNNINNMSNMNGHINNSHLSNKKGNKNNNQHNCNINHNINNNNNNNNNFV
GNHNLPSSQMQKQNRLNLVNNNNNNKNAHSNKSNTMNFKNMNFDEKNSKLFNNISASSLLMNKNILSNVNALAAQ
ISLGASSEFMKNNKLGVGHTNNNSQKNNTYNLHNHLQNELFNLPNHLQNNLMFNNNNNKSQLHQLQNSQNQNNV
HQHIQNQNASNQQINQSYNDNFTYRPTLFNLLEVLANHNITTPDQRVCIRGIVTDFLNNELPHGKIYAYIGAVVGHDIL
HDIIKKLEKDPNRNVVPDASGLARIEAAFGLSKSSYDFINNNSQNSTVGNLSNVLFNNRNLNSALLNNQFYSNILSNV
ANNALNANNLLNNNERVSLDNDKILSSKAAADISNLLKYAKNEKMSMSANNNVMNFNRKKGANFNNLLNLRNDPP
NNNNNNNNNNNNNMNTFNNNNMNTFNNNNNNNSNNNHINNNINNFNNNSRNTIPHDLISAATRNFNIQCQHKNSFS
DEEEELMKVIKKNIESYKMNNIKNILISSVFGRIKWLKIMNESPHAYLYGHSIVKFGNKLYMFGGSNGKNKKIPFTHTL
TFSLIYYNYKLLPLSGNCPEEREGHTTHLVSLHNGLSVFLFGGSNENIYYNDIYLLDMETRKWTRRSVKGKIPLPRDQ
HSSLVYPAKCEHVRGEKPNLTEGVIIFGGKCLYNNSIVSLNDMWIFSFDSILWIRINYLCDDIPMGRFGMNLVWSDTN
TICLFGGEYCEISKTHKERTLLDDMWIFKVHNNVHISANSNDGTSYNNGMDKTQNDKNHTHNNNNNNNNNSSEKN
HNMHSNDKEYADNVKDKYNNNKKFTMVGEWYRENYEGDIGCRSNYSSVFITQRHQDFKGAEPKTIERLMILCSGIT
YVYKDNKQKIVSTDEVFVYFFSQKKWYLLKGKLCNDEYLYNGRQRHVGCFFESKNVLGRANRNPVPCVFIQGGFK
KNSVFGDAWLLSLTGENPLRIQEYDTSRERISTTQMPLYYFRDTHSISLLYSFCTLQKWLFGAFANLVDNCVHAHNPA
ENVFIKYELTPEHDGMLSIQDDGEGLDFNAMNRVLRMYGNYKYQDNSSVVLYNSGTNIKKHALPNNDFINNKGDD
YNDYQYENEYSNKRNTSSKNVLLDDASSALLPHKKKQKNTTDNDDKNNNNNNENDSNNEEKDNITGDHNKNGED
ENKVGSHNAYDNDQNNGYVSDDYYTKNYDQELFYNENVNNIFDVKYGVGFKMSFARISSSCAIMSRTFNTIGIGLLS
LELMNHCEAKELATPLCMWKLPNKELINRNIANKSEHRHHQKLLMSYTPFNSPSLLAEQINILGTYSGTRLLYWDFR
DDMDFIIFSPLNNNIYLSSSPLSVDEIKYNKKKKNNNKNNKNMLNDDNNNKQVSCVEDVKLNNRADIKRKGNFDEE
NVKKVKVQHDESCANVYAKNDEENEDSQLVTNEGSDKDASTKDENMKKEHPNEKDDDNNNNNNNNNENGDDNN
KSYNDQIFKENEQYQYYNSTIKKLNLFEYNSHLNTSISKDKYKASQIFPLWDHPKDSIDYCLSTYLYWLYLRRNTNIF
LQNTLLIPTCMRKNDNDVNSEKKKKKKKKKKGKKLNAKKKNLQEESNTTEQTSSLSKDSNSNKDSEENVNLNQYN
DEERNSKRRNNDDESNESSSTSNRDKSDADNMNNDVIKNDNKKIGKEEMHKIKFEEALEYGISQESSRKNSMKYKEE
DDEEEEEDDDDEEDDDDDDEEDEEEEGEDEEDEDEEKEDQEKEEDQENQNENQDENQDENQDENQDENQDENQDE
NQDENRDENQDESQNENQNENQDDNENEEKPNEGSNENEEKPNDGSIENNEEADKEAKDSDENNNSSSNNNGEENI
ENTNECKQKKKKQEDNEVQEVHEIRTRTRVKNEKNLSKKKKNVDSSTDSKNNDSEKTRQGSYVNTYMDGLKIKDE
YYINNTSKYTLYNFLRKKLHKMVEFHYLFTPSDYEYGSFIMMGFLNDNNSPSIEVNRVCETGILLYYKNRLIKRLDAP
FIDTAYNLALAKYPPNPSLYEGNLYKYALTVIVNVPYWLKPSISKQEFIHENNYAFLVFKKKLIGLIKHYLFICQDNVK
LRKWRESRDLKLKRYLDKSSFSFDKSKNESDNDDENDYKITNQEKENAQSEKEGKGKNAQSPNNDNDQNEVVGAN
EREDDSTNRNYNNGKSSNEEENEGTPADNEDENDDSNNSNNSNQEQKEKILENDEEEATDDNEEKNEEEKNDDN 
EEEEEYENNDNEKYNKNNSDDVNEDNKSLEDAEEEDTI 
 
>PF3D7_1468100 sent to GeneartAG 
SKINGANIDEMNHIENQLNSANNQLNDDNYNAAKNFSLSNYNLDLIKCLQDDSGIYFILDPSKAINEKKQSDVYDIFV
PEDTEGVTLHVQKMNDEYKCIGVSITKKGIDINSGTRIFNSKISDWLEQLFVFNKNLINNGLQMNEKMKKIPNNAAVL
NTNNVNSGASFMNGDINGNINIPINAINYKNDKFINKGSNINIINEGSNLAHSKNTNYNNMKRASGTSNLQDTTTTNLI
KNKYNNLEYFENKEKNNLMLPNNNNNNINNMSNMNGHINNSHLSNKKGNKNNNQHNCNINHNINNNNNNNNNFV
GNHNLPSSQMQKQNRLNLVNNNNNNKNAHSNKANTMNFKNMNFDEKNSKLFNNIAASSLLMNKNILSNVNALAA
QISLGASSEFMKNNKLGVGHTNNNSQKNNTYNLHNHLQNELFNLPNHLQNNLMFNNNNNKAQLHQLQNSQNQNN
VHQHIQNQNAANQQINQSYNDNFAYRPTLFNLLEVLANHNIATPDQRVCIRGIVTDFLNNELPHGKIYAYIGAVVGH
DILHDIIKKLEKDPNRNVVPDASGLARIEAAFGLSKSSYDFINNNSQNSTVGNLANVLFNNRNLNSALLNNQFYSNILS
NVANNALNANNLLNNNERVSLDNDKILSSKAAADISNLLKYAKNEKMSMSANNNVMNFNRKKGANFNNLLNLRN
DPPNNNNNNNNNNNNNMNTFNNNNMNTFNNNNNNNSNNNHINNNINNFNNNSRNTIPHDLISAATRNFNIQCQHK
NSFSDEEEELMKVIKKNIESYKMNNIKNILISSVFGRIKWLKIMNESPHAYLYGHSIVKFGNKLYMFGGSNGKNKKIPF
THTLTFSLIYYNYKLLPLSGNCPEEREGHTTHLVSLHNGLSVFLFGGSNENIYYNDIYLLDMETRKWTRRSVKGKIPLP
RDQHSSLVYPAKCEHVRGEKPNLAEGVIIFGGKCLYNNSIVSLNDMWIFSFDSILWIRINYLCDDIPMGRFGMNLVWS
DTNTICLFGGEYCEISKTHKERTLLDDMWIFKVHNNVHISANSNDGTSYNNGMDKTQNDKNHTHNNNNNNNNNSSE
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KNHNMHSNDKEYADNVKDKYNNNKKFTMVGEWYRENYEGDIGCRSNYASVFITQRHQDFKGAEPKTIERLMILCS
GITYVYKDNKQKIVSTDEVFVYFFSQKKWYLLKGKLCNDEYLYNGRQRHVGCFFESKNVLGRANRNPVPCVFIQGG
FKKNSVFGDAWLLSLTGENPLRIQEYDTSRERISTTQMPLYYFRDTHSISLLYSFCTLQKWLFGAFANLVDNCVHAHN
PAENVFIKYELTPEHDGMLSIQDDGEGLDFNAMNRVLRMYGNYKYQDNSSVVLYNSGTNIKKHALPNNDFINNKGD
DYNDYQYENEYSNKRNTSSKNVLLDDASSALLPHKKKQKNTADNDDKNNNNNNENDSNNEEKDNIAGDHNKNGE
DENKVGSHNAYDNDQNNGYVSDDYYTKNYDQELFYNENVNNIFDVKYGVGFKMSFARISSSCAIMSRTFNTIGIGLL
SLELMNHCEAKELATPLCMWKLPNKELINRNIANKSEHRHHQKLLMSYTPFNSPSLLAEQINILGTYSGTRLLYWDFR
DDMDFIIFSPLNNNIYLSSSPLSVDEIKYNKKKKNNNKNNKNMLNDDNNNKQVSCVEDVKLNNRADIKRKGNFDEE
NVKKVKVQHDESCANVYAKNDEENEDSQLVTNEGSDKDASTKDENMKKEHPNEKDDDNNNNNNNNNENGDDNN
KSYNDQIFKENEQYQYYNSAIKKLNLFEYNSHLNTSISKDKYKASQIFPLWDHPKDSIDYCLSTYLYWLYLRRNTNIF
LQNTLLIPTCMRKNDNDVNSEKKKKKKKKKKGKKLNAKKKNLQEESNTAEQTSSLSKDSNSNKDSEENVNLNQYN
DEERNSKRRNNDDESNESSSTSNRDKSDADNMNNDVIKNDNKKIGKEEMHKIKFEEALEYGISQESSRKNSMKYKEE
DDEEEEEDDDDEEDDDDDDEEDEEEEGEDEEDEDEEKEDQEKEEDQENQNENQDENQDENQDENQDENQDENQDE
NQDENRDENQDESQNENQNENQDDNENEEKPNEGSNENEEKPNDGSIENNEEADKEAKDSDENNNSSSNNNGEENI
ENTNECKQKKKKQEDNEVQEVHEIRTRTRVKNEKNLSKKKKNVDSSTDSKNNDSEKTRQGSYVNTYMDGLKIKDE
YYINNTSKYTLYNFLRKKLHKMVEFHYLFTPSDYEYGSFIMMGFLNDNNSPSIEVNRVCETGILLYYKNRLIKRLDAP
FIDTAYNLALAKYPPNPSLYEGNLYKYALTVIVNVPYWLKPSISKQEFIHENNYAFLVFKKKLIGLIKHYLFICQDNVK
LRKWRESRDLKLKRYLDKSSFSFDKSKNESDNDDENDYKITNQEKENAQSEKEGKGKNAQSPNNDNDQNEVVGAN
EREDDSTNRNYNNGKSSNEEENEGTPADNEDENDDSNNSNNSNQEQKEKILENDEEEATDDNEEKNEEEKNDDN 
EEEEEYENNDNEKYNKNNSDDVNEDNKSLEDAEEEDTI 
 
7. 
>PF3D7_0525800_IMC1g 
MCSTNKNLACCKGDNVFDGQINGNESYPQVVNKQLPPKVLEPIIQNKIVEIPKEVYLEKIVEVPQIKTVERIVEQIRPVI
KYKNVYKPKIVYVEKVKNVDKIIYQEKIVEVPQIKTVEKIVEVPVYVNRERIITVPRYMVVEKVIPVLKTSKRESIMEV
PEVNCPHIDISKEVEDKEEIPINELKENQTISLADEKEIQILNDLTSQKVDSNATINMEGEQDTTVDTITQENFCGTVSCN
FLPNYPNFSKIGNPLCKGGPEKEKRFSSISIYKSKDSGFPSIRIAKTPQMFQRNLYCSYA 
 
>PF3D7_0525800_IMC1g sent to GeneartAG 
CSTNKNLACCKGDNVFDGQINGNEAYPQVVNKQLPPKVLEPIIQNKIVEIPKEVYLEKIVEVPQIKTVERIVEQIRPVIK
YKNVYKPKIVYVEKVKNVDKIIYQEKIVEVPQIKTVEKIVEVPVYVNRERIITVPRYMVVEKVIPVLKTSKRESIMEVP
EVNCPHIDISKEVEDKEEIPINELKENQAISLADEKEIQILNDLTSQKVDSNAAINMEGEQDTTVDTITQENFCGTVSCN
FLPNYPNFAKIGNPLCKGGPEKEKRFSSISIYKSKDSGFPSIRIAKTPQMFQRNLYCSYA 
 
8.  
>PF3D7_1343700 KELCH PROTEIN 
MEGEKVKTKANSISNFSMTYDRESGGNSNSDDKSGSSSENDSNSFMNLTSDKNEKTENNSFLLNNSSYGNVKDSLLE
SIDMSVLDSNFDSKKDFLPSNLSRTFNNMSKDNIGNKYLNKLLNKKKDTITNENNNINHNNNNNNLTANNITNNLIN
NNMNSPSIMNTNKKENFLDAANLINDDSGLNNLKKFSTVNNVNDTYEKKIIETELSDASDFENMVGDLRITFINWLK
KTQMNFIREKDKLFKDKKELEMERVRLYKELENRKNIEEQKLHDERKKLDIDISNGYKQIKKEKEEHRKRFDEERLR
FLQEIDKIKLVLYLEKEKYYQEYKNFENDKKKIVDANIATETMIDINVGGAIFETSRHTLTQQKDSFIEKLLSGRHHVT
RDKQGRIFLDRDSELFRIILNFLRNPLTIPIPKDLSESEALLKEAEFYGIKFLPFPLVFCIGGFDGVEYLNSMELLDISQQC
WRMCTPMSTKKAYFGSAVLNNFLYVFGGNNYDYKALFETEVYDRLRDVWYVSSNLNIPRRNNCGVTSNGRIYCIG
GYDGSSIIPNVEAYDHRMKAWVEVAPLNTPRSSAMCVAFDNKIYVIGGTNGERLNS 
IEVYEEKMNKWEQFPYALLEARSSGAAFNYLNQIYVVGGIDNEHNILDSVEQYQPFNKRW 
QFLNGVPEKKMNFGAATLSDSYIITGGENGEVLNSCHFFSPDTNEWQLGPSLLVPRFGHS VLIANI 
 
>PF3D7_1343700 KELCH PROTEIN sent to GeneartAG 
EGEKVKTKANSISNFAMTYDRESGGNSNSDDKSGSSSENDANSFMNLASDKNEKTENNSFLLNNAAYGNVKDSLLE
SIDMSVLDSNFDSKKDFLPSNLARTFNNMAKDNIGNKYLNKLLNKKKDTITNENNNINHNNNNNNLAANNIANNLIN
NNMNSPSIMNTNKKENFLDAANLINDDSGLNNLKKFSTVNNVNDAYEKKIIETELSDASDFENMVGDLRITFINWLK
KTQMNFIREKDKLFKDKKELEMERVRLYKELENRKNIEEQKLHDERKKLDIDISNGYKQIKKEKEEHRKRFDEERLR
FLQEIDKIKLVLYLEKEKYYQEYKNFENDKKKIVDANIATETMIDINVGGAIFETSRHTLTQQKDSFIEKLLSGRHHVT
RDKQGRIFLDRDSELFRIILNFLRNPLTIPIPKDLSESEALLKEAEFYGIKFLPFPLVFCIGGFDGVEYLNSMELLDISQQC
WRMCTPMSTKKAYFGSAVLNNFLYVFGGNNYDYKALFETEVYDRLRDVWYVSSNLNIPRRNNCGVTSNGRIYCIG
GYDGSSIIPNVEAYDHRMKAWVEVAPLNTPRSSAMCVAFDNKIYVIGGTNGERLNSIEVYEEKMNKWEQFPYALLE
ARSSGAAFNYLNQIYVVGGIDNEHNILDSVEQYQPFNKRW 
QFLNGVPEKKMNFGAATLSDSYIITGGENGEVLNSCHFFSPDTNEWQLGPSLLVPRFGHS VLIANI 
 
9. 
>PF3D7_0822900 
MEVLQNMNRMDRRIEEIQNLKNIINNKLNKNVNDDVDGYMRQLVDLYLKSQKSKSKNLGSKKGKSNSKIRSVSRKS
ERKINVGKGIEKMQHYENNDQNNINNKNNDNNDNNNYDNNNNNNNDNNNNNNNNDNNNNNNNDNNNNNNNDN
NNNNNYDNNSKQSFSQKNSSENYDNGSGSDDEEKKNNNYNEENENNTQKKKKKKKKGNKKNKNKNKNKNSDKS
ETNDEEEVTVEMEEKENIIEQLNEQQNEKLDEQLNEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQP
NENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENSD
EQSNNTNKDEPNTSNYVNTENVIDQGKGNNSECGNIVEEQNNGDSLDERKEKNMKSAIRFMKESNYEDPHLNACLS
DSNIDGVNINQNEEELKVKDILSNPFTTSSYNEENEKVSNMEMHSNNIENISNCIQKKKTQINLNNVLKELKFKSANNI
KYGRDNNFDDITEKYINDGSDDLETYKKNSSINDEEPYHYTNFVKHYVTKVGIYNNMEKNKLNFNVPSQSYGINHLY
NMNKNSYDTNSFQYNKSYSSTTNEEQEKDKREYGFNNCMNYTNINCSNINQSYSNMIRNYNTMVNDHNINCTKTNI
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NCTNPKLDCLSKSFSKIRKINLCNSAYYPHCTYSNPLKSIKKYSCTNTKNYINEYNCTKNATSMLPDFSCMNGVEIMK
KHINIDNIKKHVNLENVKKNMDLKNVKKLINLENIKNKINFENVKERVNIKNVTDHINIESISKNVECFDNNYYDIFEE
AYKNYINKYVNNVKNTIKEKKEYYKKNVNCNYELINKNLLKVAANNINNLNNMYLKNKSKLQGLNTKKYIAFNHN
KYVRFLNSCYEKKMNSVKKKIELNKKFLNNYFHACYFECSDNPMLSNDISRVSSCPEYQNSNEQYHQKQSSMTNSIN
SKSNIYNNSSSHKLLNTEKKKNTSNDSEQINNNLSFPNSNKEFNSNSEIDISCFNNGVKTFKYMKGIFEDSGGAENEIIY
DQEKNMYFDLNDNAYINVKGNLYFNTKDKLFYDIEYIKDISYDNVKNNLFHFGNYLITEKYAPCKII 
MKMCAHINQFMYNLLGVAKYDIYYKHKDNLVEIIIK 
 
 
>PF3D7_0822900 sent to GeneartAG 
EVLQNMNRMDRRIEEIQNLKNIINNKLNKNVNDDVDGYMRQLVDLYLKSQKSKSKNLGSKKGKSNSKIRSVSRKSE
RKINVGKGIEKMQHYENNDQNNINNKNNDNNDNNNYDNNNNNNNDNNNNNNNNDNNNNNNNDNNNNNNNDNN
NNNNYDNNAKQSFSQKNSAENYDNGAGSDDEEKKNNNYNEENENNAQKKKKKKKKGNKKNKNKNKNKNSDKSE
TNDEEEVTVEMEEKENIIEQLNEQQNEKLDEQLNEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQP
NENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENFDEQPNENSD
EQSNNTNKDEPNTSNYVNTENVIDQGKGNNAECGNIVEEQNNGDSLDERKEKNMKSAIRFMKESNYEDPHLNACLS
DSNIDGVNINQNEEELKVKDILSNPFTTSSYNEENEKVSNMEMHSNNIENIANCIQKKKTQINLNNVLKELKFKSANNI
KYGRDNNFDDITEKYINDGSDDLETYKKNSSINDEEPYHYTNFVKHYVTKVGIYNNMEKNKLNFNVPSQSYGINHLY
NMNKNSYDTNSFQYNKSYSSTTNEEQEKDKREYGFNNCMNYANINCANINQSYSNMIRNYNTMVNDHNINCAKTNI
NCANPKLDCLSKSFSKIRKINLCNSAYYPHCTYSNPLKSIKKYSCTNTKNYINEYNCAKNATSMLPDFSCMNGVEIMK
KHINIDNIKKHVNLENVKKNMDLKNVKKLINLENIKNKINFENVKERVNIKNVADHINIESISKNVECFDNNYYDIFEE
AYKNYINKYVNNVKNTIKEKKEYYKKNVNCNYELINKNLLKVAANNINNLNNMYLKNKSKLQGLNTKKYIAFNHN
KYVRFLNSCYEKKMNSVKKKIELNKKFLNNYFHACYFECSDNPMLSNDISRVSSCPEYQNSNEQYHQKQSSMTNSIN
SKSNIYNNSASHKLLNTEKKKNTSNDSEQINNNLAFPNSNKEFNSNSEIDISCFNNGVKTFKYMKGIFEDSGGAENEII
YDQEKNMYFDLNDNAYINVKGNLYFNTKDKLFYDIEYIKDISYDNVKNNLFHFGNYLITEKYAPCKII 
MKMCAHINQFMYNLLGVAKYDIYYKHKDNLVEIIIK 
 
10. 
>PF3D7_1401600 PHISTb 
MVSYNEYKLCLNNPRLDMKRKNYKYNVHEGIIRKGAKWICSMNKAFHSRFFICICVLLHMMVFGVCIYKVEGSVHV
TEPNSSSSRSLYENKGVTYESNVEVHDNFLNKLYMSPNVENNGIKEDNVFGNTDLGGMESHEKFKEKIRRSSTLSQG
NYSNFKDGGYEYSELADSMTDEEIDKEVDKLMEYTNNNKEKVYSLWWQIMRNERVKYVMIMKNLYNFFLKLKKK
YNVDNSFSEKQWNICKKRVKKNRLNYEKSINTTFLNWCNSLLLRKDYYRKLIKANRLKWKELSIKTEKACRHNMLQ
AFEEKVKAQSTKLDLDYVTEHIRKNKKKKKITKDGDGCYSTGPNGQYNECMKTSDYIDAQDSDALVEDEVTEEENI
SDESVKKEEEEEEEEEKGVDVAEDEDALKDSTASGDSSTS 
RYTVLSADSAEYMESDILSVLDVPDVNGPASARSVYVQAYTSEPKEMLYRPKIRYVTI 
 
>PF3D7_1401600 PHISTb sent to GeneartAG 
KVEGSVHVTEPNSASSRSLYENKGVTYESNVEVHDNFLNKLYMSPNVENNGIKEDNVFGNTDLGGMESHEKFKEKI
RRSSTLSQGNYANFKDGFGYEYSELADSMTDEEIDKEVDKLMEYTNNNKEKVYSLWWQIMRNERVKYVMIMKNL
YNFFLKLKKKYNVDNSFSEKQWNICKKRVKKNRLNYEKSINTTFLNWCNSLLLRKDYYRKLIKANRLKWKELSIKT
EKACRHNMLQAFEEKVKAQSTKLDLDYVTEHIRKNKKKKKITKDGDGCYSTGPNGQYNECMKTSDYIDAQDSDAL
VEDEVTEEENIADESVKKEEEEEEEEEKGVDVAEDEDALKDSTASGDSSTSRYTVLSADSAEYMESDILSVLDVPDVN
GPASARSVYVQAYTSEPKEMLYRPKIRYVTI 
11. 
>PF3D7_1407800_PM4 
MALTVKEEEFSNTLIKNASAFDRLKLGNLKNLKIQKKLQFLYLILFVLITGVFFFFLIGNFYSHRKLYQVIKNTKHTTIG
FKIDRPHDKVLSSVLKNKLSTYVKESFKFFKSGYAQKGYLGSENDSIELDDVANLMFYGEGQIGTNKQPFMFIFDTGS
ANLWVPSVNCDSIGCSTKHLYDASASKSYEKDGTKVEISYGSGTVRGYFSKDVISLGDLSLPYKFIEVTDADDLEPIYS
GSEFDGILGLGWKDLSIGSIDPVVVELKKQNKIDNALFTFYLPVHDKHVGYLTIGGIESDFYEGPLTYEKLNHDLYWQ
IDLDIHFGKYVMQKANAVVDSGTSTITAPTSFLNKFFRDMNVIKVPFLPLYVTTCDNDDLPTLEFHSRNNKYTLEPEF
YMDPLSDIDPALCMLYILPVDIDDNTF ILGDPFMRKYFTVFDYEKESVGFAVAKNL 
 
>PF3D7_1407800_PM4 sent to GeneartAG 
SHRKLYQVIKNTKHTTIGFKIDRPHDKVLSSVLKNKLSTYVKESFKFFKSGYAQKGYLGSENDAIELDDVANLMFYG
EGQIGTNKQPFMFIFDTGSANLWVPSVNCDSIGCSTKHLYDASASKSYEKDGTKVEISYGSGTVRGYFSKDVISLGDL
SLPYKFIEVTDADDLEPIYSGSEFDGILGLGWKDLSIGSIDPVVVELKKQNKIDNALFTFYLPVHDKHVGYLTIGGIESD
FYEGPLTYEKLNHDLYWQIDLDIHFGKYVMQKANAVVDSGTSTITAPTSFLNKFFRDMNVIKVPFLPLYVTTCDNDD
LPTLEFHSRNNKYTLEPEFYMDPLSDIDPALCMLYILPVDIDDNTF ILGDPFMRKYFTVFDYEKESVGFAVAKNL 
 
12. 
 
>PF3D7_0730800.2 
MVHFTKILAVTCFAATFQCSNNVILSKSYDMNKKNLNNVGFRNNRILSSKENREEPGTSGTTSGANGNKANIPDLDN
FINQTTSSCGNLGNLLAPLLKGIKSNLFSKYVNEDGTTKPNAPTAQSLTSIVKGVMHDIKPQMEALKEGIKKNIEEEGE
ESIKKDCDALKDGFKNIMKSFGGDFSNTVQGATGIPGKLFKGFLNEDESKTTENADIKDEIDILLEDDNTDDDDDDDG
DDDDDNNDDDDDEKEKEKEKENEKGKGKGKGKKKENKETSDDNNKNAGTSTLRGKKKKF 
 
>PF3D7_0730800.2 sent to GeneartAG 
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SNNVILSKSYDMNKKNLNNVGFRNNRILSSKENREEPGTSGTTSGANGNKANIPDLDNFINQTTSSCGNLGNLLAPLL
KGIKSNLFSKYVNEDGTTKPNAPTAQSLTSIVKGVMHDIKPQMEALKEGIKKNIEEEGEESIKKDCDALKDGFKNIMK
SFGGDFSNTVQGATGIPGKLFKGFLNEDESKTTENADIKDEIDILLEDDNTDDDDDDDGDDDDDNNDDDDDEKEKEK
EKENEKGKGKGKGKKKENKETSDDNNKNAGTSTLRGKKKKF 
 
13. 
>PF3D7_0831400 
MMRILYTNVFLFIAVLFCILSPGNNPLHKYVEIKEGINNLSIHAHLRLLTEIMENCSLNGFRLNDKNGEHDEEEERKCD
DDQHSENQEHECDNDQHSENQEHECDNEQNDESKCEESNNTDQADVNYLSMPIQIPYLRNEIMDDNYYSRYFDSNI
MRTDEVTTRLNDQNLIEKCLCKLKAGKYINEAKIKYAHEIIDSMKLTDKVKDIFKEFMRYYIWKRYPSHQLRLYKKI
KKDIEKYTRNHVICSLIDFETIEDELYYLIYPNREMYMSFDTAVNTKRRKKIKKLMREKARKDKEKNG YI 
 
>PF3D7_0831400 sent to GeneartAG 
KYVEIKEGINNLAIHAHLRLLTEIMENCALNGFRLNDKNGEHDEEEERKCDDDQHSENQEHECDNDQHSENQEHEC
DNEQNDESKCEESNNADQADVNYLSMPIQIPYLRNEIMDDNYYSRYFDSNIMRTDEVTTRLNDQNLIEKCLCKLKAG
KYINEAKIKYAHEIIDSMKLTDKVKDIFKEFMRYYIWKRYPSHQLRLYKKIKKDIEKYTRNHVICSLIDFETIEDELYYL
IYPNREMYMSFDTAVNTKRRKKIKKLMREKARKDKEKNG YI 
 
14. 
>PF3D7_0925900 
MIKKAVSLFFIFFLFTIIRASPGNDNNNVNNDGVVHVLSKNIDVKNLQGTFYEIATNASDKIFPGLACRCTKYEFSGLK
RDGNLGYVLINFSCARNFIFGEKKSEMTFKLILNKPLDENTTTVEEFNASIYLVQGNQQILLNGNINIIYAELNEQNEFE
HLILGGQKSIEPMIIMSKYRT VLLDTYNKLINSLYLAGYEPSLLTWPFIIQTDQTFCD 
 
>PF3D7_0925900 sent to GeneartAG 
SPGNDNNNVNNDGVVHVLSKNIDVKNLQGTFYEIATNAADKIFPGLACRCTKYEFSGLKRDGNLGYVLINFACARNF
IFGEKKSEMTFKLILNKPLDENTATVEEFNASIYLVQGNQQILLNGNINIIYAELNEQNEFEHLILGGQKSIEPMIIMSKY
RTVLLDTYNKLINSLYLAGYEPSLLTWPFIIQTDQTFCD 
 
15. 
>PF3D7_1025300 
MLLYFVIFIWSFLLCDIYETLNIRKSIDRKLTHLNNNIECALNISNYRNKKSKNLQFIGNNKIVKKCKNKYSNKVHLFG
FSSKEEINNKGKKSLNIEKYEYKNGNIFLYTKLFVNNEEKKFIIDLCSDHSFIFEKRLNEELLKCNNNNNNNNIFTQNDF
EQKSFPKNEGLNLQYEKKDIENIKELFHLNNTQVDIKKVVNIKHEKEKQFPFYVINNEELDMNFYGIIGFNFFKNYDTF
VLDTIQMKILLNWNEDGINTEDPNYDNIEYEKQKGNGEQDQKEHEYYKINLYDYFNNIKYFNIYVDNHLYKGIVDTG
TLNTILLNNSNIYNTTTDYNNKDTKTSIIIESVLKNKYKVNKTNINHINIITKDNHKIPVELNKYIYSGNLEYINKDVILL
GLDFLLNKKLIFDLKNNILIIPKKYLNNTNEFNKKYDALNIGITNVQENQKSQNDNGNNHMDQIKIEDKCKEIYNQLK
AKELNFVRITKELENDNVYMKDCKSTNDVIHKYAIKLLYGSNYLKKNDKNIEYEKRYNEVTEFFKKLNNEEKQNML
NKIVNSVLLLKRNDTIHDNNNNNNNNNNIINHQKQHSSNQGYEKASDIIHKFVNYEINNNVYSLHKFKSSNVNKNNP
KSEEEEYKFLCNLYETHPEYSFEMLNDFKKELSSKKIPYNDCNDEKDIIKKVAHSRVFNNHKNNNKRKNVIVRKYSD
DGNNIHTQIIIRGNGLNNNNNTSDDQDQNDYQYNNLDRMDDLFPNSIFSGLLKNFFIQNNNNNNNDGDGDYSSESFD
QQNSSDDNQNDLFSELNNFFGFGNLADGMFGRKKKKKVLGFKTKEPQANLENNKENADDNITQAIKQEKDVDIIYL
LNKVQKLNDINLKNFILQSLNNQNIRKILVDAVKKGYTNTYEQCKKENDNKSMYLLQMLKQSGIF 
 
 
>PF3D7_1025300 sent to GeneartAG 
YETLNIRKSIDRKLTHLNNNIECALNIANYRNKKSKNLQFIGNNKIVKKCKNKYSNKVHLFGFSSKEEINNKGKKSLNI
EKYEYKNGNIFLYTKLFVNNEEKKFIIDLCSDHSFIFEKRLNEELLKCNNNNNNNNIFTQNDFEQKSFPKNEGLNLQYE
KKDIENIKELFHLNNAQVDIKKVVNIKHEKEKQFPFYVINNEELDMNFYGIIGFNFFKNYDTFVLDTIQMKILLNWNE
DGINTEDPNYDNIEYEKQKGNGEQDQKEHEYYKINLYDYFNNIKYFNIYVDNHLYKGIVDTGTLNTILLNNANIYNTT
TDYNNKDTKTSIIIESVLKNKYKVNKANINHINIITKDNHKIPVELNKYIYSGNLEYINKDVILLGLDFLLNKKLIFDLK
NNILIIPKKYLNNANEFNKKYDALNIGITNVQENQKSQNDNGNNHMDQIKIEDKCKEIYNQLKAKELNFVRITKELEN
DNVYMKDCKSTNDVIHKYAIKLLYGSNYLKKNDKNIEYEKRYNEVTEFFKKLNNEEKQNMLNKIVNSVLLLKRND
AIHDNNNNNNNNNNIINHQKQHSSNQGYEKASDIIHKFVNYEINNNVYSLHKFKSSNVNKNNPKSEEEEYKFLCNLY
ETHPEYSFEMLNDFKKELSSKKIPYNDCNDEKDIIKKVAHSRVFNNHKNNNKRKNVIVRKYSDDGNNIHTQIIIRGNG
LNNNNNTSDDQDQNDYQYNNLDRMDDLFPNSIFSGLLKNFFIQNNNNNNNDGDGDYSSESF 
DQQNSSDDNQNDLFSELNNFFGFGNLADGMFGRKKKKKVLGFKTKEPQANLENNKENADD 
NIAQAIKQEKDVDIIYLLNKVQKLNDINLKNFILQSLNNQNIRKILVDAVKKGYTNTYEQ 
CKKENDNKAMYLLQMLKQSGIF 
 
16. 
>PF3D7_1137300 has 6 predicted TMDS (expressed the C-terminal) 
MGLSLSSPQLPANAGSNITSNNNNNNHTNENQRVPFFQKIISIIVQMLIMHMVMYFLSGGKNNMMSKSGIMDRTNVV
LKNSFEKGDIFDIYIFLSNNQSLDFEYLKNNSKLINIREKELYNHKTFSSYEKLNYTFNLNDSWKDEKYLSVVLVPIHF
YKKRNYPLIKNTTLKYEFKDKVLVENIPLTVKMVPFESEEEEKYNLMDPSNNIKRKNIEEQKKKKRNEQLYHIKRRID
INIIYDDGKHMVKEFKMPYFKNWKVNLTSNTYTPPIFLSDFWLIEKDYYVLDDNFLKSKDKRVNYICTYDPYMLTKK
QNDIHLYITEQNMDENKKLHIEINYGTCSFIYFMFIKQISYSLNMMNETAASAATTTSTTTTNNSNNNNNNNNNKIFSI
QNITNITANKEVHMMKKILMTTNIYMLIFSAIFILLHSIFSFFAFKNDMQFWYKNESMEGLSALSVITAFVCDIILALYL
YDSEKTSWLLLFEMFIGVALSAWKVTKAVHVSFSKKYPFIIFKDKKNYTESMTKKYDKIAIKYVGILLIPCLIGYAIYA
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LFYFKYKSWYSYIISVLAGTVYTFGFIMMTPQLYINYKLKSVEHLPWKALIYKSLNTFIDDVAFFLIDMPWMHKLSCF
RDDIIFLCYIYQRCIYKVDKNRNETLTQNEKID NNNNAKQNDQLRELTQEQNVVDSHDKKND 
 
>PF3D7_1137300 has 6 predicted TMDS (expressed the C-terminal) sent to GeneartAG 
LYINYKLKSVEHLPWKALIYKSLNTFIDDVAFFLIDMPWMHKLSCFRDDIIFLCYIYQRCIYKVDKNRNEALTQNEKID 
NNNNAKQNDQLRELTQEQNVVDSHDKKND 
 
17. 
>PF3D7_0830500 Tryp/Threonine rich antigen 
MNLEQFKNINKDLATNLFSQLSFLKNENKFLSQGKSLIKFLIGIAIFLVVLIFIKSSHPALKEKKKKVLEFFENLVLNKK
KKENITAAIASKELADAETTDTSDSEDEDHIINKKVKRRKRNIINNPDEKVHNVKEKNSKSKNEEDKTDESYNETSLLS
SDEEGEVNLEDWKKNEWIKWMDETEEEWQLLKLWLEGEKNKWLEGKNKEYDIWLNHMNSKWTNYNKDIDEEYD
SNVFKDSYKWNEKQWEQWMKTEGKEFMLQDFKRWLEDSEGYLKSWLIKQWIQWKNMKILECLMNEWRREEDEK
WSNLEDTDQIRVLNHKDRKEWLRWKERVTREKLEWKHWVEMKENMNIYNKWKKWIKWKKNKLANFNEWSKNF
IEKWIREKQWNNWINERKKYTSQRKSLEQQFGDNMDKMNKLKK 
KKILKFFPLFNYKSDLESIMEEDENEYNSFDENEEENDEKTGDVNVGKTEALNVAKTEGL 
NVGKTEDLNVAKTEDLNVAKTADLNAEKTTDLNSEKTADLNSDKTTDLNPEKTTNFNTYKATDLNANKTADLNSD
KTTDLNSDKTTNFNTYRTTDLNSDKTTNFNTYKTDLYAEKTTDVNLGKTTNHNVAKTTDQKVVKHSLDHEVRQMI
DQKVAQIMNHDLESTAEQKAEKKGGKAKAK TKVRTVDDDGNEINV 
 
 
>PF3D7_0830500 Tryp/Threonine rich antigen sent to GeneartAG 
KSSHPALKEKKKKVLEFFENLVLNKKKKENIAAAIASKELADAETTDTSDSEDEDHIINKKVKRRKRNIINNPDEKVH
NVKEKNSKSKNEEDKTDESYNEASLLSSDEEGEVNLEDWKKNEWIKWMDETEEEWQLLKLWLEGEKNKWLEGKN
KEYDIWLNHMNSKWTNYNKDIDEEYDSNVFKDSYKWNEKQWEQWMKTEGKEFMLQDFKRWLEDSEGYLKSWLI
KQWIQWKNMKILECLMNEWRREEDEKWSNLEDTDQIRVLNHKDRKEWLRWKERVTREKLEWKHWVEMKENMNI
YNKWKKWIKWKKNKLANFNEWSKNFIEKWIREKQWNNWINERKKYTSQRKSLEQQFGDNMDKMNKLKKKKILK
FFPLFNYKSDLESIMEEDENEYNSFDENEEENDEKTGDVNVGKTEALNVAKTEGLNVGKTEDLNVAKTEDLNVAKT
ADLNAEKTTDLNSEKTADLNSDKTTDLNPEKTTNFNTYKATDLNANKAADLNSDKTTDLNSDKTTNFNTYRTTDLN
SDKTTNFNTYKTDLYAEKTTDVNLGKTTNHNVAKTTDQKVVKHSLDHEVRQMIDQKVAQIMNHDLESTAEQKAEK
KGGKAKAK TKVRTVDDDGNEINV 
 
18. 
>PF3D7_1462300: Conserved, unknown function 
MNKLFFLCFLVIIIYSLSIYYCNDNILENANNDDSTKDINNINKNSSNKSKSEKTSNYNNDQYNIDDAYNEDEENDEEE
GDDDENDHFEVPINCSGGNCFDSMDDINKIIDNKKKKMKYRRRRGKAIQIIKPNVNHTELIIIEENLEIFKRIDKPIAIVS
VLGDMHTGKSFLLNLLNEHVIPDINKSNKYIENGFKVGNDITASTYGIWIWSEPIRINVKKLKKIYEYINENFTNFIKSY
EYEKDEYNEEIIDLLNLYKTDDWISNVEELNLSDTDEVNLILMDTQGLNSPNVNKRYDEILYALTNLISTDIIFLTMKM
INNKDLEFIENITKDANLFMLRAYTRSSGSTFSIKKNNFHKILDTLNNNLENNSLILESIASKNLMWVVHDFSQRLDVR
KGKLWLDILLNSDRRDLDIKYWKKIISNKSKDKHDAYTTKKQKIAYLTYNENSSSGLLPNNNNNNNNSNDSSSNYKL
NILYKNIDCVLLRNMYHNKEFDFTKANINDLNEEYKNDVLLLRYKIYLRALLFPKKMYSDVQINNIINKIRKEQKLRE
EQEKNKDNKKNDTNNQTNDLNSNKDETSGSQVTNRFMSGHDVYDFITFLVKSANQNLFTNVNQFFKHFKINRAEISR
NDLIFLYKKYLLQFMENEDVEFISNLNDENDDLFLQKEGNNTSVNHDENSDADSLFNDHDENMQLKEHNIKDGEDN
THQKKDSYKLPPLLNEIKKYEELIREQILNIWYKYTESDFHDEEEKELIKDIENNLYERLDQIKIEMLELGEMNIRKFCK
IACEDALQIVVEDIKMKSDQYPIKQKDLTTFFESVSYNLIKYLEKKLSKNSDKLDLIYYKDNICSPLINNTFQEFYFLKK
KNITLNENRLKSYFSNAVEKGKEVFEVLAENTENITEYFKNKNMFYTVLDKWTSEAINTYTLTLSDFAKEEKEINDEY
LNVLNNDIKLLKQKAMEKWHNHCRDKTSALYNMHKSNLKKNFLENFNFPLDELVLQDIFLNLKGQEELKYMDIYC
ANEDSWNSEYKNFLKLTDEIFQFIKDENLKAIQITCQQPLDELKNGIKGEIHKYYLWSSLKSTLYNRALIVLSSNIENIY
IKNQRENKIQSNLDEKYNNKNKNYKRISKDLMSKVINRWLNNDIYNVYYPIIRKQFLHRIVCYLGIAILIFIISLVVYFK
KFHASFLFLIILALFMVFGYQQISIYGKTFFRHVVFYMYEGIANVFGTEGAIIVSILFISVTAIYVYNYHIVKFKKRVAKN
TKKLLQSQNIMNMSGQNPYNDYNPSSKMRIFKPNFWRFQDYDKDPKYHAPNIPHDYKMHNDSSQYMDLKNRSNRP
NEMDDYTSFNNSSKFQRRSYLD 
 
>PF3D7_1462300: Conserved, unknown function sent to GeneartAG 
IYYCNDNILENANNDDSTKDINNINKNSANKAKSEKTSNYNNDQYNIDDAYNEDEENDEEEGDDDENDHFEVPINCA
GGNCFDSMDDINKIIDNKKKKMKYRRRRGKAIQIIKPNVNHAELIIIEENLEIFKRIDKPIAIVSVLGDMHTGKSFLLNL
LNEHVIPDINKSNKYIENGFKVGNDITASTYGIWIWSEPIRINVKKLKKIYEYINENFANFIKSYEYEKDEYNEEIIDLLN
LYKTDDWISNVEELNLADTDEVNLILMDTQGLNSPNVNKRYDEILYALTNLISTDIIFLTMKMINNKDLEFIENIAKDA
NLFMLRAYTRSSGSTFSIKKNNFHKILDTLNNNLENNSLILESIASKNLMWVVHDFSQRLDVRKGKLWLDILLNSDRR
DLDIKYWKKIISNKAKDKHDAYTTKKQKIAYLTYNENSASGLLPNNNNNNNNSNDASSNYKLNILYKNIDCVLLRN
MYHNKEFDFTKANINDLNEEYKNDVLLLRYKIYLRALLFPKKMYSDVQINNIINKIRKEQKLREEQEKNKDNKKNDT
NNQANDLNSNKDETSGSQVTNRFMSGHDVYDFITFLVKSANQNLFTNVNQFFKHFKINRAEISRNDLIFLYKKYLLQF
MENEDVEFISNLNDENDDLFLQKEGNNASVNHDENSDADSLFNDHDENMQLKEHNIKDGEDNTHQKKDSYKLPPLL
NEIKKYEELIREQILNIWYKYTESDFHDEEEKELIKDIENNLYERLDQIKIEMLELGEMNIRKFCKIACEDALQIVVEDIK
MKSDQYPIKQKDLTTFFESVSYNLIKYLEKKLSKNSDKLDLIYYKDNICSPLINNTFQEFYFLKKKNIALNENRLKSYF
SNAVEKGKEVFEVLAENTENIAEYFKNKNMFYTVLDKWTSEAINTYTLTLSDFAKEEKEINDEYLNVLNNDIKLLKQ
KAMEKWHNHCRDKTSALYNMHKSNLKKNFLENFNFPLDELVLQDIFLNLKGQEELKYMDIYCANEDSWNSEYKNF
LKLTDEIFQFIKDENLKAIQITCQQPLDELKNGIKGEIHKYYLWSSLKSTLYNRALIVLSSNIENIYIKNQRENKIQSNLD
EKYNNKNKNYKRISKDLMSKVINRWLN NDIYNVYYPIIRKQF 
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19. 
>PF3D7_0317100: 6-CYS (B9) 
MNRGWHVVFYFILLLMNKSLGGEEKLTKFDPVMIKEGELFGEVSYDCEYSGFLEIENDDILYYCFFVGEDDHNGLLL
RKFHMDDMVWGIPMEVLITRKKINLYILTVDYILSKLILIYSFDEKIRITVFNNYMEESVMSEKISINYEILYKANMISYI
TYFYKNKKSLCVCGMNRNENILCTFSFDYGLTMKDDHTIEFFLKKKIPLGHYKMQVTFKETEVYFNLYNDLNETNFY
ELKCVKKQDEYICDIMNKIRETQEYNYKRYTYPSSEHNKYYNDHHNKQPQGKQGQQGGAPLPNLGEEENNFIYKHI
VRNKYFQMIVFQKDQKCYLAWSFNSLNINDEITKEISSVPCSNVASYYRQERLIVTLKKNQLGSRNHFFLIYEKLTEK
GVGCEFGVGGSLYVTKTFMNNTCDMDINNMNVSTTNYDEINFSLIIPLSFQLNYSTCFIWEENVDNNEERSSLYYLEE
YTNEKEDIKVYTFYFYKYILIYKNFKKSTCTFESKNNEKLYISFRGDTYYKEYNCNILLDSCDFFLHTQSKINITYDDD
VWQVSEELYDGFVMYNGTYVSLYDVLSRSNAHGLIYIDGKENNTSINLNNIKNNNNNNNNNNNNNNTSNNNNISNN
SNSNNSFGEHEKVITIIIPYGIPSTRTIKIEFLNKQNNEEKRWAYLRLQKNEYIMKKVIGINSSDIFDLSYKYYKYNQEKI
KFILNDFSETTYLGFICQTKEEIKKSLCTISLVDHSHKNMAINNLFKTNNHILPFLYDQSPPRKIQPYNQIISEFRFVLFKN
FHLFLQENKINYILLKCMCSSSSSYINTQKNIELSYLITNEQVSHDFIHTPGILIRPRTNISHNDYQKNNKGNHKGNNKS
NNKSNDKDSNNNSNNNSNKNGNNHNDNNNNNQNKDIDINSNYSIHNNNEKVKRTKKKINDAPYDKQDEELPSYDF
NDLLHEKKNGTSVFDFNFVL FLFICITFF 
 
>PF3D7_0317100: 6-CYS (B9) sent to GeneartAG 
GEEKLTKFDPVMIKEGELFGEVSYDCEYSGFLEIENDDILYYCFFVGEDDHNGLLLRKFHMDDMVWGIPMEVLITRK
KINLYILTVDYILSKLILIYSFDEKIRITVFNNYMEESVMSEKISINYEILYKANMISYITYFYKNKKSLCVCGMNRNENI
LCTFSFDYGLTMKDDHTIEFFLKKKIPLGHYKMQVTFKETEVYFNLYNDLNEANFYELKCVKKQDEYICDIMNKIRE
TQEYNYKRYTYPSSEHNKYYNDHHNKQPQGKQGQQGGAPLPNLGEEENNFIYKHIVRNKYFQMIVFQKDQKCYLA
WSFNSLNINDEITKEISSVPCSNVASYYRQERLIVTLKKNQLGSRNHFFLIYEKLTEKGVGCEFGVGGSLYVTKTFMN
NTCDMDINNMNVATTNYDEINFALIIPLSFQLNYATCFIWEENVDNNEERSSLYYLEEYTNEKEDIKVYTFYFYKYILI
YKNFKKSTCTFESKNNEKLYISFRGDTYYKEYNCNILLDSCDFFLHTQSKINIAYDDDVWQVSEELYDGFVMYNGAY
VSLYDVLSRSNAHGLIYIDGKENNASINLNNIKNNNNNNNNNNNNNNTSNNNNISNNSNSNNSFGEHEKVITIIIPYGIP
STRTIKIEFLNKQNNEEKRWAYLRLQKNEYIMKKVIGINSADIFDLSYKYYKYNQEKIKFILNDFSETTYLGFICQTKEE
IKKSLCTISLVDHSHKNMAINNLFKTNNHILPFLYDQSPPRKIQPYNQIISEFRFVLFKNFHLFLQENKINYILLKCMCSS
SSSYINTQKNIELSYLITNEQVSHDFIHTPGILIRPRTNIAHNDYQKNNKGNHKGNNKANNKANDKDSNNNSNNNSNK
NGNNHNDNNNNNQNKDIDINSNYAIHNNNEKVKRTKKKINDAPYDKQDEELPSYDFNDLLHEKKNGASVFDFNFVL 
FLFICITFF 
 
20. 
>PF3D7_0823800: DnaJ protein, Putative 
MGRKASNDSYENSDVNGAVSKRKSKGKDDINDIMNDLNKKKMNEKKNMKDKKDGNFSGNMIGGMYKNKLRYIL
DNIIIISIILSFVVLISFKYLEEKYSIESYFEDGDSFDYYEVLKCKRGDSIQKIKKNYRDLSKQYHPDSNKNCKDCDKKFQ
EITKAYKTLSDSRLKKAYDNSKGKVLKLIESNSINLNMKNYVDLVENSNDYWIIQIYSDTDSLCLSFSNIWEESFDKY
HEYISFGRINISTDKKLIKQKVPFNVKIYPTIFILSPDGTYQLYSNIFNATSKDFQNFITSNYPNNIYDLKMLNDALYKMS
SLNVKKSGYIDKNHHVILLTNKKKLSLQAKQITYKFNNIYKTYSIKYNEIDNISNESIKKSIIDSLKVLSIKKDEYLKEN
QNIDYFILVNNNQVKIIRRISPTNIKNVYNDALKKNIVEINSINVDSVCSTMGSRKTYCYVIFVDNVDDEKNVNYMRK
TYQNINSSYNKFVSKNGSEETEEQLFIQPVYVLKKNLTKKFNKFINDKTINKYDSFLLDYSSNTFSSINEIKNLSNYSQN
KDDLSFLHNIYKDIEILNFQKIPKYCLPFNINCLFNIKTTTPYKLYNII 
NRTSKLQIIFSLIVGFMLFPTFKEYGFLKYVLFALSVGFSVIVINIKDFILLLAS 
 
 
>PF3D7_0823800: DnaJ protein, Putative sent to GeneartAG 
YLEEKYSIESYFEDGDSFDYYEVLKCKRGDSIQKIKKNYRDLSKQYHPDSNKNCKDCDKKFQEITKAYKTLSDSRLK
KAYDNSKGKVLKLIESNSINLNMKNYVDLVENSNDYWIIQIYSDTDSLCLSFSNIWEESFDKYHEYISFGRINIATDKK
LIKQKVPFNVKIYPTIFILSPDGTYQLYSNIFNATSKDFQNFITSNYPNNIYDLKMLNDALYKMSSLNVKKSGYIDKNH
HVILLTNKKKLSLQAKQITYKFNNIYKTYSIKYNEIDNIANESIKKSIIDSLKVLSIKKDEYLKENQNIDYFILVNNNQVK
IIRRISPTNIKNVYNDALKKNIVEINSINVDSVCSTMGSRKTYCYVIFVDNVDDEKNVNYMRKTYQNINSAYNKFVSK
NGSEETEEQLFIQPVYVLKKNLTKKFNKFINDKTINKYDSFLLDYSSNTFSSINEIKNLSNYSQNKDDLSFLHNIYKDIEI
LNFQKIPKYCLPFNINCLFNIKTTTPYKLYNII NRTSK 
 
 
21. 
>PF3D7_1229300 Conserved plasmodium protein 
MKLKYHLFFLIIFIQDILCLKYEDYIKSLPEAFHLAKGDSKKDEMKKENPKEENDNNNDNKSNSNSNNNYKVGMQDI
VNNISNKISDDNKNKDNNSSDKYDCNDDDNNNTSNSLFHKMMCAFKKKLFKNEQVIEKDIRNVKKGVINLKENIVK
DSSNISKHTNILKDDITKNTNYLFNLFKKSFKEEGDNVNKFSSDYFNKLKNLPDSHLFFSKLLLTLSQNDDKDKNKITH
INNYYNNKMNDNTENNTNLLQNFLSFIKNFKQKDEYNNDNNIKKENDFFHSFYLHNENDKHKNNKDKKYSWWFTN
KNDEKKNVDNNLNLLYNNSNNSFNSTFNQNQTDHENLPEQVREKKNSQEEKNKWLDIFWKYFHKNEEEIEKKEMN
EKNDLNDNNKNGVNVDDHNLNGLHNLDDKKNKFSFLNYWNDKDIPKEGSADEYSQDNNNNKTDDQNNDDNKKF
NIFMYFGKNKKNDEDMNKNKKEMNMDMDMNKDMNKDMNKDMNMDMNMNMNMNMNMNMNNMGDDTNVD
VSDTLNNNLNKNEMNKVDDDPKGFVLNLVKNYYENNKNVDNINYSLLLTSGKETNENINYHPLIKFKSCLMNCFKE
INNTEKSVEKESYLSFDDYKILEKCISKCKNNNLNDTHNEDPPMKKDDTILYMEEKNKINDTTKNNLLNDNINNLINE
NNESTEKETSSKWSDFFFKKNNKKNIKDSYEEDKNSNNPQDNIS 
VLTSNETNLENLNILNDNLSTHLMYDINNNNNKKNISNNNNKKNISNNNNNYKMKNFLIDSKFKYSNKEKTKNFIQD
EQQDKNKNVYNKPLHFFNYFNNSNINTDDNNNNNNNNNNNIYKDNLIMNNSSVNDNLLNNDDKYNSLKNINNNNN
IMLNKNDIDNDENNNYISTGFFLFLLLITFFVYLSAFTNIINQFYLSFKEKICLFIKGKYKGTFDNVYEESCESFLPKVQY
KNSHNNNNNNNNNDNNNFCQSYENIYHSFQENSLDMA 
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>PF3D7_1229300 Conserved plasmodium protein sent to GeneartAG 
KYEDYIKSLPEAFHLAKGDSKKDEMKKENPKEENDNNNDNKANSNSNNNYKVGMQDIVNNIANKISDDNKNKDNN
ASDKYDCNDDDNNNTSNSLFHKMMCAFKKKLFKNEQVIEKDIRNVKKGVINLKENIVKDSSNIAKHTNILKDDITKN
TNYLFNLFKKSFKEEGDNVNKFSSDYFNKLKNLPDSHLFFSKLLLTLSQNDDKDKNKITHINNYYNNKMNDNTENNT
NLLQNFLSFIKNFKQKDEYNNDNNIKKENDFFHSFYLHNENDKHKNNKDKKYSWWFTNKNDEKKNVDNNLNLLYN
NANNSFNSTFNQNQADHENLPEQVREKKNSQEEKNK 
WLDIFWKYFHKNEEEIEKKEMNEKNDLNDNNKNGVNVDDHNLNGLHNLDDKKNKFSFLNY 
WNDKDIPKEGSADEYSQDNNNNKADDQNNDDNKKFNIFMYFGKNKKNDEDMNKNKKEMNMDMDMNKDMNKD
MNKDMNMDMNMNMNMNMNMNMNNMGDDTNVDVSDTLNNNLNKNEMNKVDDDPKGFVLNLVKNYYENNKN
VDNINYSLLLTSGKETNENINYHPLIKFKSCLMNCFKEINNTEKSVEKESYLSFDDYKILEKCISKCKNNNLNDAHNED
PPMKKDDTILYMEEKNKINDTTKNNLLNDNINNLINENNESTEKETSSKWSDFFFKKNNKKNIKDSYEEDKNSNNPQ
DNIAVLTSNETNLENLNILNDNLSTHLMYDINNNNNKKNISNNNNKKNISNNNNNYKMKNFLIDSKFKYSNKEKTKN
FIQDEQQDKNKNVYNKPLHFFNYFNNSNINTDDNNNNNNNNNNNIYK 
DNLIMNNASVNDNLLNNDDKYNSLKNINNNNNIMLNKNDIDNDENNNYIS 
 
22. 
>PF3D7_1308000 
MEKTSFKNNQKSYSKRNSSLKKKVTNDKNDNSLLTIYSFISNYMLKEEMNYDENDNRYILLESQDIENECGLKKVSF
GEFNEKSYSLSHKRKEKNEEDIDKEEEVYEGVDQADYEEEDYEEEDYEEEDYEEDDYEEDDYEEDDYEEDDYQDDA
EEQEEEEDSAKSYNYDHNQIDRNKVNNDESVNSTYNKQNNSIRRGGKKKKNKIYNNDHFPNDEDIQIDHNTNEEKHS
RQLWKKKKKKKRKREKKMMYTNSNSKEIYKGNNLAKYFTLSMDNINEQENIFKDEKQLSRQMSYYNDAYYYTSE
MIYKNNRRNKEKFALYLRLMSLFINIIIGIYLIIYFPHTNNDMDTFDGTFKNMHIKDREDIKDIISKNLEINKDYHNYMK
KVNLNVSILNKQKEFFENKSIGNGKASSSSNFSSSNDNNNNNNNNNNNNSMHVNTFDRSINNEDSLINTNNLNNNDN
NNFLRFLRNIFSRNNYEQEDNLKSSSNLINKEKTNNNTNVTNTGYYNLYKNNNNNNNIIDVEKNIYYEKDKNNNLKK
KNFKNVKNNNYNSGVYYVNDKDMLKDIKTKEDVNNLIYMIDILNLMDDEHIMTYIYNEMNKIYKYAIYSFFGELLVI
SIIVFSLFILKILIKDNNKFSVILTMYGIFYKIFCYIFAHYVLFMGLYILSIYYNIYIHRDILTHSYNFFCYHYVYNNLYIHL
LMLFYALQNIVFTINDAFNCIRMVFILIKHVIIKIYEKITCKNFITFYELKEDKSPLSLTCFNKLKNKCNMNCKCCKDKN
CVDIDIDEMHDIDYEKNKLPLFPNFNRKPYCKNLNIKTYEQSLLNMRNPIFK 
 
>PF3D7_1308000 sent to GeneartAG 
PHTNNDMDTFDGTFKNMHIKDREDIKDIISKNLEINKDYHNYMKKVNLNVAILNKQKEFFENKAIGNGKASSSSNFA
SSN 
DNNNNNNNNNNNNSMHVNTFDRSINNEDSLINTNNLNNNDNNNFLRFLRNIFSRNNYEQEDNLKSSSNLINKEKTNN
NANVANTGYYNLYKNNNNNNNIIDVEKNIYYEKDKNNNLKKKNFKNVKNNNYNSGVYYVNDKDMLKDIKTKEDV
NNLIYMIDILNLMDDEHIMTYIYNEMNKIYK 
 
23. 
>PF3D7_1237900 
MNKGLSKILELGFFVGSFFFIWYITGEKIFKRKKKIVKENILLILRNLCYEIYTVLCETSKTTKHVYDMLKNESNTTIELS
RLEEVLLNNGYKKKIEDVEKNVLKRFNVSVEDFYEELKNYEKDPDVQKYLNSIKKMYNEALLGLQPKLPSIDEKISE
DVIINLTSLIYKEKRKIYKTKIDSMLKNNEIIDIQNTLSNAQFFENLHKSTQHVEEQIIKENNNLVPNLFTFKYLVSYYSN
DPNFLQKKKYLESKHGEKMIKILKIKTSKKKKKRAHKEDRQSSNSSVSFKSTPSLDVYNVPHLGTLEKEEDHYSQQS
KEMEHMDKDSHVDFIPHNVDANLDKRDEQIEYISESGDMQPEKEYYEGEHITIRYEEEEDISEIYEEDRASRIYEEDRA
SGIYEEEHASGIYEEDHEERYRTSQVSERSIKKSVTSQQDDIIHSHEEDNYVSDREVIHDDSFVGDKDQIFDDNYVSER
EEIKQDDDYISEREEIKQDDDYISEREEIKQDDDYISEREEFKQDESFVGDKDQIFEDDNYVSEREEIKQDDDYISEREEI
KQDDDYVNEREEIKQDDDYVSEREEIKQDESFVGDKDQIFEDDNYVSEREESKQDESFVGDKDQVFDDDYVSEREEI
KQDDDYVSEREEIKQDESFVGDKDQIFEDDNYVSEREEFKQDESFVGDKDQNFDDDYVSEREDIKQDDDYISERDEI
KQDDSFAGDKDQNFEDDNYVSEKEEIIYDNNNISDREQVIQDDNYVSDKEEIIYDNNNNNNISDSEVDKENNNYVYE
NDEIIKDNKSMNEKDSSIHYDEEGTVKNKDIIENVKEENSDIQMLENDIINNINNEIIDNNENEIINNQSKVENNTSMTE
YEDVIDMDYKSPENLFMFDQEYNINEDHKGEINNNDNDNSKSVSGMGEREVSNEENREDEMIRNEEVDYIKDDDEH
NTDDIKEDDEHNADDIKEDDEHNVDDIKEDDENNADDIKEDDEHNADDIKEDDEHNTDDIKEDDEHNTDDIKEDDE
HN ADDIKEDDENNADDIKEDDEHNTDDIKEDDEHNTDDIKEDDEHNADDIKDDEHNTDDIKD 
DEHNTDDIKDDEHNADDIKDEDNDQVEDNQELNENLEGSDVPKDDEALNIEDTSEEQKETDDKIESGSVRDKKNEGS
TEKKIETKKGGLLMGIMKRKRFMSRDPKKKS 
 
>PF3D7_1237900 sent to GeneartAG 
EKIFKRKKKIVKENILLILRNLCYEIYTVLCETSKTTKHVYDMLKNEANTAIELSRLEEVLLNNGYKKKIEDVEKNVLK
RFNVAVEDFYEELKNYEKDPDVQKYLNSIKKMYNEALLGLQPKLPSIDEKISEDVIINLASLIYKEKRKIYKTKIDSML
KNNEIIDIQNTLSNAQFFENLHKSTQHVEEQIIKENNNLVPNLFTFKYLVSYYSNDPNFLQKKKYLESKHGEKMIKILKI
KTSKKKKKRAHKEDRQSSNSAVSFKSTPSLDVYNVPHLGTLEKEEDHYSQQSKEMEHMDKDSHVDFIPHNVDANLD
KRDEQIEYISESGDMQPEKEYYEGEHITIRYEEEEDISEIYEEDRASRIYEEDRASGIYEEEHASGIYEEDHEERYRTSQV
SERSIKKSVTSQQDDIIHSHEEDNYVSDREVIHDDSFVGDKDQIFDDNYVSEREEIKQDDDYISEREEIKQDDDYISERE
EIKQDDDYISEREEFKQDESFVGDKDQIFEDDNYVSEREEIKQDDDYISEREEIKQDDDYVNEREEIKQDDDYVSEREE
IKQDESFVGDKDQIFEDDNYVSEREESKQDESFVGDKDQVFDDDYVSEREEIKQDDDYVSEREEIKQDESFVGDKDQI
FEDDNYVSEREEFKQDESFVGDKDQNFDDDYVSEREDIKQDDDYISERDEIKQDDSFAGDKDQNFEDDNYVSEKEEII
YDNNNIADREQVIQDDNYVSDKEEIIYDNNNNNNIADSEVDKENNNYVYENDEIIKDNKAMNEKDSSIHYDEEGTVK
NKDIIENVKEENSDIQMLENDIINNINNEIIDNNENEIINNQAKVENNTSMTEYEDVIDMDYKSPENLFMFDQEYNINE
DHKGEINNNDNDNSKSVSGMGEREVSNEENREDEMIRNEEVDYIKDDDEHNTDDIKEDDEHNADDIKEDDEHNVDD
IKEDDENNADDIKEDDEHNADDIKEDDEHNTDDIKEDDEHNTDDIKEDDEHNADDIKEDDENNADDIKEDDEHNTD
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DIKEDDEHNTDDIKEDDEHNADDIKDDEHNTDDIKDDEHNTDDIKDDEHNADDIKDEDNDQVEDNQELNENLEGSD
VPKDDEALNIEDTSEEQKETDDKIESGSVRDKKNEGSTEKKIETKKGGLLMGIMKRKRFMSRDPKKKS 
 
24. 
>PF3D7_1252300 
MSDPWADYDPNIISALQEAFGDIITAKPLTNLLSGESGPAIAGGCSCNRSLMIFIALMVFNAILFWVYNRGKKDIEKKI
KKHGYY 
 
>PF3D7_1252300 sent to GeneartAG 
 
SDPWADYDPNIISALQEAFGDIITAKPLTNLLSGESGPAIAGGCSCNRSL 
 
 
 
25. A&B 
 
>PF3D7_0629500 AMINO ACID TRANSPORTER, PUTATIVE 
MNKKYGTSSNNHDNKKDKKNNADKNKNKKNTTTGEENKDSNKSLVNNDSKKNDSSKNKYNIVKANIKNIFASDK
KNEKSDKNEKNESSKSSKNTETYTNVNDKKSNNLITKGSNDKKKKKKDSKKNSSNNNNNNTIVDISDGDYTNDEEG
TNKPKRNWKGRTFSRFTPGGVRSSTVLFICTAIGVGFLSIPYVFSKLGIILSIILIILNAFESYVTTNILCTSSLEHNTFVYG
NLLKKIGNKYYKTIIDFGLSFGFVSSYILILILISNFLSTIFYVFNFPTLFTNNVFLVILICLLILPITFRNKVGSLNHFLIFSL
FSLSITVLTIGLQTKSYNNLLINKEVNLFKMDKHFFKCFNILLFSFSQQPNACFITGQFNQPTHRRLNKSTFRSVILQVIF
YTLFGILGYFSFLNTAKDNIVLNYENSNVSILLCKFLLSLTFFFSVPLNFMGSYQSMLALGITTRDALYKLYTYIFRRTG
YSANLSLLLSEYTNDPYQETHADNITEHSSVSESQTDDQNQRMWISVIVTIFCALIACKVKKLSNVIGIGGGITSTLISC
LLPNLIYYKNRHNVSNKLKRYSTLFMLCFFSFMGFLSVVVT TLNLIL 
 
 
>PF3D7_0629500_SEG1 AMINO ACID TRANSPORTER, PUTATIVE sent to GeneartAG 
QTKSYNNLLINKEVNLFKMDKHFFKCFNILLFSFSQQPNACFITGQFNQPTHRRLNKATFR 
 
>PF3D7_0629500_SEG2 AMINO ACID TRANSPORTER, PUTATIVE sent to GeneartAG 
GSYQSMLALGITTRDALYKLYTYIFRRTGYSANLSLLLSEYTNDPYQETHADNIAEHSSVSESQTDDQNQRMWISVIV
TIFCALIACKVKKLSN 
 
26. 
> PF3D7_1345100 THIOREDOXIN 2 (TRX2)  
MKKYIFFFLFSFINFFFVYDVTCTKEVTSTNDDPLTPLNRFDKYYLRMFKKVPRLQQNGSNIINGVNMKNTVIVLYFF
AKWCQACTMQSTEMDKLQKYYGKRIYLLKVDLDKNESLARKF 
SVKSLPTIILLKNKTMLARKDHFVSSNDLIALIKKHL 
 
> PF3D7_1345100 THIOREDOXIN 2 (TRX2) sent to GeneartAG 
TKEVTSTNDDPLTPLNRFDKYYLRMFKKVPRLQQNGANIINGVNMKNTVIVLYFFAKWCQACTMQSTEMDKLQKY
YGKRIYLLKVDLDKNESLARKFSVKSLPTIILLKNKTMLARKDHFVSSNDLIALIKKHL 
 
27. 
>PF3D7_0206200 Pantothenate transporter (PAT) 
MAKNQYMEDRNIREPNTLLGEETEQLVDSFHYENNSSSIYKKVNSNRSKNGKHSMAFHKSLAVVNVAAGLDGCDD
QLLPASFRALEADLNLHPSLLGYITLAQTLMLSLFSPIWGFLSDKYSRKWMLVFGTALWGVATILLANINDFAHILFFR
AINGLALGSIGPISQSILADAAKNESLGLSFGLVQLSSSLGRLIGGVVTTTVALKYFGGIRGWRLCFIVVGILSVLLSIIV
ALFVEDAPRQVRKNKKMDYLDGESNTNASNNNNNSNNNNINNNINMNNSLDNNNSFTGLSHQSTRTYILYQNIVEL
LKDSLSKKSIIIILLEGFTGTIPWLALSFNTMFFQYCGLSDLQAAIITGFLLIGSAIGGVVGGHFGDIMHDISNKHGRPLL
GQLAMFGRVPLVLLIYLVIPKRKESFELFALSCFCIGLSSIAGVAVNRPIVSDIIRPDYRGTVFSLTIAIEGVGSSLIGAPL
FGYLAEKIFKYQNNNLLISDMPEDIRINNAQALSKTLFYLTIIPWILSFIFYSLLHFTYGKEYLKM 
NEIIQNEYKYDDEDEETIPEKKMLT 
 
>PF3D7_0206200 Pantothenate transporter (PAT) sent to GeneartAG 
DAPRQVRKNKKMDYLDGESNTNAANNNNNSNNNNINNNINMNNALDNNNSFTGLSHQSTR 
TYILYQNIVELLKDSLSKK 
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Appendix 5.1. Supplementary information of Nyamisati cohort and 
optimisation of antibody detection by Luminex and indirect ELISA 
 
 
 
Figure 1: Optimal antigen and antibody concentration estimated by checkerboard titrations for 
Luminex assays. A checkerboard titration using varying concentrations of antigen and serum dilution 
was performed for each antigen to determine the optimal concentration for use in the larger study. A 
pool of sera from adults (PHIS) was used as a positive control and sera from non-exposed UK adults 
was used as a negative control. As shown in A & B, antigen saturation was achieved at 1.0µg/million 
beads for AMA1 (3D7 and FVO allele) and 0.5 µg/million beads for the other antigens namely 
MSP1-19, MSP2 (DD2 and CH150/9 allele), MSP3 (3D7 and K1 allele) and RH2-2030 (C-H). There 
was low reactivity observed with the negative control sera with median fluorescent intensity (MFI) 
values of less than 500. 
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Figure 2: Optimal antigen and antibody concentration estimated by checkerboard titrations for 
Luminex assays. A pool of sera from adults (PHIS) was used as a positive control and sera from non-
exposed UK adults was used as a negative control. The GST (A) and MBP (B) tags had low 
reactivity with PHIS of less than 2500 MFI values at the highest sera dilution tested. 
 
 340 
 
Figure 3: Significantly higher PCR parasite prevalence in older children and adults. Figure showing 
the parasite prevalence by age in the entire cohort using data collected at A) 1993 B) 1994 and C) 
1995 cross-sectional survey. Blue bars show parasite prevalence determined by microscopy. Purple 
bars represent parasite prevalence determined by PCR. PCR data is not available for the 1993 survey 
and for the over 16 year olds in the 1995 survey. The parasite prevalence based on microscopy rose 
with age reaching a peak of between 68 and 80% at about seven years of age, and then declined 
gradually thereafter. The lowest parasite prevalence by microscopy ranged between 7 and 13% and 
was observed in older adults aged 30 to 85 years. Parasite prevalence estimated by PCR data showed 
overall higher parasite prevalence in all age groups when compared to microscopy. This was 
particularly striking for the older age groups (over 6 years olds) as seen in the 1994 (B) and 1995 (C) 
data. For example, using data from the 1994 survey in adults aged between 30-35 years, microscopy 
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underestimated the prevalence of asymptomatic parasitaemia by 48% when compared to the 
prevalence estimated by PCR data. 
 
 
 
 
Figure 4: Parasite densities decline significantly with age in all cross-sectional surveys. Figure shows 
the log10 parasite density by age in the entire cohort using data collected at the A) 1993 B) 1994 and 
C) 1995 cross-sectional survey. The Kruskal-Wallis H test for trend was used to compare media 
parasite density levels with age. The median parasite density dropped gradually with age in the entire 
cohort. This decline was statistically significant for all the surveys. The highest median parasite 
densities were recorded in children aged 5-7 years in the 1993 survey (560 parasites/µl, range 8-
114,025) and in children aged 0-2 years in the 1994 and 1995 surveys (2009 parasites/µl: range 8-
660,693 and 1754 parasites/µl: 16-300,000 in the 1994 and 1995 surveys respectively). The lowest 
median parasite densities recorded were 8 (range: 8-32), 8 (range: 8-160) and 100 (range: 8-560) 
parasites/l in adults aged 39-51, 36-45 and 46-85 years in the three consecutive surveys. 
 
 342 
 
Figure 5: High correlations between responses measured using different platforms. Correlation 
between antibody responses as determined by ELISA and Luminex assays using 72 serum samples 
for AMA1 (A and B) and MSP2 (C and D).  Blue graphs represent correlation between optical 
density and median fluorescent intensity values (MFI) obtained following ELISA and Luminex 
assays respectively.  Red graphs represent extrapolated antibody concentrations (AU) from a 
standard curve using a pool of purified immunoglobulins from malaria-immune IgG (MIG) of known 
concentration. 
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Figure 6: Correlations between responses measured in antigens expressed using different 
heterologous expression systems vary. Correlation between antibody responses as determined by 
ELISA and luminex assays using 72 serum samples for AMA1 (A and B) and MSP2 (C and D) 
obtained using different expression system.  Blue graphs represent correlation between optical 
density and median fluorescent intensity values (MFI) obtained following ELISA and luminex assays 
respectively.  Red graphs represent extrapolated antibody concentrations (AU) from a standard curve 
using a pool of purified immunoglobulins from malaria-immune IgG (MIG) of known concentration. 
Two constructs of AMA1 were tested, one expressed in Pichia pastoris and a second expressed using 
mammalian cells. Similarly, two constructs of MSP2 were tested, one expressed in Escherichia coli 
and a second expressed using mammalian cells. 
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Figure 7: A comparison of the age and haemoglobin levels between the adults who experienced a 
febrile malaria episode compared to those who did not. A) The median age in years in adults who 
had a clinical episode versus those who did not was 33 versus 35 years: p-value=0.8914. B) The 
median haemoglobin levels in adults who had a clinical episode versus those who did not was 128 
versus 123 g/l: p-value=0.4928.  Yellow lines indicate the normal haemoglobin levels in adult 
females while the green lines indicate normal levels in adult males. 
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Figure 8: Antibody levels to PfRH2, the only antigen among those tested in which antibody levels 
were higher in individuals who experienced a clinical episode compared to those who did not. 
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Figure 9: The majority of adults have stable responses to the well-studied antigens over a 3 year period. Plot matrix showing the seropositive response to AMA1 (FVO and 
3D7), MSP1-19, MSP2 (CH150/9 and DD2), MSP3 (K1 and 3D7), in 68 clinically immune individuals with samples collected at the 1993, 1994 and 1995 cross-sectional survey. 
Each row on the Y-axis represents an individual while the X-axis shows responses to each antigen grouped together and arranged in consecutive years. For example, for AMA1-
3D7, the three consecutive columns represent 1993,1994 and 1995 responses. Antibody measurements to AMA1-FVO were measured at the 1993 and 1994 survey only. 
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Figure 10: High correlations between two alleles of the same antigen suggesting potential cross-reactive AMA1 and MSP3 responses in adults. Scatter plots 
showing correlation between antibody responses to AMA1-3D7 and AMA1-FVO alleles, MSP2-DD2 and MSP2-CH150/9 alleles and MSP3-3D7 and MSP3-K1 
allele using sera from semi-immune adults collected at the 1993, 1994 and 1995 cross-sectional surveys. Antibody measurements for AMA1-FVO were not 
measured at the 1995 survey. Antibody responses to AMA1-3D7 and FVO alleles were highly positively correlated with Spearman correlation coefficient of 0.95 
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at both the 1993 and 1994 cross-sectional survey (figure 18A and 18D). Similarly, antibody responses to MSP3-K1 and 3D7 alleles were also highly positively 
correlated with a Spearman correlation co-efficient of 0.82 at the 1993 (figure 18C) and 1994 (figure 18F) survey and 0.89 at the 1995 cross-sectional survey 
(figure 18E). Antibody responses to MSP2-DD2 and MSP2-CH150/9 were positively but less strongly correlated with R-values of 0.51 (figure 18B), 0.35 (figure 
18E) and 0.47 (figure 18G) at the 1993,1994 and 1995 cross-sectional survey. This suggests that responses to AMA1 and MSP3 are potentially cross-reactive but 
doesn’t exclude an allele specific component that could be confirmed by competition ELISAs, while MSP2 induced a more obvious allele-specific response. 
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Appendix 5.2. Comparison of antibody breadth score between individuals who 
experienced a clinical episode versus those who did not. 
 
 
 
A
ge
C
li
n
ic
a
l	
e
p
is
o
d
e
P
F3
D
7
_
	
0
8
2
3
8
0
0
P
F3
D
7
_
	
1
2
5
2
3
0
0
P
F3
D
7
_
	
1
3
0
8
0
0
0
P
F3
D
7
_
	
0
2
0
6
2
0
0
P
F3
D
7
_
	
0
8
3
0
5
0
0
P
F3
D
7
_
	
1
3
4
5
1
0
0
P
F3
D
7
_
	
0
6
2
9
5
0
0
(
SE
G
2
)
P
F3
D
7
_
	
0
7
3
8
0
0
2
P
F3
D
7
_
	
0
9
2
5
9
0
0
P
F3
D
7
_
	
1
0
2
5
3
0
0
P
F3
D
7
_
	
1
4
0
1
6
0
0
A
M
A
1
M
SP
2
R
H
2
M
SP
1
-1
9
M
SP
3
B
re
a
d
th
	
sc
o
re
50 No 7
36 No 16
35 No 6
49 No 5
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34 No 7
45 No 13
31 No 8
32 No 7
45 No 14
53 No 4
31 No 14
29 No 5
21 No 11
45 No 4
40 No 12
35 No 10
45 No 15
41 No 15
58 No 14
40 No 12
47 No 9
25 No 8
75 No 14
24 No 4
34 No 8
40 No 8
50 No 9
31 No 14
55 No 3
27 No 6
28 No 12
53 No 14
35 No 8
19 No 12
45 No 10
45 No 8
21 No 5
50 No 3
30 No 10
47 No 11
42 No 7
17 No 12
23 No 15
25 No 7
29 No 2
37 No 5
47 No 12
25 No 12
27 No 10
27 No 3
75 No 13
80 No 12
22 No 11
39 No 12
20 No 10
29 No 15
30 No 11
37 No 6
58 No 9
30 No 16
30 No 8
22 No 4
32 No 5
35 No 2
45 No 13
30 Yes 11
60 Yes 4
31 Yes 6
33 Yes 3
31 Yes 16
22 Yes 7
50 Yes 10
30 Yes 5
45 Yes 8
38 Yes 3
33 Yes 2
Appendix	5.2:	lower	breadth	scores	in	individuals	who	experienced	a	clinical	episode	of	malaria.	The	breadth	of	antibody	responses	to	known	and	novel	
antigens	in	77	adults	of	the	Nyamisati	cohort.	
Black	squares	indicate	a	response	was	detected	while	white	squares	indicate	a	negative	response	to	a	specific	antigen	in	the	respective	individual.	Yellow	
highlights	the	individuals	who	experienced	a	clinical	episode	over	the	three	year	period
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Appendix 6.1. Supplementary data on immune effector mechanism in adults 
 
 
 
Figure 1: Relative phagocytosis indices in adults grouped by age and parasite status.  (A) A 
comparison of the median phagocytosis indices in adults 30 years and older (white box and whisker 
plots) compared to 15-29 year olds in the 1993, 1994 and 1995 crossectional surveys. (B) Median 
phagocytosis indices in adults with asymptomatic parasetemia (as measured by qPCR of the 18S 
gene) compared to those who were parasite negative (black box and whisker plots). The relative 
phagocytosis indices were significantly higher in the older age group in the 1993 and 1994 cross-
sectional survey while no significant difference were observed in the 1995 cross-sectional survey 
although a trend toward lower phagocytosis in older individuals was observed. The median RPI 
between adults aged 15 to 29 years versus those over 30 years and were as follows: a) 48.94 versus 
62.36, p-value=0.034 b) 57.71 versus 71.62, p-value=0.026 and c) 58.74 versus 47.68, p-value=0.394 
in the 1993, 1994 and 1995 crossectional surveys respectively. Similarly, the phagocytosis indices 
were compared in individuals who were parasite positive at the cross-sectional surveys as measured 
by qPCR detection of the 18S ribosomal RNA gene (B). In general, the indices were elevated in PCR 
positive individuals, although this difference was statistically significant in the 1995 cross-sectional 
survey only. The median RPI in parasite negative adults compared to parasite positive individuals 
were as follows: a) 58.69 versus 60.29, p-value=0.8479 b) 66.58 versus 76.19, p-value=0.3454 and c) 
47.02 versus 61.58,p-value=0.05 in the 1993, 1994 and 1995 crossectional survey respectively. 
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Figure 2: Optimizing the coating concentration of PEMS to measure antibody-mediated complement 
fixation on P. falciparum merozoites for longitudinal studies. A serial dilution of PEMS were coated 
and measured using a pool of sera from immune adults from Kilifi (PHIS: red line), purified 
immunoglobulins from Malawian adults (MIG: Pink line) and two serum samples from non-exposed 
Swedish adults (NEG: blue lines) 
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Figure 3: C1q-fixing antibodies in adults of the Nyamisati cohort by age and parasite status. (A) 
Median anti-C1q fixing antibodies were higher in adults 30 years (white box and whisker plots) and 
older compared to 15-29 year olds in all three crossectional surveys (black box and whisker plots). 
(B) Median anti-C1q fixing antibodies were higher in adults with asymptomatic parasetemia (as 
measured by qPCR of the 18S gene) than in those who were parasite negative (black box and 
whisker plots) in the 1993 and 1994 cross-sectional surveys. C1q-fixing antibody levels increased 
with age in all three cross-sectional surveys, although none of these were statistically significant. The 
median antibody levels in 15-29 year olds compared to 30 year olds were 0.525 versus 0.6535; p-
value=0.098, 0.510 versus 0.591; p-value=0.107 and 0.506 versus 0.580; p-value=0.249 in the 1993, 
1994 and 1995 surveys respectively. Similarly, C1q-fixing antibodies were elevated in adults with 
asymptomatic parasetemia (parasite positive) compared to those who were not in the 1993 and 1994 
cross-sectional surveys, although these were not statistically significant. 
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Figure 4: Optimizing the coating concentration of PEMS to measure antibody-dependent respiratory 
burst for longitudinal studies. A serial dilution of PEMS were coated and measured using a pool of 
sera from immune adults from Kilifi (PHIS: red line), purified immunoglobulins from Malawian 
adults (MIG: Pink line) and two serum samples from non-exposed Swedish adults (NEG: blue lines) 
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Figure 5: C1q-fixing antibodies in adults of the Nyamisati cohort by age and parasite status. (A) 
Median anti-C1q fixing antibodies were higher in adults 30 years (white box and whisker plots) and 
older compared to 15-29 year olds in all three crossectional surveys (black box and whisker plots). 
(B) Median anti-C1q fixing antibodies were higher in adults with asymptomatic parasetemia (as 
measured by qPCR of the 18S gene) than in those who were parasite negative (black box and 
whisker plots) in the 1993 and 1994 cross-sectional surveys. C1q-fixing antibody levels increased 
with age in all three cross-sectional surveys, although none of these were statistically significant. The 
median antibody levels in 15-29 year olds compared to 30 year olds were 0.525 versus 0.6535; p-
value=0.097, 0.510 versus 0.591; p-value=0.106 and 0.506 versus 0.580; p-value=0.245 in the 1993, 
1994 and 1995 surveys respectively. Similarly, C1q-fixing antibodies were elevated in adults with 
asymptomatic parasetemia (parasite positive) compared to those who were not in the 1993 and 1994 
cross-sectional surveys, although these were not statistically significant. 
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Appendix 6.2. Breadth of immune effector functions in adults who experienced 
a clinical episode versus those who did not. 
 
 
 
Age Clinical	episode ADRB Opsonic	phagocytosis C1q-fixing Breadth	score
47 0 2
40 0 1
30 0 2
47 0 3
37 0 3
30 0 1
37 0 2
35 0 1
31 0 1
35 0 1
24 0 0
49 0 1
45 0 3
40 0 2
27 0 0
27 0 2
34 0 2
25 0 0
31 0 1
55 0 1
53 0 2
19 0 3
75 0 3
42 0 0
22 0 2
39 0 3
21 0 1
29 0 1
30 0 0
21 0 0
55 0 3
45 0 3
17 0 2
75 0 3
80 0 3
41 0 3
36 0 3
35 0 0
20 0 1
32 0 1
30 0 1
45 0 2
50 0 2
34 0 2
28 0 2
29 0 2
58 0 1
31 0 3
50 0 3
35 0 3
45 0 2
47 0 1
45 0 3
45 0 0
40 0 1
53 0 1
25 0 1
45 0 0
27 0 0
50 0 0
32 0 1
25 0 1
29 0 1
22 0 2
58 0 3
23 0 3
38 1 0
31 1 2
30 1 2
33 1 1
50 1 3
45 1 2
33 1 0
60 1 2
30 1 0
22 1 0
31 1 2
Appendix	6.2:	lower	breadth	scores	in	individuals	who	experienced	a	clinical	episode	of	malaria.	The	breadth	of	stable	effector	functions	in	77	adults	of	the	Nyamisati	cohort.	
Black	squares	indicate	a	stable	response	was	detected	while	white	squares	indicate	a	non-responder	to	a	specific	effector	function	in	the	respective	individual.	Yellow	highlights	the	
individuals	who	experienced	a	clinical	episode	over	the	three	year	period
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